Investigating the epidemiology of hepatitis C virus (HCV) infection in different settings around the world by Trickey, Adam
                          
This electronic thesis or dissertation has been





Investigating the epidemiology of hepatitis C virus (HCV) infection in different settings
around the world
General rights
Access to the thesis is subject to the Creative Commons Attribution - NonCommercial-No Derivatives 4.0 International Public License.   A
copy of this may be found at https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode  This license sets out your rights and the
restrictions that apply to your access to the thesis so it is important you read this before proceeding.
Take down policy
Some pages of this thesis may have been removed for copyright restrictions prior to having it been deposited in Explore Bristol Research.
However, if you have discovered material within the thesis that you consider to be unlawful e.g. breaches of copyright (either yours or that of
a third party) or any other law, including but not limited to those relating to patent, trademark, confidentiality, data protection, obscenity,
defamation, libel, then please contact collections-metadata@bristol.ac.uk and include the following information in your message:
•	Your contact details
•	Bibliographic details for the item, including a URL
•	An outline nature of the complaint
Your claim will be investigated and, where appropriate, the item in question will be removed from public view as soon as possible.
                          
This electronic thesis or dissertation has been





INVESTIGATING THE EPIDEMIOLOGY OF HEPATITIS C VIRUS (HCV) INFECTION IN
DIFFERENT SETTINGS AROUND THE WORLD
General rights
Access to the thesis is subject to the Creative Commons Attribution - NonCommercial-No Derivatives 4.0 International Public License.   A
copy of this may be found at https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode  This license sets out your rights and the
restrictions that apply to your access to the thesis so it is important you read this before proceeding.
Take down policy
Some pages of this thesis may have been removed for copyright restrictions prior to having it been deposited in Explore Bristol Research.
However, if you have discovered material within the thesis that you consider to be unlawful e.g. breaches of copyright (either yours or that of
a third party) or any other law, including but not limited to those relating to patent, trademark, confidentiality, data protection, obscenity,
defamation, libel, then please contact collections-metadata@bristol.ac.uk and include the following information in your message:
•	Your contact details
•	Bibliographic details for the item, including a URL
•	An outline nature of the complaint
Your claim will be investigated and, where appropriate, the item in question will be removed from public view as soon as possible.
 
 
INVESTIGATING THE EPIDEMIOLOGY OF 
HEPATITIS C VIRUS (HCV) INFECTION IN 








A dissertation submitted to the University of Bristol in 
accordance with the requirements for award of the degree of 












Hepatitis C virus (HCV) is a bloodborne virus affecting the liver. An estimated 71 million 
people are infected globally and around 400,000 people die annually from HCV-related 
complications. Direct-acting antivirals (DAAs), highly effective treatments for HCV, were 
first approved in the US in 2011. Subsequently, in 2016 the WHO developed a Global Health 
Sector Strategy calling for the global elimination of HCV as a public health threat by 2030. 
To eliminate HCV requires an understanding of its epidemiology and how it varies across 
settings, which I investigate in this thesis. 
The first part of my thesis involves the use of data from two general population household 
serosurveys to investigate the risk factors associated with prevalent HCV infections in two 
high prevalence settings: Pakistan and Punjab state, India. I find various factors associated 
with HCV infection, including the number of childbirths, or the number of medical 
injections received; information that is useful to policy makers planning HCV screening 
strategies in these settings. Additionally, in Pakistan I estimate the contribution of medical, 
community, and socio-economic risk factors to the HCV epidemic, finding that they all have 
a large contribution. 
The second part of my thesis involves the development of a global model of the HCV 
epidemics in 88 countries across the world. I use this model to estimate the contribution of 
injecting drug use (IDU) to country-level HCV epidemics, as well as regionally and globally. 
I show that, globally, IDU contributes nearly half of all HCV transmission. I use the global 
model to also estimate the benefit of treatment as prevention for different subgroups of 
infected individuals. Globally, I find that, of the infected subgroups investigated, the highest 
number of infections averted are achieved through treating people who inject drugs, while a 
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CHAPTER 1. INTRODUCTION 
Hepatitis C virus (HCV) is a bloodborne virus that was first identified in 1989(63). HCV 
affects the liver, with some infected individuals developing cirrhosis of the liver and liver 
cancer(331). In 2015 there were an estimated 71 million people infected with HCV, 
globally(40), with 1.75 million incident infections occurring annually(406). Around 400,000 
people are thought to die of HCV-related complications every year(407). In 2016 the World 
Health Organization (WHO) developed targets to eliminate HCV as a public health concern 
by 2030(403). These targets include reducing the number of incident infections by 80% and 
HCV-related mortality by 65% from the 2015 levels(403). The WHO released these targets 
following the development of direct acting antiviral (DAA) treatment for HCV(51). DAAs 
result in sustained virologic response rates (an effective cure) of 95%, far above the levels of 
previously available interferon-based treatments(51). Since the development of DAAs and 
the WHO releasing their elimination targets, countries have scaled up their commitments to 
tackling HCV(409). However, in order to eliminate HCV, an understanding of its 
epidemiology is required. Such an understanding will allow policy-makers to know who to 
target for HCV testing and treatment, which could improve the yield of infected people from 
testing and the prevention benefit of treatment, which could in turn reduce the costs 
associated with HCV elimination when there are many competing healthcare priorities 
requiring investment. 
The WHO’s 2018 Access to HCV Treatment Report(409) tracks the progress that has been 
made as more countries use DAAs to treat HCV. An example of a country where there has 
been huge progress is Egypt, which has one of the highest prevalences in the world, 
estimated at 10.0% in 2015(181). Due to its high burden, the epidemiology of HCV in Egypt 
has been well studied compared to most other countries. Knowledge of the epidemiology of 
HCV in Egypt and the considerable burden it will take on the health system has in part led 
to substantial political support to meet the WHO’s elimination targets; starting in October 
2018, in four months around 30 million people were tested for HCV in Egypt(11). 
However, for the vast majority of countries progress has been much less than in Egypt, 
partially due to a lack of understanding of the epidemiology and healthcare burden of HCV 
in those countries(409). The importance of different transmission routes for HCV has 
evolved over time(95, 267). Unsafe blood transfusions were previously the most common 




introduction of blood screening, which happened at different times in different countries, 
and to varying standards(291). Following this, the use of unsterile medical injections and 
other medical procedures is thought to have made up a larger proportion of the new 
infections, as well as the sharing of equipment related to injecting drug use (IDU)(95, 283). 
Other modes of infection have also been reported, such as sexual transmission(357), child 
birth(35), or using a barber that does not sterilise their blades(259). For many countries, there 
is uncertainty around the main risk factors that are associated with HCV infection and the 
importance of different routes of transmission to each country’s epidemic have not been 
quantified. In high-income countries it is often assumed that most of the transmission is due 
to IDU, however, this is less certain in low- and middle-income countries. Additionally, the 
full epidemiological benefits of treatment have been little studied in terms of how treating 
infected individuals will not only cure that person of HCV but will prevent further onwards 
transmission. This prevention benefit could be affected by the different characteristics of the 
epidemic in each country, so understanding the epidemiology of HCV in that setting is 
important for understanding the impact of treatment. This thesis focuses on the 
epidemiology of HCV in different settings around the world, looking at where different risk 
factors are important and investigating the possible impact of treatment as prevention. 
In chapters 4 and 5, I look at the factors associated with HCV prevalence in settings where 
the epidemic is considered high prevalence and generalised, meaning that it is not focused 
among a particular subgroup, such as people who inject drugs (PWID). Elucidating the 
factors associated with HCV prevalence is of use for minimising the use of resources and 
increasing the yield when designing HCV testing programs to identify those who are 
unaware of their infection status. The WHO estimated in 2017 that the percentage of infected 
individuals that are diagnosed is around 20%(406). In Pakistan, where the prevalence has 
been estimated to be as high as 4.9% nationally and even higher in the Eastern 
provinces(295), the initial stages of a large treatment program are underway(255, 295). In 
chapter 4 I use the data from Pakistan’s 2007 national HCV serosurvey, to investigate the 
factors associated with HCV as well as calculating population attributable fractions to 
investigate the contribution of medical, community, and social factors to the epidemic in 
that setting. In chapter 5, I move across Pakistan’s Eastern border to Punjab, India, where I 
present the results of a recent HCV serosurvey from 2013-2014. This is another high 
prevalence setting, with a previously estimated prevalence of 5.2%(344). Like Pakistan, 




reports of IDU(326). I once again use a serosurvey to investigate which factors are associated 
with being HCV positive and compare between the two settings.  
In chapters 6, 7, and 8, I use mathematical modelling to investigate the epidemiology of 
HCV in 88 countries spread across the globe. Chapter 6 describes the model and methods 
used for the analyses in chapters 7 and 8. In chapter 7, I move from looking at two 
generalised epidemics in Pakistan and Punjab, India, to investigating the contribution of 
IDU to HCV epidemics across all countries where sufficient data are available. Whilst the 
previous chapters had looked at the associations with prevalent HCV infections, the analysis 
in chapter 7 focuses on HCV incidence, estimating the percentage of transmission that 
would be avoided if the HCV epidemic among PWID could be fully controlled, i.e. I remove 
the additional transmission due to the sharing of unsafe injecting equipment. The 88 
countries included in this modelling exercise are diverse and cover most of the world’s 
population, allowing me to estimate the contribution of IDU to HCV transmission for 
different regions, as well as to produce a global estimate. Importantly, we are also able to get 
insights into how country-level factors affect the contribution that IDU makes to these 
epidemics. Although such estimates highlight the importance of focusing resources to 
prevent transmission among key populations such as PWID, they also give information on 
how their importance varies globally, which is useful for prioritising resources for achieving 
the WHO’s HCV elimination targets. 
After the previous results chapters have investigated the epidemiology of how people 
became or become infected with HCV, chapter 8 uses the model from chapter 7 to get 
insights on the benefits that will be achieved through intervening on these epidemics in the 
form of treatment as prevention(156). I quantify this benefit for various subgroups, 
including PWID. These analyses were commissioned by the WHO, with there being a focus 
on determining the prevention benefits of a treat-all strategy, which subsequently fed in to 
the WHO’s 2018 recommendation to expand HCV treatment to all, for which chapter 8’s 
analyses are published as an appendix(410). Quantifying the prevention benefit of treatment 
allows policy makers to plan how intervening on their HCV epidemic will affect the future 
transmission and burden of HCV, which is crucial data in these early years of DAA 




I begin this thesis by providing a background to HCV and its epidemiology in chapter 2, as 
well as presenting a background to the mathematical modelling of infectious diseases, 






CHAPTER 2. A BACKGROUND TO THE GLOBAL 
HEPATITIS C VIRUS EPIDEMIC 
 
2.1. Introduction 
The topic of this thesis is the epidemiology of hepatitis C virus (HCV) epidemics around the 
world. This background chapter describes the global HCV epidemic in six sections. The first 
section discusses the natural history of HCV, the second focuses on the transmission routes 
of HCV, whilst in the third section I discuss the risk factors of HCV infection. Within the 
fourth and fifth sections of the chapter, I discuss prevention and treatment strategies for 
HCV. In the sixth section I review data on HCV prevalences and genotypes across and 
within different regions. 
 
2.2. HCV natural history 
2.2.1. Description of HCV and infection 
HCV was first identified in 1989(63). It is an enveloped, single-stranded RNA virus from the 
Flaviviridae family of the hepacivirus genus(216). HCV is a bloodborne virus that infects the 
body’s liver cells causing hepatitis C disease within the liver(331). Most HCV infections 
occur via unscreened blood transfusions, unsterilised medical procedures, and the sharing 
of needles and syringes for injecting drug use (IDU)(16). The initial stage of HCV infection is 
the acute stage, which can then either progress to lifelong chronic disease or, in an estimated 
26% of infections, can clear spontaneously(252, 390). Without treatment, chronic hepatitis C 
infection can lead to cirrhosis of the liver and hepatocellular carcinoma, which in turn can 
lead to the death of the infected individual(369). The virus is genetically variable, with there 
being seven major HCV genotypes that can be divided further into sixty-seven 
subtypes(340). All infected individuals develop an HCV antibody response. However, 
diagnosis of active HCV infection is done through testing for HCV RNA, for which a 





2.2.2.  Acute and chronic infection 
Upon becoming infected with HCV, individuals are in the acute phase of hepatitis C disease. 
Around 15% of individuals exhibit symptoms in this acute phase(227). These symptoms 
tend to be mild but can include jaundice in some instances(227) and in very rare, severe 
cases can also lead to death(159). Spontaneous clearance of acute infection can depend on 
various factors including gender, age, genotype, and HIV co-infection status(7). Following 
spontaneous clearance, there are no additional HCV-related side-effects in that 
individual(390), but it is uncertain whether the individual will be protected from HCV 
reinfection or if they are genetically more likely to clear the infection(126, 167, 188, 316). 
Individuals that spontaneously clear an infection are more likely to do so again(126). The 
majority who spontaneously clear the infection do so within the first six months and those 
who have not cleared it after twelve months are unlikely to do so(7). However, determining 
the timescale for how long HCV RNA must persist within the body following the initial 
infection, to define chronic infection, is difficult. This is due to the generally asymptomatic 
nature of the acute phase of infection, meaning the date of transmission is unknown in many 
cases(390).  
 
2.2.3.  Disease complications and survival 
Early chronic infections tend to be asymptomatic(232). The disease progresses slowly, and 
cases may go undiagnosed until individuals present with symptoms of end-stage liver 
disease(320). Years of inflammation due to untreated HCV infection can cause cirrhosis of 
the liver, which is estimated to affect around 16% of patients with chronic infection after 20 
years(366). The rates of progression to cirrhosis are affected by alcohol consumption and 
HIV co-infection, among other factors(320). For those with cirrhosis, there is a 3-6% annual 
risk of developing hepatic decompensation(390). Hepatic decompensation is defined as the 
rapid development of one of a range of clinical compensations including ascites and hepatic 
encephalopathy(314). Individuals with compensated, as opposed to decompensated, 
cirrhosis are also at risk of developing hepatocellular carcinoma, at a rate of roughly 1-5% 
annually(390). For untreated, chronically infected individuals with cirrhosis, the liver-
related mortality rate is around 7% per year, with the main HCV infection-related 




developed hepatocellular carcinoma(140). The 5-year survival rate for decompensated 
cirrhosis is 50%(100) 
2.2.4.  Genotypes 
There are seven distinct HCV genotype variants that are further classified into sixty-seven 
subtypes(340). There is considerable regional variation in the distribution of the HCV 
genotypes(285), which will be discussed further in section 2.7.3. Until the recent 
development of the pan-genotypic direct-acting antivirals (DAAs)(51, 420), the effectiveness 
of treatments for HCV was hampered by the variation in genotypes and subtypes(51, 420), 
with available treatments having different levels of effectiveness for different genotypes(51). 
This resulted in clinicians having to consider the genotype of their patient when prescribing 
treatment, with genotype tests being time consuming and expensive(108, 289).  
 
2.2.5.  Disease diagnosis 
Diagnosis of HCV rarely occurs during the acute phase of infection because it is mostly 
asymptomatic and usually brief so unlikely to be detected by screening. Therefore diagnosis 
is far more common at later phases of the infection(195). HCV antibody tests, such as the 
enzyme-linked immunosorbent assay (ELISA), can determine whether an individual has 
ever had acute infection(131). However, a positive HCV antibody test result does not 
indicate whether that individual spontaneously cleared their infection or is currently 
infected(131). HCV RNA tests, such as the nucleic acid test (NAT), or an HCV core antigen 
test, for example the chemiluminescence immunoassay (CLIA), are required to ascertain 
whether an active infection is present(131). A negative result for an HCV RNA or HCV core 
antigen test indicates there is no current HCV infection in that individual(131). HCV core 
antigen tests tend to be cheaper than HCV RNA tests but have been limited by their lower 
sensitivity, although this is not necessarily the case for recently developed core antigen tests, 
such as the ELISA(131). Recently, point of care tests with high diagnostic accuracy for 
detecting active infection have been developed, although currently they are not widely used 
due to high costs(214). The World Health Organization regularly updates its guidelines on 
hepatitis B and C testing, with the 2017 version declaring NAT testing for HCV RNA to be 




2.3. HCV transmission routes 
2.3.1. Historical and geographical differences in transmission routes of HCV 
An individual becomes infected with HCV through being exposed to blood contaminated 
with the virus(16). How people tend to come into contact with infected blood varies by 
region and country with these modes of exposure having changed over time(16, 283, 291). In 
high-income countries, the primary mode of transmission was through contaminated blood 
transfusions until blood screening was introduced in the early 1990s(291). Since then IDU 
has become the primary transmission risk factor in these countries(95). Though most low- 
and middle-income countries have now introduced blood screening, there is still 
transmission in healthcare settings in many countries(342). For these countries, blood 
screening methods are often sub-optimal and there is additional healthcare-related 
transmission through unsterilised equipment(342). In low- and middle-income countries 
with poor healthcare practices, IDU generally contributes less to transmission than in high-
income countries(342). Besides iatrogenic and IDU-related transmission, HCV infections can 
also occur through community(16, 371) and household activities(74, 139), mother-to-child 
transmission(37, 417), and sexual transmission(44, 357). 
 
2.3.2. Iatrogenic transmission 
Iatrogenic transmission of HCV is thought to be mostly through contaminated blood 
transfusions and the re-use of unsterile medical equipment. High-income countries 
introduced robust methods of blood screening in the early 1990s(291). Following this, the 
transmission risk due to HCV contaminated blood declined sharply from around 1 in 50 
units to around 1 in 200,000 today(291). Most, but not all, low- and middle-income countries 
have now introduced blood screening, with the WHO reporting for 2013 that 81% of 
donations are screened in lower-middle-income countries and 66% in low-income 
countries(405). However, the screening techniques used in less wealthy countries are often 
less able to detect infections than in high-income countries; a review of screening tests used 
in selected African countries found 80% sensitivity, possibly due to the prohibitive costs of 
the best screening tests(208). Haemophiliacs are particularly affected by poor screening of 
blood donations as their condition means they require a high quantity of transfusions and 




clotting protein(279). The use of unsterile medical equipment, particularly therapeutic 
injections, is still a major transmission route for many countries(16, 283). This is despite an 
almost ten-fold decline in the global re-use of syringes between 2000 and 2010(282). This re-
use of medical syringes can be due to a lack of sterile equipment among health providers, 
some of whom are not professionally trained and are unaware of the transmission risks(16). 
Evidence suggests historic vaccination campaigns with poor sterilisation practices, such as 
for schistosomiasis in Egypt in the 1950s, have led to HCV epidemics in certain settings(94). 
Healthcare related HCV transmission is very rare in high-income countries, although 
occasional reports are seen(75). Globally, iatrogenic transmission of HCV is either declining 
as countries introduce improved blood screening measures combined with less re-use of 
unsterile injecting equipment, or has already reached a very low level, depending on the 
setting(267, 283). 
 
2.3.3. Transmission via injecting drug use 
There is a high risk of HCV transmission for people who inject drugs (PWID) that use 
unsterile injecting equipment passed on from others, such as needles, syringes, filters, and 
water(16). A 2017 review estimated that 0.2-0.3% of adults inject drugs globally; about 14.9 
million people(77). Around 39% of PWID are chronically infected with HCV(127) with 
estimated chronic prevalence among PWID varying between 29% and 49% across regions, 
except for Sub-Saharan Africa where it is 16%(127). IDU in Sub-Saharan Africa is thought to 
have started more recently than in other regions, possibly explaining this discrepancy(119). 
Other factors are also important for explaining regional variations in HCV prevalences 
among PWID, including drug availability, differences in the coverage of prevention 
measures, or different risk behaviours. Estimates of chronic HCV prevalence among PWID 
are as high as 71.5% in Mexico, where almost all PWID, 97.4%, have been exposed to 
HCV(77, 127). Similar figures are seen in other countries, such as Taiwan, Portugal, Estonia, 
and Mauritius, where around 90% of PWID have been exposed to HCV and estimates of 
chronic prevalence are only slightly lower than in Mexico(77). Of all current prevalent HCV 
infections, around 8.5% are among PWID(127). However, through a study discussed at 
length in chapter 7 and published in the Lancet Gastroenterology and Hepatology, I 
estimate that around 43% of incident infections globally are due to the risks associated with 




2.3.4. Mother-to-child transmission 
Mother-to-child transmission is a major source of HCV infection among infants, particularly 
in high prevalence settings such as Egypt(36). Mother-to-child transmission is also referred 
to as perinatal or vertical transmission. Data suggests that this transmission happens in 
utero and that there is no association between breastfeeding and transmission(69). The risk 
that a mother infected with HCV will pass the virus onto her child is around 5.8%(35). On 
average, mothers that transmit the virus to their child have higher viral loads than those 
who do not(35). For mothers that are HIV co-infected, the risk of HCV transmission is 
10.8%(35). This higher rate among HIV co-infected mothers is possibly explained by HIV 
causing an elevated HCV viral load(20). 
 
2.3.5. Sexual transmission 
Rates of sexual transmission of HCV are thought to be low but as sex is common it could 
possibly impact HCV epidemics globally. A study examining incidence of sexual 
transmission in HCV-discordant heterosexual couples found the transmission rate to be low, 
3.7 per 10,000-person-years(383). However, HCV incidence among men who have sex with 
men (MSM) is higher than among heterosexual couples, estimated at around 14.8 per 10,000-
person-years(414). This could be due to an increased risk of blood contact or is possibly due 
to a higher prevalence of risky sexual practices among MSM such as chemsex that can 
combine IDU and sex, making the actual route of transmission hard to determine(83). The 
HCV incidence rate is even higher among MSM that are HIV-positive, with one study 
finding a rate of around 60.8 per 10,000-person-years(414), and another finding 134.0 per 
10,000-person-years in 2012(135). Intentionally coupling with partners that are also HIV-
positive is thought to have led to an increase in unprotected anal sex among MSM, possibly 
explaining the elevated HCV incidence rate in this group in recent years(44). However, for 
both heterosexual couples and MSM, it is difficult to separate out transmission between 
partners through sex or via shared behaviours and household activities(166). Therefore, the 






2.3.6. Transmission via community and household activities 
HCV transmission through community and household activities can happen in many forms. 
Community transmission routes include a barber using unsterilised shaving 
equipment(259), someone receiving a body-piercing(163, 367, 413) or a tattoo(53, 172, 367), or 
religious or cultural rituals, such as Matam(274, 371), circumcision(281), or female genital 
cutting(187). Household activities leading to HCV transmission include the sharing of 
toothbrushes(219) or shaving equipment(419). Evidence of HCV transmission exists for all 
these behaviours but is weaker than for other transmission routes(16, 163, 412). The evidence 
to date is mostly based on bio-behavioural surveys where these household and community 
activities are associated with HCV prevalence(163), although not in all instances(381). These 
bio-behavioural surveys may over-predict the importance of community and household 
transmission routes to HCV epidemics in settings where another transmission route is very 
common within the population, such as the use of medical injections in India, in a study 
discussed in further detail in chapter 5(346). Therefore, the extent to which these activities 
contribute to HCV epidemics is unclear, but in countries with generalised epidemics their 
impact on maintaining the epidemic could be substantial because most are common 
behaviours, particularly piercing, barbering, and tattooing(294, 412). The prevalence of these 
behaviours varies by gender(43) and age(199), and across cultures(274). The risk of HCV 
transmission for most of these community behaviours can vary by country, depending on 
the sterilisation procedures of the practitioners(172). 
 
2.4. HCV risk factors 
2.4.1. Introduction 
Many risk factors that are not themselves HCV transmission routes are associated with 
elevated prevalences of HCV within populations. These risk factors include homelessness, 
low socio-economic status, living in rural areas, being a prisoner, and being a migrant from a 
high-prevalence country. Many, if not all, of these factors are high-risk due to their 
association with particular transmission routes, for example, among prisoners and the 
homeless there is a high prevalence of IDU(198, 311). Nonetheless, consideration of these 




population subgroups is required to reduce the amount of people screened and to increase 
the yield of testing.  
 
2.4.2. HCV among prisoners 
Results from a meta-analysis estimated the prevalence of anti-HCV among prisoners to be 
15%(81). Anti-HCV prevalence among prisoners varied by region, with all regions studied 
having an estimated prevalence above 10% except for Latin America (4.7%) and east and 
southern Africa (1.8%)(81). The regions with the highest anti-HCV prevalences among 
prisoners are Asia Pacific (20.6%), and Eastern Europe and Central Asia (20.2%)(81). PWID 
are overrepresented in prisons; a systematic review found that around 58% of PWID had 
been incarcerated(77). Additionally, evidence shows that recent incarceration is associated 
with a 62% increase in risk of HCV acquisition among PWID(350), possibly due to a period 
of heightened transmission risk following release, or increased risk during 
imprisonment(350). Despite being outlawed, IDU occurs within prisons where in many 
cases there is a lack of sterile injecting equipment, which can lead to an increase in use of 
unsterile equipment(418). Aside from IDU, prisons can be places of increased HCV 
transmission due to tattooing with re-used needles or ink, behaviours that are common(153). 
Due to this combination of factors, modelling in Scotland, the USA and Eastern Europe 
suggests that incarceration can be important drivers of HCV epidemics(17, 147, 349). 
 
2.4.3. HCV among the homeless 
Homelessness is associated with IDU and, as discussed, PWID have elevated prevalences of 
HCV. PWID report high levels of housing instability(368), which is exacerbated by PWID 
often being incarcerated for drug offences(368). Research also suggests that homelessness is 
associated with the initiation of IDU as drugs are used by homeless people to cope with the 
hardships of sleeping rough, as well as mental illness(368). A global meta-analysis of studies 






2.4.4. Socio-economic status and HCV 
Various studies, including in the USA, Denmark, Vietnam, and Pakistan, have found a 
positive association between poverty and HCV prevalence(78, 271, 379, 388). After 
adjustment for IDU and other route-of-infection related risk factors this association between 
low socio-economic status and HCV remained for some studies(249, 284). One suggested 
reason for this association is the under-classification of PWID in these studies(271). In low- 
and middle-income countries, where medical transmission of HCV is more common, an 
explanation for this association could be due to increased use of unsterilised medical 
interventions in areas with more poverty(379).  
 
2.4.5. HCV and the urban/rural divide 
Prevalences of HCV in urban and rural communities have been compared across many 
countries, including India, Nigeria, and China(105, 293, 346). Most studies in low- or middle-
income countries have found higher prevalences of HCV in rural communities than in urban 
communities(105, 346, 422). For these countries where medical HCV transmission is still an 
issue, this is possibly due to people living in urban areas having better access to healthcare 
facilities such as hospitals, or due to particular traditions being more prevalent in rural 
areas, such as scarification(114). In contrast, a US study found that the states with the 
highest HCV prevalences tended to be those with highly urban populations(312), probably 
reflecting higher proportions of PWID in cities(312), although this could have changed in 
recent years with an increase of IDU in some rural areas(110). For higher-income countries 
in general where access to high-quality healthcare is good in both urban and rural areas, 
rural-urban differences in HCV prevalences most likely are driven by the distribution of 
PWID. 
 
2.4.6. HCV among migrants 
The migration of HCV-infected persons can have a large effect on the HCV prevalence in the 
destination country(385). A modelling study in the Netherlands concluded that the majority 
of infected persons in the country were migrants(385). Whilst migrants from high prevalence 




systematic reviews found instances of slightly lower prevalences(99, 128). Discrepancies 
between HCV prevalences of migrants and the countries they migrated from could possibly 
be due to a healthy migrant effect where only the healthiest are able to migrate(128). The 
prevalence of HCV among migrants varies across countries, depending largely on HCV 
prevalences of the countries of origin(40, 99). One study estimated that migration accounted 
for 34% of new infections in the EU in 2015, although this was a year with especially high 
levels of migration(302). 
 
2.5. HCV treatment 
2.5.1. Introduction 
The aim of treatment for HCV is to rid the infected person of the virus, so reducing the 
chance of cirrhosis and other complications(337). The measure for determining whether 
HCV treatment has been successful is a patient’s sustained virologic response (SVR) 12 
weeks after completing treatment, whereby they are assumed to be cured if they have an 
undetectable HCV RNA viral load(51). The history of HCV treatment can be split into two 
eras, with the first starting soon after the discovery of hepatitis C in 1989(51). In this first era, 
the main treatment for HCV was using interferon, or variants of, which was approved by 
the US Food and Drug Administration (FDA) in 1991(51, 107). In 2011, the US FDA 
approved the first DAAs, heralding the second era of vastly superior HCV treatments(51, 
102). However, most countries did not have access to DAAs in 2013 and some countries still 
do not have access to them in 2019(409). 
 
2.5.2. Interferon-based treatment 
The first interferon (IFN) based treatment regimens for HCV were for either 24 or 48 weeks 
and were administered by injection(51, 230, 248). SVR was seen in 6% of patients for the 24-
week regimen, and 15-20% for the 48-week regimen(230, 248). Interferon regimens were 
combined with ribavirin (RBV) in the 1990s to raise the SVR percentages to around 40-
50%(230). The US FDA approved pegylated IFN (PEG-IFN) for HCV treatment in 2002(247), 




percentages varied by HCV genotype(231). For people with genotype 1, SVR rates of 42-46% 
were achieved for 48-weeks of PEG-IFN/RBV(231). However, much higher SVR rates were 
seen for people with genotypes 2 or 3, around 76-82% for a 24-week regimen(231). For all of 
these IFN-based regimens, high percentages of patients reported severe adverse effects such 
as the onset of depression and anaemia due to an abnormal breakdown of red blood 
cells(230). These adverse effects often resulted in dosage reductions and, for around 10-20% 
of people, stopping treatment(111, 230). The combination of treatment taken by injection for 
long periods of time, severe side effects, and low success rates stopped people receiving 
PEG-IFN/RBV and gave many a poor opinion of HCV treatment. 
 
2.5.3. Direct acting antivirals 
The 2011 US FDA’s approval of boceprevir and telaprevir ushered in an era of more effective 
HCV treatments(51, 391). These first DAAs were taken in combination with PEG-IFN/RBV 
and led to improved SVR percentages of around 75% for genotype 1 patients that previously 
had much lower SVR percentages with just PEG-IFN/RBV(51, 102). In 2013 the US FDA 
approved two new DAAs, sofosbuvir and simprevir, both of which were taken in 
combination with RBV but without PEG-IFN(51). The development of IFN-free regimens 
meant the availability of HCV treatment with high SVR rates and few adverse effects(102). 
Additionally, these DAAs are taken in the form of a pill rather than administered by 
injection and involve much shorter courses of treatment of around 12 weeks(24). Unlike the 
first generation of DAAs, the second generation could be used to treat patients that did not 
have genotype 1(24, 51). For these initial IFN-free DAA regimens there was still some 
variation in SVR by genotype, with around 85% observed for genotype 1 and over 90% 
observed for other genotypes(51). Since the approval of the first IFN-free DAA regimens, 
many others have been developed, with even higher SVR percentages(102). Importantly, the 
very latest generation of DAAs have close to 100% SVR percentages for all genotypes(161). 







2.5.4. Access to direct acting antivirals 
Although highly effective DAAs have been developed, they are not available in all countries 
due to issues around costs(409). However, in some countries, almost exclusively low- and 
lower-middle-income countries, where patents do not cover DAAs, generic drug 
manufacturers have set up production(409). The WHO report large price reductions have 
occurred for DAAs since 2015, with the lowest prices reported by originator companies 
dropping from 300 US dollars (USD) per 28-day supply to 250 USD in 2017, and 
comparative prices of generics dropping from 300 USD to less than 50 USD(409). Increased 
competition has driven these price drops, particularly from generic manufacturers, however, 
not all countries where cheaper generic versions of DAAs are available have taken the 
opportunity to purchase them(409). Where generics are unavailable in high-income and 
most upper-middle-income countries, DAAs are very expensive, for example, a 28-day 
supply of sofusbuvir and velpatasvir cost between 10,500 and 17,000 USD in the UK in 
2016(409). Other high-income or upper-middle-income countries have found such prices to 
be too restrictive and have instead continued to use the much cheaper IFN-based regimens, 
for example Kenya(157). However, the situation regarding treatment availability and pricing 
is changing rapidly as countries negotiate directly with the manufacturers and prices 
continue to fall(409). 
 
2.6. HCV transmission prevention 
2.6.1. Introduction 
Various interventions have been developed to prevent HCV transmission. Besides reducing 
the number of people exposed to a deadly virus, preventing the transmission of HCV 
reduces the number of treatments required. Transmission prevention interventions vary 
from those that affect most of the population, such as blood screening(243), to those targeted 
at specific subgroups of individuals, such as needle and syringe provision for PWID(212). 






2.6.2. Iatrogenic transmission prevention 
The most effective transmission prevention intervention to date has been the advent of 
blood screening(291, 330). As discussed in section 2.3.2, HCV transmission in high-income 
countries decreased from roughly 1 in 50 units to around 1 in 200,000 following the 
introduction of blood screening(291). Section 2.3.2 also mentioned that between 2000 and 
2010 there has been around a ten-fold reduction in the re-use of medical syringes(282). This 
has coincided with an estimated 83% decrease in the number of HCV infections due to 
medical syringe re-use from between 0.95-1.87 million in 2000 to between 0.16-0.32 million in 
2010(283). This large decrease in the re-use of medical syringes is due to various awareness 
campaigns led by health ministries, health providers, and the WHO Safe Injection Global 
Network (SIGN)(282). Some initiatives have been developed to increase the awareness of 
iatrogenic transmission of HCV among healthcare workers but the effectiveness of these 
interventions on HCV transmission has not been evaluated(184, 228, 272). 
 
2.6.3. Counselling 
There is limited evidence to suggest that counselling people at heightened risk of HCV, or 
that are HCV-infected, reduces transmission. A study aiming to reduce HCV risk behaviours 
among PWID compared the effect of a questionnaire against a questionnaire plus a brief 
behavioural intervention(2). Both methods produced a reduction in HCV risk behaviours 
but the effect on HCV transmission itself was not evaluated(2). Another study among PWID 
compared two types of counselling but there was no comparator arm without a counselling 
intervention, so the effect of counselling on transmission could not be analysed(376). 
 
2.6.4. Community transmission prevention initiatives 
Large scale attempts to prevent community transmission of HCV have come through 
regulatory requirements such as those requiring disinfectant for equipment used in nail 
salons, tattoo parlours, and barbershops in the US(22, 412). However, the impact of the 
introduction of these regulations has not been studied. One study in New York City, USA, 




working in barberships and hair salons(213). The intervention increased HCV transmission 
knowledge but the effect on HCV transmission itself was not evaluated(213). 
 
2.6.5. Needle and syringe provision for people who inject drugs 
The purpose of needle and syringe provision (NSP), or needle and syringe programmes 
(NSPs), is to reduce the transmission of blood-borne viruses by providing clean needles and 
syringes to PWID so reducing their need to re-use or share needle/syringes(212). NSPs are 
often also providers of HCV testing as well as safe injecting advice(212). A recent systematic 
review and meta-analysis did not find evidence that NSPs are associated with reduced HCV 
acquisition risk(288). However, the same review did find that high-coverage NSP was 
associated with a reduced risk of HCV acquisition among PWID in Europe, around 56%, but 
this was not seen in North America(288). Global NSP coverage is low, with a review 
published in 2017 estimating there are just 93 countries with NSPs and only nine provide the 
WHO’s recommended 200 clean needles and syringes per PWID annually(209). 
 
2.6.6. Low dead space syringes 
Syringes with attached needles usually have a lower ‘dead space’ than those with detachable 
needles(424), as illustrated by figure 2.1. These syringes with attached needles, also known 
as low dead space syringes (LDSS), retain much less blood after an injection compared with 
detachable needle syringes (or high dead space syringes [HDSS])(39). A syringe’s volume of 
blood predicts the survival of the virus outside of the body and the viral load transmitted(1). 
A study in North Carolina, USA, found an increased prevalence of HCV with increased use 
of HDSS(425), although this finding was not replicated in a Hungarian study(133). A study 
in the UK found that the use of LDSS was associated with a 23% lower prevalence of HCV 
among PWID(372). This reduction was greater for those that had been injecting for less than 
three years, 47%(372). However, studies have so far been limited to examining associations 






Figure 2.1: Illustrations of the dead space in low and high dead space syringes†. 
 
† Artwork licensed by Creative Commons. Reproduced with permission from William Zule. 
 
2.6.7. Opioid substitution therapy 
To treat opioid dependence, drug users are given a replacement opioid, often methadone or 
buprenorphine(288), to reduce their frequency of injecting. This treatment for opioid 
dependence is usually known as opioid substitution therapy (OST) but can also be referred 
to as medication-assisted treatment (MAT)(221), or methadone maintenance treatment 
(MMT)(423). Globally, opioids are the drug of choice for around 82% of PWID(77). A recent 
systematic review found strong evidence that OST reduces the risk of HCV among opioid-
dependent drug users, around a 50% reduction(288). However, a recent systematic review 
found that only 16% of PWID use OST, with just 86 countries having OST programs(209). 
High-income countries are more likely to have OST programs and are also more likely to 
have higher OST coverage than low- or middle-income countries(209). 
 
2.6.8. Treatment as prevention 
Treatment as prevention for HCV occurs when infections are averted through treating 
individuals that would otherwise transmit the virus to others(238). A study modelling across 
the whole infected population of Egypt, which consists of few PWID, found that 0.08-0.11 
infections are averted per DAA treatment over 15 years(28). A study of Pakistan’s infected 
population, which assumed an increasing epidemic, found around 0.56 infections are 
averted per treatment over 15 years(218). A modelling study with no set location found 




infections over a period of 50 years in one study(240). However, in the same study the 
number of infections averted per treatment among PWID varied from 0.2 to 2.3 depending 
on the chronic HCV prevalence among PWID and the disease stage(240). A UK study found 
that treating MSM with DAAs would give a reduction in HCV incidence of 1.3 infections per 
100 person-years in 2025 compared with 2015(239). Various modelling studies have looked 
at HCV treatment as prevention among PWID(34, 70, 144, 238, 251, 421). Two studies found 
that treating PWID earlier in the course of disease progression would avert more 
infections(70, 144). A modelling study of PWID in the UK found 1.06 infections averted per 
PWID treated over a period of 12 years(34). A US study looked at the effect of injecting 
networks and found, in terms of treatment as prevention, that when DAA treatment 
coverage is high, selecting individuals at random was preferable to selecting PWID with the 
most injecting contacts(421). My study, described in detail in chapter 8, found that globally 
0.35 infections were averted over 20 years per randomly allocated DAA treatment, which 
varied by region and country(373). The preventative impact of treating PWID also varied by 
country and region, with around 1.27 infections averted per treatment, globally(373). 
 
2.7. HCV prevalence and genotype distributions by region 
2.7.1. Introduction 
Globally, it is estimated that around 71.1 (95% uncertainty interval: 62.5-79.4) million people 
are chronically infected with HCV, giving a global prevalence of around 1%(40). Assuming a 
viraemic rate of 76%(252) this would give an anti-HCV positive prevalence estimate of about 
1.3%. The chronic prevalence of HCV varies both by region and by countries within 
regions(40). The region with the highest is Central Asia, at around 3.6%, whilst Latin 
America and Western Europe have the lowest estimated prevalences of around 0.5%(40). 
Despite having lower prevalences than the global average, South Asia and East Asia contain 
the largest number of infected individuals, around 15.3 and 10.5 million people, respectively, 
driven by large populations(40). A recent modelling study estimated Gabon, Mongolia, and 
Egypt are the countries with the highest chronic prevalences at 7.0%, 6.4%, and 6.3%, 
respectively, whilst the Netherlands has the lowest prevalence of around 0.1%(40). Globally, 
genotype 1 is the most common genotype, affecting almost half of infected individuals. 




prevalent overall and genotype 4 being the most prevalent in Africa and the Middle 
East(285). 
 
2.7.2. HCV prevalence 
At the time of writing, the most widely used estimate of 71.1 million people living with 
chronic HCV worldwide is taken from a 2017 paper by Blach et al – the Polaris Observatory 
HCV Collaborators(40). The WHO cites this estimate in their official figures regarding 
hepatitis(407). This estimate was produced using data from a systematic review of anti-HCV 
prevalence to parameterise models fitted for 100 countries to calculate the number of people 
with chronic HCV in 2015. Model inputs and extrapolations used for countries without data 
were discussed by experts in each country. The analysis used anti-HCV prevalence data and 
multiplied this by viraemic rates. To produce the 2015 estimates from data that were mostly 
taken from years pre-dating this, information on the number of people cured, mortality, and 
HCV incidence were incorporated into the model to track how the epidemics changed over 
time. The number of people cured of HCV was calculated based on a combination of factors, 
including the number of treatments given and the sustained viral response rates, estimated 
from available data, as was information on liver-related mortality. A limitation of this 
estimation method is that HCV incidence estimates were produced by back calculation 
techniques due to a lack of available data. This involved mapping back incidence curves 
based on known risk factors in discussion with the country experts. For the countries with 
two or more prevalence studies, namely USA(15, 78, 158), France(85, 249), and Egypt(93, 
181), the annual incidence was calculated using the difference in prevalences and time 
periods between the two studies. However, for most countries the historical shape of the 
epidemic had to be estimated through discussions with a panel of experts, who used 
incidence data on acute infections where and when available.  
In general, in most settings there is considerable uncertainty in how HCV prevalence is 
changing over time due to a lack of multiple, comparable, robust, national-level general 
population surveys. Studies on HCV risk factors indicate that in recent years there has been 
better screening of donated blood(291) and less re-use of medical injections(283), two of the 
main risk factors for HCV transmission. This should have resulted in decreasing HCV 




decreasing these epidemics(104). However, the degree to which unsafe use of injecting 
equipment amongst PWID contributes to HCV epidemics is unclear and there is a lack of 
information about how its contribution is evolving(77). In certain settings, particularly the 
USA(330), there is evidence that HCV incidence is increasing(330). Additionally, in countries 
where much of the HCV incidence is due to IDU(16), general population surveys may 
underestimate HCV prevalence by not well sampling PWID because many are homeless or 
incarcerated(197). HCV prevalence studies often have many other limitations including 
small sample sizes, not being from recent years, and a lack of generalisability to the 
population of that country. This could be due to sampling from high or low prevalence 
regions or focusing on specific risk groups. Many studies only have data on prevalence of 
individuals with anti-HCV positive tests, rather than HCV RNA positivity. For 
comparability across studies, countries, and regions, sections 2.7.2.1 to 2.7.2.10 will focus on 
anti-HCV prevalence by region, as these studies are more widely available than those for 
HCV RNA. 
 
2.7.2.1. Western Europe 
Most countries in Western Europe have a lower anti-HCV prevalence than the 2015 global 
average of 1.3%, with an estimated regional average of around 0.7%(40). Data coverage for 
the region is excellent, with only countries comprising a very small percentage of Western 
Europe’s population, such as Andorra and Greenland, lacking anti-HCV prevalence data(40, 
124, 160). Countries towards the south, such as Greece, 1.8%(40), Italy, 2.4%(40), and Spain, 
1.7%(124), tend to have higher reported anti-HCV prevalences, whilst countries in the north 
such as Finland, 0.5%(40), Germany, 0.6%(40), and the UK, 0.5%(40), generally have the 
lowest prevalences in the region. France is one of only three countries globally to have two 
national surveys using similar methodology, allowing comparison over time(85, 249). These 
two surveys show a decreasing prevalence between 1994 and 2004, from 1.1%(85) to 
0.8%(249). The data underlying Greece’s estimated prevalence is also considered high 
quality based on the generalisability of the sample, the sample size, and the recency of the 
estimate. Eight other Western European countries have estimates rated as worse than this 
but are still considered to be moderate(40). As with other high-income countries and 
regions, the anti-HCV positive population in Western Europe is mostly comprised of people 




blood screening was introduced in the early 1990s(267). As people infected with 
contaminated blood transfusions are dying due to old age and liver-related causes, people 
who have injected drugs comprise an increasing proportion of the prevalent HCV 
infections(267). The estimate for the proportion of adults that are PWID in Western Europe, 
0.34%, is around the global average of 0.33%(77). HCV incidence among PWID in most 
countries in Western Europe is still high(267). Emerging epidemics have also been seen 
among MSM(135, 290), and in some countries migrants from high-prevalence countries 
account for most of the prevalent infections(267, 385). 
 
2.7.2.2. Eastern and Central Europe 
For both Central and Eastern Europe, data coverage is excellent, with estimates available for 
all countries(40, 124, 160). In Central Europe, most countries have anti-HCV prevalences 
around the global average, whilst in Eastern Europe anti-HCV prevalences are among the 
highest in the world(40). Moldova has the highest estimated anti-HCV prevalence in Eastern 
Europe, 4.5%(124), followed by Russia at 4.1%(40). Russia is Eastern Europe’s most 
populous country and comprises much of its burden. Belarus has the lowest anti-HCV 
prevalence in Eastern Europe at 1.3%, whilst all other countries have prevalences higher 
than the global average(124). For Central Europe, Romania has the highest anti-HCV 
prevalence estimate of 3.2%(40), whilst Albania’s estimate, 3.0%(160), is also high. However, 
prevalence estimates for other countries such as Slovakia (1.4%)(40), Poland (0.9%)(40), and 
Bosnia (0.1%)(160), are much lower. Romania and Slovakia’s prevalence estimates are 
considered high quality, whilst several other countries in the region have moderate quality 
data(40). Similarly to Western Europe, the HCV-positive population of Eastern and Central 
Europe mostly comprises PWID, former injectors, and people previously infected through 
blood transfusions(267). However, Central Europe and Eastern Europe have much higher 
proportions of adults that are PWID than Western Europe, with Eastern Europe having the 







2.7.2.3. Australasia and Oceania 
Australia (1.3%)(40), and New Zealand (1.4%)(40), both have average anti-HCV prevalence 
estimates. In Oceania, data coverage is poor with estimates unavailable for most of the 
Pacific Island countries, with Fiji and Samoa the exceptions(40). Fiji, with 0.1%, and Samoa, 
with 0.2%, have two of the lowest anti-HCV prevalence estimates in the world(40). Australia 
and Samoa have moderate quality estimates, whilst those for Fiji and New Zealand are 
poor(40). Australia and New Zealand have epidemic characteristics similar to those seen in 
other high-income countries(82, 113), whereas the epidemics in Oceania have been studied 
little and IDU is not very prevalent so HCV transmission in the region is not well 
understood(145).  
 
2.7.2.4. East and Southeast Asia 
The anti-HCV prevalence estimates for countries in East and Southeast Asia are generally 
lower than the global average(40, 124). However, due to the huge amount of people living in 
this region, a large proportion of the world’s anti-HCV infected population are located 
here(40). Anti-HCV prevalence estimates are available for most of the region’s countries(40). 
The country with the highest prevalence in the region is Cambodia with an estimate of 
5.8%(40), followed by Taiwan (3.3%)(40), and Papua New Guinea (2.2%)(40). The majority of 
countries in the region have middling or low anti-HCV prevalences, such as 1.2% in 
China(40), 1.0% in Japan(40), and 0.8% in Indonesia(40). Most of the region’s countries have 
moderate quality data estimates, whilst Indonesia and Papua New Guinea’s estimates are 
considered high quality(40). East and Southeast Asia comprises a diverse range of countries, 
with the high-income countries, such as Japan, having similar epidemics to those in other 
high-income countries(333, 415). However, lower-income countries, such as Papua New 
Guinea, likely have higher levels of ongoing medical transmission due to less robust blood 
screening and sterilisation practices(145). The proportion of adults that are PWID in the 







2.7.2.5. South Asia 
Data coverage is quite good for South Asia(40, 124). For all countries in the region except 
Pakistan (4.8%)(40), prevalence estimates are low(124). For example, 1.3% in Bangladesh 
(1.3%)(124), 0.8% in India (0.8%)(40, 121), and 1.1% in Afghanistan (1.1%)(40). Due to the 
huge population sizes in the region, combined with the high prevalence in Pakistan, South 
Asia is the region with the highest number of HCV infected people(40). The data estimate 
from Pakistan is considered high quality, whilst that of Afghanistan is moderate, and 
Bangladesh’s estimate is poor(40, 124). For India the overall estimate is also poor quality(40). 
India is a huge country in both size and population, and while some areas have very high-
quality data, most have almost none(121). There is also high heterogeneity in anti-HCV 
prevalences across the regions of India, varying from 3.6% in Punjab, to almost 0.0% in 
Maharashtra(121). South Asia is the region with the lowest proportion of adults that are 
PWID, 0.09%(77). Iatrogenic HCV transmission in the region is thought to be high and 
community transmission could also be a factor(333). Pakistan’s particularly high prevalence, 
which will be discussed in-depth in chapter 4, is probably driven by very high rates of 
medical syringe re-use(371). 
 
2.7.2.6. Central Asia 
The countries in Central Asia have the world’s highest anti-HCV prevalence estimates(40). 
Robust prevalence estimates are available for all the region’s countries except Armenia(40, 
124, 160). The region’s highest anti-HCV prevalences estimates have been found in 
Uzbekistan (13.1%)(40), Mongolia (9.8%)(40), and Georgia (7.7%)(40). The prevalence 
estimates for all the region’s other countries are lower than these but still far higher than the 
global average – for example, Turkmenistan, 5.6%(124), Azerbaijan, 3.7%(40), and 
Kazakhstan, 3.2%(40). Georgia and Mongolia have high quality data, whilst the data from 
Azerbaijan, Kazakhstan, and Uzbekistan are moderate(40). In Central Asia the proportion of 
adults that are PWID is high, 0.63%(77). The Georgian HCV epidemic, in particular, has been 
driven by IDU(132), where in 2004 4.2% of adults were PWID - the highest estimated 
injecting prevalence in the world(77). However, iatrogenic transmission was likely a major 
contributor to the high HCV prevalences seen in the region’s other countries, as well as 




2.7.2.7. Middle East and North Africa 
Availability of data for prevalence estimates across the Middle East and North Africa is 
excellent(40). Most countries in the Middle East and North Africa have anti-HCV prevalence 
estimates lower than or around the global average(40), for example, Saudi Arabia, 0.5%(40), 
Iraq, 0.4%(40), Libya, 1.2%(40), and Turkey, 1.0%(40). Some countries have higher estimates 
such as Israel, 2.0%(40), Syria, 2.8%(40), and Egypt, which has a much higher 
prevalence(181). Egypt is one of the few countries in the world with two robust national 
studies that use similar methodology so are comparable over time. The first of these studies 
in 2008 found an anti-HCV prevalence of 14.7%(93), whilst the 2015 study found the 
prevalence had decreased to 10.0%(181). Turkey, Syria, Libya, and, Iraq all have prevalence 
estimates considered high quality(40). However, the estimates for Syria, Libya, and Iraq all 
pre-date the wars in those countries(40). The estimates for most of the remaining countries 
are considered to be moderate quality(40). The major historical transmission route across the 
region is iatrogenic transmission, such as that seen in Egypt, with community transmission 
also a possible, lesser, contributor to the epidemic(58). IDU in the region is rare – 0.12% of 
adults are PWID(77). 
 
2.7.2.8. Sub-Saharan Africa 
Data availability is quite good for anti-HCV prevalence estimates across the countries of 
Sub-Saharan Africa(40, 309), but most available estimates are considered poor quality(40, 
124, 309). Data quality is high for the estimates from Burundi and Central African 
Republic(40) and eight countries have moderate quality estimates(40). However, the 
estimates for the remaining countries in the region, the vast majority, are poor(40, 124, 309). 
There is high heterogeneity in the prevalence estimates across Sub-Saharan African and the 
sub-regions within(40, 309). In Southern Africa, Angola has the highest prevalence with 
3.9%(309), whilst other estimates range from 1.1% in Botswana(309) to 1.7% in South 
Africa(40). In East Africa the lowest anti-HCV prevalences estimate is found in Kenya 
(0.8%)(40). However, most anti-HCV prevalence estimates are close to the global average or 
higher, such as in Madagascar (1.2%)(40) or Tanzania (2.7%)(309). For West Africa, Gambia 
(0.5%)(40) has the lowest anti-HCV prevalence but, where available, most prevalences 




most populous nation in Africa, also has a high prevalence of 2.2%(40). In Central Africa 
prevalence estimates tend to be high, except for Central African Republic (0.6%)(40). Gabon, 
at 11.2%(40), has the highest prevalence estimate in Central Africa followed by 8.2% in 
Burundi(40). Estimates for the remaining countries in Central Africa vary from 2.0% in 
Chad(40) to 4.3% in the Democratic Republic of Congo(124, 309). Most of the historic 
transmission in the region is iatrogenic, particularly through unscreened blood 
transfusions(342). Although blood screening in the region has improved over the last two 
decades, high-quality screening is not universal across the region, meaning that iatrogenic 
HCV transmission is likely ongoing and is the major contributor to incidence(342). However, 
transmission via community risks and IDU could also contribute to the epidemic(342), 
although the prevalence of adults that are PWID is low, 0.28%(77). 
 
2.7.2.9. North America 
The anti-HCV estimates available for Canada and the USA are moderate and high-quality, 
respectively(40, 78, 158). Canada’s estimated anti-HCV prevalence is 1.0%, which is lower 
than the global average(40). The USA has had several national studies of HCV prevalence 
that use similar methods making them comparable over time(15, 78, 158). The first of these 
US estimates (1988-1994) gave an anti-HCV prevalence of 1.8%(15). The next estimate 
showed a decrease, giving a prevalence of 1.3% for 2003-2010(78). The latest, very recently 
published, estimate showed an anti-HCV prevalence increase to 1.5% for 2013-2016(158). 
When additionally including incarcerated, military, homeless, and nursing home 
populations into this estimate it rises to 1.7%(158). Other data suggest a recent increase in 
HCV infections in the USA due to a rising epidemic of IDU (330). Otherwise, HCV 
transmission in North America has likely followed a similar pattern to other high-income 
countries and regions(260, 330). 
 
2.7.2.10. Latin America and the Caribbean 
Both Latin America and the Caribbean have poor coverage of anti-HCV prevalence 
estimates(40). Coverage is particularly bad for the Caribbean and Central America, whilst it 




either around the global average, or in most cases, lower(40). Argentina has the highest 
estimated anti-HCV prevalence in the region, 1.5%(40). Brazil and Mexico, the two most 
populous countries in the region, have the next highest prevalences with 1.4%(40). 
Prevalences are lower for other countries such as Chile, 0.8%(40), the Dominican Republic, 
1.0%(40), and Panama, 0.5%(40). Brazil and Mexico have high quality data, whilst Chile’s is 
considered moderate(40). However, the other countries have poor data, with expert 
consensus used to derive the estimates for the Dominican Republic and Panama(40). 
Epidemiological studies in the countries of Latin America indicate that the major route of 
transmission has been iatrogenic although this is decreasing with improved blood 
screening(375). High HCV prevalences have been found among PWID in various Latin 
American countries and IDU is now thought to be the primary risk factor for 
transmission(354). There has been a lack of research into HCV in the Caribbean and as such 
the epidemic there is poorly characterised. 
 
2.7.3.  HCV genotype distributions 
The distribution of HCV genotype distributions was previously considered very important 
due to the differing effectiveness of treatment by genotype, but there is less interest 
following the development of pan-genotypic treatments. Globally, the prevalence of HCV 
genotype 1 among infected individuals is just under half(40, 250, 285), whilst genotype 3 is 
the second most prevalent, with estimates ranging from 18% to 30%(250, 285). Genotypes 4 
and 2 are the next most common, with varying estimates of 8.3%-16.8% and 9.1%-11.0%, 
respectively(250, 285). Worldwide, genotypes 5, 6, and particularly 7, have low 
prevalence(40, 250, 285). The prevalence of genotype 1 varies regionally from the vast 
majority of all infections in parts of Latin America and the Caribbean, to just less than 20% in 
Central Sub-Saharan Africa, and South Asia, see figure 2.2(40, 285). For South Asia most 
infected individuals have HCV genotype 3(40). The most common genotype in Central Sub-
Saharan Africa is genotype 4, as is the case for North Africa and the Middle East(285). In 
South Sub-Saharan Africa genotype 5 is the most common, comprising roughly 36% of 
infections(285). There is debate about the most common genotype in West Sub-Saharan 
Africa, with some evidence suggesting genotype 2 is the most common(285), whilst other 
information suggests genotype 1 is dominant(40, 250). Regional variations in genotype 




transmission(233). Subtypes 1a, 1b, 2a, 2b, and 3a are found worldwide and constitute most 
of the HCV infected individuals(389). It is thought that these subtypes were mostly spread 
before the era of HCV testing via blood transfusion and IDU, particularly in high-income 
countries(339). The other genotypes and subtypes are rarer and are more isolated 






Figure 2.2: Genotype distribution by GBD region (A) and HCV genotype and total infected 
by GBD region (B). 
  
GBD: Global Burden of Disease.  
Reprinted from the article Global prevalence and genotype distribution of hepatitis C virus 




CHAPTER 3. A BACKGROUND TO 
MATHEMATICAL MODELLING OF HEPATITIS C 
VIRUS EPIDEMICS 
 
3.1.  Introduction 
Mathematical modelling can be used to understand how infectious diseases are spread, 
what causes the epidemic, and how an epidemic will evolve in the future(186). Models can 
also be used to investigate how transmission can be prevented, the effect of interventions 
and other factors on an epidemic, and the cost-effectiveness of such interventions(186). 
Mathematical models have advanced a lot since their first recorded use when in 1760 Daniel 
Bernoulli modelled smallpox showing that healthy people could be effectively 
inoculated(38). Since then the computational power available has developed massively, as 
have the complexity of mathematical models(215). Today’s models can be important for 
policy making around infectious diseases(200). For example, the WHO changed its 
guidelines to state that all people should start antiretroviral treatment upon being diagnosed 
with HIV regardless of CD4 cell count/µL partly based on the use of mathematical 
modelling(89, 141, 396). For HCV, there are also examples of mathematical modelling being 
used to guide policy making, however, with governments also starting to engage with 
modellers for planning the development of their treatment programs(149, 218). This chapter 
will explain how mathematical models of infectious diseases can be categorised, static or 
dynamic, deterministic or stochastic, compartmental or individual based, and what these 
categorisations mean and when they should be used. Following this, an example of a basic 
model will be given, before the chapter concludes with examples of the mathematical 
modelling of HCV. 
 
3.2.  Static or dynamic models 
One of the categorisations of mathematical models is whether they are static or 




the number of infected people that are modelled. For dynamic models, the infection rate 
depends on how many people are infectious. For example, in a dynamic model if the 
prevalence of HCV among people who inject drugs (PWID) is very high and is then reduced 
through treatment, this can reduce the risk of infections among those not infected because 
there are less infected people to transmit the virus. Alternatively, this can also increase the 
incidence rate as there are more people available to be infected. In a static model, this is not 
the case. A static model could be an appropriate choice of model when the population 
subgroup that is the target of an intervention does not contribute much to transmission, for 
example people who were infected with HCV through contaminated blood transfusions 
decades ago, that are not injecting drug users, are unlikely to transmit the virus to others. 
However, in many circumstances the intervention being investigated will impact on the 
dynamics of transmission, such as the creation of a herd immunity effect(46) where vaccines 
additionally benefit the unvaccinated when vaccine coverage is high; in such cases the use of 
dynamic models is crucial(286). 
 
3.3.  Deterministic or stochastic models 
A second categorisation of interest for mathematical models is between deterministic and 
stochastic models(286). Usually deterministic models are at the population-level, with the 
population divided into different states or compartments, for example, susceptible, infected, 
and recovered, and the number of individuals in each state changes over time. Deterministic 
models are usually defined by sets of differential equations (or difference equations) that 
correspond to the rates of population movement through the various states(286). 
Meanwhile, stochastic models are usually designed at the individual-level and probability 
distributions describe the transitions between the available model states(286). As a system of 
equations, if a deterministic model is run multiple times with exactly the same model inputs 
then each run will produce identical results(286). Whereas, the probability distributions in 
stochastic models include chance (stochasticity) that means the possibility of variation 
between any two runs produced with the same model inputs(286). Stochastic models can 
also capture individual variation in population behaviours, whereas in deterministic models 
individuals are allotted into groups and assigned average levels of behaviours. As such, 
stochastic models are often thought to be more realistic(269). Deterministic models are 




individuals, where the average of the variability produced by the probability distributions of 
the stochastic models approximates the transmission dynamics of deterministic models(286). 
Although considered more realistic than deterministic models, due to their complexity, 
stochastic models take longer to compute and can be much harder to parameterise as they 
are usually at the individual-level(70, 186, 269). Network models are another form of 
stochastic models where a contact network of individuals is designed through which 
transmission can occur(72). These network models require specific data on contact patterns 
between individuals, which can be difficult to obtain(72). Deterministic models are 
parameterised using population-level rates that, where unavailable, can often be produced 
through calibration to an observed prevalence. Whilst stochastic models incorporate chance 
through their stochasticity, the role of uncertainty can, and should, be added to deterministic 
models though the sampling of input parameters from probability distributions such as 95% 
confidence intervals(45). This addition of uncertainty across the input model parameters can 
result in very different outputs using the same deterministic model structure. Therefore, the 
role of this uncertainty can be important, for all model types, and analyses should be 
performed to investigate how much it effects the model outputs and which parameters are 
particularly influential(45). 
 
3.4.  Susceptible, Infected, Recovered model example 
The first paper on the Susceptible, Infected, Recovered (SIR) model was published by 
Kermack and McKendrick in 1927 and forms the basis of deterministic mathematical 
models(189). The SIR model is one of the simplest compartmental models from which other 
more complicated models can be derived. I will use the SIR model here to give an example 
of how deterministic models can work. In an SIR model the population is split into three 
states (or compartments): Susceptible, Infected, and Recovered. The number of individuals 
in each of these states at time t is given by 𝑆(𝑡), 𝐼(𝑡), and 𝑅(𝑡), respectively. Those in the 
Susceptible state have never been infected and are susceptible to infection, whilst those in 
the Infected state are currently infected, and the population in the Recovered state are 
individuals that have recovered from the infection and are immune to being reinfected. This 
model assumes that as soon as a person is infected, they are infectious to others and that 




Figure 3.1: SIR model schematic featuring no births or deaths. 
 
 
Individuals in the susceptible state (𝑆) become infected at a rate 𝛽, multiplied by the number 
of infected individuals (𝐼). This infection rate is denoted as 𝛽𝐼𝑆 in the model, which is all of 
these terms multiplied together. Following infection, individuals enter the Recovered state at 
rate 𝛾, which can be approximated by one divided by the duration of the infection if a 
negative exponential distribution of duration is assumed. This very basic SIR model does 
not include births or deaths; however, these can be easily added to the model. Figure 3.1 
shows a schematic of this SIR model. This model assumes that the population is perfectly 
mixed, so that every susceptible individual can be infected by any infected individual. If 
every infected individual in the model has 𝜅 contacts per a given unit time, independent of 
the total population size (𝑁 = 𝑆 + 𝐼 + 𝑅), and a proportion of these contacts, 𝛼, results in a 
transmission of the disease, then each infected individual has 
𝜅𝑆
𝑁
 contacts with susceptible 
individuals per unit time. Subsequently,  
𝛼𝜅𝑆
𝑁
 susceptible individuals are infected by each 




. This is the total number of infections per unit time and, therefore, the 
transmission rate 𝛽 can be defined 𝛽 =  
𝛼𝜅
𝑁












=  𝛾𝐼 
This SIR model can be further adapted to include more states that better represent the 
transmission dynamics and natural history of particular infectious diseases. For example, 
upon being infected with tuberculosis, individuals are not infectious for a specific period of 




be added to the basic SIR model to form an SEIR model. Conversely, for models of infections 
where recovery does not give immunity to reinfection, individuals could transfer back to the 
Susceptible state (𝑆), from which there is a probability of reinfection, such as for chlamydia. 
Such a model would not include the Recovered state (𝑅) and is known as an SIS model. 
There is no limit on the number of states that can be used to model the natural history of a 
disease, nor is there a restriction on the number of different types of states that can be 
included. Other examples of compartments are carrier states, or a state of partial immunity 
after recovering from an infection. States that differentiate between disease severity can be 
included, which is common for modelling of HCV to separate those chronically infected 
from individuals with cirrhosis. Additionally, intervention states can be included, such as 
treatment or vaccination compartments, which can alter the dynamics of transmission. The 
model population can be stratified into subgroups with differing transmission rates or 
patterns of mixing, such as by gender, age, or disease risk groups. In such examples, it can 
be assumed that individuals are more likely to have contacts with other individuals from 
their own risk group, known as assortative or like-with-like mixing. Random mixing can 
also be assumed where the number of individuals in each risk group determines the 
distribution of contacts an infected individual has with susceptible individuals from another 
risk group. The design and assumptions of each model used should be specific to that 
disease and the questions being asked. 
 
3.5.  Examples of mathematical modelling of HCV epidemics 
Mathematical modelling of HCV epidemics has taken various forms depending on the aims 
of those designing the models. These include models investigating the viral kinetics of HCV 
infection(59, 71), as well as models of HCV burden(40, 150, 218), HCV transmission(152, 
421), and cost-effectiveness models(62, 237). Viral kinetic models look at how HCV 
infections evolve within a person, whereas the other models are at individual- or 
population-level and are more relevant to this thesis, particularly those looking at HCV 
burden.  
Models of HCV burden have been designed for various settings, including 
communities(110) and countries(28, 40, 162), and for different populations, such as PWID(90, 




modelling of national HCV burden has been deterministic, but not dynamic, in the form of 
Markov models(40, 301, 308). Due to the lack of data on HCV incidence, for Markov models 
this parameter has to be pre-specified, which for most national models has been done 
through back-calculation and in some cases expert opinion(40, 217, 332), considered the 
poorest type of evidence(416). Many of the models of HCV burden that have used dynamic 
modelling have been able to estimate the incidence by calibrating to one or more HCV 
prevalence estimates(70, 110, 150). As HCV epidemics in most subgroups of interest, such as 
PWID or the general population, are well established, deterministic models are generally 
used rather than stochastic models, which are more suitable for modelling the initial spread 
of an epidemic(323). 
Whilst burden models generally include a component of HCV transmission through an 
incidence rate, network models have tended to give the most detailed investigations of HCV 
transmission(70, 251). Network models, a form of stochastic model, require in depth 
information about the contact structure of each member of the network, which can be very 
difficult and time-consuming data to gather, particularly for large scale modelling 
exercises(112). In HCV research, these network models have been used most commonly for 
epidemics among PWID where the route of transmission is most likely due to injecting drug 
use and the transmission dynamics can be modelled through drawing a picture of the 
contacts between PWID. Network models are less suited to generalised epidemics where 
transmission could occur through various routes, including blood transfusions, making it 
very difficult to model using a network. PWID network HCV models have looked at the 
effect of treatment as prevention through targeting different members of the network and 
how this differs with varying treatment coverage and HCV prevalence(152, 251, 421). 
Zelenev et al. found that targeting PWID with the most contacts is the best strategy when 
treatment coverage is low but there is less difference between who is targeted with higher 
treatment coverage levels(421).  
Cost-effectiveness studies of HCV have mostly modelled the benefits in terms of morbidity 
or mortality averted per HCV treatment, either considering interferon-based regimens or 
DAAs(62). A review of HCV cost-effectiveness studies published in 2015 found that all of 
the studies included were from high-income countries and all used static modelling 
techniques rather than dynamic models(62). Consequently, none of these models could 




underestimated the benefits of HCV treatment(62). Since that 2015 review (and before), other 
HCV cost-effectiveness studies have been published with dynamic structures(235, 382). 
Additionally, some studies have also investigated the cost-effectiveness of HCV case-finding 
or screening(26, 237). 
Aside from those looking at the cost-effectiveness of case-finding and screening, studies on 
HCV have also modelled the role of case-finding and screening in the HCV treatment 
cascade(302). Models investigating screening have tended to be deterministic, including a 
compartment or compartments for diagnosis(150, 370), although decision tree modelling has 
also been used to assign probabilities of HCV-infected individuals linking to care(26). HCV 
screening models have mostly investigated assumptions around numbers of diagnoses 







CHAPTER 4. IMPORTANCE AND CONTRIBUTION 
OF COMMUNITY, SOCIAL, AND HEALTHCARE 
RISK FACTORS FOR HEPATITIS C VIRUS 
INFECTION IN PAKISTAN 
The work in this chapter was done in collaboration with Margaret T May, Charlotte Davies, 
Huma Qureshi, Saeed Hamid, Hassan Mahmood, Quaid Saeed, Matthew Hickman, Nancy 
Glass, Francisco Averhoff, and Peter Vickerman, and is published in the American Journal of 
Hygiene and Tropical Medicine(371). 
 
4.1.  Introduction  
The prevalence of the population with hepatitis C virus (HCV) antibodies in most countries 
is low (<1%), but has been estimated to exceed 4% in at least 12 countries including Egypt, 
Georgia, and Pakistan(124, 295, 352), where the interest in reducing HCV transmission has 
been particularly high(56, 132). It is crucial to tackle the underlying risk factors that drive 
HCV transmission in order to reduce it. Additionally, to effectively scale-up treatment it is 
important to understand how to optimally target HCV testing interventions to minimise 
costs. This is especially true for countries with such a large burden of HCV as Pakistan, 
which I focus on in this chapter. Pakistan is the fifth-most populous country in the world, 
with a population of around 208 million people in 2017(276), and a gross domestic product 
per capita of $5,374 (USD) in 2016 (the world average was $15,800)(168). In Pakistan there 
are an estimated 9 million infected individuals(295), however, healthcare expenditure only 
makes up 0.9% of GDP (compared to 10.0% across the EU and 17.1% in USA(364)). 
Understanding what risk factors and markers are predictive of HCV infection could inform 
efficient, targeted screening recommendations that could reduce costs and time. 
Since 2005 a number of major hepatitis prevention and control programs in Pakistan(184, 
186) have focused on ensuring safe blood transfusions, improving disposal of syringes, 
increasing public awareness, and educating healthcare professionals and barbers(202, 324, 




Pakistan is unknown. As part of this interest in tackling HCV, in 2007 a large (n=46,843) 
national sero-prevalence survey for HCV was carried out in Pakistan. It found an anti-HCV 
prevalence of 4.9% overall, 6.7% amongst adults (aged ≥16 years), which did not differ by 
sex(295). HCV infection prevalence was higher in the more populous Eastern provinces of 
Punjab (6.7%) and Sindh (5.0%), than in the less populated provinces of North West Frontier 
(1.5%) and Baluchistan (1.1%). Previous analyses using this dataset have only considered 
univariable associations with HCV sero-prevalence, therefore these associations did not 
account for the effects of other variables and were open to issues of confounding. Those 
previous analyses found that increasing age, being married, shaving, sharing a toothbrush, 
sharing smoking equipment, tattooing or acupuncture, ear or nose piercing, a history of 
surgery, a higher number of injections received, and re-using syringes for these injections 
were associated with a higher prevalence of HCV(295). They also found associations 
between HCV prevalence and socio-economic characteristics such as the type of housing, the 
source of water, sanitation source, education, and employment type. 
In this chapter, I extend these previous unadjusted analyses by undertaking a multivariable 
analysis of the associations between exposures or risk factors and prevalent HCV infection. I 
investigate which of socio-economic, community, and medical risk reduction interventions 
are likely to be the most effective in reducing HCV acquisition in different populations 
defined by age, sex, and geographical location. This information is also useful for targeting 
testing, to know which risk factors are most predictive of HCV prevalence. I estimate the 
population attributable fraction (PAF) of HCV due to grouped community or healthcare 
exposures and risk factors. The PAF assesses the proportion of prevalent infections 
attributable to different exposures and depends both on the strength of association with 
HCV infection and the population prevalence of the risk factor. I also assess the cumulative 




4.2.  Materials and methods 
The serosurvey used in this chapter was designed previously by others. I performed all 
statistical analyses described in this chapter. 
 
4.2.1.  Description of the survey 
The survey(295) was conducted in all four of Pakistan’s provinces that are not classed as 
federally administered tribal areas or security-compromised areas (which account for 
roughly 3% of Pakistan’s population). The survey was designed from enumeration blocks, 
the primary sampling units, of 200-250 households using the 1998 census survey, and a 2004 
update for urban areas. For 14 large cities a separate structure was used that was divided 
into low-, middle-, and high-income groups. For the survey structure, urban areas were 
either considered part of these 14 cities or formed a separate group of all other urban areas. 
Urban and rural areas were considered separately, apart from in Balochistan which is too 
sparsely populated and so provincial administrative divisions were instead used as the 
stratifying unit. Households were drawn from 350 primary sampling units, 138 of which 
were urban and 212 rural. Included subjects gave consent to being tested. It was calculated 
that 7,000 households would be necessary for sampling. These households were sampled 
using a probability proportional to size method from with 3,500 drawn from Punjab 
province, 1,560 from Sindh, 1,100 from the North-Western Frontier Province, and 840 from 
Balochistan, with an average family size of 6.5 people. Appendix figures 4.1 and 4.2 show 
the household and individual survey questionnaires, respectively. 
 
4.2.2.  Demographic information 
Age, sex, marital status (never married, married, divorced/separated/widowed), and the 
relationship with the survey responder were collected for all members of the household. 
Each person and household had a unique identifier and was labelled with the district and 
province. Age was grouped as 0-9, 10-19, 20-29, 30-39, 40-49, 50-59, and ≥60 years. The 





4.2.3.  Outcome variable 
Participants were only tested for antibodies to HCV (anti-HCV), not active infection. Sample 
testing for HCV was carried out using the rapid Advanced Quality One Step HCV Test 
(Bionike Inc.) system, which is estimated to have a sensitivity of 97.1% (95% confidence 
interval [CI]: 89.8–99.6%) and specificity of 96.3% (95% CI: 92.5–98.5%)(395). All further 
mentions of HCV in this chapter refer to anti-HCV. 
 
4.2.4.  Exposures and risk factors collected in the survey 
Data were collected on whether participants had ever received haemodialysis, a blood 
transfusion, had a history of surgery, had a history of dental surgery, had a family history of 
hepatitis infection, practised matam (which ranges from ceremonial chest beating to self-
flagellation with implements such as chains, and blades)(41, 66), visit a barber for shaving, 
shared a toothbrush, shared smoking equipment, had received either a tattoo or 
acupuncture, and had either an ear or nose piercing. The number of medical injections 
received in the last year (0, 1-4, 5-10, >10), and the type or syringe used (none, new 
disposable, re-used syringe, don’t know) were recorded, as was whether they had a history 
of intravenous/injecting drug use. Occupation was dichotomised as labourer or not, 
education was dichotomised as illiterate or not.  
 
4.2.5.  Grouped exposures and risk factors 
Risk factors and exposures that are surrogates for risk factors (for example, literacy as an 
indicator of socio-economic status) were grouped as socio-economic status, healthcare risk, 
and community risk exposures. Socio-economic status for all individuals was defined using 
data on the survey responder (assumed to be the head of the household). An individual was 
defined to have low socio-economic status if the head of the household was either a labourer 
or illiterate. Risk due to healthcare exposures was high if the person had previously had 
haemodialysis, a blood transfusion, or ≥5 injections in the last year. Lower numbers of 
yearly injections were not included as a healthcare risk exposure because 77% of the 
population reported at least one injection in the last year. Community exposures included 




tattoo or acupuncture. For each of the healthcare and community grouped risk/exposure 
variables, I counted the number of exposures and categorised them as 0, 1, or ≥2 risk factors. 
I also counted the total cumulative number of exposures (0, 1, 2, 3, 4, or ≥5 risk factors). 
 
4.2.6.  Childbirth variable 
I hypothesised that unsafe childbirth practices could be a risk factor for HCV acquisition in 
adult females. Although the survey did not directly ask respondents about their number of 
childbirths, it did list each household member and what their relationship was to the head of 
the household. Therefore, for females aged 20-59 years that described themselves as wife or 
head of household, and who identified themselves as married, the number of childbirths (0, 
1, 2, 3, 4, ≥5 children) was estimated by counting the number of children in the household 
described as sons or daughters. I did not estimate number of childbirths for older females 
because of the increased likelihood that some of their children will have left home. Age was 
grouped as 20-29, 30-39, 40-49, and 50-59 years in this analysis.  
 
4.2.7.  Associations with HCV infection 
4.2.7.1. Individual variable associations 
I used logistic regression to estimate the unadjusted and mutually adjusted odds ratio (OR) 
(with 95% CI) for HCV infection for each individual exposure/risk factor. Separate models 
were estimated for each age group (0-19, 20-29, ≥30 years) and sex to see how associations 
varied across these groups. I also estimated the association of age with HCV prevalence by 
fitting separate models for males and females (for all age groups) that included age as a 
covariate. Robust standard errors accounted for clustering by household. 
 
4.2.7.2. Grouped variable associations 
To assess which of social, healthcare, or community interventions might have more impact 
on the risk of HCV, I grouped variables into these domains and re-estimated mutually 




(referred to below as the “main analysis”). As the prevalence of HCV was much higher in 
the more populated provinces (Punjab and Sindh compared to Baluchistan and North-West 
Frontier), I performed sensitivity analyses of the main analysis looking at the grouped 
variables (i) without adjusting for province, (ii) omitting Baluchistan and North-west 
Frontier provinces.  
A separate analysis was performed splitting the derived group variables into their 
individual components. I also investigated if the associations between the grouped variables 
and HCV infection varied by age as well as sex by repeating the main analysis separately for 
different age and sex combinations (male/female, age 0-19, 20-29, and ≥30 years old), 
adjusting for marital status, province, and further by age where appropriate. Community 
risk, medical risk, and socio-economic status risk were used as binary variables in this 
analysis (counting if participants had any of the individual factors associated risks or not). 
 
4.2.7.3. Cumulative variable associations 
The relationship between HCV prevalence and the total number of risk factor exposures was 
examined by fitting sex-specific models adjusted for age and province. Exposures included 
in this analysis were having ≥5 injections, haemodialysis, blood transfusions, going to the 
barber, ear/nose piercing, tattoo/acupuncture, sharing smoking equipment, marriage, 
illiteracy, and being a labourer. 
 
4.2.8.  Population attributable fractions 
The population attributable fraction (PAF) (equation 4.1) was defined here as the 
proportional reduction in HCV prevalence that would occur if the risk factor were reduced 
to no exposure(207). I calculated this for each of the three risk factor domains. I also 
stratified the analysis by age and sex to observe whether the PAFs for each of the grouped 
variables differed by age as well as sex.  




Pe = current prevalence of exposure (e.g. ≥5 medical injections) 




4.2.9.  Associations between HCV and childbirth 
I investigated the importance of childbirth for HCV acquisition in wives aged 20-59 years, 
adjusting associations for age, province, socio-economic status, healthcare, and community 
risk. I did this among women that were categorised in the survey as wives, assuming only 
those who are married have children in Pakistan. This analysis was repeated stratifying the 
age-groups of the wives into a younger age-group, 20-29 years, and an older age-group, 30-
59 years, to see if any associations between childbirths and HCV infection status differed 
based on age, possibly reflecting more recent improvements in healthcare. I then repeated 
this analysis in men aged 20-59 by assigning the childbirths of wives to their husbands, to 
see if childbirths themselves were associated with HCV (which would be the case if the 
number of childbirths were only associated with HCV in women), or if childbirths were a 
marker for low socio-economic status and possible poor healthcare, in which case an 
association would be seen in the husbands as well. 
 
4.2.10. Association of re-use of syringes and socio-economic status 
A study set in Pakistan found that socio-economic status was positively associated with the 
proportion of injections received using a new syringe, compared to re-use(177). To 
investigate whether this effect was evident in this dataset, logistic regression was performed 
with the outcome variable as whether or not the last syringe for a medical injection was re-
used (“not” also included “don’t know”, and “no previous injection recorded”). The 
dependent variables included in this analysis were low socio-economic status (as a binary 
variable), age group (0-19, 20-29, 30-39, 40-49, 50-59, and ≥60 years), province, and sex, with 





4.3.  Results 
4.3.1.  Prevalence and study characteristics 
Overall 46,843 people were included (96% of those sampled, with the 4% not tested because 
of migration, non-availability, or refusal) in the study and 2,290 [4.9% (95% CI: 4.7, 5.1%)] of 
the participants had HCV antibodies. The HCV prevalence was 4.8% (95% CI: 4.6, 5.1%) and 
4.9% (95% CI: 4.7, 5.2%) for females and males, respectively. The prevalence of HCV was 
6.7% (95% CI: 6.4, 7.0%), 5.1% (95% CI: 4.6, 5.5%), 1.1% (95% CI: 0.9, 1.3%), and 1.5% (95% CI: 
1.2, 1.8%) in Punjab, Sindh, Baluchistan, and the North-west Frontier, respectively, which is 
shown in the map of Pakistan’s regions in figure 4.1.  
 







4.3.2.  Association of individual exposures and risk factors with HCV  
Table 4.1 summarises the exposures associated with HCV stratified by age categories (0-19, 
20-29, ≥30 years) and gender, which can be seen in further detail in table 4.2. Prevalence of 
exposures and association with HCV infection varied by age and gender. The prevalence of 
HCV infection was higher among married persons (both males and females) compared to 
those never married, and HCV prevalence increased with age and with the number of 
community and healthcare exposures. Only 0.1% of respondents said they had a history of 
injecting drug use and among these 14.0% were infected with HCV. In multivariable 
analyses injecting drug use was not associated with HCV for any of the groups split by age 
and gender. Exposures associated with increased odds of HCV among young males aged 0-
19 years included, but were not limited to, visiting the barber [adjusted OR (aOR) 1.74 (95% 
CI: 1.09, 2.78)], re-use of syringes [aOR 1.52 (95% CI: 1.00, 2.31)], and having a family history 
of hepatitis infection [aOR 2.63 (95% CI: 1.34, 5.16)]. Among young females the risk factors 
included ear or nose piercing [aOR 1.59 (95% CI: 1.19, 2.13)], re-use of syringes [aOR 1.78 
(95% CI: 1.19, 2.67)], being illiterate [aOR 1.62 (95% CI: 1.19, 2.21)], and having been tattooed 
or treated with acupuncture [aOR 13.8 (95% CI: 3.67, 51.5)], although very few (0.1%) 
reported tattoo or acupuncture. Females aged 20-29 had higher odds of HCV infection if 
they were married (versus single) [aOR 1.58 (95% CI: 1.15, 2.19)] or had ever received a 
blood transfusion [aOR 5.76 (95% CI: 1.73, 19.2)], however, numbers exposed to blood 
transfusions were small (1.3%). Males aged 20-29 were at higher risk of HCV if they reported 
haemodialysis [aOR 10.1 (95% CI: 1.19, 86.5)] or being a labourer [aOR 1.75 (95% CI: 1.18, 
2.59)]. Females aged over 30 years had higher odds if they received haemodialysis [aOR 4.37 
(95% CI: 1.61, 11.9)] or a blood transfusion [aOR 2.49 (95% CI: 1.55, 3.99)], whereas older 
males had higher odds if they were married [aOR 1.61 (95% CI: 1.15, 2.22)] or visit a barber 
[aOR 1.45 (95% CI: 1.24, 1.70)]. For both males and females aged over 30 years, illiteracy, 
being a labourer, a family history of hepatitis, and using a high number of syringes were all 
associated with increased odds of HCV infection, whilst there was a lower odds of HCV 





Table 4.1: Variables associated* with HCV infection, stratified by age category and gender, 
summarising tables 4.2a, 4.2b, and 4.2c. 
Males aOR (95% CI) Females aOR (95% CI) 
Aged 0-19 years: 
Barber (vs not) 1.74 (1.09, 2.78) 
Tattoo or acupuncture (vs 
not) 
13.8 (3.67, 51.5) 
Ear or nose piercing (vs not) 2.71 (1.47, 4.99) 
Ear or nose piercing (vs 
not) 
1.59 (1.19, 2.13) 
Labourer (vs not) 1.99 (1.24, 3.21) Illiterate (vs not) 1.62 (1.19, 2.21) 
Re-used syringe (vs 
none/new) 
1.52 (1.00, 2.31) 
Re-used syringe (vs 
none/new) 
1.78 (1.19, 2.67) 
Family history of hepatitis (vs 
not) 
2.63 (1.34, 5.16)   
Aged 20-29 years: 
Barber (vs not) 1.43 (1.01, 2.01) Married (vs never) 1.58 (1.15, 2.19) 
Labourer (vs not) 1.75 (1.18, 2.59) 
Other marital status (vs 
never) 
3.76 (1.07, 13.3) 
Family history hepatitis (vs 
not) 
2.83 (1.47, 5.43) Barber (vs not) 4.22 (1.01, 17.6) 
Haemodialysis 10.1 (1.19, 86.5) 
Tattoo or acupuncture (vs 
not) 
3.42 (1.05, 11.2) 
  Ear or nose piercing (vs 
not) 
2.30 (1.40, 3.76) 
  Family history of hepatitis 
(vs not)  
1.96 (1.09, 3.51) 
  Blood transfusion (vs 
never) 
5.76 (1.73, 19.2) 
Aged ≥30 years: 
Married (vs never) 1.61 (1.16, 2.22) Illiterate (vs not) 1.43 (1.15, 1.78) 
Barber (vs not) 1.45 (1.24, 1.70) Labourer (vs not) 2.05 (1.30, 3.23) 
Illiterate (vs not) 1.30 (1.11, 1.52) 5-10 injections (vs 0) 1.65 (1.17, 2.33) 
Labourer (vs not) 1.41 (1.18, 1.67) >10 injections (vs 0) 1.92 (1.32, 2.79) 
1-4 injections (vs 0) 1.69 (1.29, 2.20) 
Re-used syringe (vs 
none/new) 
0.65 (0.51, 0.82) 
5-10 injections (vs 0) 1.64 (1.23, 2.20) 
Family history of hepatitis 
(vs not) 
2.57 (1.87, 3.53) 
>10 injections (vs 0) 2.37 (1.68, 3.33) Haemodialysis (vs never) 4.44 (1.63, 12.1) 
Re-used syringe (vs 
none/new) 
0.54 (0.44, 0.67) 
Blood transfusion (vs 
never) 
2.45 (1.53, 3.93) 
Unknown syringe type (vs 
none/new) 
0.42 (0.29, 0.62)   
Family history of hepatitis (vs 
not) 
1.90 (1.38, 2.63)   





Table 4.2: Prevalence of risk factors/exposures and HCV infection, unadjusted and mutually adjusted ORs of HCV infection by age and sex. 
Table 4.2a: Males and females aged 0-19 years. 
 Males Aged 0-19  Females aged 0-19 
 HCV OR (95% CI) p-
value 
  HCV OR (95% CI)    p-
value Risk factor N (%) N (%) Unadjusted Adjusted  N (%) N (%) Unadjusted Adjusted 
Marital status (v. never) 11518 (98.7) 220 (1.9) 1 1   10415 (96.3) 219 (2.1) 1 1  
  Married 129 (1.1) 4 (3.1) 1.64 (0.60, 4.51) 1.15 (0.44, 3.01) 0.771  392 (3.6) 12 (3.1) 1.47 (0.82, 2.65) 1.12 (0.61, 2.03) 0.722 
  other 22 (0.2) 1 (4.6) 2.45 (0.32, 18.4) 2.15 (0.26, 18.0) 0.478  14 (0.1) 0 (0.0) NA NA  
Urban (v. rural) 4463 (38.3) 80 (1.8) 0.89 (0.66, 1.19) 0.91 (0.67, 1.25) 0.574  4360 (40.4) 79 (1.8) 0.77 (0.55, 1.06) 0.84 (0.58, 1.22) 0.363 
IDU (v. never) 10 (0.1) 1 (10.0) 5.67 (0.72, 45.0) 6.73 (0.84, 53.7) 0.072  11 (0.1) 1 (9.1) 4.60 (0.58, 36.2) 4.02 (0.37, 44.0) 0.254 
Community risk            
Barber 587 (5.2) 24 (3.9) 2.21 (1.44, 3.40) 1.74 (1.09, 2.78) 0.020  22 (0.2) 0 (0.0) NA NA  
Sharing smoking eqpt. 49 (0.4) 1 (2.0) 1.06 (0.15, 7.73) 0.62 (0.09, 4.17) 0.621  15 (0.1) 0 (0.0) NA NA  
Sharing a toothbrush 86 (0.7) 2 (2.3) 1.21 (0.30, 4.90) 1.21 (0.31, 4.75) 0.780  75 (0.7) 2 (2.7) 1.26 (0.30, 5.30) 1.16 (0.27, 4.97) 0.844 
Tattoo or acupuncture 24 (0.2) 0 (0.0) NA NA   11 (0.1) 3 (27.3) 17.4 (4.38, 69.2) 13.8 (3.67, 51.5) <0.001 
Ear or nose piercing 268 (2.3) 13 (4.9) 2.69 (1.47, 4.91) 2.71 (1.47, 4.99) 0.001  6151 (56.6) 155 (2.5) 1.56 (1.17, 2.08) 1.59 (1.19, 2.13) 0.002 
Matam 23 (0.2) 1 (4.3) 2.32 (0.37, 14.7) 1.38 (0.19, 10.1) 0.748  8 (0.1) 0 (0.0) NA NA  
Socio-economic status           
Illiterate 3809 (32.6) 78 (2.1) 1.10 (0.83, 1.46) 1.03 (0.76, 1.39) 0.850  4406 (40.5) 122 (2.8) 1.65 (1.24, 2.20) 1.62 (1.19, 2.21) 0.002 
Labourer 575 (4.9) 25 (4.4) 2.48 (1.61, 3.80) 1.99 (1.24, 3.21) 0.005  175 (1.6) 2 (1.1) 0.53 (0.13, 2.10) 0.42 (0.11, 1.70) 0.225 
Healthcare risk            
No. of injections (v. 0) 3447 (29.6) 61 (1.8) 1 1   2996 (27.7) 59 (2.0)  1  
  1-4 injections 5934 (50.9) 108 (1.8) 1.03 (0.73, 1.44) 0.88 (0.62, 1.26) 0.481  5617 (51.8) 130 (2.3) 1.18 (0.84, 1.65) 0.91 (0.65, 1.29) 0.601 
  5-10 injections 1905 (16.2) 48 (2.5) 1.43 (0.95, 2.16) 1.02 (0.65, 1.61) 0.933  1838 (17.0) 37 (2.0) 1.02 (0.67, 1.55) 0.68 (0.44, 1.07) 0.098 
  >10 injections 383 (3.3) 8 (2.1) 1.18 (0.56, 2.50) 0.89 (0.41, 1.94) 0.771  370 (3.4) 5 (1.4) 0.68 (0.27, 1.70) 0.51 (0.20, 1.30) 0.160 
Syringe use (v. none/new) 9826 (84.2) 173 (1.8) 1 1   9118 (84.4) 176 (1.9) 1 1  
  Re-used syringe 1201 (10.3) 37 (3.1) 1.77 (1.22, 2.59) 1.52 (1.00, 2.31) 0.048  1096 (10.0) 37 (3.4) 1.74 (1.13, 2.67) 1.78 (1.19, 2.67) 0.005 
  Unknown syringe type 642 (5.5) 15 (2.3) 1.33 (0.76, 2.36) 1.30 (0.71, 2.36) 0.392  607 (5.6) 18 (3.0) 1.52 (0.64, 3.60) 1.48 (0.62, 3.53) 0.374 
Dentist 31 (0.3) 0 (0.0) NA NA   44 (0.4) 2 (4.6) 2.19 (0.52, 9.22) 2.54 (0.59, 10.8) 0.209 
Family history hepatitis 205 (1.8) 10 (4.9) 2.68 (1.36, 5.29) 2.63 (1.34, 5.16) 0.005  213 (2.0) 4 (1.9) 0.88 (0.32, 2.36) 0.94 (0.34, 2.58) 0.905 
Haemodialysis 10 (0.1) 0 (0.0) NA NA   13 (0.1) 0 (0.0) NA NA  
Blood transfusion 16 (0.1) 0 (0.0) NA NA   19 (0.2) 2 (10.5) 5.43 (1.24, 23.73) 11.0 (0.89, 137) 0.061 
History of surgery 132 (1.1) 1 (0.8) 0.38 (0.05, 2.73) 0.41 (0.06, 3.05) 0.386  104 (1.0) 3 (2.9) 1.37 (0.43, 4.33) 0.55 (0.07, 4.21) 0.566 
TOTAL 11669 (100) 225 (1.9)     10821 (100) 213 (2.0)    





Table 4.2b: Males and females aged 20-29 years. 
 Males Aged 20-29  Females aged 20-29 
 HCV OR (95% CI) p-
value 
  HCV OR (95% CI) p-
value Risk factor N (%) N (%) Unadjusted Adjusted  N (%) N (%) Unadjusted Adjusted 
Marital status (v. never) 3121 (70.6) 108 (3.5) 1 1   1870 (43.7) 63 (3.4) 1 1  
  Married 1284 (29.1) 64 (5.0) 1.45 (1.05, 1.99) 1.32 (0.95, 1.84) 0.097  2373 (55.5) 138 (5.8) 1.77 (1.31,2.40) 1.58 (1.15, 2.19) 0.005 
  Other 15 (0.3) 0 (0.0) NA NA   29 (0.7) 3 (10.3) 3.31 (0.98,11.2) 3.76 (1.07, 13.3) 0.039 
Urban (v. rural) 1897 (42.9) 69 (3.6) 0.89 (0.64, 1.22) 0.89 (0.64, 1.24) 0.501  1799 (42.1) 77 (4.3) 0.83 (0.62,1.11) 0.84 (0.61, 1.17) 0.311 
IDU (v. never) 7 (0.2) 0 (0.0) NA NA   6 (0.1) 0 (0.0) NA NA  
Community risk            
Barber 1823 (41.2) 90 (4.9) 1.59 (1.17, 2.17) 1.43 (1.01, 2.01) 0.042  26 (0.6) 3 (11.5) 2.62 (0.78,8.87) 4.22 (1.01, 17.6) 0.048 
Sharing smoking eqpt. 217 (4.9) 12 (5.5) 1.48 (0.82, 2.67) 1.15 (0.61, 2.16) 0.661  37 (0.9) 4 (10.8) 2.44 (0.85,7.02) 1.45 (0.46, 4.55) 0.523 
Sharing a toothbrush 72 (1.6) 5 (6.9) 1.87 (0.77, 4.51) 1.51 (0.59, 3.87) 0.388  29 (0.7) 2 (6.9) 1.48 (0.33,6.58) 1.61 (0.36, 7.11) 0.532 
Tattoo or acupuncture 47 (1.1) 3 (6.4) 1.70 (0.53, 5.46) 1.14 (0.35, 3.74) 0.832  24 (0.6) 4 (16.7) 4.05 (1.35,12.2) 3.42 (1.05, 11.2) 0.042 
Ear or nose piercing 111 (2.5) 8 (7.2) 1.94 (0.93, 4.07) 2.20 (0.99, 4.88) 0.053  3349 (78.4) 181 (5.4) 2.23 (1.44,3.46) 2.30 (1.40, 3.76) 0.001 
Matam 14 (0.3) 1 (7.1) 1.91 (0.33, 11.0) 2.04 (0.39, 10.7) 0.402  6 (0.1) 0 (0.0) NA NA  
Socio-economic status           
Illiterate 1168 (26.5) 47 (4.0) 1.05 (0.74, 1.48) 0.93 (0.64, 1.34) 0.687  2129 (50.2) 111 (5.2) 1.21 (0.91,1.61) 0.98 (0.71, 1.37) 0.927 
Labourer 817 (18.5) 51 (6.2) 1.92 (1.35, 2.72) 1.75 (1.18, 2.59) 0.005  88 (2.1) 5 (5.7) 1.21 (0.48,3.03) 1.15 (0.45, 2.91) 0.771 
Healthcare risk            
No. of injections (v. 0) 1049 (23.7) 35 (3.3) 1 1   798 (18.7) 31 (3.9) 1 1  
  1-4 injections 2032 (46.0) 80 (3.9) 1.19 (0.79, 1.79) 1.13 (0.64, 2.00) 0.671  2043 (47.8) 82 (4.0) 1.03 (0.67,1.60) 0.80 (0.44, 1.47) 0.477 
  5-10 injections 1090 (24.7) 42 (3.9) 1.16 (0.73, 1.86) 1.07 (0.57, 2.00) 0.841  1122 (26.3) 68 (6.1) 1.60 (1.02,2.49) 1.12 (0.58, 2.16) 0.729 
  >10 injections 249 (5.6) 15 (6.0) 1.86 (0.98, 3.53) 2.02 (0.92, 4.47) 0.081  309 (7.2) 23 (7.4) 1.99 (1.13,3.51) 1.44 (0.68, 3.05) 0.342 
Syringe use (v. none/new) 1600 (36.2) 62 (3.9) 1 1   1341 (31.4) 57 (4.3) 1 1  
  Re-used syringe 2559 (57.9) 103 (4.0) 1.22 (0.82, 1.81) 0.91 (0.57, 1.46) 0.710  2656 (62.2) 131 (4.9) 1.28 (0.85,1.94) 0.95 (0.59, 1.55) 0.844 
  Unknown syringe type 261 (5.9) 7 (2.7) 0.80 (0.32, 1.98) 0.55 (0.21, 1.40) 0.209  275 (6.4) 16 (5.8) 1.53 (0.80,2.92) 1.10 (0.53, 2.26) 0.805 
Dentist 49 (1.1) 0 (0.0) NA NA   52 (1.2) 2 (3.9) 0.80 (0.19,3.30) 0.75 (0.17, 3.29) 0.701 
Family history hepatitis 132 (3.0) 14 (10.6) 3.10 (1.63, 5.92) 2.83 (1.47, 5.43) 0.002  163 (3.8) 16 (9.8) 2.27 (1.30,3.97) 1.96 (1.09, 3.51) 0.024 
Haemodialysis 6 (0.1) 1 (16.7) 4.96 (0.58, 42.7) 10.1 (1.19, 86.5) 0.034  6 (0.1) 1 (16.7) 4.00 (0.47,34.4) 2.34 (0.14, 38.7) 0.552 
Blood transfusion 9 (0.2) 0 (0.0) NA NA   56 (1.3) 8 (14.4) 3.42 (1.60,7.31) 5.76 (1.73, 19.2) 0.004 
History of surgery 151 (3.4) 2 (1.3) 0.32 (0.08, 1.32) 0.29 (0.06, 1.28) 0.103  185 (4.3) 11 (6.0) 1.28 (0.68,2.38) 0.45 (0.16, 1.27) 0.132 
TOTAL 4420 (100) 172 (3.9)     4272 (100) 204 (4.8)    






Table 4.2c: Males and females aged ≥30 years. 
 Males aged ≥ 30 years  Females aged ≥ 30 years 
 HCV OR (95% CI) p-
value 
  HCV OR (95% CI) p-
value Risk factor N (%) N (%) Unadjusted Adjusted  N (%) N (%) Unadjusted Adjusted 
Marital status (v. never) 654 (7.9) 39 (6.0) 1 1   422 (5.6) 23 (5.5)    
  Married 7310 (88.8) 739 (10.1) 1.77 (1.28, 2.44) 1.61 (1.16, 2.22) 0.004  6317 (85.1) 569 (9.0) 1.70 (1.11, 2.61) 1.51 (0.98, 2.34) 0.061 
  Other 272 (3.3) 27 (9.9) 1.73 (1.05, 2.85) 1.44 (0.86, 2.40) 0.167  686 (9.3) 61 (8.9) 1.68 (1.02, 2.76) 1.42 (0.85, 2.36) 0.183 
Urban (v. rural) 3257 (39.6) 330 (10.1) 1.07 (0.92, 1.24) 1.17 (0.99, 1.37) 0.061  3039 (41.1) 255 (8.4) 0.92 (0.77, 1.09) 0.96 (0.79, 1.15) 0.636 
IDU (v. never) 12 (0.2) 3 (25.0) 3.08 (0.83, 11.4) 1.89 (0.42, 8.45) 0.404  11 (0.2) 3 (27.3) 3.90 (1.17, 13.0) 2.38 (0.74, 7.70) 0.147 
Community risk            
Barber 3580 (43.5) 441 (12.3) 1.66 (1.43, 1.92) 1.45 (1.24, 1.70) <0.001  49 (0.7) 4 (8.2) 0.92 (0.33, 2.57) 0.97 (0.33, 2.78) 0.948 
Sharing smoking eqpt. 991 (12.0) 132 (13.3) 1.50 (1.23, 1.83) 1.23 (0.99, 1.53) 0.064  126 (1.7) 10 (7.9) 0.89 (0.46, 1.72) 0.70 (0.36, 1.37) 0.398 
Sharing a toothbrush 161 (2.0) 22 (13.6) 1.46 (0.93, 2.29) 1.27 (0.78, 2.06) 0.335  62 (0.8) 8 (12.9) 1.55 (0.74, 3.22) 1.47 (0.68, 3.20) 0.330 
Tattoo or acupuncture 78 (1.0) 8 (10.3) 1.06 (0.51, 2.20) 0.88 (0.40, 1.89) 0.735  46 (0.6) 1 (2.2) 0.23 (0.03, 1.68) 0.20 (0.03, 1.53) 0.121 
Ear or nose piercing 159 (1.9) 14 (8.8) 0.89 (0.51, 1.54) 1.01 (0.58, 1.77) 0.968  6098 (82.1) 563 (9.2) 1.39 (1.09, 1.77) 1.27 (0.98, 1.66) 0.070 
Matam 36 (0.4) 2 (5.6) 0.54 (0.13, 2.30) 0.42 (0.10, 1.81) 0.243  10 (0.1) 2 (20.0) 2.60 (0.53, 12.7) 2.62 (0.49, 14.1) 0.263 
Socio-economic status           
Illiterate 3765 (45.7) 410 (10.9) 1.26 (1.09, 1.46) 1.30 (1.11, 1.52) 0.001  5494 (74.0) 518 (9.4) 1.38 (1.13, 1.69) 1.43 (1.15, 1.78) 0.001 
Labourer 1736 (21.1) 232 (13.4) 1.59 (1.35, 1.88) 1.41 (1.18, 1.67) <0.001  145 (2.0) 25 (17.2) 2.20 (1.43, 3.41) 2.05 (1.30, 3.23) 0.002 
Healthcare risk            
No. of injections (v. 0) 1536 (18.7) 130 (8.5) 1 1   1081 (14.6) 83 (7.8) 1 1  
  1-4 injections 3649 (44.3) 362 (9.9) 1.19 (0.97, 1.47) 1.69 (1.29, 2.20) <0.001  3275 (44.1) 244 (7.5) 0.95 (0.73, 1.24) 1.23 (0.89, 1.70) 0.218 
  5-10 injections 2280 (27.7) 221 (9.7) 1.16 (0.93, 1.46) 1.64 (1.23, 2.20) 0.001  2222 (30.0) 224 (10.1) 1.33 (1.02, 1.73) 1.65 (1.17, 2.33) 0.004 
  >10 injections 771 (9.4) 92 (11.9) 1.47 (1.10, 1.95) 2.37 (1.68, 3.33) <0.001  847 (11.4) 101 (11.9) 1.60 (1.18, 2.19) 1.92 (1.32, 2.79) 0.001 
Syringe use (v. none/new) 2532 (30.7) 290 (11.5) 1 1   2002 (27.0) 191 (9.6) 1 1  




1.09 (0.89, 1.34) 0.54 (0.44, 0.67) <0.001 
 4937 (66.5) 415 (8.4) 
1.09 (0.85, 1.40) 0.65 (0.51, 0.82) <0.001 
  Unknown syringe type 520 (6.3) 40 (7.7) 0.90 (0.62, 1.30) 0.42 (0.29, 0.62) <0.001  486 (6.6) 46 (9.5) 1.24 (0.85, 1.81) 0.76 (0.52, 1.12) 0.164 
Dentist 245 (3.0) 30 (12.2) 1.30 (0.88, 1.92) 1.14 (0.77, 1.70) 0.520  270 (3.6) 29 (10.7) 1.26 (0.85, 1.87) 1.08 (0.73, 1.60) 0.695 
Family history hepatitis 296 (3.6) 53 (17.9) 2.08 (1.53, 2.84) 1.90 (1.38, 2.63) <0.001  280 (3.8) 60 (21.4) 3.01 (2.22, 4.08) 2.57 (1.87, 3.53) <0.001 
Haemodialysis 13 (0.2) 2 (15.4) 1.68 (0.37, 7.59) 1.67 (0.38, 7.34) 0.499  18 (0.2) 6 (33.3) 5.22 (1.95, 13.9) 4.44 (1.63, 12.1) 0.004 
Blood transfusion 77 (0.9) 12 (15.6) 1.71 (0.92, 3.19) 1.95 (0.95, 4.01) 0.068  222 (3.0) 47 (21.2) 2.92 (2.09, 4.08) 2.45 (1.53, 3.93) <0.001 
History of surgery 594 (7.2) 56 (9.4) 0.96 (0.72, 1.27) 0.83 (0.60, 1.16) 0.276  673 (9.1) 86 (13.2) 1.60 (1.25, 2.03) 0.99 (0.70, 1.39) 0.942 
TOTAL 8236 (100) 805 (9.8)     7425 (100) 653 (8.8)    




4.3.3.  Association of grouped exposures and risk factors with HCV 
The HCV prevalence and the unadjusted and adjusted ORs (95% CI) of HCV infection for 
the community, healthcare, and socio-economic status grouped exposures are shown in 
table 4.3, separately for males and females. Community, healthcare, and socio-economic 
status exposures were all strongly associated with HCV infection. The increase in adjusted 
odds of prevalent HCV infection associated with one community exposure (versus none), 
aOR for males 1.22 (95% CI: 1.06, 1.41) and for females 1.46 (95% CI: 1.21, 1.76), was similar 
to that associated with one healthcare exposure (versus none), aOR for males 1.21 (95% CI: 
1.06, 1.39) and for females 1.40 (95% CI: 1.22, 1.61). Although the association of HCV 
infection with multiple healthcare exposures (versus none) [aOR for males 3.31 (95% CI: 
1.69, 6.47) and females 4.17 (95% CI: 2.84, 6.14)] was much stronger than that for multiple 
community factors (versus none) [aOR for males 1.34 (95% CI: 1.06, 1.69) and for females 
2.07 (95% CI: 1.25, 3.44)], only a small proportion of the population was exposed to multiple 
healthcare exposures (females 0.8%; males 0.2%). Older age was associated with HCV 
infection, with a more than doubling of the odds among males aged ≥40 years compared 
with those aged 20-29 years, aORs 2.43 (95% CI: 1.90, 3.09), 2.41 (95% CI: 1.85, 3.14), and 2.22 
(95% CI: 1.71, 2.88), for those aged 40-49, 50-59, and ≥60, respectively. Ever being married 
(versus never) was also associated with HCV infection, aOR for males 1.43 (95% CI: 1.14, 
1.78) and for females 1.54 (95% CI: 1.23, 1.94). Results from the sensitivity analyses – both 
those excluding provinces with very low prevalence (table 4.4) and those not adjusting for 
province (table 4.5) – were similar to the main analysis, which included all provinces and 
adjusted for province.  
A separate analysis where I did not group the exposures that comprised the community, 
healthcare, and socio-economic status variables (table 4.6) showed that a high percentage of 
those who had had haemodialysis (10% and 19% for men and women, respectively) or a 
blood transfusion (12% and 19% for men and women) had HCV infection. However, few 
individuals had undergone these procedures – less than 500 altogether. There was also a 





Table 4.3: Prevalence of risk factors/exposures and HCV infection, unadjusted and mutually adjusted ORs of HCV infection by sex. 
Risk Factor     OR (95% CI) for HCV infection       OR (95% CI) for HCV infection   
   Males    Females  












Never married 15,293 2% 1 1   12,707 2% 1 1   
Ever married 9,032 9% 4.14 (3.65, 4.70)  1.43 (1.14, 1.78)  p=0.002 9,811 8% 3.53 (3.07, 4.06)  1.54 (1.23, 1.94)  p<0.001 
Community risks 0 17,306 3% 1 1   6,796 3% 1 1   
Community risks 1 6,105 9% 2.73 (2.41, 3.10)  1.22 (1.06, 1.41)  p=0.006 15,492 6% 2.18 (1.85, 2.58)  1.46 (1.21, 1.76)  p<0.001 
Community risks ≥2 914 12% 4.10 (3.30, 5.10)  1.34 (1.06, 1.69)  p=0.013 230 10% 3.82 (2.41, 6.07)  2.07 (1.25, 3.44)  p=0.005 
S-ES risks 0 14,166 4% 1 1  10,389 3% 1 1  
S-ES risks ≥1 10,159 7% 1.84 (1.64, 2.07)  1.33 (1.17, 1.51)  p<0.001 12,129 6% 2.00 (1.75, 2.30)  1.55 (1.33, 1.81)  p<0.001 
Healthcare risks 0 17,570 4% 1 1   15,660 4% 1 1   
Healthcare risks 1 6,701 6% 1.45 (1.28, 1.65)  1.21 (1.06, 1.39)  p=0.005 6,675 7% 1.75 (1.54, 1.99)  1.40 (1.22, 1.61)  p<0.001 
Healthcare risks ≥2 54 20% 5.57 (2.86, 10.83)  3.31 (1.69, 6.47)  p<0.001 183 22% 7.16 (5.00, 10.26)  4.17 (2.84, 6.14)  p<0.001 
Punjab (Province) 13,186 7% 1 1  11,926 7% 1 1  
Sindh 4,640 5% 0.73 (0.63, 0.86)  0.69 (0.59, 0.82)  p<0.001 4,221 5% 0.75 (0.64, 0.89)  0.67 (0.56, 0.79)  p<0.001 
Baluchistan 3,831 1% 0.15 (0.11, 0.22)  0.16 (0.11, 0.22)  p<0.001 3,766 1% 0.16 (0.11, 0.22)  0.14 (0.10, 0.19)  p<0.001 
North West Frontier 2,668 1% 0.18 (0.13, 0.27)  0.19 (0.13, 0.28)  p<0.001 2,605 2% 0.24 (0.17, 0.33)  0.20 (0.14, 0.29)  p<0.001 
Age 0-9 5,309 2% 0.36 (0.27, 0.49)  0.48 (0.35, 0.66)  p<0.001 5,013 2% 0.39 (0.30, 0.50)  0.63 (0.46, 0.85)  p=0.003 
Age 10-19 6,360 2% 0.59 (0.47, 0.74)  0.77 (0.60, 0.99)  p=0.041 5,808 2% 0.48 (0.38, 0.60)  0.69 (0.53, 0.89)  p=0.005 
Age 20-29 4,420 4% 1 1  4,272 5% 1 1  
Age 30-39 2,831 7% 1.90 (1.54, 2.34)  1.53 (1.20, 1.95)  p<0.001 2,910 8% 1.84 (1.52, 2.23)  1.47 (1.20, 1.81)  p<0.001 
Age 40-49 2,292 11% 3.17 (2.60, 3.88)  2.43 (1.90, 3.09)  p<0.001 2,109 9% 1.88 (1.54, 2.31)  1.40 (1.12, 1.75)  p=0.003 
Age 50-59 1,479 11% 3.04 (2.43, 3.80)  2.41 (1.85, 3.14)  p<0.001 1,289 10% 2.20 (1.75, 2.76)  1.55 (1.21, 1.98)  p<0.001 
Age ≥60 1,634 11% 3.06 (2.47, 3.79)  2.22 (1.71, 2.88)  p<0.001 1,117 9% 1.90 (1.48, 2.43)  1.25 (0.96, 1.63)  p=0.100 





Table 4.4: Prevalence of risk factors/exposures and HCV infection, unadjusted and mutually adjusted ORs of HCV infection by sex, with the 
Baluchistan and North-West Frontier provinces omitted. 
Risk Factor     OR (95% CI) for HCV infection       OR (95% CI) for HCV infection   
   Males    Females  












Never married 11,175 3% 1 1   9,267 3% 1 1   
Ever married 6,651 12% 4.22 (3.70, 4.82)  1.47 (1.17, 1.86)  p=0.001 6,880 10% 3.67 (3.17, 4.25)  1.57 (1.23, 2.01)  p<0.001 
Community risks 0 11,858 4% 1 1   5,076 3% 1 1   
Community risks 1 5,138 10% 2.45 (2.15, 2.80)  1.27 (1.10, 1.48)  p=0.002 10,948 7% 2.25 (1.90, 2.67)  1.44 (1.18, 1.75)  p<0.001 
Community risks ≥2 830 13% 3.50 (2.80, 4.37)  1.43 (1.13, 1.81)  p=0.003 123 15% 5.15 (3.07, 8.63)  2.22 (1.27, 3.87)  p=0.005 
S-ES risks 0 10,206 5% 1 1  8,002 4% 1 1  
S-ES risks ≥1 7,620 8% 1.74 (1.54, 1.97) 1.28 (1.12, 1.46)  p<0.001 8,145 8% 2.21 (1.91, 2.55)  1.52 (1.30, 1.78)  p<0.001 
Healthcare risks 0 13,165 6% 1 1   11,409 5% 1 1   
Healthcare risks 1 4,619 8% 1.50 (1.31, 1.72)  1.18 (1.02, 1.36)  p=0.024 4,584 9% 1.82 (1.58, 2.09)  1.39 (1.21, 1.61)  p<0.001 
Healthcare risks ≥2 42 26% 5.99 (3.00, 11.96)  3.54 (1.76, 7.14)  p<0.001 154 25% 6.27 (4.28, 9.17)  4.05 (2.71, 6.07)  p<0.001 
Punjab (Province) 13,186 7% 1 1  11,926 7% 1 1  
Sindh 4,640 5% 0.73 (0.63, 0.86)  0.70 (0.59, 0.82) p<0.001 4,221 5% 0.75 (0.64, 0.89)  0.67 (0.56, 0.79)  p<0.001 
Age 0-9 3,737 2% 0.40 (0.30, 0.54)  0.53 (0.38, 0.72) p<0.001 3,587 3% 0.41 (0.32, 0.54)  0.67 (0.49, 0.92)  p=0.012 
Age 10-19 4,641 3% 0.61 (0.48, 0.77)  0.79 (0.61, 1.02) p=0.076 4,175 3% 0.48 (0.38, 0.61)  0.70 (0.53, 0.92)  p=0.010 
Age 20-29 3,350 5% 1 1  3,079 6% 1 1  
Age 30-39 2,121 9% 1.98 (1.59, 2.47)  1.55 (1.21, 2.00) p<0.001 2,055 11% 1.89 (1.54, 2.31)  1.46 (1.17, 1.81)  p=0.001 
Age 40-49 1,706 14% 3.38 (2.74, 4.16)  2.45 (1.90, 3.15) p<0.001 1,477 12% 2.03 (1.64, 2.52)  1.45 (1.15, 1.83)  p=0.002 
Age 50-59 1,058 15% 3.40 (2.69, 4.29)  2.48 (1.88, 3.26) p<0.001 925 13% 2.24 (1.76, 2.86)  1.54 (1.19, 1.99)  p=0.001 






Table 4.5: Prevalence of risk factors/exposures and HCV infection, unadjusted and mutually adjusted ORs of HCV infection by sex, without 
adjustment for province. 
Risk Factor     OR (95% CI) for HCV infection       OR (95% CI) for HCV infection   
   Males    Females  












Never married 15,293 2% 1 1   12,707 2% 1 1   
Ever married 9,032 9% 4.14 (3.65, 4.70)  1.34 (1.07, 1.67)  p=0.010 9,811 8% 3.53 (3.07, 4.06)  1.46 (1.17, 1.83)  p<0.001 
Community risks 0 17,306 3% 1 1   6,796 3% 1 1   
Community risks 1 6,105 9% 2.73 (2.41, 3.10)  1.63 (1.42, 1.87)  p<0.001 15,492 6% 2.18 (1.85, 2.58)  1.45 (1.21, 1.73)  p<0.001 
Community risks ≥2 914 12% 4.10 (3.30, 5.10) 1.89 (1.50, 2.38)  p<0.001 230 10% 3.82 (2.41, 6.07)  1.62 (0.99, 2.63)  p=0.052 
S-ES risks 0 14,166 4% 1 1  10,389 3% 1 1  
S-ES risks ≥1 10,159 7% 1.84 (1.64, 2.07)  1.35 (1.19, 1.53)  p<0.001 12,129 6% 2.00 (1.75, 2.30)  1.35 (1.16, 1.57)  p<0.001 
Healthcare risks 0 17,570 4% 1 1   15,660 4% 1 1   
Healthcare risks 1 6,701 6% 1.45 (1.28, 1.65)  1.02 (0.89, 1.17)  p=0.747 6,675 7% 1.75 (1.54, 1.99)  1.26 (1.10, 1.44)  p<0.001 
Healthcare risks ≥2 54 20% 5.57 (2.86, 10.83)  2.69 (1.37, 5.28)  p=0.004 183 22% 7.16 (5.00, 10.26)  3.96 (2.72, 5.76)  p<0.001 
Age 0-9 5,309 2% 0.36 (0.27, 0.49)  0.50 (0.37, 0.69)  p<0.001 5,013 2% 0.39 (0.30, 0.50)  0.60 (0.45, 0.82)  p<0.001 
Age 10-19 6,360 2% 0.59 (0.47, 0.74)  0.80 (0.63, 1.03)  p=0.087 5,808 2% 0.48 (0.38, 0.60)  0.65 (0.51, 0.85)  p<0.001 
Age 20-29 4,420 4% 1 1  4,272 5% 1 1  
Age 30-39 2,831 7% 1.90 (1.54, 2.34)  1.54 (1.21, 1.95)  p<0.001 2,910 8% 1.84 (1.52, 2.23)  1.51 (1.23, 1.85)  p<0.001 
Age 40-49 2,292 11% 3.17 (2.60, 3.88)  2.41 (1.90, 3.07)  p<0.001 2,109 9% 1.88 (1.54, 2.31)  1.46 (1.17, 1.81)  p<0.001 
Age 50-59 1,479 11% 3.04 (2.43, 3.80)  2.35 (1.81, 3.06)  p<0.001 1,289 10% 2.20 (1.75, 2.76)  1.66 (1.31, 2.11)  p<0.001 






Table 4.6: Prevalence of individual risk factors/exposures and HCV infection, unadjusted and mutually adjusted ORs of HCV infection by sex. 
Risk Factor     OR (95% CI) for HCV infection       OR (95% CI) for HCV infection   
   Males    Females  












Never married 15,293 2% 1 1   12,707 2% 1 1   
Ever married 9,032 9% 4.14 (3.65, 4.70)  1.42 (1.14, 1.78)  p=0.002 9,811 8% 3.53 (3.07, 4.06)  1.52 (1.21, 1.92)  p<0.001 
Barber 6,014 9% 2.78 (2.46, 3.13) 1.18 (1.03, 1.35)  p=0.020 97 7% 1.54 (0.71, 3.33) 1.46 (0.66, 3.24)  p=0.356 
Ear or nose piercing 539 6% 1.35 (0.93, 1.95)  1.58 (1.07, 2.33)  p=0.022 15,603 6% 2.18 (1.85, 2.56) 1.49 (1.23, 1.79)  p<0.001 
Tattoo/acupuncture 149 7% 1.54 (0.83, 2.85)  1.04 (0.56, 1.94)  p=0.900 81 10% 2.17 (1.07, 4.38) 2.42 (1.12, 5.25)  p=0.025 
Sharing smoking eqpt. 1,257 12% 2.72 (2.26, 3.27) 1.13 (0.93, 1.38)  p=0.218 178 8% 1.69 (0.97, 2.95) 1.00 (0.57, 1.75)  p=0.991 
Illiterate 8,744 6% 1.46 (1.29, 1.64) 1.15 (1.01, 1.31)  p=0.038 12,029 6% 2.01 (1.75, 2.30) 1.57 (1.35, 1.83)  p<0.001 
Labourer 3,128 10% 2.48 (2.16, 2.85) 1.25 (1.07, 1.46)  p=0.004 408 8% 1.70 (1.19, 2.42)  1.30 (0.90, 1.88)  p=0.161 
≥5 Medical Injections 6,678 6% 1.48 (1.30, 1.68) 1.24 (1.08, 1.42)  p=0.002 6,708 7% 1.77 (1.55, 2.01) 1.37 (1.19, 1.57)  p<0.001 
Haemodialysis 29 10% 2.22 (0.67, 7.36)  2.01 (0.59, 6.80)  p=0.261 37 19% 4.62 (2.06, 10.4)  3.20 (1.38, 7.39)  p=0.007 
Blood transfusion 102 12% 2.58 (1.41, 4.73)  1.52 (0.82, 2.82)  p=0.181 297 19% 4.88 (3.61, 6.60) 2.90 (2.10, 4.00)  p<0.001 
Punjab (Province) 13,186 7% 1 1  11,926 7% 1 1  
Sindh 4,640 5% 0.73 (0.63, 0.86)  0.69 (0.58, 0.81)  p<0.001 4,221 5% 0.75 (0.64, 0.89)  0.65 (0.55, 0.77)  p<0.001 
Baluchistan 3,831 1% 0.15 (0.11, 0.22)  0.16 (0.11, 0.23)  p<0.001 3,766 1% 0.16 (0.11, 0.22)  0.14 (0.10, 0.19)  p<0.001 
North West Frontier 2,668 1% 0.18 (0.13, 0.27)  0.20 (0.14, 0.28)  p<0.001 2,605 2% 0.24 (0.17, 0.33)  0.20 (0.14, 0.28)  p<0.001 
Age 0-9 5,309 2% 0.36 (0.27, 0.49)  0.49 (0.36, 0.67)  p<0.001 5,013 2% 0.39 (0.30, 0.50)  0.63 (0.46, 0.85)  p=0.003 
Age 10-19 6,360 2% 0.59 (0.47, 0.74)  0.76 (0.59, 0.97)  p=0.028 5,808 2% 0.48 (0.38, 0.60)  0.69 (0.53, 0.89)  p=0.004 
Age 20-29 4,420 4% 1 1  4,272 5% 1 1  
Age 30-39 2,831 7% 1.90 (1.54, 2.34)  1.55 (1.22, 1.97)  p<0.001 2,910 8% 1.84 (1.52, 2.23)  1.47 (1.19, 1.81)  p=0.003 
Age 40-49 2,292 11% 3.17 (2.60, 3.88)  2.45 (1.92, 3.12)  p<0.001 2,109 9% 1.88 (1.54, 2.31)  1.39 (1.11, 1.74)  p=0.004 
Age 50-59 1,479 11% 3.04 (2.43, 3.80)  2.45 (1.88, 3.18)  p<0.001 1,289 10% 2.20 (1.75, 2.76)  1.55 (1.21, 1.98)  p<0.001 





4.3.4.  Differences by age in associations of grouped risk factors with HCV 
I repeated the analyses examining the grouped risk factors seen in table 4.3, stratifying by age as 
well as sex (figure 4.2) and presenting the risk factors as binary variables (any exposure versus 
none). Low socio-economic status and having community risks were associated with an 
increased odds of HCV for females aged 0-19, whilst having medical and community risks were 
associated for women aged 20-29, and low socio-economic status and having medical risks were 
associated with increased odds of HCV for women aged ≥30. For men aged 0-19, having 
medical and community risks were associated with increased odds of HCV, whilst for those 
aged 20-29 HCV was positively associated with low socio-economic status. For men aged ≥30 all 
of the risk domains were associated with prevalent HCV. 
 
Figure 4.2: Trends in adjusted odds ratio of HCV infection by age for community, medical, and 
S-ES risk (presence versus absence), stratified by sex. 
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4.3.5.  Association of cumulative number of risk factors/exposures with HCV 
The cumulative number of exposures increased with age, among both females and males (figure 
4.3). The prevalence of HCV infection also increased as the number of exposures increased 
(figure 4.4). The HCV prevalence for individuals with 0, 1, 2, 3, 4, and ≥5 lifetime exposures was 
2%, 3%, 5%, 8%, 11%, and 15%, respectively, with the majority of HCV infections (77%) being 
among individuals with two or more risk factor exposures. Figure 4.5 plots HCV prevalence by 
number of risk factors, for males and females. A clear association between more risk factors and 
increasing HCV prevalence is shown, with similar prevalence for both sexes. The aOR of HCV 
per additional exposure was 1.51 (95% CI: 1.41, 1.61) for females and 1.21 (95% CI: 1.15, 1.27) for 







Figure 4.3: Proportion of the population experiencing different numbers of exposures* for HCV 
infection by age and sex.  
 
* Exposures included in this analysis were having ≥5 injections, haemodialysis, blood 
transfusions, going to the barber, ear/nose piercing, tattoo/acupuncture, sharing smoking 




Figure 4.4: Percentage of population, HCV prevalence, and percentage of infections among 






Figure 4.5: Mean HCV antibody prevalence by number of risk factors, by sex. 
 
 
4.3.6.  Population attributable fraction of HCV prevalence due to different exposures 
and risk factors  
Figure 4.6 shows most HCV infections were not attributable to an identified risk 
factor/exposure. A greater proportion of HCV infections among females, 38% compared to 15% 
of males, were attributable to either a community or healthcare exposure, with community 
factors accounting for a greater proportion of HCV infections among both females and males. 
The PAFs suggest that prevention of exposure to community risks could potentially reduce 
HCV prevalence by 25% (95% CI: 13, 35%) and 9% (95% CI: 2, 16%) in females and males, 
respectively. In contrast, prevention of exposure to healthcare risks could potentially reduce 
HCV prevalence by 13% (95% CI: 8, 19%) in females and 6% (95% CI: 2, 10%) in males. Among 
both females and males, a high proportion of HCV appeared to be attributable to the exposures 









The PAFs for the grouped risk factor analyses stratified by age and sex can be seen in figure 4.7. 
For males of all ages socio-economic status appeared to be the most important in this analysis, 
with higher PAFs than for the other risk domains – 10%, 13%, and 13% for those aged 0-19, 20-
29, and ≥30, respectively.   
For the females aged 0-19, community risks and socio-economic status risks were both 
important predictors of HCV and accounted for 29% and 24% of the population attributable risk 
of HCV, respectively. Community risks accounted for half of the population attributable risk of 
HCV in females aged 20-29. Medical and socio-economic status risks were important HCV risk 
factors and accounted for 20% and 25% of the population attributable risk, respectively, for 




Figure 4.7: Trends in PAFs of HCV infection by age for community, medical, and S-ES risk 
(presence versus absence), stratified by sex. 
 
S-ES: socio-economic status 
 
4.3.7.  Association of childbirth with HCV 
There were 5,556 women categorised in the survey as wives that were aged 20-59 years old. 
There was an increase in HCV infection prevalence associated with the number of children; 
linear trend, aOR per child 1.06 (95% CI: 1.01, 1.11). Figure 4.8 shows that being a childless wife 
was associated with having a higher risk of HCV than those with one child, aOR 1.81 (95% CI: 
1.01, 3.24). The aOR of HCV for wives with 2-3 and ≥4 children compared to those with one 
child was 1.86 (95% CI: 1.19, 2.92) and 2.08 (95% CI: 1.32, 3.28), respectively. I repeated this 
analysis stratifying by the wives aged 20-29 (N=1,167) and those aged 30-59 (N=4,399), figure 
4.9. The same associations observed in figure 4.10 with childless wives and women with 2-3 or 
≥4 children having higher risk than those with one child were also seen here and appeared 
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children compared to those with one child was 1.96 (95% CI: 0.86, 4.46) and 2.58 (95% CI: 1.03, 
6.43), respectively, and for wives aged 30-59 years the aOR was 1.83 (95% CI: 1.07, 3.12) and 2.00 
(95% CI: 1.17, 3.42) for the same comparison. The prevalence of HCV amongst the wives aged 
20-59 was 7% in those aged 20-29 and approximately 10% (30-39: 10.0%, 40-49: 9.6%, 50-59: 
9.8%) in those aged 30-59. This analysis was repeated in men aged 20-59, by assigning the 
childbirths of wives to husbands, and no association was found between childbirths and HCV: 0 
childbirths (versus 1) aOR 0.94 (95% CI: 0.55, 1.59), 2-3 childbirths (versus 1) aOR 0.86 (95% CI: 
0.59, 1.25), and ≥4 childbirths (versus 1) aOR 1.29 (95% CI: 0.88, 1.89). 
 
Figure 4.8: Association of number of children with odds of HCV infection for wives, adjusted 
for age, province, and community, medical, and S-ES risks. 
 
S-ES: socio-economic status 
 
1.81 (1.01, 3.24) - HCV prev: 8.1% - PAF: 2.5%
1 - HCV prev: 4.8%
1.86 (1.19, 2.92) - HCV prev: 8.8% - PAF: 20.4%
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Figure 4.9: Association of number of children with odds of HCV infection for women of 
different ages (20-29 and 30-59 years), adjusted for province and community, medical, and S-ES 
risks. 
 
S-ES: socio-economic status 
 
4.3.8.  Variables associated with syringe re-use 
Table 4.7 shows the associations between syringe re-use and socio-economic status, as well as 
other demographic variables. The analysis found that those with low socio-economic status had 
higher odds that the previous medical injection they received was with a re-used syringe, aOR 
1.08 (95% CI: 1.02, 1.16). Increasing age was positively associated with syringe re-use, whilst 
males were less likely to have received their last medical injection from a re-used syringe, aOR 
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Table 4.7: Unadjusted and adjusted ORs that the previous medical injection received was with a 
re-used syringe.  
 Odds ratios (95% Confidence intervals) 
Risk factor Unadjusted Adjusted 
Low S-ES status (vs high) 1.69 (1.61, 1.78) 1.08 (1.02, 1.16) 
Male (vs female) 0.93 (0.89, 0.96) 0.91 (0.87, 0.95) 
Age 0-19 years 0.08 (0.07, 0.08) 0.07 (0.06, 0.07) 
Age 20-29 years 1 1 
Age 30-39 years 1.17 (1.09, 1.27) 1.16 (1.07, 1.25) 
Age 40-49 years 1.23 (1.13, 1.33) 1.21 (1.11, 1.31) 
Age 50-59 years 1.33 (1.22, 1.45) 1.26 (1.15, 1.38) 
Age ≥60 years 1.19 (1.09, 1.31) 1.19 (1.09, 1.31) 
Punjab (Province) 1 1 
Sindh 1.75 (1.62, 1.90) 2.35 (2.10, 2.64) 
Baluchistan 1.97 (1.83, 2.12) 2.82 (2.57, 3.09) 
North West Frontier 1.46 (1.34, 1.60) 1.93 (1.72, 2.16) 







4.4.  Discussion 
4.4.1.  Main findings 
My findings identified healthcare associated exposures, including childbirth, as an important 
source of risk associated with HCV infection in Pakistan. In addition, these findings also 
suggest that various community risk factors/exposures, low socio-economic status, and 
marriage are associated with increased risk of HCV infection in the country. I estimated that the 
risk of HCV infection increases with cumulative lifetime healthcare exposures and accounts for 
13% of female and 6% of male infections, whereas community exposures and low socio-
economic status together account for over 20% and 10% of infections in females and males, 
respectively. The associations between these grouped variables (community, medical, and 
socio-economic risks) varied with age as well as sex, possibly explained by changing behaviours 
and improving healthcare practices that would be more noticeable amongst the younger age 
groups.  
Marriage also emerged as an important surrogate marker of risk for both sexes, accounting for 
about 20% of all prevalent infections. The factors in marriage that contribute to HCV infection in 
Pakistan need additional study. Possible explanations could be shared practices or activities not 
recorded in the survey, or household transmission risks specific to the married couple, that are 
not specific to other members of the household. There is some evidence of transmission of HCV 
through sex, however this has mostly been anal sex between men who have sex with men(106, 
377).  
Unrecognised or unidentified risk factors beyond those associated with marriage, may also play 
an important role in transmission, as demonstrated by the large proportion of infections not 
attributable to either community or healthcare exposures identified in this survey. One potential 
important contributor could be injection drug use, which is a well-documented risk factor for 
HCV transmission, and is more prevalent in men than women(77). This could explain why 
more of the PAF for HCV was unaccounted for by the other variables in the model for males 
compared to females. Injecting drug users have a very high prevalence of HCV infection(6, 9, 
164, 268). Of those surveyed, 0.1% responded that they had a history of injecting drug use, 




be more important than this analysis suggests; there was a high prevalence of receiving medical 
injections in the population, amongst both HCV exposed and unexposed individuals, limiting 
the degree to which the association could be ascertained.  
 
4.4.2. Strengths and limitations 
This study was based on a very large sample size which included children as well as adults. The 
results should be generalisable to the population of Pakistan as data were gathered from 100 
districts in four provinces. However, the risk factor/exposure questions were limited in scope, 
often asking whether behaviours had ever occurred, which may have curtailed the degree to 
which elevated risk could be ascribed to them. HCV is a chronic condition and thus infection 
could have resulted throughout the lifetime of the study subject, further limiting the ability to 
associate recent exposures with infection. I was unable to determine why marriage and low 
socio-economic status were associated with increased prevalence of HCV infection – they may 
be surrogate markers for risk factors on which data were not available, or they could possibly 
be markers for shared healthcare utilisation and other behaviours. I also lacked direct data on 
the number of childbirths amongst females, or where the births occurred, for example, home or 
facility-based deliveries, and what type of delivery was performed, which limited the scope of 
the analyses on this risk factor. My method for measuring the number of childbirths is likely to 
underestimate the total number as some children will have died or left home; however, it 
should still be a useful proxy measure for the number of childbirths that a woman has had. The 
survey did not enquire about female genital mutilation or male circumcision, both of which 
could result in parenteral exposures(16, 187, 281). It is possible that risk associated with 
community risk factors may have been overestimated, as accurate attribution of risk to specific 
medical/healthcare interventions to a chronic infection such as HCV may not reflect the risk of 
specific exposures. This is particularly the case for exposures such as medical injections that are 
common in the population(175). As with all self-report surveys, there are likely to be problems 
with recall that can potentially bias the results. The nature of how the survey was administered 




Anti-HCV prevalence was used to determine associations with HCV infection because testing 
for current HCV infection (eg. PCR testing for presence of HCV RNA) was not performed. 
Further, I could not determine acute vs. chronic HCV infection; very few studies have assessed 
risk factors for recent, acute, or incident HCV infections amongst the general population(117, 
182, 254, 275). This limits the degree to which I could determine current risk factors for HCV 
transmission as individuals with HCV antibodies may have been infected in the distant past or 
more recently. Importantly, this analysis found similar associations with HCV prevalence in 
younger and older individuals suggesting similar risk factors may exist now as in the past. One 
exception was the number of medical injections, which was only associated with HCV infection 
among study subjects aged over 30 years. From the data I cannot determine whether this is 
because cumulative exposure is more important or there has been a reduction in the risk due to 
medical injections in recent years(283). Despite an estimated reduction in the re-use of medical 
injections for every region globally(282), the 2018/2019 HIV outbreak in Kot Imrana, Pakistan, 
shows medical injections administered by “quacks” are likely still an issue for the transmission 
of bloodborne viruses, although in that example it was not possible to determine whether or not 
the infections could also have occurred through barbering or sexual transmission(386). 
The main limitation of the study is the inability to accurately ascertain the extent of unsafe 
medical injections on the HCV epidemic in Pakistan. Much literature points to this as a major 
cause of HCV infection in Pakistan(13, 192, 256), however, this study can only report on the 
association between patterns of recent medical injection use and HCV infection. The WHO 
interventions to increase the use of sterilised needles are thought to have been effective(283, 398, 
401) but this study cannot differentiate if infections occurred 20-years ago when the use of 
unclean injections was more prevalent(282, 296). Investigations into these associations are 
further hindered by the very high prevalence of injections for medical purposes in Pakistan in 
general(175), and the likely correlation between being ill, possibly from a previous HCV 
infection, and receiving these injections – a chicken and egg scenario. Although the type of 
syringe last used (new, re-used, don’t know) was recorded, the survey does not contain 
information on the provider of the medical injections. My next chapter shows that this could be 
an important risk factor in some settings, with the type of healthcare provider being associated 
with different prevalences of HCV, likely due to different practices around use of unsterilised 




quantity of medical injections, as a single unsterilised medical injection poses far more risk for 
transmitting HCV than hundreds of sterilised medical injections. For those aged over 30 years I 
found a protective effect for the last medical injection received being with a re-used syringe. 
This finding may highlight the problem of recall bias, although it should be noted that in 
younger groups this trend was reversed. 
Another limitation is the lack of weighting for the importance of each individual risk factor in 
the analysis looking at the association between HCV prevalence and the number of risk factors. 
However, these weights would differ by age and sex, which would make the results of a 
weighted analysis difficult to interpret. The method of determining socio-economic status is 
perhaps not accurate in all cases as it is based on the householder rather than on individuals 
within the household but is likely to be a good proxy. Although subgroup analyses were carried 
out, for which multiple testing could be an issue, the very large sample size in each group will 
mitigate this and the need to use p-value corrections such as the Bonferroni method(23). 
 
4.4.3.  Comparison with other studies 
My findings are consistent with previous studies examining risk factors for HCV infection in 
Pakistan(9, 29, 146, 164, 176, 194). In agreement with some studies, I found the importance of 
healthcare and community exposures for HCV transmission, including medical injections, 
childbirth, going to the barber, and ear/nose piercing(31, 176, 194, 222, 244, 280, 318, 355, 356). 
However, not all studies are in agreement, and some did not find an association with ear/nose 
piercing(6, 9, 29, 164, 173, 176), barbering or medical injections(6, 164), although these were 
much smaller surveys. Another study on women in Pakistan found that higher socio-economic 
status was associated with a higher proportion of injections received using a new syringe, as 
opposed to re-use(177). This is one of the possible explanations of the protective association of 
socio-economic status on HCV infection that I found and was confirmed in our dataset. This 
variable could also be a marker of accessing better quality health care which could also have a 
similar effect on reducing HCV risk. Therefore, socio-economic status may be masking medical 




As found in other studies in Pakistan and elsewhere(8, 123, 134, 139, 183, 275), marriage is 
associated with HCV infection in both sexes. The reasons for this are uncertain, with some 
studies suggesting sexual HCV transmission or shared use of personal items(134, 139). For 
females in this study, the dominant exposures included ear and nose piercing, while a separate, 
restricted analysis also found childbirth to be an important exposure, possibly due to parenteral 
exposures(193). For almost every female in Pakistan, ear and nose piercing is a cultural ritual 
which is undertaken in very early years of life (<5 years)(115). Contact with barbers was 
associated with HCV infection among males. Barbering may be an important risk exposure 
among children, as well as adults, as every child (both male and female) undergoes head 
shaving around seven days of age(190). Also, most male children undergo circumcision, which 
is generally carried out by barbers in rural areas, but less so in urban areas(12).  
Importantly for planning screening interventions, the cumulative number of risk factor 
exposures reported by an individual was highly predictive of HCV infection, with the sero-
prevalence of HCV exceeding 10% among individuals with four exposures, and 15% in those 
with five or more. The effect was even more pronounced, 13% and 17% respectively, if they 
were from Punjab or Sindh. 
 
4.4.4.  Implications 
My results highlight the importance of HCV prevention interventions not only targeting 
potential healthcare risks/exposures in Pakistan, but also community settings and family 
behaviours where exposures may occur. These are likely to include barbering and ear piercing, 
and family behaviours such as sharing personal items like razors and toothbrushes, and 
practices associated with childbirth(9, 29, 176, 318). More research is needed to better 
understand the main risk behaviours occurring in different settings. For instance, childbirth 
may be high-risk only in certain settings, or when specific obstetric or gynaecological 
procedures are involved(146, 292, 318). A recent meta-analysis found that caesarean section 
conferred a high-risk for HCV infection (OR=3.35)(92), and other studies have documented the 




A number of educational interventions have been undertaken in Pakistan over the past decade 
to tackle community and general risk exposures such as barbering, tattooing, and body 
piercing(202, 298, 324, 325). For instance, in 2014/2015, the Health Foundation developed an 
HCV educational intervention in Karachi, Pakistan, that aimed to educate the general public on 
healthcare and community risk factors through health educator volunteers and electronic and 
print media(188). A similar intervention is being done in Azad Kashmir in Northern 
Pakistan(270). There is a need to better understand the effectiveness and impact of these 
interventions on practices and HCV transmission.   
 
4.4.5.  Conclusions 
In summary, my results highlight the multitude of community and healthcare exposures that 
drive HCV transmission in Pakistan; similar risk factors for transmission have been identified in 
Egypt, another high prevalence setting(92, 130, 134, 275, 305). These findings underscore the 
urgent need for implementation of strategies to decrease HCV transmission in Pakistan and 
other countries with similar risk profiles. Treatment scale-up for HCV infection, with the new 
highly effective direct acting antivirals(101, 103), is planned in Pakistan, and many are already 
receiving treatment(60). The finding from the study that HCV infection is strongly associated 
with cumulative number of self-reported risk factors/exposures could help inform screening 
strategies to efficiently target individuals at highest risk for HCV infection. While scaling-up 
treatment is urgently needed to tackle the huge burden of HCV in Pakistan, policy makers 
should also remember the need for large-scale prevention interventions to curtail the continued 
transmission of HCV. Indeed, the low prevalence of HCV in many neighbouring countries(19, 
65) suggests the required changes in behaviour are possible with suitable interventions, 
including education campaigns, to improve knowledge on HCV transmission risks. These 
education campaigns need to be tailored to the local situation, which may require further 
research to identify the reasons why marriage, childbirth, and socio-economic status are 





CHAPTER 5. THE BURDEN OF HEPATITIS C VIRUS 
INFECTION IN PUNJAB, INDIA: A POPULATION-
BASED SEROSURVEY 
The work in this chapter was done in collaboration with Ajit Sood, Anil Suryaprasad, Subodh 
Kanchi, Vandana Midha, Monique A Foster, Eddas Bennett, Saleem Kamili, Fernando Alvarez-
Bognar, Shaun Shadaker, Vijay Surlikar, Ravinder Garg, Parmod Mittal, Suresh Sharma, 
Margaret T May, Peter Vickerman, and Francisco Averhoff, and is published in PLOS 
ONE(346). 
 
5.1.  Introduction  
In order to establish effective hepatitis C virus (HCV) prevention and treatment programs, there 
is a need to understand the epidemiology and burden of disease in the country or community. 
However, such data are lacking in many countries, particularly in low- and middle-income 
countries which shoulder most of the burden(124). In India, population-based studies on HCV 
infection prevalence are lacking and the epidemiology is not well understood. Some studies 
from India suggest the HCV prevalence may be low, however, there are significant variations 
within regions and sub-populations, with some studies demonstrating very high prevalence 
rates(262, 333). Despite a recent systematic review(121), the HCV burden in India is poorly 
described because of a paucity of community level data(121).   
Due to the high cost of direct acting antivirals (DAAs), it has been postulated that for some 
countries treating all HCV-infected persons would cost more than their total expenditure on 
pharmaceuticals(171). However, India produces the bulk of the world’s generic licensed DAAs, 
and prices are lower than most countries, removing this barrier to treatment access(220). In 





Punjab is a state in Northern India with an estimated population of around 28 million 
people(358). A survey conducted in one district of Punjab in 2003 found a 5% anti-HCV positive 
rate; in that study, infection was associated with reuse of needles and syringes, history of 
surgery, and history of dental extraction(344). Elevated rates of HCV infection have also been 
identified among high risk populations (eg. people who inject drugs [PWID]) in Punjab(179, 
278), which may reflect the growing epidemic of injection drug use, a high-risk behaviour for 
HCV infection(359). Epidemiological assessment of the burden of disease and characteristics 
and behaviours associated with HCV infection in the state are essential for public health 
planning strategies to combat this disease.  
In chapter 4, I investigated the associations of risk factors for HCV infection in Pakistan, which 
neighbours Punjab, India. Punjab also has a high anti-HCV prevalence, 4.9% (95% CI: 4.7%, 
5.1%). I found in chapter 4 that a mixture of healthcare and community factors, such as medical 
injections and barbering, as well as low socio-economic status are associated with HCV 
antibody positivity. In this chapter, I aim to assess the prevalence of HCV infection in Punjab, 
India, and, similarly to chapter 4, identify behaviours and characteristics associated with HCV 






5.2.  Materials and methods 
The serosurvey used in this chapter was designed by my collaborators. I performed all 
statistical analyses. 
 
5.2.1. Sample design 
A cross-sectional seroprevalence survey was conducted in the state of Punjab, India, during 
October 2013 – April 2014. Punjab is divided into three major geographical areas, Doaba, Majha, 
and Malwa, which contain a total of 22 districts. The survey sample size was calculated to 
enable estimation of HCV prevalence among individuals age 5 years and older, using the 
statistical software PASS (NCSS, LLC. 2011 Kaysville, Utah, USA). For an expected HCV 
prevalence of 5% with a 95% confidence interval (CI) of 4-6%, the effective sample size was 
estimated to include 1,924 households. Those designing the study assumed a design effect of 2 
(how different a survey’s expected sampling error is from the sampling error expected with 
simple random sampling(242)) and an overall response rate of 70%, with a target sample size of 
5,500 individuals. 
The study included testing for past and current HCV infection, past infections with hepatitis A 
virus and hepatitis E virus, and past or current infection with hepatitis B virus (HBV). This 
chapter, and thesis, is only concerned with the results for HCV. The sample size of 5,500 
individuals was expected to be large enough to produce combined estimates with relative 
standard errors of 10-20%. For a stratified analysis, a minimum sample size of 1,000 per strata 
(eg. stratification based on rural/urban dwelling) was expected to produce estimates with 
relative standard errors of 25% or less. Estimates based on relative standard errors >25% are 
considered unreliable(27). 
The survey used a multi-stage stratified cluster sampling design using 2011 Punjab Census 
data(358), and 10 of the 22 districts in Punjab were selected with probability proportionate to 
size. In rural areas, 22 sub districts and 87 villages were selected proportionate to size, and 813 
households were systematically selected in groups of five. To ensure the selection of a sufficient 




and villages with 5-49 households were combined with neighbouring villages, for a minimum 
of 50 households per sampling unit. In urban areas, 13 sub districts and 41 wards were selected 
proportionate to size; 1 census enumeration block of 150-200 households was randomly selected 
per ward; and 586 households were systematically selected in groups of five. For large sampling 
units, villages and census enumeration blocks with 500 or more households were divided into 
three or more segments and two segments were selected proportionate to size. 
All household residents and guests 5 years of age and older who stayed at the household the 
previous night were eligible to participate in the study. Selected adults aged ≥18 years who 
provided informed consent were included. Children aged 5-17 years who provided assent and 
for whom informed parental/guardian consent was also given were included. Pregnant women 
were included, since participation in the study did not pose any risk to the mother or her 
unborn child. Individuals under 5 years of age and those who did not provide consent or assent 
were not included. No replacement was made if selected household was not available during 
data collection.  
 
5.2.2.  Data collection 
Trained survey teams consisting of a doctor, a phlebotomist, a nurse, and a social worker visited 
selected households and administered the survey questionnaire, after obtaining informed 
consent and assent from children willing to participate. The study questionnaire was 
administered as a face-to-face interview and inquired about socio-demographic data, medical 
history, lifestyle information, obstetric history (if applicable), and potential exposures to HCV, 
including healthcare and lifestyle associated exposures. Each completed questionnaire was 
reviewed in the field by the team doctor, and if inconsistencies or gaps were identified, an 
attempt to correct or fill in the missing information was made by revisiting the surveyed 
individual before leaving the cluster. Each completed interview was labelled with a bar code 






5.2.3.  Sample storage and testing 
After completing the interview, a blood sample of approximately 16ml was drawn in a serum 
separator tube and labelled with a barcode matching the interview form completed by the study 
subject. Within one hour of collection, the sample was centrifuged for 15 minutes at 3,000 
revolutions per minute. Separated serum was pipetted into 2ml cryovials, which were also 
labelled with bar codes matching the study subjects. Up to eight aliquots of sample per subject 
were prepared and frozen at -80C. Specimens were shipped every 2 weeks to a central 
laboratory (Oncquest Laboratories Ltd) in Delhi for testing. All samples were tested for anti-
HCV (Vitros Immunodiagnostic Anti-HCV, Johnson and Johnson Co., New Brunswick, NJ, 
USA) and all anti-HCV positive samples were tested for HCV RNA (COBAS® TaqMan® HCV 
Test, Roche, Indianapolis, IN, USA). All HCV RNA positive samples were genotyped by Linear 
Array HCV genotyping test (Roche, Indianapolis, IN, USA). The sensitivity and specificity of 
the anti-HCV test used were 100% and 96.5%, respectively(196), and for the HCV RNA test 
were 100% and 95%, respectively(116). Survey participants who tested positive for anti-HCV 
were considered infected with HCV, regardless of HCV RNA results. Survey participants who 
tested positive for anti-HCV and HCV RNA were considered to have current infection, and 
those that tested anti-HCV positive and HCV RNA negative were considered to have past 
infection. Specimens were also tested for hepatitis A virus, HBV, and hepatitis E virus markers 
of infection (methods and results not described in this thesis). Unused blood was disposed of as 
per healthcare waste management guidelines and all specimens were destroyed following 
completion of the study. 
 
5.2.4.  Counselling and notification of test results 
For consenting participants, pre-test counselling and educational brochures on HCV 
transmission and prevention were administered prior to interview and venepuncture. Study 
participants were notified of their test results for HCV, HBV, hepatitis A virus, and hepatitis E 
virus infection or immunity by telephone and mail within three weeks of the interview date. 




by appointment. All participants were counselled about measures to prevent the risk of 
transmission of the various forms of viral hepatitis. 
 
5.2.5.  Ethical considerations 
The protocol for this study underwent approval from the Institutional Review Board (IRB) at 
Dayanand Medical College, Ludhiana, and the Merck Investigator Initiated Study Protocol-
Review Committee (MISP-RC). Participation was voluntary and confidentiality was strictly 
adhered to during the survey. Written consent was documented by the study subject’s dated 
signature or thumbprint on a consent form along with the dated signature of the person who 
conducted the consent discussion. A copy of the consent form was given to the subject prior to 
participating in the survey. Consent forms were available in English, Punjabi, and Hindi. If the 
subject was illiterate, a witness was present during the entire informed consent reading and 
discussion. Afterward, the subjects signed and dated the consent if literate, or a thumb 
impression was taken. The witness also signed and dated the consent form along with the study 
staff who read and discussed the consent. Children ≥5 years and <18 years of age provided 
assent in addition to having parental permission.  
 
5.2.6.  Statistical methods 
My analyses of the survey data were weighted according to the population sizes of the wards 
and villages estimated from the 2011 population census. This weighting was stratified by 
urban/rural status to account for expected differences. The HCV prevalence was estimated for 
the state overall, by urban/rural residence, and by district. I used a chi-squared test to examine 
whether the proportion of HCV RNA positive patients with each genotype differed by district. 
Participant characteristics and HCV risk factors were tabulated against the percentage of 
individuals with each characteristic/risk factor testing positive for anti-HCV and those testing 
positive for HCV RNA. The variables included in these tabulations were district, age-group (5-
18, 19-29, 30-45, 46-60, >60), sex, urban/rural status, household income in rupees (<20,000, 




graduate/above), the number of injections received in the last 6 months (0, 1-3, 4-8, >8), who 
administered the last injection received (Medical Doctor, Registered Nurse/Medical 
Practitioner, Other/Unknown (including chemists and unlicensed practitioners), the number of 
lifetime blood donations (0, 1-3, 4-6, >7), the number of blood transfusions received (0, 1-3, >3), 
if ever received a permanent tattoo, the number of childbirths, whether they have a history of 
surgery, whether they have a history of dental surgery, whether they have ever received a body 
piercing, and whether they shave at the barber, if they have ever used injectable drugs, or had 
ever received renal dialysis. Proportions and numbers presented in the tabulations were 
weighted (as mentioned at the start of this paragraph) to represent the population surveyed. 
Tabulations were stratified by urban/rural status and by gender.  
The variables investigated in the paper this chapter is based on were selected a priori. However, 
for comparability with chapter 4 the analyses presented in this chapter were additionally 
adjusted for the number of childbirths, whether they have a history of surgery, whether they 
have a history of dental surgery, whether they have ever received a body piercing, and whether 
they shave at the barber. 
 
5.2.7.  Association of HCV with patient characteristics and risk factors 
I estimated the association of patient characteristics and HCV risk factors with HCV status 
using weighted logistic regression models for the total survey population, stratified by 
urban/rural status, and clustered by household. Age, the number of injections received in the 
last 6 months, the number of times the person had donated blood, and the number of blood 
transfusions received were included in models as continuous variables. Results are presented as 
weighted unadjusted and mutually adjusted odds ratios (OR) of having a positive anti-HCV 
test, with 95% confidence intervals (CI). I also estimated the association of the year of the first 
blood transfusion received (grouped as before 2002, 2002 or later year, year unknown, and no 
blood transfusions received; of note, blood bank testing for HBV and HCV became mandatory 
in Punjab by law in 2002(264)) with HCV status. I used the same mutually adjusted model as 




receiving a blood transfusion. I did not include the variables (dialysis, injecting drug use) with 
very few observations in the regression models in order to increase power. 
 
5.2.8.  Sensitivity analyses 
A sensitivity analysis excluded participants 18 years of age or under because some risk factors 
only applied to adults. Another sensitivity analysis only included participants aged 40-59 years 
of age to investigate whether risk factors were different for the two highest prevalence age 
groups. 
 
5.2.9.  Cumulative risk factors 
I examined the number of injections (categorised: 0, 1-3, 4-8, >8) received in the last 6 months by 
anti-HCV prevalence. I examined the relationship of cumulative number of different types of 
potential exposures found to be associated with anti-HCV prevalence by univariable analysis 
(including having ever received a blood transfusion, having ever received surgery, having ever 
received dental surgery, having received a medical injection within the last 6 months, and 
whether they shave at a barber) and testing positive for anti-HCV. I used logistic regression to 
estimate the adjusted OR (aOR) of anti-HCV positivity for number of risk factors (1, 2-3) 
compared with no risk factors. 
 
5.3.  Results 
5.3.1.  Serosurvey participant characteristics 
A total of 5,548 individuals agreed to participate in the serosurvey and completed the 
questionnaire. However, 5 lacked HCV testing results and were excluded, resulting in 5,543 
subjects for inclusion in the analyses. Data is unavailable on how many individuals refused to 
participate. The median age of the sample was 35 years (interquartile range: 21, 50) while the 




than men (46.2%) that participated in the serosurvey, and 62.4% of all participants resided in 
rural areas (table 5.1). Of the serosurvey participants, 12.5% attended graduate school, and 
81.9% lived in households with an income of less than 20,000 Indian rupees (about 300 US 
dollars), which is below the national average of 27,857 Indian rupees(358) (table 5.1).  
Examining potential exposures for HCV infection, 34.8% of participants had received one or 
more medical injections in the previous 6 months in the weighted analysis. When asked who 
administered their last medical injection, 20.4% identified a medical doctor and 56.9% identified 
a registered nurse or registered medical practitioner (eg. medical care provider not having the 
qualifications/training of a medical doctor). For those who had received at least one medical 
injection in the last 6 months, 24% received it from a medical doctor, 71% from a registered 
nurse or registered medical practitioner, and 5% from other sources (eg. chemist or pharmacist, 
unlicensed practitioner, or did not specify). Of all participants, 6.5% stated they had received at 
least one blood transfusion. Additionally, 8.6% of patients had received a permanent tattoo, 
while few (0.1%) participants admitted to ever using injectable drugs. The median number of 
childbirths for the females surveyed was 2 (interquartile range: 0-3). Body piercings were 
mostly among females, with 96% of females having one but only 6% of males. All participants 
reporting shaving at the barber were male. 
 
5.3.2.  HCV prevalence 
Overall, of the 5,543 persons tested for hepatitis C, 3.6% (95% CI: 3.0%, 4.2%) tested positive for 
anti-HCV, and 2.6% (95% CI: 2.0%, 3.1%) tested positive for HCV RNA. Among the 138 that 
tested positive for RNA, 130 were successfully tested for genotype: the majority were classified 
as genotype 3 (61.2%), followed by genotype 1 (27.5%) and genotype 4 (11.3%). No participants 
in the serosurvey were found to have genotype 2. The proportions of RNA positive patients 
with each genotype differed by province (p=0.038). Anti-HCV prevalence was higher among 
rural residents [4.7% (95% CI: 3.8%, 5.7%)] than urban residents [1.6% (95% CI: 1.1%, 2.2%)] 
(table 5.1). The proportion of serosurvey participants testing positive for HCV antibodies 
differed by district, ranging from 1.1% in Gurdaspur to 9.0% in Moga (figure 5.1). However, 




as this serosurvey was designed to estimate prevalence for Punjab as a whole, not to estimate 





Table 5.1: Participant demographic characteristics and prevalence of potential exposures and risk factors associated with HCV 






% with positive anti-HCV 
(95% confidence intervals) 
% with HCV RNA (95% 
confidence intervals) 
Overall 5543 100% 3.6% (3.0%, 4.2%) 2.6% (2.0%, 3.1%) 
Age Group (years)     
5-18 1107 20.2% 0.7% (0.1%, 1.2%) 0.4% (0.0%, 0.8%) 
19-29 1024 18.3% 1.7% (0.8%, 2.5%) 1.2% (0.5%, 1.9%) 
30-39 998 18.0% 4.3% (2.9%, 5.7%) 3.1% (1.8%, 4.3%) 
40-49 870 15.7% 6.2% (4.4%, 8.0%) 4.7% (3.1%, 6.2%) 
50-59 721 13.0% 5.8% (3.9%, 7.7%) 4.5% (2.7%, 6.2%) 
≥60 823 14.9% 4.3% (2.7%, 5.8%) 2.7% (1.4%, 3.9%) 
Sex     
    Female 3005 53.8% 3.2% (2.5%, 3.9%) 2.3% (1.7%, 2.9%) 
Male 2538 46.2% 4.0% (3.1%, 5.0%) 2.8% (2.1%, 3.6%) 
Setting     
Urban 2083 37.6% 1.6% (1.1%, 2.2%) 1.0% (0.6%, 1.4%) 
Rural 3460 62.4% 4.7% (3.8%, 5.7%) 3.5% (2.7%, 4.3%) 
Household income (rupees)      
<20,000 4546 81.9% 3.8% (3.1%, 4.5%) 2.7% (2.1%, 3.3%) 
≥20,000 997 18.1% 2.5% (1.2%, 3.7%) 1.9% (0.8%, 2.9%) 
Education     
Never/Primary School 2114 37.7% 4.7% (3.6%, 5.8%) 3.8% (2.8%, 4.8%) 
Middle/Secondary School 2735 49.8% 3.4% (2.6%, 4.1%) 2.1% (1.5%, 2.7%) 
Graduate/Above 694 12.5% 1.1% (0.3%, 1.8%) 0.6% (0.1%, 1.2%) 
No. injections in last 6 months     
0 3639 65.2% 3.1% (2.4%, 3.8%) 2.2% (1.7%, 2.8%) 
1-3 1155 21.1% 3.8% (2.6%, 5.0%) 2.5% (1.6%, 3.4%) 
4-8 461 8.3% 4.7% (2.5%, 6.9%) 3.7% (1.6%, 5.7%) 
>8 288 5.4% 7.0% (3.5%, 10.4%) 5.0% (2.1%, 7.9%) 
Last injection given by     
Medical Doctor 1149 20.4% 2.1% (1.2%, 2.9%) 1.3% (0.6%, 2.0%) 
Registered Nurse/Medical 
Practitioner 
3090 56.9% 4.4% (3.6%, 5.2%) 3.3% (2.5%, 4.0%) 
Other/Unknown 1304 22.7% 2.9% (2.9%, 4.0%) 1.9% (1.0%, 2.9%) 
     









% with positive anti-HCV 
(95% confidence intervals) 
% with HCV RNA (95% 
confidence intervals) 
Number of times blood donated     
0 4808 86.5% 3.6% (2.9%, 4.2%) 2.5% (1.9%, 3.0%) 
1-3 528 9.8% 3.3% (1.5%, 5.1%) 3.2% (1.4%, 5.0%) 
4-6 115 2.1% 4.6% (0.5%, 8.6%) 3.6% (0.0%, 7.3%) 
≥7 92 1.7% 5.3% (0.2%, 10.3%) 2.4% (0.0%, 5.8%) 
Number of transfusions received     
0 5175 93.6% 3.4% (2.8%, 4.0%) 2.4% (1.9%, 2.9%) 
1-3 353 6.3% 5.9% (3.2%, 8.6%) 4.6% (2.2% (6.9%) 
>3 15 0.2% 25.8% (0.0%, 53.7%) 25.8% (0.0%, 53.7%) 
Number of childbirths     
0 3416 62.0% 3.4% (2.4%, 4.8%) 2.4% (1.6%, 3.6%) 
1-2 1109 20.2% 3.6% (2.5%, 5.4%) 2.8% (1.9%, 4.2%) 
    3-4 809 14.2% 3.5% (2.2%, 5.4%) 2.3% (1.4%, 4.0%) 
≥5 209 3.6% 6.2% (3.5%, 10.9%) 5.3% (2.8%, 9.9%) 
Use of Injectable Drugs     
    Yes 5 0.1% 25.1% (0.0%, 66.8%) 25.1% (0.0%, 66.8%) 
No 5538 99.9% 3.6% (2.9%, 4.2%) 2.5% (2.0%, 3.1%) 
Any dialysis     
Yes 26 0.4% 0.0% (0.0%, 0.0%) NA 
No 5517 99.5% 3.6% (3.0%, 4.2%) 2.6% (2.0%, 3.1%) 
History of surgery     
Yes 2353 42.8% 4.4% (3.2%, 6.1%) 3.3% (2.3%, 4.6%) 
No 3190 57.2% 2.9% (2.1%, 4.0%) 2.0% (1.4%, 3.0%) 
History of dental surgery     
Yes 2173 39.5% 4.6% (3.4%, 6.3%) 3.4% (2.3%, 5.0%) 
No 3370 60.5% 2.9% (2.1%, 4.0%) 2.0% (1.4%, 2.8%) 
Received a permanent tattoo     
Yes 479 8.6% 5.2% (2.8%, 4.1%) 3.7% (1.9%, 5.4%) 
No 5064 91.4% 3.4% (3.1%, 7.3%) 2.5% (1.9%, 3.0%) 
Received a piercing     
Yes 3061 54.6% 3.3% (2.5%, 4.4%) 2.4% (1.7%, 3.2%) 
No 2482 45.4% 3.9% (2.7%, 5.6%) 2.8% (1.8%, 4.3%) 
Shaves at a barber     
Yes 1081 19.6% 4.9% (3.5%, 6.7%) 3.4% (2.2%, 5.1%) 











5.3.3.  HCV prevalence by age 
I found the anti-HCV prevalence increased with age up to the 40-49-year group where it peaked 
[6.6% (95% CI: 4.4%, 8.0%)] and then decreased with increasing age (table 5.1). Overall, anti-
HCV prevalence among men [4.0% (95% CI: 3.1%, 5.0%)] and women [3.2% (95% CI: 2.5%, 
3.9%)] was similar (table 5.1). When stratified by age, there were some differences in 
seroprevalence by age groups among men and women (figure 5.2). Men aged 30-39 had a 
higher anti-HCV prevalence (7.0%) than women aged 30-39 (2.3%), whilst males aged 5-18 had 
a lower prevalence (0.0%) than females aged 5-18 (1.4%).  
 
Figure 5.2: Prevalence of HCV antibodies by age category and sex*. 
 






5.3.4.  Associations of HCV with healthcare, community, and other variables 
When I examined the prevalence of HCV antibody positivity by potential exposures and risk 
factors, I found that prevalences were higher as the number of injections received increased (see 
figure 5.3). Anti-HCV prevalences were highest for those whose last injection was administered 
by a nurse, registered medical practitioner, or other non–medical doctor, 4.4% (95% CI: 3.6%, 
5.2%), compared with those receiving their last injection from a medical doctor, 2.1% (95% CI: 
1.2%, 2.9%), or other/unknown, 2.9% (95% CI: 2.9%, 4.0%). Prevalences increased with the 
number of blood transfusions received, ranging from 3.4% (95% CI: 2.8%, 4.0%) for those that 
had received none, to 5.9% (95% CI: 3.2%, 8.6%) for those receiving 1-3 transfusions, up to 25.8% 
(95% CI: 0.0%, 53.7%) for the 15 participants with >3 blood transfusions. Women who had had 5 
or more childbirths had an HCV prevalence of 6.2% (95% CI: 3.5%, 10.9%), whilst women who 
had had 3-4 children, 1-2 children, or people that had 0 children all had similar, lower HCV 
prevalences; 3.5% (95% CI: 2.2%, 5.4%), 3.6% (95% CI: 2.5%, 5.4%), and 3.4% (95% CI: 2.4%, 
4.8%), respectively. Participants with a history of surgery had a higher HCV prevalence, 4.4% 
(95% CI: 3.2%, 6.1%), than those that had never had surgery, 2.9% (95% CI: 2.1%, 4.0%), whilst 
those with a history of dental surgery had a higher anti-HCV prevalence, 4.6% (95% CI: 3.4%, 
6.3%), than those without, 2.9% (95% CI: 2.1%, 4.0%).  
Anti-HCV prevalence decreased with increasing educational attainment, with a prevalence of 
4.7% (95% CI: 3.6%, 5.8%) in those educated up to a primary school level or less, 3.4% (95% CI: 
2.6%, 4.1%) prevalence among those with middle/secondary school education, and 1.1% (95% 
CI: 0.3%, 1.8%) prevalence for those with a “Graduate/above” level of education. Anti-HCV 
prevalence was lower among persons with higher household incomes (≥20,000 rupees), 2.5% 
(95% CI: 1.2%, 3.7%), than those with lower incomes, 3.8% (95% CI: 3.1%, 4.5%). HCV antibody 
prevalence was higher among persons who had received a permanent tattoo, 5.2% (95% CI: 
2.8%, 4.1%) than those who had not, 3.4% (95% CI: 3.1%, 7.3%). Similarly, it was higher for 
people that go to a barber for shaving, 4.9% (95% CI: 3.5%, 6.7%), than those who do not 3.3% 
(95% CI: 2.4%, 4.5%). The prevalence was lower among those with a body piercing, 3.3% (95% 
CI: 2.5%, 4.4%), than those without, 3.9% (95% CI: 2.7%, 5.6%). There were no HCV infections 
among persons who had a history of receiving dialysis (table 5.1). However, the number 




drug use (n=5), were small. The anti-HCV prevalence among those with a history of injecting 
drug use was 25.1% (95% CI: 0.0%, 66.8%). 
 








5.3.5.  Multivariable associations 
I examined demographic and potential exposures and risk factors in a multivariable model, 
with odds ratios presented in table 5.2. I found similar results to the univariable analysis: that 
testing positive for anti-HCV was associated with increasing age up to age 40-49 years [aOR 
3.51 (95% CI: 1.50, 6.67)] with the odds decreasing slightly for older age groups. Testing anti-
HCV positive was also associated with rural residence [aOR 2.58 (95% CI: 1.36, 4.88) vs urban 
residence]. Anti-HCV positivity was associated with lower educational attainment [aOR 0.35 
(95% CI: 0.16, 0.78) for the highest vs lowest level] and receipt of blood transfusions [aOR 1.34 
(95% CI: 1.07, 1.69) per transfusion]. When I stratified the analysis by urban and rural residence 
(table 5.3), these associations, except educational attainment, persisted among rural residents, 
while among urban residents, only age remained associated with anti-HCV positivity. I did not 
find a difference in the prevalence of anti-HCV infection among those who received a blood 
transfusion before 2002 [6.4% (95% CI: 3.1%, 9.7%)] and those who received one during or after 
2002 [4.5% (95% CI: 0.9%, 8.1%)], OR 0.88 (95% CI: 0.34, 2.28).  
Table 5.4 shows the multivariable associations stratified by sex. For both males and females 
higher age was associated with increased odds of HCV infection. Living in a rural setting was 
associated with a higher odds of anti-HCV positivity for males [aOR 3.39 (95% CI: 1.40, 8.22)] 
but was only weakly associated among females [aOR 1.96 (95% CI: 0.99, 3.90)]. Similarly, the 
number of medical injections received in the last 6 months [aOR 1.02 (95% CI: 1.00, 1.03)] and 
the number of blood transfusions received [aOR 1.37 (95% CI: 1.00, 1.86)] were both associated 
with increased odds of HCV infection among males but not females [aOR 0.99 (95% CI: 0.96, 
1.02) and 1.32 (95% CI: 0.96, 1.81), respectively]. Having the last injection given by a registered 
nurse or medical practitioner as opposed to a medical doctor was positively associated with 
HCV among females [aOR 1.97 (95% CI: 1.05, 3.70)] but not males [aOR 1.25 (95% CI: 0.63, 
2.46)]. A higher education was associated with a lower odds of HCV infection among females 
[aOR 0.53 (95% CI 0.34, 0.84) for middle/secondary school education vs none/primary] but not 
males [aOR 1.11 (95% CI: 0.69, 1.79)]. Having a body piercing was not associated with HCV 
among females [aOR 0.79 (95% CI: 0.21, 2.99)], nor was shaving at a barber among males [aOR 
1.08 (95% CI: 0.64, 1.81)]. Although in a univariable analysis the number of childbirths among 




the multivariable analysis there was no evidence of such an effect [aOR 0.96 (95% CI: 0.76, 
1.20)]. 
 
5.3.6.  Sensitivity analyses 
Results in table 5.2 were similar to those for a sensitivity analysis restricted to individuals aged 
over 18 years old (table 5.5), and a sensitivity analysis restricted to the two highest prevalence 
age groups – 40-49 and 50-59 years (table 5.6).       
 
5.3.7.  Cumulative exposures 
When I examined anti-HCV prevalence by the number of unique potential exposures, compared 
to persons without these potential exposures, the HCV prevalence increased as the cumulative 
number of unique exposures increased (figure 5.4). The same analysis revealed that overall 77% 





Table 5.2: Weighted unadjusted and mutually adjusted ORs for having HCV antibodies, by 
participant characteristics and risk factors. 
 Total Odds Ratio (95% Confidence Interval) 
Variables Anti-HCV % (95% CI) Unadjusted OR Adjusted OR 
Age (years)    
   5-18 0.7% (0.1%, 1.2%) 0.39 (0.15, 1.01) 0.35 (0.15, 0.79) 
   19-29 1.7% (0.8%, 2.5%) 1 1 
   30-39 4.3% (2.9%, 5.7%) 2.64 (1.43, 4.89) 2.45 (1.18, 5.07) 
   40-49 6.2% (4.4%, 8.0%) 3.91 (2.20, 6.96) 3.51 (1.50, 6.67) 
   50-59 5.8% (3.9%, 7.7%) 3.66 (2.12, 6.31) 3.13 (1.73, 5.69) 
   ≥60 4.3% (2.7%, 5.8%) 2.65 (1.43, 4.90) 2.01 (1.00, 4.06) 
Setting    
   Urban 1.6% (1.1%, 2.2%) 1 1 
   Rural 4.7% (3.8%, 5.7%) 3.01 (2.00, 4.55) 2.58 (1.36, 4.88) 
Sex    
    Female 3.2% (2.5%, 3.9%) 1 1 
Male 4.0% (3.1%, 5.0%) 1.28 (0.95, 1.72) 1.09 (0.34, 3.51) 
Household income    
0-20,000 Rupees 3.8% (3.1%, 4.5%) 1 1 
>20,000 Rupees 2.5% (1.2%, 3.7%) 0.64 (0.38, 1.09) 0.93 (0.54, 1.58) 
Education    
None/Primary 4.7% (3.6%, 5.8%) 1 1 
Middle/Secondary 3.3% (2.6%, 4.1%) 0.70 (0.52, 0.95) 0.78 (0.57, 1.06) 
Graduate 1.1% (0.3%, 1.8%) 0.21 (0.10, 0.46) 0.35 (0.16, 0.78) 
Last injection given by    
Medical Doctor 2.1% (1.2%, 2.9%) 1 1 
Registered Nurse/Medical 
Practitioner 
4.4% (3.6%, 5.2%) 2.16 (1.37, 3.42) 1.58 (0.98, 2.55) 
Other/Unknown 2.9% (1.7%, 4.0%) 1.38 (0.78, 2.45) 1.28 (0.72, 2.28) 
Number injections received last 6 
months 
NA 1.02 (1.01, 1.03) 1.01 (0.99, 1.02) 
Number of times donating blood NA 0.99 (0.93, 1.05) 0.96 (0.87, 1.05) 
Number of blood transfusions received NA 1.36 (1.10, 1.69) 1.34 (1.07, 1.69) 
Number of childbirths NA 1.08 (0.98, 1.19) 0.93 (0.76, 1.14) 
History of surgery    
No 2.9% (2.1%, 4.0%) 1 1 
Yes 4.4% (3.2%, 6.1%) 1.54 (1.16, 2.04) 1.16 (0.87, 1.55) 
History of dental surgery    
No 2.9% (2.1%, 4.0%) 1 1 
Yes 4.6% (3.4%, 6.3%) 1.62 (1.22, 2.14) 1.16 (0.85, 1.57) 
Received a permanent tattoo    
No 3.4% (2.8%, 4.1%) 1 1 
Yes 5.2% (3.1%, 7.3%) 1.54 (0.97, 2.45) 1.19 (0.78, 1.83) 
Received a piercing    
    No 3.9% (2.7%, 5.6%) 1 1 
Yes 3.3% (2.5%, 4.4%) 0.84 (0.62, 1.13) 0.95 (0.35, 2.54) 
Shaves at a barber    
No 3.3% (2.4%, 4.5%) 1 1 




Table 5.3: Weighted unadjusted and mutually adjusted ORs for having HCV antibodies, by participant characteristics and risk factors, 
stratified by urban/rural setting. 
 Urban OR (95% Confidence Interval) Rural OR (95% Confidence Interval) 
Variables Anti-HCV % (95% CI) Unadjusted OR Adjusted OR Anti-HCV % (95% CI) Unadjusted OR Adjusted OR 
Age (years): 5-18 0.5% (0.0%, 1.2%) 0.53 (0.10, 2.92) 0.59 (0.08, 4.27) 0.7% (0.0%, 1.5%) 0.34 (0.11, 1.08) 0.31 (0.13, 0.73) 
   19-29 1.0% (0.0%, 1.9%) 1 1 2.1% (0.9%, 3.3%) 1 1 
   30-39 1.0% (0.0%, 2.0%) 1.02 (0.25, 4.12) 1.14 (0.23, 5.58) 6.4% (4.2%, 8.6%) 3.17 (1.58, 6.37) 2.87 (1.24, 6.66) 
   40-49 4.1% (2.0%, 6.2%) 4.36 (1.41, 13.5) 5.26 (1.48, 18.73) 7.5% (4.9%, 10.1%) 3.78 (1.94, 7.40) 3.12 (1.50, 6.46) 
   50-59 2.4% (0.8%, 4.1%) 2.55 (0.83, 7.89) 3.45 (0.75, 15.94) 8.2% (5.2%, 11.3%) 4.18 (2.23, 7.82) 3.04 (1.63, 5.70) 
   ≥60 1.2% (0.0%, 2.5%) 1.20 (0.27, 5.44) 1.57 (0.20, 12.14) 5.8% (3.6%, 8.0%) 2.86 (1.43, 5.70) 2.03 (0.95, 4.34) 
Sex: Female 1.7% (0.9%, 2.5%) 1 1 4.1% (3.1%, 5.0%) 1 1 
Male 1.6% (0.8%, 2.3%) 0.94 (0.49, 1.77) 0.69 (0.09, 5.32) 5.5% (4.1%, 7.0%) 1.38 (0.98, 1.93) 1.20 (0.29, 4.99) 
Household income: 0-20,000 Rupees 1.8% (1.1%, 2.6%) 1 1 4.8% (3.8%, 5.7%) 1 1 
>20,000 Rupees 1.2% (0.4%, 2.0%) 0.65 (0.29, 1.44) 0.76 (0.26, 2.19) 4.7% (1.7%, 7.7%) 0.99 (0.50, 1.96) 1.02 (0.57, 1.82) 
Education: None/Primary 1.7% (0.6%, 2.8%) 1 1 5.9% (4.4%, 7.3%) 1 1 
Middle/Secondary 2.0% (1.1%, 2.8%) 1.16 (0.53, 2.56) 1.21 (0.52, 2.80) 4.2% (3.1%, 5.3%) 0.74 (0.55, 0.99) 0.71 (0.50, 1.00) 
Graduate 0.8% (0.0%, 1.5%) 0.45 (0.13, 1.50) 0.58 (0.12, 2.77) 1.6% (0.0%, 3.3%) 0.31 (0.09, 1.04) 0.35 (0.13, 0.90) 
Last injection given by: Medical Doctor 1.1% (0.3%, 2.0%) 1 1 3.1% (1.6%, 4.6%) 1 1 
Registered Nurse/Medical Practitioner 2.3% (1.3%, 3.4%) 2.08 (0.87, 4.99) 1.73 (0.62, 4.84) 5.3% (4.2%, 6.4%) 2.16 (1.28, 3.66) 1.57 (0.91, 2.72) 
Other/Unknown 0.9% (0.1%, 1.7%) 0.80 (0.25, 2.52) 0.71 (0.27, 1.82) 4.3% (2.5%, 6.2%) 1.60 (0.71, 3.58) 1.49 (0.75, 2.97) 
Number injections received last 6 months NA 1.03 (0.99, 1.07) 1.01 (0.97, 1.06) NA 1.01 (1.00, 1.03) 1.00 (0.99, 1.02) 
Number of times donating blood NA 0.99 (0.91, 1.08) 0.97 (0.88, 1.06) NA 1.01 (0.94, 1.08) 0.96 (0.84, 1.09) 
Number of blood transfusions received NA 1.05 (0.69, 1.60) 1.02 (0.66, 1.58) NA 1.56 (1.15, 2.10) 1.43 (1.05, 1.96) 
Number of childbirths NA 1.14 (0.92, 1.42) 0.94 (0.60, 1.47) NA 1.06 (0.95, 1.17) 0.93 (0.73, 1.18) 
History of surgery: No 1.4% (0.8%, 2.5%) 1 1 3.8% (2.6%, 5.4%) 1 1 
    Yes 1.9% (0.9%, 3.9%) 1.36 (0.59, 3.09) 0.98 (0.43, 2.23) 6.1% (4.3%, 8.6%) 1.64 (1.22, 2.20) 1.24 (0.91, 1.69) 
History of dental surgery: No 1.5% (0.9%, 2.5%) 1 1 3.6% (2.5%, 5.2%) 1 1 
    Yes 1.7% (0.8%, 3.7%) 1.12 (0.55, 2.31) 0.83 (0.39, 1.78) 6.7% (4.8%, 9.4%) 1.92 (1.40, 2.64) 1.27 (0.90, 1.80) 
Received a permanent tattoo: No 1.6% (1.0%, 2.2%) 1 1 4.5% (3.6%, 5.5%) 1 1 
Yes 2.2% (0.1%, 4.3%) 1.42 (0.49, 4.09) 1.40 (0.49, 4.05) 6.9% (3.9%, 10.0%) 1.57 (0.94, 2.63) 1.15 (0.71, 1.87) 
Received a piercing: No 1.5% (0.7%, 3.1%) 1 1 5.4% (3.6%, 8.0%) 1 1 
Yes 1.7% (1.0%, 3.1%) 1.16 (0.52, 2.58) 1.17 (0.31, 4.43) 4.2% (3.1%, 5.8%) 0.78, (0.56, 1.08) 0.89 (0.26, 3.03) 
Shaves at a barber: No 1.4% (0.8%, 2.5%) 1 1 4.3% (3.0%, 6.2%) 1 1 




Table 5.4: Weighted unadjusted and mutually adjusted ORs for having HCV antibodies, by participant characteristics and risk factors, 
stratified by sex. 
 Male OR (95% Confidence Interval) Female OR (95% Confidence Interval) 
Variables Anti-HCV % (95% CI) Unadjusted OR Adjusted OR Anti-HCV % (95% CI) Unadjusted OR Adjusted OR 
Age (years): 5-18 0.0% (0.0%, 0.0%) NA NA 0.1% (0.1%, 3.0%) 1.12 (0.46, 2.74) 0.75 (0.20, 2.77) 
   19-29 2.1% (1.0%, 4.4%) 1 1 1.3% (0.1%, 3.2%) 1 1 
   30-39 7.0% (4.3%, 11.2%) 3.44 (1.44, 8.22) 3.76 (1.65, 8.59) 2.3% (1.4%, 3.9%) 1.88 (0.61, 5.74) 1.45 (0.53, 3.98) 
   40-49 6.5% (3.8%, 10.8%) 3.15 (1.34, 7.43) 3.38 (1.47, 7.74) 6.0% (4.0%, 8.9%) 5.04 (1.99, 12.77) 3.22 (1.36, 7.64) 
   50-59 7.3% (4.6%, 11.3%) 3.58 (1.58, 8.12) 3.72 (1.61, 8.63) 4.7% (2.9%, 7.4%) 3.83 (1.55, 9.50) 2.25 (1.01, 5.00) 
   ≥60 4.4% (2.5% (7.5%) 2.08 (0.79, 5.47) 1.95 (0.77, 4.94) 4.2% (2.4%, 7.4%) 3.47 (1.40, 8.58) 1.77 (0.85, 3.71) 
Setting: Urban 1.6% (0.1%, 3.1%) 1 1 1.7% (0.9%, 3.0%) 1 1 
Rural 5.5% (3.8%, 8.0%) 3.67 (1.67, 8.08) 3.39 (1.40, 8.22) 4.1% (2.9%, 5.7%) 2.50 (1.24, 5.03) 1.96 (0.99, 3.90) 
Household income: 0-20,000 Rupees 4.4% (3.2%, 6.0%) 1 1 3.4% (2.4%, 4.6%) 1 1 
>20,000 Rupees 2.6% (1.2%, 5.6%) 0.58 (0.28, 1.22) 0.82 (0.36, 1.86) 2.4% (1.3%, 4.4%) 0.71 (0.35, 1.40) 1.06 (0.55, 2.03) 
Education: None/Primary 4.3% (2.8%, 6.5%) 1 1 5.0% (3.6%, 7.0%) 1 1 
Middle/Secondary 4.4% (3.1%, 6.3%) 1.03 (0.68, 1.57) 1.11 (0.69, 1.79) 2.2% (1.5%, 3.4%) 0.43 (0.28, 0.67) 0.53 (0.34, 0.84) 
Graduate 1.6% (0.6%, 4.6%) 0.37 (0.12, 1.13) 0.67 (0.20, 2.20) 0.6% (0.2%, 1.9%) 0.11 (0.03, 0.40) 0.19 (0.05, 0.73) 
Last injection given by: Medical Doctor 2.8% (1.6%, 4.8%) 1 1 1.6% (0.9%, 2.8%) 1 1 
Registered Nurse/Medical Practitioner 4.7% (3.3%, 6.6%) 1.72 (0.94, 3.17) 1.25 (0.63, 2.46) 4.1% (3.0%, 5.6%) 2.69 (1.43, 5.08) 1.97 (1.05, 3.70) 
Other/Unknown 3.3% (1.6%, 6.7%) 1.21 (0.58, 2.52) 1.14 (0.53, 2.43) 2.4% (1.3%, 4.6%) 1.56 (0.61, 4.01) 1.37 (0.54, 3.47) 
Number injections received last 6 months NA 1.03 (1.01, 1.04) 1.02 (1.00, 1.03) NA 1.01 (0.99, 1.03) 0.99 (0.96, 1.02) 
Number of times donating blood NA 0.98 (0.91, 1.05) 0.94 (0.83, 1.06) NA 0.56 (0.16, 2.03) 0.69 (0.19, 2.55) 
Number of blood transfusions received NA 1.28 (0.98, 1.68) 1.37 (1.00, 1.86) NA 1.47 (1.07, 2.01) 1.32 (0.96, 1.81) 
Number of childbirths NA NA NA NA 1.23 (1.09, 1.40) 0.96 (0.76, 1.20) 
History of surgery: No 3.5% (2.4%, 4.9%) 1 1 2.4% (1.6%, 3.5%) 1 1 
    Yes 5.1% (3.3%, 7.8%) 1.49 (0.95, 2.35) 1.19 (0.74, 1.92) 4.0% (3.0%, 5.5%) 1.74 (1.21, 2.49) 1.25 (0.88, 1.77) 
History of dental surgery: No 3.4% (2.3%, 5.0%) 1 1 2.4% (1.6%, 3.5%) 1 1 
    Yes 5.1% (3.4%, 7.6%) 1.50 (0.96, 2.35) 1.08 (0.68, 1.71) 4.3% (3.0%, 6.0%) 1.82 (1.22, 2.72) 1.23 (0.80, 1.89) 
Received a permanent tattoo: No 3.7% (2.5%, 5.5%) 1 1 3.2% (2.4%, 4.3%) 1 1 
Yes 6.0% (4.1%, 8.6%) 1.66 (0.99, 2.77) 1.32 (0.77, 2.27) 1.6% (0.2%, 10.8%) 0.48 (0.07, 3.16) 0.39 (0.04, 3.47) 
Received a piercing: No 4.0% (2.8%, 5.7%) 1 1 2.2% (0.6%, 8.3%) 1 1 
Yes 4.5% (2.2%, 9.1%) 1.14 (0.50, 2.56) 1.14 (0.50, 2.58) 3.2% (2.4%, 4.3%) 1.49 (0.41, 5.36) 0.79 (0.21, 2.99) 
Shaves at a barber: No 3.4% (2.1%, 5.4%) 1 1 3.2% (2.4%, 4.3%) 1 1 




Table 5.5: Weighted unadjusted and mutually adjusted ORs for having HCV antibodies, by 
participant characteristics and risk factors for adults aged over 18 years old. 
 Total Odds Ratio (95% Confidence Interval) 
Variables Anti-HCV % (95% CI) Unadjusted OR Adjusted OR 
Total 4.3% (3.6%, 5.1%)   
Age (years)    
   19-29 1.7% (0.8%, 2.5%) 1 1 
   30-39 4.3% (2.9%, 5.7%) 2.64 (1.43, 4.89) 2.39 (1.15, 4.97) 
   40-49 6.2% (4.4%, 8.0%) 3.91 (2.20, 6.96) 3.31 (1.72, 6.37) 
   50-59 5.8% (3.9%, 7.7%) 3.66 (2.12, 6.31) 2.86 (1.52, 5.39) 
   ≥60 4.3% (2.7%, 5.8%) 2.65 (1.43, 4.90) 1.77 (0.86, 3.63) 
Setting 
   
    Urban 1.9% (1.1%, 3.2%) 1 1 
    Rural 5.8% (4.2%, 7.9%) 3.20 (2.09, 4.89) 2.64 (1.37, 5.11) 
Sex 
   
    Female 3.6% (2.8%, 4.3%) 1 1 
Male 5.2% (4.0%, 6.5%) 1.50 (1.10, 2.04) 1.79 (0.55, 5.83) 
Household income 
   
0-20,000 Rupees 4.7% (3.8%, 5.5%) 1 1 
>20,000 Rupees 2.8% (1.3%, 4.2%) 0.58 (0.34, 1.00) 0.93 (0.53, 1.64) 
Education 
   
None/Primary 6.1% (4.6%, 7.5%) 1 1 
Middle/Secondary 4.1% (3.1%, 5.0%) 0.66 (0.48, 0.90) 0.75 (0.54, 1.06) 
Graduate 1.1% (0.3%, 1.8%) 0.17 (0.08, 0.36) 0.37 (0.16, 0.82) 
Last injection given by 
   
Medical Doctor 2.3% (1.2%, 3.3%) 1 1 
Registered Nurse/Medical Practitioner 5.3% (4.3%, 6.3%) 2.43 (1.48, 3.97) 1.76 (1.10, 2.82) 
Other/Unknown 3.6% (2.2%, 5.1%) 1.64 (0.90, 2.99) 1.49 (0.80, 2.78) 
Number injections received last 6 months NA 1.02 (1.00, 1.03) 1.01 (0.99, 1.02) 
Number of times donating blood NA 0.97 (0.89, 1.04) 0.95 (0.86, 1.05) 
Number of blood transfusions received NA 1.32 (1.07, 1.63) 1.35 (1.07, 1.70) 
Number of childbirths NA 0.99 (0.89, 1.10) 1.00 (0.83, 1.22) 
History of surgery    
    No 3.9% (2.8%, 5.4%) 1 1 
    Yes 4.7% (3.4%, 6.5%) 1.22 (0.90, 1.67) 1.19 (0.88, 1.62) 
History of dental surgery    
    No 3.9% (2.9%, 5.3%) 1 1 
    Yes 4.8% (3.5%, 6.6%) 1.24 (0.93, 1.64) 1.16 (0.85, 1.57) 
Received a permanent tattoo 
   
No 4.2% (3.4%, 5.0%) 1 1 
Yes 5.5% (3.3%, 7.7%) 1.35 (0.85, 2.14) 1.13 (0.73, 1.76) 
Received a piercing    
No 5.3% (3.7%, 7.5%) 1 1 
Yes 3.6% (2.7%, 4.8%) 0.68 (0.49, 0.94) 1.06 (0.39, 2.88) 
Shaves at a barber    
No 4.1% (3.0%, 5.5%) 1 1 
Yes 5.1% (3.7%, 7.1%) 1.27 (0.91, 1.78) 1.19 (0.73, 1.93) 
Table 5.6: Weighted unadjusted and mutually adjusted ORs for having HCV antibodies, by 




 Total Odds Ratio (95% Confidence Interval) 
Variables Anti-HCV % (95% CI) Unadjusted OR Adjusted OR 
Total 6.0% (4.3%, 8.3%)   
Setting    
   Urban 3.3% (1.7%, 6.4%) 1 1 




    Female 5.4% (3.7%, 7.8%) 1 1 




0-20,000 Rupees 6.3% (4.6%, 8.8%) 1 1 




None/Primary 8.6% (6.0%, 12.3%) 1 1 
Middle/Secondary 4.7% (3.0%, 7.6%) 0.53 (0.31, 0.90) 0.60 (0.34, 1.06) 
Graduate 1.6% (0.5%, 4.9%) 0.17 (0.05, 0.56) 0.26 (0.07, 0.89) 
Last injection given by 
 
  
Medical Doctor 2.9% (1.6%, 5.5%) 1 1 
Registered Nurse/Medical Practitioner 7.9% (5.6%, 11.1%) 2.83 (1.53, 5.22) 2.19 (1.13, 4.21) 
Other/Unknown 4.1% (2.4%, 6.8%) 1.40 (0.65, 3.00) 1.34 (0.63, 2.86) 
Number injections received last 6 months NA 1.01 (0.99, 1.03) 1.00 (0.98, 1.02) 
Number of times donating blood NA 0.91 (0.76, 1.08) 0.91 (0.75, 1.12) 
Number of blood transfusions received NA 1.35 (1.01, 1.81) 1.46 (1.12, 1.90) 
Number of childbirths NA 0.99 (0.86, 1.14) 1.08 (0.85, 1.36) 
History of surgery    
    No 5.1% (3.5%, 7.3%) 1 1 
    Yes 6.8% (4.6%, 9.9%) 1.37 (0.91, 2.06) 1.45 (0.95, 2.21) 
History of dental surgery    
    No 6.9% (4.8%, 9.9%) 1 1 
    Yes 5.4% (3.6%, 8.0%) 0.77 (0.51, 1.15) 0.84 (0.56, 1.25) 
Received a permanent tattoo 
 
  
No 5.9% (4.3%, 8.1%) 1 1 
Yes 7.6% (3.7%, 14.9%) 1.30 (0.66, 2.56) 0.98 (0.44, 2.19) 
Received a piercing    
No 6.8% (4.4%, 10.3%) 1 1 
Yes 5.5% (3.8%, 7.8%) 0.80 (0.51, 1.27) 1.18 (0.25, 5.53) 
Shaves at a barber    
No 5.7% (4.0%, 8.2%) 1 1 





Figure 5.4: Prevalence of HCV antibodies by unique potential exposures†. 
       
† Whether they had a history of surgery, whether they had a history of dental surgery, 
whether they shave at a barber, whether they had ever received a blood transfusion, and 




5.4.  Discussion 
5.4.1.  Main findings 
In this serosurvey in Punjab, India, there was an overall weighted prevalence of anti-HCV of 
3.6% and HCV RNA of 2.6%. I found that males, persons aged 40-59, and persons living in 
rural areas had the greatest odds of being infected with HCV. Additionally, HCV infection 
was more common among those who lacked education, had received a blood transfusion, 
and had their last injection given by a nurse or other medical practitioner as compared to a 
medical doctor. Through multivariable analysis, I found no increased likelihood of being 
anti-HCV positive with increases in the reported number of participants’ medical injections 
received by participants in the last 6 months.   
Due to the increasing prevalence with age, it may be tempting to consider that transmission 
risk has decreased over time and younger people are at lower risk. However, the youngest 
age groups studied, 5-18- and 19-29-year olds, had HCV seropositive rates of over 1% and 
2% respectively, suggesting that transmission risk persists in Punjab. In fact, a rise in 
prevalence of injection drug use in Punjab has been described among teens and the youth 
population(261) and may present an emerging risk for HCV infection in similarly aged 
populations in the years to come. Very few disclosed injecting drug use in the serosurvey, 
which may reflect social desirability bias on the part of participants – the role of injecting 
drug use to HCV transmission is examined in chapter 7. 
Residence in a rural versus urban area was determined to be an effect modifier in this 
analysis. Individuals in rural areas of Punjab had 2.5 times the odds of being anti-HCV 
positive as those in urban settings after adjusting for covariates, a result comparable to 
another study from North India(226). Upon stratification, I found that age, education, and 
blood transfusions were associated with HCV among participants in rural areas, whereas in 
urban areas the only association was with age. Poverty, defined by a household income 
<20,000 rupees, was not associated with infection in this analysis. There is a paucity of 
trained healthcare professionals in rural areas of Punjab, so healthcare in those regions is 
often delivered by unqualified practitioners who may adopt unsafe injection practices(336), 
possibly contributing to the elevated prevalence of HCV among rural residents in Punjab 




The finding that blood transfusions were associated with HCV highlights the need for 
improved blood safety practices in Punjab. Mandatory testing for HCV was implemented in 
blood banks in India in 2002(303). However, participants in the serosurvey who received 
their first transfusion in 2002 or later were no less likely to be anti-HCV positive than those 
who received transfusions before mandatory testing began. Despite the existence of state-
wide blood safety guidelines, an association between receipt of a blood transfusion and 
having HCV infection persisted in this serosurvey, regardless of when the blood 
transfusions were received, and may suggest a persistent mode of HCV transmission in 
Punjab. These findings underscore the need for greater enforcement and monitoring of 
blood banks to ensure proper testing procedures are followed to prevent transmission in 
these settings.   
 
5.4.2.  Strengths and limitations 
This analysis is subject to several limitations. First, it was not possible to independently 
verify any of the responses on the questionnaire. Also, the number of non-responders could 
not be determined, although it was reported from the field that interest was very high and 
98% of households participated. False positive anti-HCV among those that tested negative 
for RNA cannot be ruled out. As with any cross-sectional study that examines a chronic 
condition, it is challenging to attribute risk due to lack of temporality, as the HCV infection 
could have occurred at any time during the lifetime of the study subjects. A global analysis 
found a large reduction in the re-use of medical syringes, and the viruses that arise from 
them, in each region from 2000 to 2010(282, 283). This serosurvey asks about the use of 
medical injections in the last 6 months, so many infections due to HCV could have occurred 
in the time period before this. As discussed in chapter 4, associations in cross-sectional 
studies can be particularly challenging to discern with highly prevalent behaviours, such as 
medical injections in this setting.  
The sampling method of this study, which included multiple participants from a single 
household, could lead to potential selection bias. Persons living together are more likely to 
exhibit similar behaviours and could lead to disproportionate risks in the sample that may 
not be representative of the greater population. Additionally, the sampling method of the 




a preponderance of people surveyed from rural areas in districts that were found to have a 
high prevalence of HCV. These results should be interpreted with caution, as this could lead 
to overestimation of the prevalence in these areas. The face-to-face nature of the 
questionnaire creates the potential for social desirability bias. Injection drug use is a 
significant risk factor for HCV, but self-report of this behaviour was extremely low (0.09%) 
among participants in this serosurvey despite reports of worrisome trends of increased 
injection drug use in the state(326, 359). The number of persons associated with some of the 
exposures and risk factors, notably dialysis (n=26) and injection drugs (n=5), was small, 
making associations of these risk factors with HCV seropositivity difficult to determine. 
Thus, an important risk behaviour may be substantially underrepresented in this analysis. 
 
5.4.3.  Comparison with other literature 
The association of HCV with age and rural residence has been observed in previous studies 
from Punjab(335). Studies from other countries have also identified a particular age or birth 
cohort with a high prevalence of HCV compared to others, consistent with the analyses in 
Pakistan in chapter 4(165, 351). This cohort effect is demonstrated by persons born between 
1945 and 1965, so called “Baby Boomers” in the United States(266, 338). In the United States, 
the higher HCV prevalence among Baby Boomers has been attributed largely to injection 
drug use during their youth, the lack of an HCV screening test for blood and blood products 
prior to 1990, and to the effect of the HIV epidemic, recognised during the 1980s(266, 338). 
The reason behind the greater HCV prevalence in Punjab among those aged 40-59 is unclear; 
perhaps transmission rates were higher in the past and infected individuals aged ≥60 years 
have died more quickly. My sensitivity analysis examining associations among this age 
group found similar results to that the analysis containing all age groups. 
Previous studies have also found inadequate infection control practices among healthcare 
workers in India(87, 253), however, the number of medical injections was not associated 
with HCV after adjusting for covariates in this study. It is important to note that in a cross-
sectional study, to identify associations with medical practices is challenging. However, we 
found an increased likelihood of being anti-HCV positive among those who received their 
last injection from someone other than a medical doctor. As discussed in chapter 4, Kot 




particularly HIV(386); it is thought that this outbreak was initially sparked by the re-use of 
medical injections by untrained medical practitioners(386). A 2002 study in Punjab (India) 
found that a considerable percentage of physicians with knowledge of parenteral HCV 
transmission risk nevertheless reused needles and syringes with their patients(343). 
Furthermore, in Punjab and throughout India, treatment with injectable medicine is 
perceived to be the treatment that ensures rapid therapeutic relief(297). This belief has been 
inculcated over many years by physicians themselves, and there are financial incentives to 
deliver treatment through a “procedure”, such as an injection(297). Although increased 
availability of disposable syringes helps temper these risks, healthcare workers throughout 
Punjab could benefit from further training on safe injection practices to prevent the spread of 
HCV and other diseases.  
Unlike in this chapter focusing on Punjab, India, in chapter 4 I found an association between 
the number of medical injections received and HCV infection in Pakistan. This could be 
because the use of unsafe medical injections is less prevalent in Punjab. In Pakistan there 
was evidence of a positive association between childbirth and HCV infection, however, this 
was not evident in Punjab perhaps due to different practices surrounding childbirths. Both 
this chapter and chapter 4 found that having received blood transfusions was associated 
with HCV prevalence. Neither analysis found a history of surgery or of dental surgery were 
associated with HCV infection, whilst both chapters identified socio-economic markers 
associated with HCV infection: illiteracy and employment type in Pakistan, and education in 
Punjab. However, whilst community risk factors (body-piercings, tattoos, shaving at the 
barbers) were associated with HCV in Pakistan, in Punjab none were associated with HCV 
prevalence, which is possibly due to different equipment sterilisation practices in each 
setting. 
 
5.4.4.  Implications 
The prevalence of chronic HCV infection found in this serosurvey was slightly less than was 
determined by a 2012 study in the region(344), but in a population of roughly 28 million, still 
translates to nearly three quarters of a million people chronically infected in the state of 
Punjab alone. Future screening efforts need to address this burden of disease to identify 




the study in Punjab presented here, can address key information gaps and inform policy 
makers in efforts to alleviate the public health burden of HCV infection across afflicted 
regions worldwide(387). As with chapter 4 in Pakistan, the results of this study can be used 
to target screening and linkage to care efforts in Punjab state, to ensure the highest yield of 
HCV infected individuals, whilst minimising costs. Screening efforts in Punjab should target 
rural districts, persons aged 30 and older, and those with history of receiving blood 
transfusions. India’s expenditure on health care as a percentage of its gross domestic 
product (1.3% in 2015-2016) is among the lowest in the world, and the country has no system 
to monitor patients(5). Nationwide surveillance of hepatitis is also lacking in the country 
and focuses primarily on hepatitis A and E(203). Testing for incident HCV and HBV cases is 
only supported by the country’s national Integrated Disease Surveillance Programme (IDSP) 
in outbreak situations(203). Fortunately, treatment costs for HCV infection in India have 
decreased significantly with the introduction of direct acting antiviral drugs in 2015, which 
have proven to be highly effective(345). In 2016, Punjab became the first state in India to 
make the commitment to treat HCV patients free of charge(80, 361). Through July 2017, over 
32,000 patients have been treated through the program(361), representing an important step 
in control of the disease. With treatment options becoming more effective, affordable, and 
available to patients, there is hope that Punjab could be reaching a turning point to mitigate 
the burden of HCV. However, access to treatment alone cannot end the epidemic of HCV 
globally or in Punjab. Indeed, as DAA access has expanded in other settings, such as 
Australia, after the first couple years the initial very high numbers of people starting 
treatment have declined(205). This has been called a warehousing effect as whilst waiting for 
treatment to become available, the number of people that know they are HCV-infected 
builds up – the “warehousing”(205). This leads to high initial numbers that start treatment 
as those already diagnosed are able to access treatment, but these numbers reduce when 
there are less diagnosed people to treat(205). Therefore, more information on screening 
strategies is required to enable high rates of diagnosis so the high numbers of people 
starting HCV treatment can continue. This will be influenced by analysing data from 
serosurveys such as in this chapter. 
Additionally, when designing a treatment programme such as that in Punjab, it is important 
to understand how different subgroups of infected individuals contribute to the HCV 
epidemic in that setting. To this end, in chapter 7 I investigate the contribution of injecting 




programmes, it is also important to understand the preventative effect of treatment on 
further transmission. In chapter 8 I estimate the infections averted per each DAA treatment 





CHAPTER 6. MODELLING THE GLOBAL 
HEPATITIS C VIRUS EPIDEMIC 
The work in this chapter was done in collaboration with Hannah Fraser, Aaron G Lim, Amy 
Peacock, Samantha Colledge, Josephine G Walker, Janni Leung, Jason Grebely, Sarah 
Larney, Natasha K Martin, Matthew Hickman, Louisa Degenhardt, Margaret T May, and 
Peter Vickerman. This chapter forms the basis of the methods used in chapters 8 and 9. 
 
6.1.  Introduction 
The model presented in this chapter is of country-level hepatitis C virus (HCV) 
transmission, incorporating HCV transmission among people who inject drugs (PWID) and 
the general population (non-PWID). The HCV transmission model is stratified into nine 
disease and treatment strata (figure 6.1), with each of these then stratified by seven age and 
injecting status strata (figure 6.2). This makes up 63 model compartments in total. Chapter 7 
uses the model presented in this chapter to investigate the contribution of injection drug use 
(IDU) to HCV transmission globally, whilst chapter 8 uses this model to estimate the impact 
of treatment as prevention for different infected population subgroups. 
These dynamic, deterministic HCV transmission models simulating country-level HCV 
epidemics among the general population and PWID, incorporate age distributions (0–14, 15–
34, and ≥35–year olds), IDU, population growth, and HCV progression.  
 
6.2.  Model structure 
6.2.1.  Age and injecting model structure 
Individuals transition through age and injecting model strata as shown in figure 6.1. Most 
individuals enter the model at a rate R(t) into the 0-14-year-old compartment as susceptible 
to infection (except those that enter as infected via vertical transmission). The rate R(t) is set 
to balance all non-HCV-related and non-drug related deaths (DR1, DR2 and DR3 for those 




specified rate. Other than becoming infected, young individuals can age (at rate a) to become 
young adults that do not inject drugs – referred to in the diagram as non-PWID - (aged 15-34 
years), from which they can age (at rate b) to becoming older adults that do not inject drugs 
(aged ≥35 years). Adults that do not inject drugs (aged 15-34 years) can also transition (at 
rate φ) to become PWID (current injectors). I assume that adults aged ≥35 do not start 
injecting drugs. However, adults aged ≥35 can be current injectors by ageing from the 
currently injecting aged 15-34 category; ageing at rate b. This assumption was based on data 
from a recent global meta-analysis that identified the average age of onset of injecting drug 
use across studies to be 22 years old, with the minimum average age of onset being 13 and 
maximum 39(77). PWID inject for an average duration until they transition (at rate v) to 
become people who used to inject drugs (referred to in the diagram as ex-PWID). Young 
adults (age 15-34 years) that are PWID or used to inject drugs age to their respective older 
adult (aged ≥35 years) classes just as young adults that do not inject drugs do. All 
individuals are subject to age category dependent death rates (DR1, DR2, DR3, for those aged 
0-14, 15-34, and ≥35 years, respectively), with PWID also being subject to an additional drug-
related death rate (µ).   
 
6.2.2. Disease modelling structure 
Within the disease state model component, most individuals enter as susceptible individuals 
(S), from which they can then become infected and transition to the chronically infected state 
(I) at a per capita transmission rate, (1 − 𝛿)𝑃, for the general population (not people who 
inject drugs), which is increased for PWID to (1 − 𝛿)(𝑃 + 𝜋). P is the force of infection that 
acts on the whole population, 𝜋 is the additional force of infection that acts on PWID, and 𝛿 
is the proportion of new infections that spontaneously clear their infection and so do not 
progress to chronic infection. Individuals who spontaneously clear infection remain 
susceptible to re-infection (assuming no immunity after clearance as previous modelling has 
shown it has little effect on model projections(384)). A certain number of individuals, V(t), 
which is time varying, enter the model chronically infected due to vertical transmission, this 
is described in section 6.8.  
Once they are chronically infected, individuals progress through different infection and 




at rate 𝛾. Individuals that are cirrhotic infected (CI) can then progress to the decompensated 
cirrhosis infected state (DI) at rate χ. Individuals in each of these infected groups (chronic [I], 
cirrhotic [CI], and decompensated [DI]) can receive HCV treatment (and move to the 
treatment [T], cirrhotic treatment [CT], or decompensated treatment groups [DT], 
respectively) at a per capita rate, denoted λ. If treatment is successful, individuals achieve a 
sustained viral response (SVR – effective cure) at a rate αω, where α is the proportion of 
people that achieve SVR following treatment, and 1/ω is the length of treatment. Individuals 
achieving SVR transition from the treatment to their respective susceptible disease stage 
(susceptible [S], cirrhotic susceptible [CS], or decompensated susceptible groups [DS], 
depending on their disease stage when they were treated). However, some individuals that 
receive treatment fail to achieve SVR and move back to their prior infection disease stage at 
rate (1-α)ω, either chronic (I), cirrhotic (CI), or decompensated infected (DI) groups. We 
assume disease progression ceases for cured individuals whose HCV infection had not 
progressed to cirrhosis or later(61), while those with cirrhosis who are cured experience 
further disease progression at a slower rate (rate  – slower than χ) than those not achieving 
SVR or who are infected. There is a further additional liver-related mortality rate, 𝜇4, for 
those in the decompensated infected (DI), decompensated treatment (DT), and 
decompensated susceptible groups (DS). Those in the susceptible, cirrhotic susceptible (CS) 
and decompensated susceptible groups (DS) can be re-infected at the same rate as for 
primary infection, but depending on their injecting drug use (IDU) status, and move to the 
chronically infected (I), cirrhotic infected (CI) and decompensated infected (DI) groups, 
respectively. 
Of note, I assume no transient increase in transmission risk during the acute phase of 
infection because viral load data suggests no evidence for a peak in HCV viremia during 
acute infection (except for those that subsequently clear their infection). Therefore, early 
viral load levels should not affect transmission and so have not been included within the 
model. Please see "Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The 






Figure 6.1: Schematic of how people move through the seven age and injecting stage groups 
of the model*. 
 
* PWID denotes people who inject drugs, Ex-PWID denotes those individuals that used to 


















Figure 6.2: Schematic of how people move through the HCV stages of the model*.  
 





6.3.  Model parameterisation  
Country-specific data from recent systematic reviews, particularly Blach et al.(40) and 
Degenhardt et al.(77), and United Nations (UN) datasets were used to parameterise and 
calibrate the model, including data on the prevalence of HCV among PWID and the general 
population, estimates for the population percentage of PWID, and data on population 
growth rates and age distributions. Table 6.1 gives details on the sources of the data used, 
whilst table 6.2 gives information on the model parameters, and table 6.3 provides details of 
parameters that vary by region. Section 6.13 gives information about country-level inputs. 
The study by Degenhardt et al., from which most estimates of injecting population sizes 
were taken, states that they preferentially selected size and HCV prevalence estimates that 
defined current injectors as individuals that have injected drugs in the previous 12 months. 
However, other estimates using alternative definitions (eg. injecting in the last 6 months) 
were still included in the review in the absence of the preferred definition. For country-level 
HCV prevalence estimates, HCV antibody prevalence was taken from the reviews, and was 
adjusted using region-specific viraemic rates(252) to estimate the prevalence of chronic 
infection in the survey year – these region-specific viraemic rates do not account for HIV 
prevalence. Historical treatment numbers were taken from various sources, which are 
described in section 6.15. All key parameters had uncertainty associated with them, with 
bounds generally obtained directly from studies. Where bounds were unavailable for 
prevalence inputs, ±33% uncertainty bounds were applied, which equates to the median 
level of uncertainty for those parameters that did have bounds - this was to avoid ascribing 





Table 6.1: Global model data source summary. 
Data Source 
Population sizes and growth rate United Nations(380) 
Age distributions United Nations(380) 
Fertility rates United Nations(380) 
Age-group specific mortality rates United Nations(380) 
Proportion of adults (aged ≥15) that are PWID 
Degenhardt et al.(77) and other 
reviews where necessary, see table 6.8 
HCV antibody prevalence among PWID 
Degenhardt et al.(77) and other 
reviews where necessary, see table 6.8 
HCV antibody prevalence among the general 
population* 
Blach et al.(40) and other reviews 
where necessary, see table 6.8 
Region-specific viraemic rates amongst sero-
positive individuals to estimate chronic 
infection 
Petruziello et al.(285) 
Duration of injecting** Degenhardt et al.(77) 
Injecting drug use by gender† Degenhardt et al.(77) 
HIV prevalence among PWID† Degenhardt et al.(77) 
HIV prevalences for women aged 15-24***† World Bank(365) 
Historical treatment numbers Various, see table 6.10 
* Only USA, Egypt, and France have two “robust surveys”(40) (large, national surveys with 
very similar methodology), with these data being used to model their HCV epidemic 
dynamics. 
** Taken from data on the current duration of injecting, with wide uncertainty bounds being 
applied (-50%, +100%) to account for uncertainty in how this parameter relates to total 
duration of injecting. 
*** Used to proxy HIV prevalence among women of childbearing age, assumed to be 15-34 
years old in my model. 







Table 6.2: Model parameters with sampled ranges*. 
Parameter Parameter description Point value and sampled range Reference 
a The rate of aging from 0-14 to 15-34 1/15  
b The rate of aging from 15-34 to ≥35 1/20  
δ 
Proportion of individuals spontaneously clearing 
infection 




The rate of progressing from chronic infection to 
cirrhosis 
0.037 (0.025-0.052); Triangular distribution Shepherd 2007(328) 
χ 
The rate of progressing from compensated cirrhosis to 
decompensated cirrhosis if infected (or on treatment) 
0.0453 (0.0363-0.0566); Triangular distribution Hallager 2017(140) 
ε 
The rate of progressing from cirrhosis to the 
decompensated cirrhosis if cured and susceptible 
0.01 (0.006-0.0165); Triangular distribution Hallager 2017(140) 
µ4 
Additional death rate for an individual with 
decompensated cirrhosis 
0.13 [Beta distribution: alpha = 14.6, beta = 360.2] 
Greive 2006 (129); Shepherd 
2007(328); Wright 2003(411) 
φ 
The initiation rate of becoming a person who currently 
injects drugs 
Fitted to the proportion of adults that are PWID in data 
from systematic reviews 
  
v The rate of ceasing injecting drugs 




Additional mortality rate for people who currently inject 
drugs 
High-income countries: 0.0217 (0.0192, 0.0247); Triangular 
distribution 
Mathers 2013(246) 
Low and middle-income countries: 0.0353 (0.0281, 




Parameter Parameter description Point value and sampled range Reference 
λ Treatment rate 
Country-specific and varying with time. Treatment 
numbers in 2017 (when the data ends) are carried 
forward, apart from in 2018 when an extra 50 infections 
are treated in specific groups for the intervention 
scenarios in chapter 8. If the number of possible annual 
treatments exceeds the number infected, then a treatment 
rate of 0.95 is used 
See historical treatment numbers 
section 
  
1/ω Duration of treatment 
Until 2010: 48 weeks for Pegylated interferon. From 2011-
2014: 24 weeks due to 1st wave DAAs. From 2015 
onwards: 12 weeks due to 2nd wave DAAs 
Palumbo 2011 (277); Brouard 
2017(48); WHO 2016(400) 
α 
Proportion achieving sustained virological response 
with HCV treatments 
Until 2010: Uniform between 0.4-0.5 for 
Pegylated interferon. From 2011-2014: 0.65-0.75. From 
2015 onwards: Uniform between 0.9-0.99 due to 2nd 
wave DAAs 
Palumbo 2011(277); Brouard 
2017(48) Hezode 2017(155) 
q1 
Chance of vertical transmission of HCV RNA per birth 
among women with HCV RNA that are HIV negative 
0.058 (0.042, 0.078); Triangular distribution Benova 2014(35) 
q2 
Chance of vertical transmission of HCV RNA per birth 
among women with HCV RNA that are HIV positive 
0.108 (0.076, 0.152); Triangular distribution Benova 2014(35) 








Percentage of PWID 
that are female (95% 
CI)† 
HIV prevalence 
among PWID (95% 
CI)† 
Central Asia 48.7% (45.2%, 52.2%) 12.6% (9.7%, 15.6%) 10.5% (8.6%, 12.5%) 
Eastern Europe 69.6% (66.1%, 73.1%) 25.4% (22.0%, 28.6%) 24.7% (15.6%, 33.9%) 
Australasia 74.8% (71.3%, 78.3%) 33.4% (31.0%, 35.6%) 1.1% (0.8%, 1.4%) 
East and South East 
Asia 
63.6% (60.1%, 67.1%) 20.8% (16.1%, 25.4%) 15.2% (9.9%, 20.4%) 
South Asia 78.5% (75.0%, 82.0%) 3.1% (2.1%, 4.1%) 19.4% (15.0%, 23.8%) 
North America 75.7% (72.2%, 79.2%) 30.0% (28.5%, 31.5%) 9.0% (7.0%, 11.1%) 
Western Europe 71.0% (67.5%, 74.5%) 28.6% (12.7%, 44.4%) 4.5% (3.2%, 6.0%) 
Sub-Saharan Africa 70.5% (67.0%, 74.0%) 11.6% (7.8%, 15.6%) 18.3% (11.3%, 25.4%) 
Latin America 74.0% (70.5%, 77.5%) 13.0% (5.0%, 21.3%) 35.7% (15.0%, 56.6%) 
Middle East and 
North Africa 
68.8% (65.3%, 72.3%) 3.5% (2.5%, 5.2%) 3.6% (1.5%, 6.2%) 
GBD: Global Burden of Disease 
* Only regions from countries in the analysis are included. Parameters were sampled from 
triangular distributions due to the often-skewed nature of the data. The percentage of PWID 
that are female and the HIV prevalence among PWID are used only for estimating the rate of 
vertical HCV transmission. 
¥ Petruzziello et al. Global epidemiology of hepatitis C virus infection: An up-date of the 
distribution and circulation of hepatitis C virus genotypes. 2016(285).  
± Micallef et al. Spontaneous viral clearance following acute hepatitis C infection: a 
systematic review of longitudinal studies. 2006(252). Note: as no bounds were available in 
the Petruzziello paper, bound sizes of 3.5% were taken to give the same magnitude as those 
from Micallef et al. 
† Degenhardt et al. Global prevalence of injecting drug use and sociodemographic 
characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a 




6.4.  Country inclusion criteria 
Countries were considered for inclusion in the model if data were available on the 
population percentage of PWID, HCV prevalence for PWID, and HCV prevalence for the 
general population.  
• For the general population, HCV prevalence estimates were taken from Blach 
2017(40), and if not available for a particular country then values were taken from 
Gower 2014, Hope 2014, Riou 2015, and Lavanchy 2011(124, 160, 210, 309), prioritised 
in this order.  
• For HCV prevalence among PWID, estimates were taken from Degenhardt 2017(77), 
and where not available were taken from Hope 2014(160) and Aceijas 2007(3), 
prioritising in that order.  
• The estimates for the population percentage of adults that are PWID were taken from 
Degenhardt 2017(77), and when estimates were unavailable for a particular country 
were then taken from Mathers 2008, Hope 2014, Mumtaz 2014, Aceijas 2007, and 
Reid 2009(3, 160, 245, 258, 304), prioritised in the order given.  
Subnational studies, as opposed to countries, (eg. England, rather than the UK) were 
omitted. The year of the estimate was recorded. Where the estimate was recorded over 
multiple years the model was calibrated to the middle year of the range, e.g. a serosurvey 
recorded from 2004-2008 would be taken as 2006.  
Data were available on the population percentage of PWID, and HCV prevalence for PWID 
and the general population for 91 countries. Three countries were excluded. For Côte 
d’Ivoire and the Maldives, the HCV prevalence among PWID was unrealistically low, 1.8% 
and 0.7% respectively, which is lower than that of the general population. Other estimates 
were not available, so these two countries were omitted. For Syria, where the PWID HCV 
prevalence was 3.3%, the situation was similar, however, another estimate for this parameter 
was available (60.5%) from Nelson et al.(268), and was used instead so Syria was included in 
the analysis. Seychelles was also omitted from the model (in the absence of other data) as the 
number of infections among current PWID was higher than among the general population, 
due to a high estimate of the prevalence of injecting from Degenhardt et al., 2.3%(77), and a 




mathematically incompatible. The prevalence data by country are shown in table 7.6. The 
model was calibrated to the data for these 88 countries. 
 
6.5.  Model calibration 
From 1990 onwards, the model start year, a four-step calibration method using different sub-
models, was used to calibrate the overall model for each country. These four sub-models 
were used to ease the fitting process. Table 6.4 shows the parameters that were fitted by each 
of the four sub-models. At each step, required model parameters were randomly sampled 
from their uncertainty bounds, as was data used to calibrate the sub-model, and then other 
unknown model parameters (see table 6.4) were estimated through fitting the sub-model to 
the calibration data using the Matlab function lsqnonlin. For each sampled parameter set, it 
was not always possible to fit the sub-models to the sampled calibration data (e.g. to the 
prevalence of HCV in the general population), and so these model runs were rejected. A 33% 
tolerance was allowed in fitting the model to a specific quantity (to match the uncertainty 
applied around parameters without bounds). I sampled parameter sets until 1000 full model 
fits were produced for each country. The step-by-step process of calibrating the model is 
described in detail below in sections 6.5.1-6.5.4, with model equations given in sections 6.6 
and 6.7.  
 
Table 6.4: Parameters fit by each of the four sub-models. 
Sub-model Country-specific parameters fitted 
1 Population growth rates between 1990 and 2015 
2 Age-specific death rates 
3 The rate individuals initiate injecting 






6.5.1.  Sub-model 1 
Firstly, a simple population growth sub-model (sub-model 1) was used to calculate the 
average population growth rate (A) that gave the change in each countries total population 
size between 1990 and 2015, calibrating to population size estimates from UN datasets(380). 
Once the growth rate has been calibrated, if the projected population size in 2015 was not 
within 33% of the sampled value, then the run was rejected. After 2015, the country-specific 
UN predicted growth rates for 5-year intervals from 2015 up until 2040 were used.  
 
6.5.2.  Sub-model 2 
Following this, the population growth sub-model was extended to incorporate three age 
classes (0-14, 15-34, and ≥35 years, 𝑥1, 𝑥2 and 𝑥3 respectively [sub-model 2]). The model 
includes aging between these classes (a for aging from 0-14 to 15-34, and b for aging from 15-
34 to ≥35), births and population growth (both into the 0-14 age group), and age-dependent, 
country-specific death rates (𝐷𝑅1, 𝐷𝑅2, 𝐷𝑅3 for those aged 0-14, 15-34, and ≥35, respectively). 
These demographic data are taken from the UN(380) and are included so that the model 
could be calibrated to data on the population age distribution for each country in 2015. R(t) 
balances age-related mortality, while allowing for a specified rate of population growth. 
Sub-model 2 assumed the same level of population growth as estimated by sub-model 1, 
with all age-dependent deaths being balanced by additional births such that sub-model 2 
has the same overall population dynamics as sub-model 1. The death rates for the youngest 
age group (0-14 years), 𝐷𝑅1, were estimated from 2015 data from the UN(380), while the 
death rates for the older age groups (15-34 years, 𝐷𝑅2, and ≥35 years, 𝐷𝑅3) were fitted to 
give the UN estimated population age distribution for each country in 2015, allowing for 
33% accuracy in the proportion in each age group. For the fitting, lower bounds for the 15-
34-year age-group mortality rate (𝐷𝑅2) were set as 80% of the 15-34-year-old death rate 
taken from the UN population data, whilst the lower bound for the ≥35-year age group 
(𝐷𝑅3) was specified as 0.0202 to equate to 49.4 years life expectancy (1/0.0202=49.4), which 
was deemed the upper limit for life expectancy for those aged 35 years (taken from Japan, 
the country with the highest life expectancy of 84.4). The upper bounds were each set very 





6.5.3.  Sub-model 3 
Sub-model 2 was then extended to include PWID, to give sub-model 3, shown in figure 6.1. 
As with the full model, sub-model 3 includes compartments for current injectors aged 15-34 
and age ≥35, and ex-injectors aged 15-34 and ≥35. Sub-model 3 is similar to sub-model 2 in 
that people enter and leave the model in the same way – entering through recruitment 
(birth) in the 0-14 age group and leaving the model from any compartment due to age-
specific death rates. However, in addition, current injectors have an additional high or 
low/middle-income country-specific drug-related death rate, µ, obtained from Mathers et al. 
WHO Bulletin 2013(246) – these were used instead of regional estimates, as not all regions 
had IDU death rate information available. Sub-model 3 used the parameter sets that 
successfully fitted the population growth and age distribution sampled data in sub-models 1 
and 2. For each parameter set, the rate that individuals initiate injecting, φ, from the young 
adult age group (15-34 years) was calibrated to give the sampled number of PWID in each 
country in 2015, obtained from the distribution range from Degenhardt et al.(77) - within 
33% accuracy. Each of these parameter sets also incorporated a sampled rate that PWID 
aged 15-34 and ≥35 cease injecting and transition into the corresponding people who used to 
inject drugs age class (v). This is parameterised using country-specific estimates for the 
duration of current injecting taken from Degenhardt et al. and presented in table 6.9(77). 
 
6.5.4.  Full model 
The model parameter sets that successfully fitted sub-model 3 for each country were then 
used within the full model, which additionally includes HCV disease transmission and 
progression as described in section 6.2.2, see figure 6.2. The fourth step fitted the HCV 
transmission rates for the general population and PWID to give the prevalence of HCV 
amongst PWID and the general population (within 33% accuracy), which were both 




6.6.  Model equations for sub-models used in calibration 
Sub-model 1: Population growth 
𝑑𝑁
𝑑𝑡
= 𝐴𝑁  
Where A is the population growth rate, and N is the population size. 
 
Sub-model 2: Age distributions 
The model equations for the total population (xi, for i=1, 2 and 3) in each of three age groups 
(0-14 for i=1, 15-34 for i=2, and ≥35 years for i=3) are given below: 
𝑑𝑥1
𝑑𝑡
= 𝑅(𝑡) − (𝐷𝑅1 + 𝑎)𝑥1 
𝑑𝑥2
𝑑𝑡
= 𝑎𝑥1 − (𝐷𝑅2 + 𝑏)𝑥2 
𝑑𝑥3
𝑑𝑡
= 𝑏𝑥2 − 𝐷𝑅3𝑥3 
Where the recruitment rate 𝑅(𝑡) is set to balance all non-HCV and drug related deaths and 
also incorporates the growth rate A from sub-model 1 as follows:  
𝑅(𝑡) = 𝐴𝑁 + 𝐷𝑅1𝑥1 + 𝐷𝑅2𝑥2 + 𝐷𝑅3𝑥3    where 𝑁, 𝑥1, 𝑥2 and 𝑥3 all vary with time.  
 
Sub-model 3: Prevalence of injecting drug use 
Risk-group equations, for y1, …, y7 – the 0-14 group, the 15-34 people who do not inject 
drugs group, the ≥35 people who do not inject drugs group, the 15-34 PWID group, the ≥35 
PWID group, the 15-34 people who used to inject drugs group, and the ≥35 people who used 































= 𝑏𝑦6 + 𝑣𝑦5 − 𝐷𝑅3𝑦7 





6.7.  Full model equations 
Subscripts 1-7 indicate the age and injecting group: 1 for aged 0-14, 2 for people who do not 
inject drugs (non-PWID) aged 15-34, 3 for people who do not inject drugs (non-PWID) aged 
≥35, 4 for PWID aged 15-34, 5 for PWID aged ≥35, 6 for people who used to inject drugs (ex-






































= 𝛼𝜔𝐷𝑇1 + 𝐶𝑆1 − 𝑃(1 − 𝛿)𝐷𝑆1 − (𝐷𝑅1 + 𝜇4 + 𝑎)𝐷𝑆1   
 







































=  𝑎𝐷𝑆1 + 𝛼𝜔𝐷𝑇2 +  𝐶𝑆2 − 𝑃(1 − 𝛿)𝐷𝑆2 − (𝐷𝑅2 + 𝜇4 + 𝜙 + 𝑏)𝐷𝑆2    
 




































=  𝑏𝐷𝑆2 + 𝛼𝜔𝐷𝑇3 + 𝐶𝑆3 − 𝑃(1 − 𝛿)𝐷𝑆3 − (𝐷𝑅3 + 𝜇4)𝐷𝑆3 
 







































= 𝜙𝐷𝑆2 + 𝛼𝜔𝐷𝑇4 + 𝐶𝑆4 − (𝑃 +  𝜋)(1 − 𝛿)𝐷𝑆4 − (𝐷𝑅2 + 𝜇 + 𝜇4 + 𝑣 + 𝑏)𝐷𝑆4 
 













































































= 𝑣𝐷𝑆4 + 𝛼𝜔𝐷𝑇6 + 𝐶𝑆6 − 𝑃(1 − 𝛿)𝐷𝑆6 − (𝐷𝑅2 + 𝜇4 + 𝑏)𝐷𝑆6 
 







































= 𝑏𝐷𝑆6 + 𝛼𝜔𝐷𝑇7 + 𝑣𝐷𝑆5 + 𝐶𝑆7 − 𝑃(1 − 𝛿)𝐷𝑆7 − (𝐷𝑅3 + 𝜇4)𝐷𝑆7 
 
The birth rate R(t) is set to balance all non-HCV related and non-drug related deaths while 
also incorporating the time-varying population growth rate A, and time-varying population 
size N, as follows: 
𝑅(𝑡) = 𝐴𝑁 + 𝐷𝑅1𝑌1 + 𝐷𝑅2(𝑌2 + 𝑌4 + 𝑌6) + 𝐷𝑅3(𝑌3 + 𝑌5 + 𝑌7) − 𝑉(𝑡) 
where for each age group 𝑖 defined by sub-model 3 I define  
𝑌𝑖 = 𝑆𝑖 + 𝐼𝑖 + 𝑇𝐼𝑖 + 𝐶𝐼𝑖 + 𝐶𝑇𝑖 + 𝐶𝑆𝑖 + 𝐷𝐼𝑖 + 𝐷𝑇𝑖 + 𝐷𝑆𝑖 
and V(t) is the number of chronically infected births due to vertical transmission, described 





6.8.  Vertical transmission of HCV calculations 
To calculate the number of chronically infected births due to vertical transmission, vertical 
transmission rates for HCV, varying by whether a woman is HIV-coinfected or not (HIV 
prevalences for women aged 15-24 taken from the World Bank(365)), are multiplied by the 
estimated number of HCV-infected women aged 15-34 years in each of the four possible 
combinations of ever/never being PWID, and being HIV-coinfected or not, see the table 
below. These are then summed and multiplied by the region-specific fertility rate (F: the 
average number of childbirths a woman of childbearing age will have) divided by 20 (giving 
the births per year in the 15-34 age category) to produce the estimated number of HCV 
infected births each year. Although some births will occur among women of other ages, 
most will occur in this age group and so we associate all the births to this group. Fertility 
was assumed to be the same between female PWID and non-injectors. 









Table 6.5: Calculations for the vertical transmission rate. 
Term Description 
𝑒1 = (𝐼2 + 𝐶𝐼2 + 𝐷𝐼2)/2  The number of HCV infected women aged 15-34 years old that have never been PWID* 
𝑒2 = (𝐼4 + 𝐶𝐼4 + 𝐷𝐼4 + 𝐼6 + 𝐶𝐼6 + 𝐷𝐼6)𝑅𝐹 where 𝑅𝐹 
is the region-specific percentage of PWID that are 
female 
The number of HCV infected women aged 15-34 years old that have ever been PWID 
𝑒3 = 𝑒1𝐶𝐻 where 𝐶𝐻 is the country-specific HIV 
prevalence for young women (aged 15-24) 
The number of HCV infected women aged 15-34 years old that have never been PWID that 
are coinfected with HIV 
𝑒4 = 𝑒2𝑅𝐻 where 𝑅𝐻 is the region-specific HIV 
prevalence among PWID 
The number of HCV infected women aged 15-34 years old that have ever been PWID that are 
coinfected with HIV 
𝑒5 = 𝑒1 − 𝑒3  
The number of HCV infected women aged 15-34 years old that have never been PWID that 
are not coinfected with HIV 
𝑒6 = 𝑒2 − 𝑒4  
The number of HCV infected women aged 15-34 years old that have ever been PWID that are 
not coinfected with HIV 
 𝑞1 
Probability of vertical transmission of HCV RNA confirmed infection per birth among 
women with HCV RNA that are HIV negative.  
 𝑞2 
Probability of vertical transmission of HCV RNA confirmed infection per birth among 
women with HCV RNA that are HIV negative. 




6.9.  Forces of infection 
For the different forces of infection, I have: 
Size of total population: 




Size of the PWID population: 




The proportion of the population that are infected: 
𝜉 = (𝐼1 + 𝐶𝐼1 + 𝐷𝐼1 + 𝐼2 + 𝐶𝐼2 + 𝐷𝐼2 + 𝐼3 + 𝐶𝐼3 + 𝐷𝐼3 + 𝐼4 + 𝐶𝐼4 + 𝐷𝐼4 + 𝐼5 + 𝐶𝐼5 + 𝐷𝐼5 + 𝐼6
+ 𝐶𝐼6 + 𝐷𝐼6 + 𝐼7 + 𝐶𝐼7 + 𝐷𝐼7)/𝑁 
The force of infection for the whole population: 
𝑃 =  𝛽𝜉 
where 𝛽 is the transmission rate in the general population. The additional force of infection 
which acts on PWID is given by: 
𝜋 =  𝜃(𝐼4 + 𝐼5 + 𝐶𝐼4 + 𝐶𝐼5 + 𝐷𝐼4 + 𝐷𝐼5)/𝑁𝐼  
where 𝜃 is the additional transmission rate due to injecting. The transmission rate in the 
general population (𝛽) and PWID population (θ), are found by solving the model equations 
(1-63) and calibrating the prevalence of chronic HCV amongst PWID and the general 
population in the model to the PWID and general population chronic HCV prevalence from 





6.10.  HCV epidemic trajectory assumptions 
To determine the trajectory of country-level epidemics, it is important to assess both 
whether there is evidence for changes in HCV prevalence or incidence over time, but also 
whether there have been any major changes in the prevalence or frequency of important risk 
behaviours or interventions. Section 2.3 discussed HCV transmission in detail. 
 
6.10.1. Changes in HCV risk behaviours 
HCV is transmitted through several known risk behaviours, principally unscreened blood 
donations, unsafe medical injections, and IDU. Evidence suggests the risk of receiving an 
HCV-infected blood transfusion has decreased over time following the introduction of blood 
donation safety guidelines and improved screening practices, with some estimates for 
developing countries suggesting a decline from 1/50 transfusions in the late 1980s to 
1/200,000 transfusions in 2000(291). However, this same review from 2006 states that such a 
decline had not occurred in many low and middle income countries by the early 2000s(291). 
Since then, a 2016 WHO report stated that 174 of 180 countries report a policy of testing all 
blood for HCV(399), an improvement from 107 out of 148 in 2006(362). The UK introduced 
screening guidelines for HCV in 1991(363), whereas many countries in the South Asia region 
(which has the highest number of infections) introduced such guidelines in the early 
2000s(64), whilst guideline introductions tended to be later in Africa, for example 2005 in 
Ethiopia(329), and 2006 in Nigeria(18). The introduction of these guidelines has brought 
progress, although in many countries blood donation safety could still be improved(178).  
Similarly to the reduction seen in the transmission risk for blood transfusions, the HCV 
transmission risk due to unsafe medical injections has also decreased since 2000(283), which 
followed an emphasis on preventing re-use of syringes led by the Safe Injection Global 
Network (SIGN)(394). Using population surveys, injection safety assessments and published 
studies, Pepin et al. found that the re-use of injection devices fell from 39.8% of all syringes 
in 2000, to 5.5% in 2010(282). Subsequently, using a mass action model and these estimates, 
Pepin et al. estimated that between these years there was an 83% reduction in new HCV 
infections transmitted through medical injections, although there was heterogeneity in the 
sources of data used for the two time points(283). To calculate this, Pepin et al used HCV 




estimate the trajectory of the HCV epidemic at the regional and global level, and is discussed 
in section 6.10.2(142).  
The main interventions for reducing HCV transmission among PWID, a group with 
particularly high prevalence and incidence of HCV(77), are needle and syringe programmes 
and opioid substitution therapy(287). Larney et al. performed a systematic review of the 
number of countries implementing these interventions and found an increase from 2010 to 
2017 for both; from 81 to 93 countries for needle and syringe programmes, and from 70 to 86 
countries for opioid substitution therapy(209). Theoretically this would indicate a reduction 
in HCV transmission risk for PWID, however, the review notes that the coverage of these 
interventions is generally too poor to prevent HCV epidemics among PWID. 
Aside from the already discussed interventions, there is not enough evidence for the 
effectiveness of other interventions to reduce HCV transmission risk, especially community-
based risks, which are wide ranging and uncertain(13, 219, 321). 
 
6.10.2. Changes in HCV epidemic data 
The gold standard measure for assessing changes in an epidemic trajectory is observing 
changes in the incidence of infection over time. However, incidence estimates are rare even 
amongst PWID, for whom infections are more common, and so we generally must rely on 
changes in HCV prevalence over time for determining whether HCV epidemics are 
expanding or in decline. Several studies have done this for HCV, which are described below.   
As mentioned in section 6.10.1, Hanafiah et al. undertook a systematic review and meta-
analysis of general population HCV prevalence estimates (excluding grey literature and 
non-English language studies), splitting studies performed before and after 1997 as early 
(ascribed to 1990) and late (ascribed to 2005), and estimated the HCV epidemic trajectories 
by comparing these pooled prevalence estimates(142). In this study, global anti-HCV 
prevalence increased from 2.3% to 2.8% between 1990 and 2005. These trajectories varied by 
region, but for most there was no statistical change in HCV prevalence between the time 
points. Such a method for determining a change in prevalence is limited by heterogeneity 
between the studies included in each time point (1990 and 2005) and is particularly sensitive 




both time points. Notably a study could be included in the estimate for 2005 if it occurred in 
1998, which was before blood donation safety guidelines were introduced in many 
countries, and before the reduction in the re-use of medical injections(282, 291). 
The Global Burden of Disease study modelled changes in the burden of disease due to HCV 
between 1990 and 2013 and found an increase in deaths and life years lost. However, they 
did not present how HCV prevalence had changed between these time points(347). 
Importantly, mortality can still increase with a stable or decreasing epidemic and so these 
projections are not useful for understanding the overall epidemic dynamics. 
Recently, Blach et al. modelled and presented the change in viremic HCV prevalence 
globally and by region between 1980 to 2015, based on changes in age-specific HCV 
prevalence over time(40). Globally, they estimated the total number of viremic infections to 
be around 36 million in 1980, which increased to around 71 million by 2000 and then 
remained steady until 2015. When accounting for the increasing global population this 
means an increase from around 0.8% viremic HCV prevalence in 1980, to around 1.2% in 
2000, decreasing to around 1.0% by 2015. These numbers were estimated approximately off 
published graphs as the exact numbers were not made available (UN global population 
numbers were used as the denominator). These HCV epidemic trajectories vary by region 
(after accounting for population changes), with decreases in most regions from 1990 
onwards, but with increases estimated in Eastern Europe, Australasia, and South and 
Central Asia. Estimations of the prevalence changes by region from the paper by Blach et al. 
are shown in table 6.5 (regional populations were taken from the Global Burden of Disease 
study). The regional numbers were not made explicitly available in their paper and the 
estimates could not be accurately obtained from the regional graphs. Additionally, the 
uncertainty around these estimates was not given. The analysis by Blach et al. used a 
Markov model starting from 1950 when there is assumed to be negligible HCV infections, 
with the epidemic increasing from then. However, there is uncertainty in these modelled 
HCV prevalence trends. Many countries in the analysis only have one data point on HCV 
prevalence, making it hard to determine trajectory. Additionally, for some countries, expert 
opinion, which is generally considered the lowest grade of evidence(416), is relied on for 
determining how the epidemics may be evolving rather than data. More generally, there is a 
lack of data feeding into the Blach model for less recent time-points, with less robust data 




epidemic used in that model, which is not discussed. Only Egypt(93, 181), France(85, 249), 
and the USA(15, 78) have two HCV prevalence surveys for the general population that were 
described as robust by Blach et al.(40) – all of which suggested a decreasing trend. Only two 
other countries (China and Thailand) had multiple surveys, but they were not considered 
robust enough (possibly regarding comparability between survey methods) by Blach et al., 
although they also suggested a decreasing trend of prevalence. 
 
6.10.3. HCV epidemic trajectories among PWID 
Regarding the trajectory of the HCV epidemics among PWID, data were available from the 
latest review by Degenhardt et al(77). Prevalence estimates from surveys among PWID were 
compared across time for each region, and overall. For most regions there was insufficient 
power to look at trends over time, and for others no change over time was detected. For East 
and South East Asia and North America, a decreasing trend was detected. For East and 
South East Asia, the change in prevalence was driven by studies in China, when China was 
omitted there was no reduction in prevalence in East and South East Asia. However, China 
itself is vast and heterogeneous, and the studies were across various regions of China – only 
one was national, so the decrease seen is not necessarily a robust assumption. Data from the 
Degenhardt review suggests there is evidence for a decrease in HCV prevalence among 
PWID in North America. However, conflicting evidence from the US (which makes up 90% 
of the population of North America) show acute incident cases are increasing, as reviewed 
by Shiffman(57, 330), suggesting a recent increasing epidemic in this setting. The data in the 
Degenhardt review are mostly from studies before this recent upturn in infections in the US, 
so this is investigated in sensitivity analyses. All sensitivity analyses are listed in sections 






Table 6.6: Regional changes in viraemic prevalence from 1990 to 2015, estimated from Blach 





(millions) Viraemic prevalence 
Region 1990 2015 1990 2015 1990 2015 
Annual 
Change 
Asia, Central 1.1 3.3 68.8 87.0 1.6% 3.8% 5.49% 
Asia, East 10.8 10.5 1194.9 1432.9 0.9% 0.7% -0.76% 
Asia Pacific, High Income 3.1 1.2 168.9 182.9 1.8% 0.7% -2.57% 
Asia, South 9 15.3 1103.9 1691.0 0.8% 0.9% 0.44% 
Asia, Southeast 3.1 4.7 461.5 651.0 0.7% 0.7% 0.30% 
Australasia 0.1 0.2 20.4 28.9 0.5% 0.7% 1.65% 
Caribbean 0.2 0.3 35.8 45.3 0.6% 0.7% 0.74% 
Europe, Central 0.7 1.2 123.1 116.7 0.6% 1.0% 3.24% 
Europe, Eastern 3.5 6.7 221.2 215.0 1.6% 3.1% 3.88% 
Europe, Western 2.1 2.3 381.3 433.6 0.6% 0.5% -0.15% 
Latin America, Andean 0.3 0.4 39.0 58.3 0.8% 0.7% -0.44% 
Latin America, Central 1.1 1.3 169.0 251.8 0.7% 0.5% -0.83% 
Latin America, Southern 0.4 0.4 49.0 64.8 0.8% 0.6% -0.98% 
Latin America, Tropical 1.9 1.9 154.8 214.5 1.2% 0.9% -1.11% 
North America, High 
Income 3.5 3.1 277.7 359.9 1.3% 0.9% -1.27% 
North Africa/Middle East 8 8.5 336.1 566.2 2.4% 1.5% -1.48% 
Oceania 0.1 0.1 6.6 11.0 1.5% 0.9% -1.59% 
Sub-Saharan Africa, Central 2.4 2.3 53.1 114.8 4.5% 2.0% -2.23% 
Sub-Saharan Africa, East 1.3 2.1 186.1 377.0 0.7% 0.6% -0.81% 
Sub-Saharan Africa, 
Southern 0.6 0.6 53.4 77.4 1.1% 0.8% -1.24% 
Sub-Saharan Africa, West 3 5.1 198.7 391.1 1.5% 1.3% -0.55% 
GBD: Global Burden of Disease 
 
6.10.4. Conclusions for the HCV epidemic assumptions 
In summary, evidence suggests levels of transmission risk due to blood transfusions(291) 
and re-use of medical injections(283) have decreased since 2000, with Blach et al.’s 
review(40) and modelling also suggesting that the global prevalence of infection has 
decreased by around 17% from 2000 to 2015. Conversely, HCV prevalence was stable or may 




although there is greater uncertainty around the trajectory of the epidemic at this time. 
Accounting for this evidence on decreases in risk behaviours and HCV prevalence, the most 
likely scenario is that the global HCV epidemic is decreasing slowly, with possible variations 
by region, although there is not robust evidence to calculate these regional changes.  
For my model, I assume a slow decrease in the general population HCV epidemic over time. 
This was accounted for by seeding the initial modelled HCV prevalence (1990) in the setting 
as higher than the prevalence estimate we are fitting to, with the model then calibrating a 
force of infection to result in a decreasing HCV epidemic to fit the estimate for the general 
population HCV prevalence. Specifically, the HCV prevalence in the general population in 
1990 was seeded as 1.13% (17% decline over 15 years) higher for each year between 1990 and 
when the general population HCV prevalence estimate was available for each country. For 
example, if the estimate was taken from 2005, 15 years after 1990, then the seeded HCV 
prevalence was set to be (100+(1.13*15)) = 116.95% of the 2005 value. However, due to the 
poor data used in making this assumption I assumed large uncertainty bounds around this 
estimate of decrease between 0% and 1.5% per year. I also examine in sensitivity analyses 
how my results would vary if I assumed a stable HCV epidemic or regional variations in 
annual change in HCV prevalence as given in table 6.5 using the same method as described 
above.  
For, Egypt(93, 181), France(85, 249) and USA(15, 78), where multiple robust and comparable 
surveys exist, a separate method was used, section 6.2.6. The available information about the 
trajectory of the HCV epidemics among PWID shows great uncertainty, due to this I 
assumed the epidemic among PWID to be stable, but this assumption is also tested in my 
model using sensitivity analyses that assume a decrease in HCV prevalence among PWID at 
the same rate as in the general population.  
 
6.10.5. Assumptions around the population percentage of PWID among adults 
The population percentage of PWID among adults was assumed to be stable between 1990 
and the year of the estimate due to a lack of robust information about these trends in most 
countries. For Sub-Saharan African and Eastern European countries evidence suggests IDU 
in these regions expanded later than in other settings(96, 119), so in 1990 I assumed this 




test the effect of removing the assumption of later IDU epidemics in Sub-Saharan Africa and 
Eastern Europe. A sensitivity analysis also investigated the effect of an increasing proportion 
of adults that are PWID in the US. See sections 7.2.2 and 8.2.3 for information about 
sensitivity analyses performed. 
 
6.11.  Alternative model structure for Egypt, France, and USA 
The extra information from the multiple surveys on the direction of the general population 
HCV epidemic for Egypt(93, 181), France(85, 249), and USA(15, 78) was incorporated into 
the modelling for these countries by using a slightly different calibration technique to other 
countries.  
For Egypt, the two anti-HCV survey values used were 14.7% (95% confidence interval: 
14.1%, 15.4%) in 2008 and 10.0% (95% confidence interval: 9.5%, 10.5%) in 2015, whilst for 
France the values were 1.05% (95% confidence interval: 0.75%, 1.34%) in 1994 and 0.84% 
(95% confidence interval: 0.65, 1.10%) in 2004, and 1.8% (95% confidence interval: 1.5%, 
2.3%) for 1994 and 1.3% (1.2%, 1.5%) in 2010 for the USA. For each of these three countries 
the model was calibrated to the first survey value (in the year of the general population 
survey) to produce a general population transmission rate. The general population 
transmission rate was then adjusted by multiplying it by a random number between 0 and 1 
from the year of the first survey onwards. Runs were accepted if the general population 
chronic HCV prevalence was ±33% of the 2nd survey sampled HCV prevalence estimate, as 
well as ±33% relative to the PWID HCV prevalence estimate. 
 
6.12.  Detailed data issues 
A revised, lower estimate for the population percentage of PWID in Canada from Grebely 
2018(127) was used instead of Degenhardt 2017(77) – 0.39% (Uncertainty interval: 0.31%, 
0.47%) instead of 1.22% (Uncertainty interval: 1.04%, 1.40%). Both papers utilise data from 
the same systematic review but the data point in Grebely is updated. For Spain and 
Netherlands, the population percentage of PWID, 0.03%, appeared low for Western 
European countries. For these countries, the PWID prevalence estimates were investigated 




number of people on OST was very low(98) so the estimate of 0.03% was accepted. For 
Spain, a 2011 estimate suggested 15,000 OST admissions for people with heroin dependence, 
which was combined with a back-calculation based on 60% of PWID reporting being on 
OST(97). This method gave an updated estimate of 25,000 PWID, and an updated 
population percentage of PWID of 0.075% for Spain. Bounds of ±33% were added to this 
point estimate. 
For Cyprus, Estonia, FYR Macedonia, Iceland, Luxembourg, Malta, Montenegro, and 
Slovenia, the UN does not have detailed enough information about age-specific general 
population death rates for 2010-15. This is because numbers of deaths are rounded to the 
nearest 1,000, meaning for some countries with a low number of deaths the mortality rate 
appears to be 0 for some age categories in this period, or more recent time periods in 
general. For these countries, estimates for death rates were taken from other nearby 
countries that appear to have similar death rates for previous time periods and age 
categories – Greece, Latvia, Greece, Sweden, France, Italy, Serbia, and Austria were used, 
respectively. 
For Turkmenistan’s estimate of HCV prevalence among PWID from Aceijas 2007(3), only the 
bounds (46.2%, 75.0%) were available so the mid-point was taken (60.6%). For Finland’s 
estimate of HCV prevalence among the general population from Blach 2017(40), the mid-
point given (0.5%) does not fit within the given bounds (0.6%, 0.9%). Therefore, I took the 
midpoint (0.7%) to which the bounds applied - from Gower 2014. For several general 
population HCV estimates from Blach 2017(40), one or both of the lower or upper bounds 
given do not fit around the point estimate given, so I replaced these bounds by ±33% of the 
point estimate. This was for Colombia and Luxembourg (both upper), Thailand (lower), and 
Saudi Arabia (both). For Pakistan’s general population HCV prevalence estimate from Blach 
2017(40), the bounds did not fit around the estimate so were instead taken from the national 
survey(295). National survey data were also used for Georgia’s general population HCV 
prevalence estimate (the same source used in Blach 2017)(132). 
The injecting duration estimates for Afghanistan (2.8 years), and Turkey (3 years), appeared 
low so these were adjusted to their respective regional estimates, 6.4 years and 7.8 years, 
respectively, with the lower estimates being used as the lower bound to the sampling 
interval, while the upper bound of the sampling interval was estimated by multiplying the 




6.13.  Country-level data 
Table 6.7 gives the country-level data on population sizes, age distributions, mortality rates, 
fertility rates, and prevalences of HIV among females aged 15-24, that were used to 
parameterise the model. 
Country-level sampled ranges for antibody prevalence of HCV among the general 
population and PWID, as well as the population percentage of PWID among adults are 
given in table 6.8. Table 6.8 also includes the estimate source, year, and grade (discussed 
further in section 6.14), where available. 
Country-level injecting durations are given in table 6.9, whilst table 6.10 gives country-level 





Table 6.7: Sampled population sizes, age distributions, mortality rates by age-group, fertility rates, and HIV prevalences for women aged 15-24 
by country*. 
Country Population (1000s) 
1990 age distributions 
(proportions) 
2015 age distributions 
(proportions) 
Mortality rates per 100 
person years, 2015, age: 
Fertility rates 2015 (lifetime 
births per woman) 
Female (15-24) HIV 
% 2016 
 1990 2015 0-14 15-34 ≥35 0-14 15-34 ≥35 0-14  15-34   
Afghanistan 12249 32526 0.48 0.32 0.20 0.44 0.35 0.21 0.857 0.288 5.26 0.10 
Albania 3281 2925 0.33 0.36 0.31 0.18 0.30 0.52 0.114 0.068 1.71 0.10 
Argentina 32729 43416 0.31 0.30 0.39 0.25 0.31 0.44 0.128 0.089 2.34 0.10 
Armenia 3538 3018 0.30 0.35 0.35 0.18 0.32 0.49 0.108 0.062 1.65 0.10 
Australia 17041 23970 0.22 0.33 0.45 0.19 0.28 0.53 0.040 0.045 1.88 0.10 
Austria 7724 8542 0.17 0.31 0.52 0.14 0.25 0.61 0.033 0.038 1.45 0.00 
Azerbaijan 7243 9753 0.33 0.37 0.30 0.22 0.35 0.43 0.430 0.081 2.10 0.10 
Bangladesh 106189 160995 0.42 0.35 0.23 0.29 0.37 0.34 0.327 0.097 2.22 0.10 
Belarus 10216 9496 0.23 0.30 0.47 0.16 0.27 0.56 0.052 0.161 1.64 0.20 
Belgium 10006 11301 0.18 0.30 0.52 0.17 0.24 0.59 0.031 0.051 1.78 0.00 
Bosnia 4463 3810 0.24 0.35 0.41 0.13 0.27 0.59 0.078 0.058 1.31 0.00 
Brazil 149352 207846 0.35 0.36 0.29 0.23 0.33 0.44 0.179 0.141 1.78 0.20 
Bulgaria 8841 7149 0.20 0.27 0.52 0.14 0.23 0.63 0.079 0.084 1.51 0.10 
Canada 27690 35942 0.21 0.33 0.46 0.16 0.27 0.57 0.045 0.048 1.61 0.00 
China 1172442 1376048 0.29 0.38 0.33 0.17 0.30 0.53 0.116 0.065 1.60 0.00 
Croatia 4776 4242 0.20 0.29 0.51 0.15 0.24 0.61 0.032 0.058 1.49 0.10 
Cyprus 767 1165 0.25 0.33 0.42 0.17 0.32 0.51 0.025 0.056 1.38 0.00 
Czech Republic 10341 10544 0.22 0.28 0.50 0.15 0.24 0.61 0.025 0.064 1.48 0.10 
Denmark 5141 5668 0.17 0.30 0.53 0.17 0.25 0.58 0.021 0.043 1.73 0.00 
Egypt 57412 91507 0.41 0.32 0.27 0.33 0.34 0.32 0.218 0.091 3.38 0.10 
Estonia 1565 1311 0.22 0.29 0.49 0.16 0.25 0.59 0.068 0.123 1.59 0.00 
Finland 4996 5504 0.19 0.28 0.52 0.16 0.24 0.59 0.022 0.059 1.77 0.00 
France 56957 64395 0.20 0.30 0.50 0.18 0.24 0.58 0.032 0.046 1.98 0.10 
FYROM 1996 2079 0.26 0.33 0.41 0.17 0.30 0.54 0.057 0.056 1.50 0.10 
Georgia 5410 3998 0.25 0.31 0.44 0.17 0.29 0.53 0.144 0.086 2.00 0.10 




Country Population (1000s) 
1990 age distributions 
(proportions) 
2015 age distributions 
(proportions) 
Mortality rates per 100 
person years, 2015, age: 
Fertility rates 2015 (lifetime 
births per woman) 
Female (15-24) HIV 
% 2016 
 1990 2015 0-14 15-34 ≥35 0-14 15-34 ≥35 0-14  15-34    
Ghana 14628 27411 0.44 0.34 0.22 0.39 0.35 0.26 0.754 0.331 4.18 1.00 
Greece 10248 10955 0.20 0.30 0.50 0.15 0.23 0.63 0.025 0.056 1.34 0.00 
Hungary 10377 9856 0.20 0.27 0.52 0.15 0.25 0.61 0.042 0.057 1.33 0.00 
Iceland 255 331 0.25 0.33 0.42 0.20 0.28 0.52 0.024 0.049 1.98 0.00 
India 870129 1311049 0.38 0.34 0.28 0.29 0.35 0.36 0.423 0.176 2.44 0.10 
Indonesia 181437 257563 0.36 0.37 0.27 0.28 0.33 0.39 0.258 0.159 2.45 0.20 
Iran 56226 79108 0.45 0.32 0.23 0.24 0.39 0.37 0.145 0.086 1.75 0.10 
Ireland 3569 4688 0.28 0.31 0.41 0.22 0.25 0.53 0.020 0.068 2.00 0.10 
Israel 4500 8066 0.31 0.32 0.37 0.28 0.29 0.43 0.036 0.035 3.04 0.00 
Italy 57125 59796 0.16 0.31 0.53 0.14 0.20 0.66 0.022 0.036 1.43 0.10 
Japan 124513 126575 0.18 0.28 0.53 0.13 0.21 0.66 0.026 0.044 1.41 0.00 
Kazakhstan 16539 17624 0.31 0.34 0.34 0.27 0.32 0.41 0.157 0.172 2.70 0.10 
Kenya 23402 46052 0.49 0.33 0.18 0.42 0.36 0.22 0.774 0.418 4.10 3.50 
Kyrgyzstan 4373 5941 0.37 0.34 0.28 0.31 0.36 0.33 0.214 0.113 3.12 0.10 
Latvia 2664 1971 0.21 0.29 0.49 0.15 0.25 0.60 0.068 0.124 1.50 0.30 
Lebanon 2703 5851 0.34 0.34 0.31 0.24 0.37 0.39 0.071 0.037 1.72 0.10 
Libya 4437 6279 0.42 0.35 0.23 0.30 0.33 0.37 0.235 0.135 2.40 0.00 
Lithuania 3696 2880 0.23 0.31 0.46 0.15 0.25 0.60 0.048 0.138 1.59 0.10 
Luxembourg 382 568 0.17 0.30 0.52 0.16 0.27 0.56 0.032 0.046 1.55 0.00 
Madagascar 11599 24234 0.46 0.33 0.21 0.42 0.35 0.24 0.531 0.251 4.40 0.10 
Malaysia 18038 30331 0.37 0.36 0.27 0.25 0.37 0.38 0.073 0.083 2.11 0.10 
Malta 364 429 0.23 0.30 0.47 0.14 0.27 0.59 0.022 0.036 1.41 0.10 
Mauritius 1056 1276 0.29 0.39 0.32 0.19 0.30 0.50 0.081 0.103 1.49 0.00 
Mexico 85355 127016 0.39 0.36 0.25 0.28 0.34 0.38 0.181 0.100 2.29 0.10 
Moldova 4364 4070 0.28 0.31 0.41 0.16 0.33 0.51 0.094 0.088 1.27 0.20 
Montenegro 615 627 0.25 0.33 0.42 0.18 0.28 0.54 0.069 0.061 1.71 0.20 
Morocco 24879 34377 0.40 0.36 0.24 0.27 0.34 0.38 0.250 0.056 2.60 0.10 
Mozambique 13248 27978 0.47 0.31 0.22 0.45 0.33 0.21 0.964 0.629 5.45 4.60 
Myanmar 40626 53899 0.38 0.36 0.27 0.28 0.34 0.39 0.465 0.205 2.30 0.30 




Country Population (1000s) 
1990 age distributions 
(proportions) 
2015 age distributions 
(proportions) 
Mortality rates per 100 
person years, 2015, age: 
Fertility rates 2015 (lifetime 
births per woman) 
Female (15-24) HIV 
% 2016 
 1990 2015 0-14 15-34 ≥35 0-14 15-34 ≥35 0-14 15-34   
Netherlands 14965 16924 0.18 0.33 0.49 0.17 0.24 0.60 0.029 0.030 1.73 0.10 
New Zealand 3398 4529 0.23 0.33 0.44 0.20 0.26 0.53 0.044 0.067 2.04 0.00 
Nigeria 95270 182203 0.45 0.32 0.23 0.44 0.33 0.23 0.295 0.609 5.74 1.60 
Norway 4247 5212 0.19 0.30 0.51 0.18 0.27 0.55 0.021 0.058 1.82 0.00 
Pakistan 107678 188927 0.43 0.32 0.25 0.35 0.36 0.29 0.751 0.135 3.72 0.10 
Philippines 61947 100700 0.41 0.36 0.24 0.32 0.35 0.33 0.252 0.155 3.05 0.10 
Poland 37954 38267 0.25 0.30 0.45 0.15 0.28 0.57 0.046 0.072 1.33 0.00 
Portugal 9953 10352 0.21 0.31 0.49 0.14 0.22 0.64 0.027 0.043 1.28 0.00 
Romania 23489 19512 0.24 0.30 0.46 0.16 0.23 0.61 0.092 0.075 1.48 0.10 
Russia 147558 143456 0.23 0.30 0.47 0.17 0.28 0.56 0.095 0.252 1.70 0.00 
Saudi Arabia 16327 31557 0.42 0.37 0.22 0.26 0.34 0.40 0.149 0.078 2.72 0.10 
Senegal 7556 15127 0.47 0.32 0.22 0.44 0.34 0.22 0.514 0.213 5.00 0.10 
Serbia 9518 8850 0.24 0.29 0.47 0.16 0.26 0.58 0.069 0.061 1.59 0.10 
Slovakia 5288 5426 0.25 0.31 0.44 0.15 0.28 0.57 0.049 0.066 1.39 0.10 
Slovenia 2006 2068 0.21 0.31 0.49 0.15 0.23 0.62 0.430 0.081 1.58 0.10 
Spain 39304 46122 0.20 0.32 0.48 0.15 0.21 0.64 0.029 0.035 1.33 0.10 
Sweden 8567 9777 0.18 0.27 0.55 0.17 0.25 0.57 0.024 0.049 1.90 0.10 
Switzerland 6675 8298 0.17 0.30 0.53 0.15 0.25 0.60 0.033 0.038 1.53 0.00 
Syria 12446 18735 0.47 0.34 0.19 0.38 0.34 0.28 0.356 0.082 3.10 0.00 
Taiwan 20312 23486 0.27 0.37 0.36 0.14 0.28 0.58 0.043 0.069 1.11 0.00 
Tajikistan 5283 8483 0.44 0.33 0.23 0.35 0.37 0.28 0.481 0.101 3.50 0.10 
Tanzania 25460 53471 0.46 0.33 0.21 0.45 0.33 0.22 0.521 0.315 5.24 2.30 
Thailand 56582 67959 0.30 0.38 0.31 0.18 0.27 0.55 0.130 0.188 1.53 0.20 
Tunisia 8233 11274 0.37 0.35 0.28 0.24 0.33 0.43 0.172 0.059 2.25 0.10 
Turkey 53921 78271 0.36 0.35 0.30 0.26 0.33 0.42 0.178 0.125 2.12 0.00 
Turkmenistan 3684 5563 0.41 0.36 0.24 0.30 0.36 0.34 0.484 0.151 3.00 0.00 
UK 57179 64714 0.19 0.30 0.51 0.18 0.26 0.56 0.056 0.129 1.88 0.00 
Ukraine 51462 44822 0.21 0.28 0.50 0.15 0.27 0.58 0.069 0.069 1.49 0.60 
Uruguay 3110 3433 0.26 0.30 0.44 0.21 0.29 0.50 0.109 0.081 2.04 0.10 




Country Population (1000s) 
1990 age distributions 
(proportions) 
2015 age distributions 
(proportions) 
Mortality rates per 100 
person years, 2015, age: 
Fertility rates 2015 (lifetime 
births per woman) 
Female (15-24) HIV 
% 2016 
 1990 2015 0-14 15-34 ≥35 0-14 15-34 ≥35 0-14 15-34   
Uzbekistan 20461 29892 0.41 0.35 0.24 0.29 0.37 0.34 0.469 0.133 2.38 0.00 
Viet Nam 68208 93448 0.37 0.36 0.26 0.23 0.35 0.42 0.207 0.116 1.96 0.10 




6.14.  Data quality 
Table 6.8 shows the data estimates for the HCV prevalence among the general population 
and PWID, and the estimates for the population percentage of PWID among adults. Also 
presented in table 6.8 are the estimate source, year, and the data quality grades taken from 
the literature. These data quality grades were available from Blach et al. 2017, Gower et al. 
2014, Degenhardt et al. 2017, Grebely et al. 2018, and Mathers et al. 2008(40, 77, 124, 127, 
245). The Blach and Gower papers used the same system to produce a grade for data quality, 
whilst the Degenhardt and Grebely papers used the same system as each other, and the 
Mathers paper used a similar system. These grading systems are described below briefly; the 
original papers describe them in more detail. 
 
For HCV prevalence among the general population, Blach et al. 2017 and Gower et al. 2014 
initially scored studies on a scale of 0-10, based on a combined score of the generalisability, 
sample size, and year of the analysis. The generalisability score (0-10) was assigned based on 
geographic scope and the population type. The sample size score (0-10) was the log of the 
sample size, capped at 10. The analysis year score was given as 6 for 2000-3, 8 for 2004-10, 
and 10 for those after 2010. The overall score was calculated as the sum of 0.6 multiplied by 
the generalisability score, 0.2 multiplied by the sample size score, and 0.2 multiplied by the 
year score. The 0-10 overall scores were then converted to produce a data quality scale of 
(lowest to highest) 1-3; where 0.0<4.0 became a score of 1, 4.0<8.0 became 2, and 8.0<10.0 
became 3. Modelling studies were scored as 2, whilst studies without a formal assessment 
were given a score of 1. 
 
For HCV prevalence among PWID, Degenhardt et al. 2017 and Grebely et al. 2018 assigned a 
grade from U to A (lowest to highest: U, D2, D1, C, B2, B1, A). Estimates were graded as 
follows: U – estimate with methodology unknown; D2 – self-report; D1 – registration or 
notification data; C – single-site seroprevalence study with one sample type (eg. treatment or 
outreach sample); B2 – single-site seroprevalence study with multiple sample types; B1 – 
multi-site seroprevalence study with one sample type; A – multi-site seroprevalence study 
with at least two sample types.  
 
For data on the population percentage of PWID among adults, the Degenhardt and Grebely 




estimates with unknown methodology; D1 – official government estimate with methodology 
unknown; C – expert judgement with method by which estimate was obtained known; 
Delphi method or other consensus estimate; government registrations of drug users; B – 
general population household survey; A3 – network scale-up method; A2 – indirect 
prevalence estimation methods; A1 – multi-parameter evidence synthesis. Mathers et al. 
2008, used the same method but for the estimate grade but grouped A3, A2, and A1 together 
as A. 
 
For general population HCV prevalence, 14 (16%) country estimates were scored as 3, 34 
(39%) were scored 2, and 28 (32%) were scored 1, whilst 12 (14%) country estimates did not 
come from reviews with scores. For PWID HCV prevalence estimates, 22 (25%) had at least 
one estimate of A (eg. if they were scored “A; B1” then A was taken), 48 (55%) had a grade 
of B (47 B1), and 16 (18%) were graded C or lower, whilst 2 (2%) countries did not have 
scores. For the proportion of the population that are PWID, 49 (56%) of country estimates 
were graded A, 5 (6%) were given B, and 14 (16%) were given a grade of C or lower. There 
were 14 (23%) countries that did not have graded estimates. Most ungraded estimates are 




Table 6.8: Country-level sampled ranges for antibody prevalence of HCV among the general population and PWID, as well as the population 
percentage of PWID among adults, and the estimate source, year, and grades*.  
 Prevalence of HCV among general population Prevalence of HCV among PWID Population percentage of PWID 
Country 
Estimate (Estimate 
range) Year Grade Source 
Estimate (Estimate 
range) Year Grade Source 
Estimate (Estimate 
range) Year Grade Source 
Afghanistan 1.10% (0.40%, 1.92%) 2007 2 (40) 37.8% (27.5%, 48.1%) 2012 A; B1; C (77) 0.80% (0.50%, 1.09%) 2012 A2 (77) 
Albania 3.00% (2.01%, 3.99%) 2008 NA (160) 34.0% (27.5%, 41.0%) 2011 B1 (77) 0.42% (0.28%, 0.56%) 2008 NA (160) 
Argentina 1.50% (0.32%, 2.00%) 2007 1 (40) 54.6% (51.1%, 58.1%) 2001 B1 (77) 0.29% (0.29%, 0.30%) 1999 D1 (77) 
Armenia 4.00% (2.68%, 5.32%) 2010 NA (210) 42.7% (29.3%, 56.1%) 2012 B1 (77) 0.62% (0.41%, 1.35%) 2010 A2 (77) 
Australia 1.30% (1.20%, 1.85%) 2012 2 (40) 53.5% (50.2%, 56.9%) 2014 B1 (77) 0.60% (0.43%, 0.76%) 2016 A (77) 
Austria 0.50% (0.10%, 0.70%) 2008 1 (40) 60.9% (54.8%, 67.0%) 2012 A; B1: C (77) 0.32% (0.22%, 0.42%) 2000 A (77) 
Azerbaijan 3.70% (2.48%, 4.92%) 2010 2 (40) 62.1% (47.1%, 77.2%) 2012 B2 (77) 0.61% (0.49%, 0.74%) 2011 A2 (77) 
Bangladesh 1.26% (0.20%, 2.23%) 2010 1 (124) 33.9% (22.4%, 45.4%) 2013 A; C (77) 0.07% (0.06%, 0.07%) 2016 A2 (77) 
Belarus 1.26% (0.86%, 2.85%) 2006 1 (124) 58.3% (43.3%, 73.3%) 2015 B1 (77) 0.59% (0.22%, 0.96%) 2015 A2 (77) 
Belgium 0.87% (0.12%, 1.10%) 1994 1 (40) 58.4% (47.0%, 69.7%) 2014 B1; C (77) 0.35% (0.24%, 0.49%) 2014 A2 (77) 
Bosnia 0.10% (0.07%, 0.13%) 2008 NA (160) 39.9% (27.5%, 52.4%) 2014 B1; C (77) 0.17% (0.11%, 0.23%) 2008 NA (160) 
Brazil 1.38% (1.12%, 1.64%) 2007 3 (40) 63.9% (60.5%, 67.3%) 2001 B1 (77) 0.67% (0.51%, 0.87%) 2003 D1 (77) 
Bulgaria 1.50% (0.70%, 2.43%) 2012 1 (40) 68.7% (64.3%, 73.0%) 2014 A (77) 0.38% (0.30%, 0.45%) 2005 A (77) 
Canada 0.96% (0.61%, 1.34%) 2011 2 (40) 70.6% (60.1%, 93.9%) 2014 A; B1 (77) 0.39% (0.31%, 0.47%) 2004 B (127) 
China 1.21% (0.93%, 1.49%) 2015 2 (40) 43.1% (27.5%, 58.6%) 2015 A; B1; C (77) 0.25% (0.19%, 0.31%) 2005 A (77) 
Croatia 0.90% (0.50%, 1.40%) 2011 2 (40) 36.7% (28.1%, 45.3%) 2015 B1 (77) 0.23% (0.18%, 0.29%) 2015 A2 (77) 
Cyprus 0.56% (0.45%, 1.87%) 2001 1 (124) 49.7% (44.4%, 55.0%) 2014 A; B1 (77) 0.08% (0.04%, 0.12%) 2014 A2 (77) 
Czech Republic 0.57% (0.20%, 0.70%) 2012 1 (40) 18.3% (14.5%, 22.1%) 2015 B1 (77) 0.64% (0.61%, 0.67%) 2014 A2 (77) 
Denmark 0.63% (0.48%, 0.72%) 2007 2 (40) 42.6% (36.1%, 49.1%) 2011 B1 (77) 0.45% (0.35%, 0.52%) 2009 A2 (77) 
Egypt 10.00% (9.50%, 10.50%) 2015 3 (181) 49.4% (35.8%, 63.0%) 1995 C (77) 0.21% (0.13%, 0.28%) 2005 NA (258) 
Estonia 1.97% (1.50%, 2.00%) 2013 1 (40) 79.2% (67.4%, 91.0%) 2014 B1; C (77) 0.94% (0.69%, 1.73%) 2009 A2 (77) 
Finland 0.68% (0.60%, 0.90%) 2013 1 (124) 73.7% (69.9%, 77.2%) 2014 B1 (77) 0.46% (0.41%, 0.67%) 2012 D2 (77) 
France 0.84% (0.45%, 1.10%) 2004 3 (249) 64.0% (60.8%, 67.0%) 2011 A (77) 0.20% (0.16%, 0.23%) 2011 D2 (77) 




 Prevalence of HCV among general population Prevalence of HCV among PWID Population percentage of PWID 
Country 
Estimate (Estimate 
range) Year Grade Source 
Estimate (Estimate 
range) Year Grade Source 
Estimate (Estimate 
range) Year Grade Source 
Georgia 5.40% (4.51%, 6.32%) 2015 3 (132) 69.1% (58.0%, 80.2%) 2015 B1; C (77) 4.19% (0.48%, 7.90%) 2004 C (77) 
Germany 0.58% (0.30%, 0.90%) 2012 1 (40) 65.0% (60.6%, 69.4%) 2014 B1 (77) 0.24% (0.03%, 0.45%) 2000 A (77) 
Ghana 2.10% (1.20%, 5.50%) 2014 2 (40) 40.1% (34.8%, 45.4%) 2005 B1 (77) 0.05% (0.03%, 0.07%) 2008 NA (304) 
Greece 1.79% (0.50%, 2.61%) 2011 3 (40) 65.7% (61.8%, 69.5%) 2014 A (77) 0.07% (0.06%, 0.09%) 2014 A2 (77) 
Hungary 0.70% (0.40%, 2.70%) 2014 1 (40) 46.4% (30.4%, 62.8%) 2015 A (77) 0.06% (0.03%, 0.08%) 2005 A (77) 
Iceland 0.41% (0.33%, 0.48%) 2013 2 (40) 63.0% (59.8%, 66.2%) 1993 C (77) 0.24% (0.16%, 0.32%) 2008 NA (160) 
India 0.84% (0.50%, 1.50%) 2013 1 (40) 40.0% (33.9%, 46.1%) 2015 B1; C (77) 0.02% (0.01%, 0.03%) 2006 A (77) 
Indonesia 0.80% (0.10%, 1.70%) 2007 3 (40) 89.2% (85.3%, 92.3%) 2015 C (77) 0.11% (0.09%, 0.13%) 2012 A2 (77) 
Iran 0.50% (0.20%, 1.00%) 2006 2 (40) 44.1% (28.2%, 59.9%) 2014 C; B1; A (77) 0.28% (0.19%, 0.37%) 2013 A3 (77) 
Ireland 0.70% (0.67%, 1.60%) 2010 2 (40) 74.6% (72.3%, 76.9%) 2003 C (77) 0.27% (0.20%, 0.33%) 1996 A (77) 
Israel 1.96% (0.90%, 2.10%) 2006 2 (40) 45.3% (38.1%, 52.6%) 2010 C (77) 0.41% (0.27%, 0.55%) 2008 NA (160) 
Italy 2.43% (1.60%, 7.30%) 2001 1 (40) 57.9% (52.5%, 63.3%) 2014 B1; C (77) 0.83% (0.57%, 1.14%) 1996 A (77) 
Japan 0.98% (0.49%, 2.20%) 2011 2 (40) 64.8% (55.0%, 74.5%) 1994 C (77) 0.47% (0.36%, 0.58%) 2004 D1 (77) 
Kazakhstan 3.20% (1.30%, 4.26%) 2010 2 (40) 58.8% (54.0%, 63.6%) 2005 C (77) 0.96% (0.64%, 1.42%) 2006 A (77) 
Kenya 0.76% (0.20%, 1.01%) 2007 2 (40) 16.4% (10.9%, 23.3%) 2013 C (77) 0.12% (0.03%, 0.20%) 2012 A2 (77) 
Kyrgyzstan 2.45% (1.60%, 6.70%) 2010 1 (124) 43.9% (40.6%, 47.2%) 2013 B1 (77) 0.74% (0.50%, 1.11%) 2006 A (77) 
Latvia 2.40% (1.70%, 3.30%) 2008 2 (40) 74.4% (67.6%, 81.2%) 2014 B1 (77) 0.92% (0.73%, 1.17%) 2012 A2 (77) 
Lebanon 0.21% (0.11%, 0.70%) 2011 2 (40) 23.4% (15.3%, 33.3%) 2013 C (77) 0.14% (0.09%, 0.19%) 2005 NA (258) 
Libya 1.20% (1.10%, 1.30%) 2005 3 (40) 94.5% (91.5%, 96.7%) 2010 B1 (77) 0.05% (0.01%, 0.10%) 2001 C (77) 
Lithuania 1.96% (1.21%, 2.71%) 2010 2 (40) 41.1% (38.1%, 44.2%) 2014 B1; C (77) 0.22% (0.12%, 0.34%) 2006 C (77) 
Luxembourg 1.34% (0.56%, 1.61%) 2006 1 (40) 81.3% (76.2%, 85.8%) 2005 A (77) 0.57% (0.45%, 0.69%) 2009 A1 (77) 
Madagascar 1.20% (0.75%, 1.72%) 2004 2 (40) 5.5% (2.1%, 9.0%) 2012 B1 (77) 0.12% (0.02%, 0.59%) 2014 A2 (77) 
Malaysia 1.90% (0.30%, 7.70%) 2011 2 (40) 67.1% (62.9%, 71.1%) 2007 B1 (77) 1.33% (1.11%, 1.56%) 2002 C (77) 
Malta 0.36% (0.26%, 0.60%) 2010 1 (40) 25.2% (13.1%, 37.3%) 2014 A (77) 0.26% (0.17%, 0.35%) 2008 NA (160) 
Mauritius 2.10% (1.41%, 2.79%) 2010 NA (210) 97.1% (96.0%, 98.1%) 2011 B1 (77) 0.78% (0.39%, 1.54%) 2014 B1 (77) 
Mexico 1.40% (1.10%, 1.60%) 2000 3 (40) 95.3% (93.3%, 97.3%) 2005 A (77) 0.18% (0.12%, 0.25%) 2011 B (77) 




 Prevalence of HCV among general population Prevalence of HCV among PWID Population percentage of PWID 
Country 
Estimate (Estimate 
range) Year Grade Source 
Estimate (Estimate 
range) Year Grade Source 
Estimate (Estimate 
range) Year Grade Source 
Montenegro 1.20% (0.80%, 1.60%) 2008 NA (160) 43.4% (39.8%, 47.1%) 2008 B1 (77) 0.40% (0.27%, 0.53%) 2008 NA (160) 
Morocco 1.20% (1.10%, 1.93%) 2008 2 (40) 53.9% (33.7%, 74.0%) 2013 B1 (77) 0.13% (0.07%, 0.20%) 2013 A2; B (77) 
Mozambique 1.30% (0.10%, 6.90%) 2011 NA (309) 67.1% (62.9%, 71.2%) 2014 B1 (77) 0.20% (0.00%, 0.41%) 2014 A1; A2 (77) 
Myanmar 1.69% (0.95%, 2.66%) 2009 1 (124) 29.5% (26.9%, 32.2%) 2010 B1; C (77) 0.48% (0.32%, 0.65%) 2014 A2 (77) 
Nepal 0.64% (0.43%, 0.85%) 2010 NA (210) 44.5% (30.8%, 58.2%) 2015 B1 (77) 0.20% (0.19%, 0.21%) 2011 A2 (77) 
Netherlands 0.22% (0.07%, 0.37%) 2009 2 (40) 55.3% (49.7%, 60.9%) 2014 A; B1 (77) 0.03% (0.02%, 0.04%) 2001 A (77) 
New Zealand 1.43% (0.81%, 2.15%) 2013 1 (40) 71.9% (63.2%, 80.6%) 2015 B1 (77) 0.73% (0.49%, 0.97%) 2006 B (77) 
Nigeria 2.20% (2.10%, 2.50%) 2012 2 (40) 5.8% (3.5%, 8.9%) 2010 C (77) 0.35% (0.23%, 0.47%) 2008 NA (304) 
Norway 0.55% (0.45%, 0.70%) 2012 1 (40) 64.8% (60.4%, 69.1%) 2012 A (77) 0.24% (0.21%, 0.29%) 2013 A2 (77) 
Pakistan 4.80% (4.70%, 5.10%) 2008 3 (40) 36.5% (5.1%, 79.1%) 2013 C; B1; A (77) 0.37% (0.32%, 0.42%) 2011 A3 (77) 
Philippines 0.94% (0.33%, 2.00%) 2003 2 (40) 35.2% (15.9%, 54.5%) 2011 B1 (77) 0.04% (0.03%, 0.05%) 2011 C (77) 
Poland 0.86% (0.59%, 1.14%) 2009 2 (40) 58.7% (55.1%, 66.2%) 2005 A (77) 0.27% (0.18%, 0.36%) 2008 NA (160) 
Portugal 1.50% (0.47%, 2.87%) 1995 1 (40) 87.7% (80.5%, 95.0%) 2016 B1 (77) 0.22% (0.19%, 0.25%) 2012 D2 (77) 
Romania 3.23% (2.94%, 3.55%) 2007 3 (40) 83.8% (80.6%, 87.1%) 2009 B1; C (77) 0.62% (0.46%, 0.84%) 2014 A2 (77) 
Russia 4.10% (1.16%, 5.60%) 2010 2 (40) 68.7% (59.6%, 77.9%) 2012 B1; B2 (77) 1.78% (0.94%, 2.71%) 2007 D1 (77) 
Saudi Arabia 0.51% (0.41%, 0.61%) 2011 1 (40) 77.8% (73.2%, 81.9%) 2012 C (77) 0.20% (0.13%, 0.27%) 2005 NA (258) 
Senegal 1.00% (0.00%, 4.60%) 2009 NA (309) 39.3% (31.1%, 47.9%) 2011 B1 (77) 0.08% (0.05%, 0.11%) 2008 NA (304) 
Serbia 0.50% (0.34%, 0.67%) 2008 NA (160) 25.9% (22.1%, 29.7%) 2014 B1 (77) 0.49% (0.41%, 0.58%) 2016 A2 (77) 
Slovakia 1.40% (0.88%, 1.98%) 2011 3 (40) 56.1% (35.6%, 76.7%) 2014 B1; C (77) 0.49% (0.35%, 0.89%) 2006 A (77) 
Slovenia 0.40% (0.30%, 0.50%) 2015 1 (40) 30.5% (26.4%, 34.5%) 2014 B1 (77) 0.42% (0.30%, 0.55%) 2012 C (77) 
Spain 1.50% (0.40%, 2.64%) 2012 2 (40) 71.0% (69.5%, 72.5%) 2012 B1 (77) 0.08% (0.05%, 0.10%) 2011 NA (97) 
Sweden 0.56% (0.47%, 0.69%) 2012 2 (40) 81.7% (79.6%, 83.6%) 2014 C (77) 0.13% (0.03%, 0.62%) 2011 A2 (77) 
Switzerland 1.55% (0.80%, 1.75%) 1998 2 (40) 74.6% (69.3%, 79.4%) 2014 B1 (77) 0.24% (0.19%, 0.29%) 2006 A2 (77) 
Syria 2.80% (0.60%, 3.72%) 2004 3 (40) 60.5% (40.5%, 80.5%) 1999 C (268) 0.07% (0.04%, 0.09%) 2005 NA (258) 
Taiwan 3.28% (2.50%, 8.60%) 2000 2 (40) 91.0% (89.5%, 92.4%) 2011 C (77) 0.30% (0.20%, 0.40%) 2005 NA (3) 
Tajikistan 3.06% (1.10%, 6.70%) 2010 1 (124) 61.3% (56.8%, 65.6%) 2004 B1 (77) 0.45% (0.30%, 0.66%) 2006 A (77) 




 Prevalence of HCV among general population Prevalence of HCV among PWID Population percentage of PWID 
Country 
Estimate (Estimate 
range) Year Grade Source 
Estimate (Estimate 
range) Year Grade Source 
Estimate (Estimate 
range) Year Grade Source 
Thailand 0.94% (0.75%, 3.66%) 2014 2 (40) 88.5% (82.6%, 92.9%) 2005 C (77) 0.11% (0.03%, 0.18%) 2013 A3 (77) 
Tunisia 1.27% (0.20%, 1.70%) 1996 2 (40) 29.1% (25.7%, 32.6%) 2009 B1 (77) 0.21% (0.14%, 0.29%) 2005 NA (258) 
Turkey 0.95% (0.60%, 2.10%) 2009 3 (40) 44.9% (41.7%, 48.2%) 2015 B1 (77) 0.42% (0.28%, 0.56%) 2008 NA (160) 
Turkmenistan 5.55% (1.10%, 6.70%) 2010 1 (124) 60.6% (46.2%, 75.0%) 2005 NA (3) 0.40% (0.27%, 0.53%) 2008 NA (160) 
UK 0.50% (0.40%, 0.75%) 2005 2 (40) 46.0% (36.8%, 55.2%) 2008 NA (160) 0.39% (0.38%, 0.42%) 2005 A (245) 
Ukraine 3.58% (0.86%, 4.46%) 2010 1 (124) 53.9% (49.2%, 58.7%) 2015 B1 (77) 0.97% (0.52%, 1.79%) 2012 A2 (77) 
Uruguay 1.00% (0.67%, 1.33%) 2010 NA (210) 21.9% (19.0%, 24.8%) 2003 C (77) 0.30% (0.10%, 0.87%) 2007 B (77) 
USA 1.30% (1.20%, 1.50%) 2007 3 (78) 53.1% (38.1%, 68.0%) 2016 C; B2; A (77) 1.40% (0.57%, 1.88%) 2007 A2 (77) 
Uzbekistan 13.10% (6.40%, 13.11%) 2000 2 (40) 51.7% (46.8%, 56.6%) 2001 A (77) 0.47% (0.32%, 0.70%) 2006 A (77) 
Viet Nam 1.49% (1.20%, 2.00%) 2012 1 (40) 58.3% (42.7%, 74.0%) 2014 A; B1 (77) 0.25% (0.19%, 0.31%) 2005 D1 (77) 
NA: Not available 
Prevalence ranges are taken from the literature, and where they were not available ranges of ±33% are used. 
* Countries listed in green have moderate to good quality data estimates for all of the prevalence of HCV among the general population 
(graded as 2 or above), the prevalence of HCV among PWID (graded as B or above), and the population percentage of adults that are PWID 
(graded as B or above), whilst countries listed in orange have two of these estimates graded as moderate to good quality, and countries listed in 





Table 6.9: Country-level injecting durations taken from Degenhardt et al(77)†. 
Country Injecting drug use duration, years (Range†) 
Afghanistan 6.8 (3.4, 13.6) 
Albania 12.4 (6.2, 24.8)* 
Argentina 13.2 (6.6, 26.4)* 
Armenia 11.8 (5.9, 23.6)* 
Australia 15.4 (7.7, 30.8) 
Austria 13.0 (6.5, 26.0) 
Azerbaijan 8.8 (4.4, 17.6) 
Bangladesh 6.0 (3.0, 12.0) 
Belarus 10.9 (5.5, 21.8) 
Belgium 13.3 (6.7, 26.6) 
Bosnia 15.0 (7.5, 30.0) 
Brazil 13.2 (6.6, 26.4)* 
Bulgaria 9.0 (4.5, 18.0) 
Canada 14.3 (7.2, 28.6) 
China 7.1 (3.6, 14.2) 
Croatia 13.5 (6.8, 27.0) 
Cyprus 8.8 (4.4, 17.6) 
Czech Republic 11.8 (5.9, 23.6)* 
Denmark 18.2 (9.1, 36.4) 
Egypt 5.2 (2.6, 10.4)* 
Estonia 8.1 (4.1, 16.2) 
Finland 12.4 (6.2, 24.8)* 
France 12.4 (6.2, 24.8)* 
FYROM 12.4 (6.2, 24.8)* 
Georgia 14.1 (7.1, 28.2) 
Germany 13.9 (7.0, 27.8) 
Ghana 10.0 (5.0, 20.0) 
Greece 11.7 (5.9, 23.4) 
Hungary 9.6 (4.8, 19.2) 
Iceland 7.0 (3.5, 14.0) 
India 7.2 (3.6, 14.4) 
Indonesia 7.1 (3.6, 14.2) 
Iran 8.2 (4.1, 16.4) 
Ireland 12.4 (6.2, 24.8)* 
Israel 14.0 (7.0, 28.0) 
Italy 9.0 (4.5, 18.0) 
Japan 7.3 (3.7, 14.6)* 
Kazakhstan 5.0 (2.5, 10.0) 
Kenya 5.3 (2.7, 10.6) 
Kyrgyzstan 6.3 (3.2, 12.6) 
Latvia 9.1 (4.6, 18.2) 
Lebanon 5.2 (2.6, 10.4)* 
Libya 5.2 (2.6, 10.4)* 
Lithuania 10.0 (5.0, 20.0) 
Luxembourg 12.4 (6.2, 24.8)* 




Country Injecting drug use duration, years (Range†) 
Malaysia 13.9 (7.0, 27.8) 
Malta 12.4 (6.2, 24.8)* 
Mauritius 14.0 (7.0, 28.0) 
Mexico 16.1 (8.1, 32.2) 
Moldova 12.7 (6.4, 25.4) 
Montenegro 6.0 (3.0, 12.0) 
Morocco 10.0 (5.0, 20.0) 
Mozambique 7.8 (3.9, 15.6)* 
Myanmar 3.4 (1.7, 6.8) 
Nepal 5.2 (2.6, 10.4) 
Netherlands 12.4 (6.2, 24.8)* 
New Zealand 15.4 (7.7, 30.8)* 
Nigeria 8.0 (4.0, 16.0) 
Norway 14.0 (7.0, 28.0) 
Pakistan 5.1 (2.6, 10.2) 
Philippines 6.8 (3.4, 13.6) 
Poland 14.4 (7.2, 28.8) 
Portugal 12.4 (6.2, 24.8)* 
Romania 9.8 (4.9, 19.6) 
Russia 7.6 (3.8, 15.2) 
Saudi Arabia 5.2 (2.6, 10.4)* 
Senegal 7.8 (3.9, 15.6)* 
Serbia 8.8 (4.4, 17.6) 
Slovakia 11.8 (5.9, 23.6) 
Slovenia 12.4 (6.2, 24.8)* 
Spain 11.2 (5.6, 22.4) 
Sweden 21.0 (10.5, 42.0) 
Switzerland 12.4 (6.2, 24.8)* 
Syria 5.2 (2.6, 10.4)* 
Taiwan 15.5 (7.8, 31.0) 
Tajikistan 5.9 (3.0, 11.8) 
Tanzania 4.3 (2.2, 8.6) 
Thailand 7.3 (3.7, 14.6)* 
Tunisia 5.2 (2.6, 10.4)* 
Turkey 4.0 (2.0, 8.0) 
Turkmenistan 5.9 (3.0, 11.8)* 
UK 10.0 (5.0, 20.0) 
Ukraine 12.2 (6.1, 24.4) 
Uruguay 13.2 (6.6, 26.4)* 
USA 16.2 (8.1, 32.4) 
Uzbekistan 5.9 (3.0, 11.8)* 
Viet Nam 5.8 (2.9, 11.6) 
† Ranges for injecting duration are taken as 50% and 200% of the estimate for the current 
duration of injecting.  




6.15.  Historical treatment numbers 
Historical annual treatment numbers were included, where available, for the years 2004 to 
2017. Data from the Centre for Disease Analysis (CDA) covering 2004-2016 were used for 
China and Taiwan and the 2016 estimates were extended to 2017(54). Treatment numbers for 
2014-2017 were also taken from WHO access to treatment reports where available(400, 409). 
The data underlying a paper by Hill et al. on the treatment numbers for 2015-2017 were also 
made available to me(157). To obtain the treatment numbers for the years prior to this, firstly 
data were taken from the series of Journal of Viral Hepatitis papers on the Historical 
Epidemiology of hepatitis C virus in selected countries(49, 217, 223, 319). Estimates from 
these papers were available for one year. For the 48 countries that had estimates from these 
papers, the estimates of treatment numbers (e.g. for 2011) were extended to cover the time 
span of 2004-2017 (where data were not available for the later years). 2004 was chosen as the 
earliest year of treatment to coincide with the earliest estimates available from the CDA.  
 
Additionally, to increase the information available on treatment numbers, for each country 
in the model two Google searches were performed (Google was chosen over Pubmed or 
Web of Science to give a broader range of source types), the first with the words “HCV 
treated DAA” and the country name, and the second with “hepatitis c treatment” and the 
country name. Estimates were included if there was evidence of treatment in the countries 
not included in the Journal of Viral Hepatitis series. Multiple sources could be used for each 
country to cover the different years. Sources could include government treatment databases, 
news briefings, published papers, posters, presentations, reports, and white papers. For 
some posters and presentations, visual estimates had to be made as the exact figures were 
not available. More information on the sources of information for annual treatment numbers 
are available in table 6.10. 
 
To improve the treatment number estimates over time, the Journal of Viral Hepatitis series 
estimates that had been extended to cover multiple years were then overwritten if other 
information on treatment numbers was available from these other sources. Any previous 
estimate (from any of the sources listed in the paragraph above) not from the Journal of 
Viral Hepatitis series was carried forward across subsequent years or any later estimate was 
carried backwards, whichever number was lower. For example, Finland had an estimate of 




200 from 2010 onwards. Another example is Belgium, which had an estimate of 900 annual 
treatments in 2004(300) and 710 in 2010(49, 300, 348), so 710 was used for 2005-2009 and was 
also carried forwards until 2014, as an updated estimate of 1300 was available in 2015(154). 
More generally, 2016 estimates were extended to 2017 if no other information was available. 
 
Absolute treatment numbers are converted to rates to be input into the model by dividing 
with the total number of infected individuals as the denominator. Although these treatment 
numbers are not varied, the treatment rates vary due to changes in other parameters. Due to 
a lack of information for treatment numbers in particular subgroups, eg. PWID or those with 
cirrhosis, treatment was spread throughout different subgroups proportional to the number 
of infections in each group. However, this assumption was investigated in a sensitivity 
analysis where the treatment rates among PWID were halved and among people with 






Table 6.10: Historical HCV treatment numbers 2004-2017. 
 Treatments per year   
Country 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Sources 
Afghanistan 0 0 0 0 0 0 0 0 0 0 0 1 10 10 (157) 
Albania 0 0 0 0 0 0 0 0 0 117 117 117 48 48 (32) 
Argentina 200 200 200 200 200 200 200 200 200 200 350 200 1204 1204 (157, 307, 319) 
Armenia 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
Australia 2245 2134 3215 3800 3650 3800 3750 3050 2726 3540 2800 7300 40000 30000 (137, 157, 409) 
Austria 1200 1100 1100 1100 1100 1100 1100 1100 1100 1100 1100 2000 1500 1500 (49, 154, 157, 300) 
Azerbaijan 0 0 0 0 0 0 0 0 0 0 0 210 210 210 (157) 
Bangladesh 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
Belarus 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
Belgium 900 710 710 710 710 710 710 710 710 710 710 1300 1080 1080 (49, 154, 157, 300, 348) 
Bosnia 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
Brazil 10000 10000 10000 10000 10000 10000 10000 11700 7500 7500 7500 7500 41000 45016 (42, 49, 157, 409) 
Bulgaria 346 346 346 346 346 346 346 400 380 377 549 611 350 350 (157, 334) 
Canada 4800 4800 4800 4800 4800 4800 4800 4800 4800 4800 4800 14200 9500 9500 (49, 157) 
China 5000 13636 22273 30909 39545 48182 56818 65455 74091 82727 91364 100000 100000 100000 (54, 157) 
Croatia 300 300 300 300 300 300 300 300 150 150 150 150 150 150 (154, 157, 223) 
Cyprus 0 0 0 0 0 0 0 0 0 0 0 46 46 46 (154) 
Czechia 800 800 800 800 800 800 900 880 880 880 880 880 910 910 (49, 154, 157, 300) 
Denmark 100 100 100 100 100 100 200 100 100 100 344 630 511 511 (49, 154, 157, 300, 341) 
Egypt 0 0 0 65000 65000 65000 65000 65000 30000 30000 30000 170000 700000 600000 (49, 55, 91, 400, 409) 
Estonia 500 500 500 500 500 500 500 500 500 500 500 450 908 908 (154, 157, 217) 
Finland 100 100 100 100 100 100 200 300 300 300 300 300 300 300 (154, 157, 300, 319) 
France 14000 13287 13287 13287 12269 11332 9935 10325 12488 8382 11630 15189 16000 19300 (48, 55, 300) 
FYROM 0 0 0 0 0 0 0 0 0 0 0 0 76 76 (170) 
Georgia 0 0 0 0 0 0 0 0 0 0 0 6000 21500 15400 (55, 263) 




 Treatments per year  
Country 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Sources 
Ghana 20 20 20 20 20 20 20 20 20 20 20 20 20 20 (157, 223) 
Greece 1970 1970 1970 1970 1970 1970 3000 1970 1970 1970 1970 2100 900 1134 (154, 157, 300, 319, 353) 
Hungary 600 600 600 600 600 600 1200 1200 1200 1200 1200 1200 1477 1477 (154, 157, 217, 300) 
Iceland 30 30 30 30 30 30 30 30 30 30 30 40 450 200 (55, 157, 319) 
India 15000 15000 15000 15000 15000 15000 15000 15000 15000 15000 15000 42000 115000 115000 (157, 319, 400) 
Indonesia 230 230 230 230 230 230 230 230 230 230 230 230 600 600 (157, 217, 257) 
Iran 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 4500 6000 6000 (157, 217) 
Ireland 100 100 100 100 100 100 200 400 400 400 400 840 840 840 (154, 157, 300, 319) 
Israel 1010 1010 1010 1010 1010 1010 1010 1010 1010 1010 1010 1500 1500 1500 (157, 319) 
Italy 22000 12500 12500 12500 12500 12500 12500 12500 12500 12500 12500 35000 30000 43000 (4, 55, 300) 
Japan 26900 26900 26900 26900 26900 26900 26900 26900 26900 26900 26900 26900 87900 38000 (55, 157, 217) 
Kazakhstan 1800 1800 1800 1800 1800 1800 1800 1800 1800 1800 1400 1400 1132 1750 (157, 223, 229) 
Kenya 0 0 0 0 0 0 0 0 0 0 0 0 0 6 (157) 
Kyrgyzstan 0 0 0 0 0 0 0 0 0 0 0 0 100 100 (201) 
Latvia 840 840 840 840 840 840 862 840 840 840 840 910 1071 1071 (25, 154, 157, 217) 
Lebanon 170 170 170 170 170 170 170 170 170 170 170 170 325 325 (157, 217) 
Libya 0 0 0 0 0 0 0 0 0 0 0 290 288 288 (157) 
Lithuania 450 450 450 450 450 450 450 450 450 450 890 550 936 1518 (157, 174, 217) 
Luxembourg 100 100 100 100 100 100 100 100 100 100 100 168 280 300 (21, 157, 319) 
Madagascar 0 0 0 0 0 0 0 0 0 0 0 0 3 3 (157) 
Malaysia 540 540 540 540 540 540 540 540 540 540 540 550 550 550 (157, 223) 
Malta 0 0 0 0 0 0 0 0 0 0 0 12 70 70 (154, 157) 
Mauritius 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
Mexico 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3100 3800 480 480 (157, 319) 
Moldova 0 0 0 0 0 0 0 0 0 0 0 300 300 300 (229) 
Montenegro 0 0 0 0 0 0 0 0 0 0 0 0 0 0  




 Treatments per year  
Country 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Sources 
Mozambique 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
Myanmar 0 0 0 0 0 0 0 0 0 0 0 0 0 2000 (206) 
Nepal 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
Netherlands 900 900 900 900 900 900 1100 900 880 880 880 2000 2000 1200 (55, 154, 300, 319, 392) 
New Zealand 900 900 900 900 900 900 900 900 900 900 900 1100 1882 1882 (157, 319) 
Nigeria 300 300 300 300 300 300 300 300 300 300 300 300 300 300 (157, 223) 
Norway 300 300 300 300 300 300 400 600 600 600 600 1100 1000 1000 (157, 300, 319) 
Pakistan 0 23000 23000 23000 23000 23000 23000 55000 55000 55000 55000 65000 161000 161000 (157, 218, 409) 
Philippines 0 0 0 0 0 0 0 0 0 0 0 550 550 550 (157) 
Poland 1000 1000 1000 1000 1000 1000 2500 2100 2100 2100 2100 4000 5800 5800 (154, 157, 300, 319) 
Portugal 200 200 200 200 200 200 2000 1200 1200 1200 1200 5449 8248 4836 (49, 67, 157, 300, 400) 
Romania 2500 2500 2500 2500 2500 2500 6000 4100 4100 4100 4100 3400 6000 8131 (154, 157, 217, 300, 409) 
Russia 500 500 500 500 500 500 6000 5500 5500 5500 8800 5500 8792 5500 (157, 201, 229, 300, 319) 
Saudi Arabia 1900 1900 1900 1900 1900 1900 1900 1900 380 380 380 7500 2800 2800 (14, 157, 217) 
Senegal 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
Serbia 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
Slovakia 200 200 200 200 200 200 500 300 300 300 300 350 316 316 (154, 157, 300, 319) 
Slovenia 150 150 150 150 150 150 150 150 150 150 150 150 200 200 (154, 157, 217) 
Spain 8000 8000 8000 8000 8000 8000 9800 9800 9800 9800 9800 38000 32000 29700 (49, 55, 154, 300) 
Sweden 1500 1500 1500 1500 1500 1500 2000 1100 1100 1100 1130 2300 2500 2500 (49, 84, 154, 157, 300) 
Switzerland 800 800 800 800 800 800 1100 1100 1100 1100 1100 1100 2300 3200 (49, 55, 300) 
Syria 0 0 0 0 0 0 0 0 0 0 0 0 10 10 (157) 
Taiwan 3549 4154 4967 5567 5117 5490 13515 11262 10586 9000 8000 8000 4000 4000 (54, 157) 
Tajikistan 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
Tanzania 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
Thailand 0 0 0 0 0 0 0 0 0 0 0 920 3000 3000 (157) 




 Treatments per year  
Country 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Sources 
Turkey 4170 4170 4170 4170 4170 4170 4170 4170 4170 4170 4170 4170 194 194 (157, 273) 
Turkmenistan 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
UK 2500 2500 3000 4468 5091 5904 6449 6202 4000 4000 4000 9000 12000 14800 (55, 148, 154, 300, 409) 
Ukraine 0 0 0 0 0 0 0 0 0 0 1100 2000 2500 1750 (157, 229, 409) 
Uruguay 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
USA 0 125000 105000 80000 75000 70000 60000 72500 57500 30000 140000 260000 231000 231000 (50, 157) 
Uzbekistan 0 0 0 0 0 0 0 0 0 0 0 1500 1500 1500 (157) 





CHAPTER 7. THE CONTRIBUTION OF INJECTING 
DRUG USE FOR HEPATITIS C VIRUS 
TRANSMISSION GLOBALLY, REGIONALLY, AND 
AT COUNTRY-LEVEL: A MODELLING STUDY 
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Larney, Natasha K Martin, Matthew Hickman, Louisa Degenhardt, Margaret T May, and 
Peter Vickerman, and is published in the Lancet Gastroenterology and Hepatology(371). 
 
7.1.  Introduction 
Injecting drug use (IDU) is an important risk factor for the transmission of bloodborne 
viruses, due to sharing of used needles and injecting equipment(77). Although hepatitis C 
virus (HCV) prevalence amongst people who inject drugs (PWID) is generally high 
(>30%)(77), the prevalence of IDU in most countries is low (<1% of adults)(77). It is therefore 
generally assumed that IDU is usually only an important contributor to HCV transmission 
in low prevalence settings, mainly high-income countries (HICs) in Europe, Australasia, and 
North America(16). Conversely, its role in low and middle-income countries (LMICs), some 
of which have higher HCV prevalence(40), is thought to be small(327). In these settings, it is 
assumed that transmission is driven by other risk factors, such as unsterile medical 
injections, other medical procedures, unscreened blood transfusions, and community risks 
(e.g. barbering, tattooing, and body piercings)(16, 327, 367).  
This role of different risk factors to HCV transmission in LMICs was discussed in relation to 
Pakistan in chapter 4 and Punjab, India, in chapter 5. Both settings had medical factors that 
were associated with prevalent infection and Pakistan also had community factors. In 
Punjab there is some evidence that IDU is a growing source of HCV transmission(326). 
However, the analysis in chapter 5 cannot truly quantify the role of IDU to HCV 





Additionally, due to the survey sampling from households, PWID are likely to be under-
represented. Two recent analyses attempted to quantify the role of IDU to the transmission 
and disease burden of HCV globally(76, 127). These estimated two very distinct measures; 
the proportion of global prevalent HCV infections that are amongst people who have 
recently injected drugs, around 8.5%(127), and the proportion of the global HCV morbidity 
burden attributable to IDU, roughly 39%(76). Neither measured the future HCV 
transmissions resulting from IDU and neither accounted for current or ex-injectors infected 
due to IDU conferring additional transmission risk through iatrogenic or other routes. This 
transmission can be through routes such as tattooing in and outside prisons(153, 367), 
mother-to-child transmission(306), needlestick injuries to healthcare workers(265), and 
general access to healthcare leading to iatrogenic transmission(122).  
Policy-makers should plan the most efficient use of resources to prevent and treat HCV 
infections in response to the WHO’s 2030 elimination targets(403). To do this, it is important 
to understand the future role of IDU to HCV transmission as well as the current burden of 
the epidemic that is among PWID. To address this knowledge gap, in this chapter I use 
country-specific HCV transmission modelling to estimate the contribution of IDU to HCV 
transmission at the country-level, regionally, and globally. I estimate the percentage of HCV 
infections that would be prevented from 2018-2030 if HCV transmission due to injecting 
risks were removed. I also investigate the factors associated with the percentage of HCV 
transmission due to IDU at the country-level. 
 
7.2.  Methods 
The model structure, parameterisation, and calibration used in this chapter are the same as 
that described in Chapter 6. 
 
7.2.1.  Population attributable fraction of HCV transmission 
The calibrated models for each country were used to project the HCV epidemic for 12 years 
from 2018 up to 2030, defined as the baseline projections for each country. To investigate the 





attributable fraction (PAF) of HCV transmission (henceforth referred to as the tPAF) due to 
IDU in each country, regionally, and globally, was estimated. To do this, the baseline model 
fits for each country were re-run with the transmission risk due to IDU set to zero from 2018 
onwards. For each paired parameter set, the tPAF was estimated over 1 and 12 years as the 
relative reduction in the overall number of HCV infections over that period from setting the 
transmission risk due to IDU to zero (from 2018), compared to the baseline projections. The 
projections for all paired parameter sets from each country were averaged to produce 
country-specific estimates, which were then combined to produce regional and global 
estimates with the average tPAFs for each country weighted by that country’s relative 
burden of HCV compared to the regional or global burden. The variation across the different 
model fits for each country were used to produce 95% credibility intervals (CrI) using the 
2.5th and 97.5th percentiles of the 1,000 simulated runs, with the main estimate calculated as 
the median. 
 
7.2.2.  Sensitivity analyses 
Sensitivity analyses investigated the effect on the tPAF estimates of: (a) general population 
HCV prevalence being stable, rather than declining from 1990; (b) HCV prevalence among 
PWID decreasing at the same rate as the general population HCV prevalence, rather than 
being stable; (c) the proportion of adults that are PWID in 1990 being stable in Eastern 
Europe and Sub-Saharan Africa, rather than increasing; (d) the same annual HCV treatment 
numbers, but with the treatment rate among PWID being halved and the treatment rate 
among people with cirrhosis being doubled; (e) the rate of initiating injecting in USA 
increasing 2.9-fold from 2010 onwards, to capture the recent opioid epidemic(109); and (f) 
varying the temporal changes in general population HCV prevalence by region.  
I investigated the effect on the global tPAF estimate of only including the 66 countries with 
≥2 of the key prevalence parameters having a quality rating that was scored as moderate or 
better (re-weighting by the new selection of countries), see table 6.7. An additional 
sensitivity analysis was performed by comparing the baseline scenario with a scenario 
where the additional transmission rate among PWID was set to zero and all infected PWID 





Because it is likely that there is considerable sub-national variation in HCV epidemics, there 
is a question about whether the tPAF estimates of our ‘average’ national models will reliably 
capture the average tPAF of a set of sub-national epidemics. I investigated this by 
considering a similar question, whether my tPAF estimate for an ‘average’ regional model 
approximates the combined average tPAF for the set of national models for that region. For 
each country in Central Asia (chosen as the first listed region), I took the weighted national 
prevalence estimates of HCV prevalence among PWID and the general population, and the 
percentage of adults that are PWID, as well as other weighted national parameters. I used 
the average ‘regional’ parameter values to calibrate a regional model for Central Asia. I 
compared the 12-year tPAF estimate for this regional model with the combined average 
regional tPAF calculated by averaging across the different national estimates (from the 
national models, presented in table 7.1). 
All sensitivity analyses (and the main analysis for better comparison) were ran to produce 
100 model fits rather than 1,000, as comparison runs show running for 100 or 1,000 fits 
produced very similar results (which can be seen by comparing table 7.1 with appendix 
table 7.4). 
 
7.2.3.  Variables associated with country-level tPAFs 
I used generalised linear regression models to determine what country-level factors are 
associated with the tPAF of HCV due to risks associated with IDU. The 12-year tPAF was 
logit transformed (log(tPAF/1-tPAF)) as it is a proportion, and was regressed on the 
covariates for the percentage of the adult population that are PWID, HCV prevalence among 
PWID, HCV prevalence among the general population, the injecting duration of PWID in 
the country, the percentage of the country’s prevalent infections that are among PWID, and 
the World Bank Gross National Income (GNI) per capita (which could possibly act as a 
confounder for the amount of spending on a country’s healthcare system) – all from 2017. 
The non-linear association between the tPAF of HCV due to IDU and the percentage of the 
country’s prevalent infections that are among PWID was plotted using a fractional 





Lastly, I undertook a regression analysis to consider how differences in the growth of each 
HCV epidemic affects the tPAF. This involved a mixed-effects regression analysis with 
country as the panel variable to account for the variation between the runs for each country. 
The 12-year tPAF was the dependent variable and the general population annual HCV 
epidemic growth as the independent variable (calculated between 2018 and 2038). For each 
country all of the 1,000 fitted runs were included, with the HCV prevalence growth and 
tPAF varying between runs. 
 
7.3.  Results 
7.3.1.  Fitting 
The model was successfully calibrated for 88 countries. Appendix table 7.1 shows the 
country-level HCV transmission parameters among the general population (ranging from 0 
in various countries to 0.0569 in Senegal) and PWID (ranging from 0.1533 in Nigeria to 
0.9148 in Libya). Appendix table 7.2 gives the median percentage differences between the 
target prevalences and fitted values for the key prevalence parameters [adult % PWID: 
0.0000% (95% CrI: 0.0000%, 0.0000%); PWID % chronic HCV: 0.0000% (95% CrI: 0.0000%, 
23.1888%); gen-pop % chronic HCV: 0.0000% (95% CrI: 0.0000%, 19.5878%)]. Appendix table 
7.3 compares the prior and posterior distributions, which, as per the results in appendix 
table 7.2, are similar. 
Appendix figure 7.1 graphs the model fits. Note, country-level treatment numbers are 
already high as of 2015 in some countries, eg. 600,000 in Egypt, 15,400 in Georgia, 43,000 for 
Italy, and 29,700 for Spain for 2017(55). In such countries, these modelled treatment numbers 
result in the HCV epidemic decreasing rapidly over the next 10 to 15 years with the WHO 
elimination targets for incidence being reached over the modelled time period. 
 
7.3.2.  tPAF results 
For the countries simulated, the model predicts that in 2017 0.23% (95% CrI: 0.16%, 0.31%) of 





are among people who currently inject drugs. Figures 7.1 and 7.2, and table 7.1 show the 
country, regional, and global estimates of the tPAF of IDU to HCV transmission for 2018 to 
2030. Figure 7.3 plots the country-level 12-year tPAFs against each country’s percentage of 
the global prevalent HCV infections.  
Globally, the model estimates 43% (95% CrI: 25%, 67%) of all new HCV infections could be 
prevented over 12-years if the heightened HCV risk associated with IDU was removed, 
varying from 14% (95% CrI: 2%, 43%) in Sub-Saharan Africa to 96% (95% CrI: 69%, 99%) in 
Eastern Europe. The 12-year tPAFs of IDU to HCV are over 50% for five other global 
regions: Western Europe, North America, Latin America, Australasia, and East and 
Southeast Asia, while they are less than 50% for Central Asia, South Asia, and Middle East 
and North Africa. The contribution of IDU to HCV transmission is greatest in HICs, where 
79% (95% CrI: 57%, 97%) of new HCV infections could be prevented if the transmission risk 
due to IDU was removed, compared to 38% (95% CrI: 24%, 64%) in LMICs. The 1-year 
global tPAF of IDU to HCV over 2018-19, 39% (95% CrI: 21%, 64%), is slightly lower than the 
12-year tPAF (2018-2030). The model also estimates that, globally, 43% (95% CrI: 24%, 80%) 
of infections occurring between 2018 and 2030 would be among PWID. 
 
Figure 7.1: Map of PAF of HCV transmission due to IDU from 2018-2030*. 
 





Figure 7.2: Regional and global estimates for the PAF of IDU to HCV transmission from 
2018-2030*. 
 





Table 7.1: Country-level fitted demographic data values in 2017, model projections of the PAF of IDU to HCV transmission from 2018-2019 and 
2018-2030, and the percentage of the setting’s prevalent infections in 2017 that are among PWID*. 
 Estimate (95% credibility interval) 
  Fitted demographic data values  tPAF of HCV infections due to IDU 




Chronic HCV prevalence 
(%) among general 
population 
Percentage of the setting’s 
prevalent infections that 
are among PWID 
2018-2019 2018-2030 
Global 0.32 (0.23, 0.42) 34.5 (25.8, 42.0) 1.0 (0.7, 1.4) 8 (5, 12) 39% (21%, 64%) 43% (25%, 67%) 
Central Asia 0.61 (0.44, 0.81) 26.4 (21.0, 29.8) 2.4 (1.5, 3.3) 4 (3, 6) 32% (16%, 69%) 37% (19%, 73%) 
Kazakhstan 0.94 (0.67, 1.25) 27.4 (18.9, 30.8) 1.3 (0.8, 1.7) 14 (9, 20) 98% (60%, 100%) 99% (67%, 100%) 
Kyrgyzstan 0.76 (0.56, 1.01) 21.6 (19.5, 23.6) 1.5 (0.8, 2.6) 7 (5, 10) 42% (19%, 94%) 50% (24%, 95%) 
Tajikistan 0.46 (0.34, 0.62) 30.4 (27.8, 32.9) 1.5 (0.7, 2.6) 6 (4, 8) 31% (14%, 76%) 39% (19%, 81%) 
Turkmenistan 0.38 (0.28, 0.48) 29.9 (24.1, 35.9) 2.0 (0.9, 2.7) 4 (3, 5) 26% (11%, 66%) 32% (15%, 72%) 
Uzbekistan 0.47 (0.35, 0.63) 25.1 (21.4, 29.0) 3.6 (2.3, 4.8) 2 (2, 3) 18% (7%, 59%) 23% (9%, 64%) 
Eastern Europe 1.13 (0.71, 1.61) 45.8 (34.0, 53.6) 2.0 (1.2, 2.6) 21 (12, 31) 95% (64%, 99%) 96% (69%, 99%) 
Armenia 0.74 (0.47, 1.22) 36.0 (26.6, 44.5) 2.4 (1.8, 3.1) 9 (5, 15) 68% (35%, 100%) 73% (41%, 100%) 
Azerbaijan 0.60 (0.51, 0.69) 48.1 (39.5, 56.1) 2.4 (1.8, 3.0) 9 (7, 11) 46% (26%, 81%) 52% (32%, 84%) 
Belarus 0.57 (0.29, 0.86) 52.8 (40.3, 61.1) 1.1 (0.8, 1.7) 21 (11, 34) 96% (58%, 100%) 96% (62%, 100%) 
Bosnia 0.17 (0.12, 0.21) 41.7 (34.0, 49.1) 0.1 (0.1, 0.1) 52 (36, 72) 100% (96%, 100%) 100% (97%, 100%) 
Bulgaria 0.37 (0.30, 0.44) 50.0 (38.0, 54.6) 1.0 (0.6, 1.5) 15 (10, 20) 100% (62%, 100%) 100% (67%, 100%) 
Czech Republic 0.64 (0.61, 0.67) 14.8 (12.0, 17.5) 0.3 (0.2, 0.4) 23 (18, 28) 80% (56%, 100%) 88% (68%, 100%) 
Estonia 1.04 (0.74, 1.53) 46.6 (36.2, 57.0) 1.3 (1.1, 1.4) 32 (21, 48) 100% (89%, 100%) 100% (94%, 100%) 
Georgia 4.30 (1.34, 7.32) 40.5 (28.7, 48.3) 4.6 (4.0, 5.3) 29 (10, 51) 100% (59%, 100%) 100% (70%, 100%) 
Hungary 0.06 (0.04, 0.08) 34.3 (24.6, 42.2) 0.8 (0.3, 1.5) 2 (1, 3) 24% (8%, 73%) 30% (11%, 79%) 
Latvia 0.90 (0.74, 1.08) 52.4 (39.6, 59.8) 1.6 (1.2, 2.0) 25 (17, 33) 100% (81%, 100%) 100% (86%, 100%) 
Lithuania 0.22 (0.14, 0.31) 34.2 (27.4, 36.8) 1.1 (0.8, 1.5) 6 (4, 9) 68% (32%, 100%) 76% (42%, 100%) 
Moldova 0.41 (0.29, 0.52) 41.5 (30.8, 50.4) 2.3 (1.6, 2.8) 6 (4, 8) 46% (23%, 100%) 52% (28%, 100%) 
Poland 0.28 (0.21, 0.35) 49.1 (44.8, 53.0) 0.5 (0.4, 0.7) 20 (15, 27) 81% (54%, 100%) 86% (63%, 100%) 
Romania 0.61 (0.48, 0.76) 62.3 (46.5, 66.5) 2.0 (1.8, 2.2) 16 (11, 21) 100% (65%, 100%) 100% (71%, 100%) 
Russia 1.69 (1.06, 2.41) 47.6 (35.1, 56.6) 2.7 (1.6, 3.6) 24 (14, 36) 100% (72%, 100%) 100% (76%, 100%) 
Slovakia 0.58 (0.40, 0.85) 44.1 (32.9, 55.2) 1.0 (0.7, 1.2) 21 (13, 35) 86% (55%, 100%) 88% (62%, 100%) 





 Fitted demographic data values  tPAF of HCV infections due to IDU 




Chronic HCV prevalence 
(%) among general 
population 
Percentage of the setting’s 
prevalent infections that 
are among PWID 
2018-2019 2018-2030 
Australasia 0.60 (0.46, 0.73) 35.7 (32.0, 39.3) 0.8 (0.7, 1.1) 19 (13, 24) 58% (34%, 94%) 66% (43%, 96%) 
Australia 0.58 (0.45, 0.70) 32.4 (29.7, 35.1) 0.8 (0.7, 1.0) 17 (12, 21) 54% (32%, 93%) 62% (41%, 95%) 
New Zealand 0.69 (0.51, 0.87) 50.6 (42.8, 57.1) 1.0 (0.6, 1.4) 26 (19, 34) 74% (45%, 100%) 82% (57%, 100%) 
East & Southeast Asia 0.23 (0.19, 0.28) 31.5 (23.8, 38.2) 0.7 (0.5, 1.0) 7 (5, 10) 53% (26%, 98%) 58% (32%, 98%) 
China 0.22 (0.18, 0.27) 27.1 (19.5, 35.0) 0.7 (0.6, 0.9) 6 (4, 9) 50% (24%, 100%) 56% (30%, 100%) 
Indonesia 0.11 (0.09, 0.12) 57.5 (54.3, 60.4) 0.5 (0.2, 0.8) 9 (7, 11) 61% (27%, 100%) 67% (32%, 100%) 
Japan 0.44 (0.36, 0.53) 32.9 (23.5, 40.6) 0.6 (0.4, 1.0) 19 (13, 26) 100% (68%, 100%) 100% (76%, 100%) 
Malaysia 1.26 (1.09, 1.43) 42.6 (32.5, 45.7) 1.8 (0.6, 3.8) 20 (15, 24) 57% (26%, 100%) 65% (32%, 100%) 
Myanmar 0.47 (0.35, 0.59) 19.4 (13.5, 21.5) 1.0 (0.6, 1.4) 6 (5, 9) 70% (35%, 100%) 75% (42%, 100%) 
Philippines 0.04 (0.03, 0.05) 24.9 (14.9, 35.4) 0.5 (0.2, 0.8) 1 (1, 2) 11% (3%, 35%) 14% (5%, 42%) 
Taiwan 0.27 (0.20, 0.34) 55.6 (48.5, 59.9) 1.8 (1.0, 3.1) 7 (5, 9) 57% (18%, 100%) 64% (22%, 100%) 
Thailand 0.10 (0.05, 0.16) 55.7 (51.9, 59.4) 1.0 (0.5, 1.9) 5 (2, 7) 38% (11%, 100%) 43% (13%, 100%) 
Viet Nam 0.23 (0.18, 0.27) 37.5 (29.7, 45.7) 0.9 (0.7, 1.1) 7 (5, 9) 52% (28%, 100%) 58% (34%, 100%) 
South Asia 0.09 (0.07, 0.11) 30.3 (16.2, 44.0) 0.9 (0.6, 1.3) 2 (1, 3) 10% (3%, 25%) 14% (4%, 31%) 
Afghanistan 0.80 (0.56, 1.03) 30.5 (23.6, 36.9) 0.9 (0.5, 1.3) 15 (10, 22) 46% (23%, 98%) 58% (32%, 99%) 
Bangladesh 0.07 (0.06, 0.07) 27.7 (20.3, 34.9) 0.9 (0.3, 1.4) 1 (1, 2) 12% (5%, 37%) 15% (6%, 43%) 
India 0.02 (0.01, 0.03) 31.2 (27.4, 35.0) 0.7 (0.4, 1.0) 1 (0, 1) 4% (2%, 11%) 6% (2%, 15%) 
Iran 0.27 (0.21, 0.34) 35.5 (25.4, 44.8) 0.4 (0.2, 0.6) 18 (12, 26) 78% (45%, 100%) 85% (55%, 100%) 
Nepal 0.20 (0.19, 0.21) 35.7 (27.7, 44.0) 0.5 (0.4, 0.6) 10 (8, 13) 60% (34%, 100%) 67% (42%, 100%) 
Pakistan 0.36 (0.32, 0.40) 28.3 (7.3, 52.9) 3.0 (2.7, 3.4) 2 (1, 4) 13% (2%, 37%) 18% (2%, 47%) 
North America 1.08 (0.63, 1.51) 30.7 (22.2, 40.7) 0.9 (0.6, 1.2) 30 (16, 47) 67% (43%, 100%) 77% (56%, 100%) 
Canada 0.37 (0.30, 0.43) 50.7 (42.4, 63.2) 0.6 (0.4, 0.8) 23 (17, 30) 74% (44%, 100%) 83% (56%, 100%) 
USA 1.16 (0.67, 1.63) 30.0 (21.2, 40.0) 0.9 (0.6, 1.2) 30 (16, 48) 67% (43%, 100%) 77% (56%, 100%) 
Western Europe 0.32 (0.23, 0.40) 37.9 (27.3, 44.7) 0.6 (0.3, 1.0) 15 (10, 20) 80% (45%, 93%) 83% (53%, 94%) 
Albania 0.39 (0.28, 0.48) 25.5 (17.3, 30.1) 1.7 (1.3, 2.2) 5 (3, 6) 55% (22%, 100%) 60% (26%, 100%) 
Austria 0.30 (0.22, 0.37) 34.0 (27.3, 38.9) 0.3 (0.1, 0.4) 31 (21, 42) 100% (69%, 100%) 100% (79%, 100%) 
Belgium 0.35 (0.26, 0.45) 38.1 (28.5, 47.3) 0.4 (0.2, 0.6) 25 (16, 36) 100% (53%, 100%) 100% (61%, 100%) 
Croatia 0.23 (0.19, 0.27) 26.3 (21.5, 31.2) 0.6 (0.4, 0.8) 9 (7, 12) 66% (29%, 100%) 71% (34%, 100%) 





 Fitted demographic data values  tPAF of HCV infections due to IDU 




Chronic HCV prevalence 
(%) among general 
population 
Percentage of the setting’s 
prevalent infections that 
are among PWID 
2018-2019 2018-2030 
Denmark 0.42 (0.35, 0.48) 27.3 (23.4, 31.2) 0.4 (0.3, 0.4) 26 (20, 31) 89% (51%, 100%) 92% (60%, 100%) 
FYROM (Macedonia) 0.15 (0.11, 0.19) 45.1 (42.4, 47.6) 0.3 (0.2, 0.4) 17 (13, 22) 97% (54%, 100%) 98% (61%, 100%) 
Finland 0.48 (0.41, 0.61) 47.7 (36.6, 52.8) 0.5 (0.4, 0.7) 33 (24, 43) 100% (84%, 100%) 100% (87%, 100%) 
France 0.19 (0.16, 0.22) 35.9 (28.5, 45.0) 0.3 (0.2, 0.5) 16 (12, 21) 90% (50%, 100%) 93% (62%, 100%) 
Germany 0.22 (0.07, 0.37) 40.9 (36.4, 44.8) 0.4 (0.2, 0.5) 21 (7, 36) 83% (34%, 100%) 89% (44%, 100%) 
Greece 0.07 (0.06, 0.08) 45.4 (42.2, 48.5) 1.0 (0.4, 1.5) 3 (2, 3) 19% (8%, 64%) 23% (10%, 70%) 
Iceland 0.23 (0.17, 0.29) 24.4 (18.9, 28.3) 0.2 (0.1, 0.3) 25 (16, 36) 100% (78%, 100%) 100% (82%, 100%) 
Ireland 0.26 (0.21, 0.32) 49.5 (46.0, 52.2) 0.6 (0.4, 0.9) 17 (13, 21) 70% (37%, 100%) 79% (46%, 100%) 
Italy 0.80 (0.59, 1.02) 35.5 (19.8, 42.4) 1.7 (0.9, 3.2) 13 (7, 19) 100% (47%, 100%) 100% (55%, 100%) 
Luxembourg 0.56 (0.46, 0.65) 47.5 (39.2, 52.7) 0.6 (0.4, 0.9) 29 (23, 36) 88% (56%, 100%) 94% (72%, 100%) 
Malta 0.27 (0.21, 0.33) 18.8 (14.3, 23.8) 0.2 (0.2, 0.3) 15 (13, 21) 72% (36%, 100%) 79% (45%, 100%) 
Montenegro 0.37 (0.27, 0.47) 30.1 (21.4, 34.4) 0.8 (0.6, 1.0) 11 (7, 15) 100% (64%, 100%) 100% (69%, 100%) 
Netherlands 0.03 (0.02, 0.04) 30.3 (19.3, 35.7) 0.1 (0.0, 0.2) 7 (4, 9) 41% (18%, 88%) 52% (25%, 91%) 
Norway 0.24 (0.21, 0.27) 40.2 (37.0, 43.5) 0.3 (0.3, 0.4) 22 (18, 26) 74% (47%, 100%) 83% (61%, 100%) 
Portugal 0.21 (0.18, 0.23) 53.9 (42.1, 61.8) 0.7 (0.3, 1.1) 14 (10, 17) 100% (54%, 100%) 100% (67%, 100%) 
Serbia 0.49 (0.42, 0.55) 17.1 (12.4, 20.8) 0.4 (0.3, 0.4) 19 (14, 25) 100% (85%, 100%) 100% (88%, 100%) 
Slovenia 0.40 (0.31, 0.50) 20.2 (15.8, 23.0) 0.3 (0.2, 0.3) 24 (18, 32) 93% (54%, 100%) 95% (64%, 100%) 
Spain 0.07 (0.05, 0.09) 43.1 (32.4, 46.9) 0.8 (0.3, 1.4) 3 (2, 4) 22% (8%, 60%) 31% (13%, 69%) 
Sweden 0.22 (0.06, 0.49) 52.1 (48.2, 67.1) 0.3 (0.3, 0.4) 26 (7, 60) 73% (29%, 100%) 85% (45%, 100%) 
Switzerland 0.23 (0.20, 0.27) 46.4 (40.8, 51.9) 0.6 (0.4, 0.8) 14 (11, 17) 77% (38%, 100%) 85% (51%, 100%) 
UK 0.42 (0.37, 0.45) 42.0 (33.5, 49.8) 0.4 (0.3, 0.5) 33 (24, 42) 97% (73%, 100%) 98% (83%, 100%) 
Sub-Saharan Africa 0.40 (0.26, 0.55) 14.2 (10.5, 17.7) 1.4 (0.9, 2.2) 3 (1, 4) 11% (2%, 39%) 14% (2%, 43%) 
Ghana 0.05 (0.04, 0.06) 29.8 (26.5, 33.0) 1.8 (1.0, 3.2) 1 (0, 1) 2% (1%, 6%) 3% (1%, 8%) 
Kenya 0.12 (0.05, 0.18) 18.8 (13.2, 24.5) 0.4 (0.2, 0.6) 3 (1, 5) 22% (8%, 51%) 31% (13%, 61%) 
Madagascar 0.22 (0.06, 0.51) 5.3 (2.0, 9.6) 0.6 (0.5, 0.9) 1 (0, 3) 4% (0%, 18%) 6% (1%, 27%) 
Mauritius 0.82 (0.47, 1.33) 70.9 (54.3, 74.0) 1.5 (1.1, 1.9) 29 (17, 48) 88% (55%, 100%) 90% (59%, 100%) 
Mozambique 0.20 (0.05, 0.36) 49.4 (46.1, 52.6) 1.6 (0.4, 3.9) 3 (1, 6) 17% (3%, 59%) 21% (4%, 67%) 
Nigeria 0.36 (0.26, 0.46) 4.0 (2.6, 5.8) 1.4 (1.3, 1.6) 1 (0, 1) 1% (0%, 3%) 2% (0%, 4%) 





 Fitted demographic data values  tPAF of HCV infections due to IDU 




Chronic HCV prevalence 
(%) among general 
population 
Percentage of the setting’s 
prevalent infections that 
are among PWID 
2018-2019 2018-2030 
Tanzania 1.23 (0.84, 1.63) 20.0 (16.5, 23.9) 2.4 (0.7, 4.5) 6 (4, 8) 29% (9%, 87%) 37% (13%, 91%) 
Latin America 0.44 (0.35, 0.53) 49.7 (44.1, 52.8) 0.8 (0.7, 1.0) 18 (14, 23) 66% (41%, 98%) 71% (49%, 98%) 
Argentina 0.29 (0.28, 0.32) 41.1 (38.3, 43.9) 0.8 (0.4, 1.2) 11 (9, 12) 51% (25%, 99%) 58% (31%, 99%) 
Brazil 0.63 (0.50, 0.76) 47.1 (41.0, 50.2) 0.9 (0.8, 1.1) 23 (18, 30) 77% (49%, 100%) 83% (59%, 100%) 
Mexico 0.17 (0.13, 0.22) 72.4 (69.1, 75.2) 0.7 (0.6, 0.9) 12 (8, 15) 48% (27%, 94%) 53% (32%, 95%) 
Uruguay 0.39 (0.15, 0.75) 16.3 (14.4, 18.4) 0.6 (0.5, 0.8) 8 (3, 15) 43% (16%, 100%) 49% (20%, 100%) 
Middle East & North Africa 0.24 (0.17, 0.30) 31.7 (23.6, 36.8) 2.5 (2.0, 3.1) 2 (1, 3) 13% (6%, 25%) 16% (8%, 28%) 
Egypt 0.21 (0.14, 0.26) 26.1 (18.8, 33.7) 6.3 (5.3, 7.6) 1 (0, 1) 3% (1%, 9%) 5% (2%, 12%) 
Israel 0.41 (0.30, 0.51) 28.3 (24.3, 32.6) 0.9 (0.6, 1.1) 9 (6, 12) 28% (14%, 59%) 37% (20%, 69%) 
Lebanon 0.14 (0.10, 0.18) 15.6 (11.3, 20.6) 0.2 (0.1, 0.4) 7 (4, 10) 35% (14%, 86%) 46% (20%, 92%) 
Libya 0.05 (0.02, 0.08) 65.0 (62.0, 68.2) 0.6 (0.5, 0.7) 3 (1, 6) 35% (12%, 86%) 42% (15%, 89%) 
Morocco 0.13 (0.08, 0.18) 38.0 (26.9, 48.3) 0.8 (0.6, 1.0) 5 (2, 7) 29% (11%, 72%) 37% (16%, 80%) 
Saudi Arabia 0.19 (0.13, 0.24) 50.8 (45.1, 54.3) 0.3 (0.3, 0.4) 19 (14, 25) 88% (54%, 100%) 92% (65%, 100%) 
Syria 0.06 (0.04, 0.08) 43.6 (32.6, 53.5) 1.3 (0.5, 1.9) 1 (1, 2) 12% (4%, 34%) 15% (6%, 41%) 
Tunisia 0.20 (0.14, 0.25) 28.2 (23.4, 32.5) 0.5 (0.2, 0.8) 8 (6, 11) 79% (35%, 100%) 84% (43%, 100%) 




Figure 7.3: Bar chart of each country’s PAF of IDU to HCV transmission 2018-2030 against 
the percentage of the global prevalent HCV infections (2017) in that country*. 
 
* Countries with the largest chronic HCV burdens in 2017 are labelled. 
 
7.3.3.  Sensitivity analyses 
Figure 7.4, table 7.2, and appendix table 7.4 show the results of various sensitivity analyses, 
with the most important changes indicating the tPAF could be lower, 33% (95% CrI: 20%, 
54%), if the HCV prevalence trends among the general population were assumed to be 
stable instead of decreasing, or 30% (95% CrI: 15%, 51%) if trends varied by region. There 
were large changes for the tPAF of individual countries for these two sensitivity analyses. 
For example, Australia's tPAF drops from 66% (95% CrI: 41%, 10%) in the main analysis to 
48% (95% CrI: 32%, 81%) when assuming a stable general population HCV prevalence, or 
44% (95% CrI: 27%, 75%) when assuming that epidemic trajectories vary by region. 
Sensitivity analyses also showed that the tPAF for USA rose from 67% (95% CrI: 41%, 100%) 
in the baseline model to 85% (95% CrI: 62%, 100%) when I assumed an increasing epidemic 
of IDU since 2010 (table 7.3). This increase occurs due to there being 2.9 times more PWID in 
the modified model during the analysis period than for the baseline model. The sensitivity 
analyses where I separately assumed (i) a decreasing HCV prevalence among PWID, (ii) the 
population percentage of PWID in Eastern Europe and Sub-Saharan Africa was stable from 
1990 (rather than increasing), (iii) treatment rates are halved among PWID and doubled 




analysis including only the 66 countries with better data, the global average tPAF increases 
slightly to 49% (95% CrI: 29%, 73%). Table 7.4 shows that the global tPAF increases to 46% 
(95% CrI: 26%, 65%) if the heightened burden of HCV among PWID was also removed as 
well as their elevated transmission risk.  
The regional ‘average’ model for Central Asia produced very similar results, with a tPAF of 
34% (95% CrI: 19%, 71%), compared to the average tPAF across the different national models 





Figure 7.4: Scatter plots of country-level results of the main 2018-2030 tPAF estimates against 
sensitivity analysis results. 
7.4a) Assuming stable general population HCV prevalence. 
 















































































7.4c) Assuming altered treatment rates are halved among PWID and doubled among people 
with cirrhosis. 
 
7.4d) Assuming the proportion of adults that are PWID was stable in 1990 in Eastern Europe 
































































































































7.4e) Assuming varied HCV epidemic trajectories by region. 
 
 
Table 7.2: Sensitivity analysis where the proportion of adults that are PWID in the USA 
expands from 2010 onwards*. 
  Fitted demographic data values  
tPAF of HCV 
infections due to 
IDU 
Assumptions 









Percentage of the 
setting’s prevalent 
infections that are 
among PWID 
2018-2030 
Original 1.19 (0.72, 1.69) 30.2 (20.9, 41.2) 0.9 (0.5, 1.2) 29 (13, 50) 67% (41%, 100%) 
Expanding 
PWID 
epidemic 2.18 (1.47, 3.19) 18.1 (12.3, 26.3) 0.9 (065, 1.3) 34 (16, 55) 85% (62%, 100%) 
*From 2010 onwards the rate of initiating injecting is multiplied by 2.9 due to evidence of 
incidence of viral hepatitis C increasing by this amount between 2010 and 2015(57), which is 













































Table 7.3: tPAF of IDU to HCV for 2018-2030 and percentages of incident infections 2018-
2030 among the general population that would be avoided if all HCV among PWID was 
treated in 2018 and transmission was reduced to levels in the general population*. 
 
Infections avoided among general 
population 
2018-2030 tPAF  
Country 
Percentage (95% Credibility 
Intervals) Main analysis 
Treating all PWID 
in 2018 
Global 6% (3%, 12%) 43% (24%, 66%) 46% (26%, 65%) 
Central Asia 6% (3%, 12%) 36% (18%, 76%) 39% (21%, 72%) 
Eastern Europe 15% (10%, 21%) 96% (65%, 99%) 96% (70%, 99%) 
Australasia 27% (20%, 39%) 69% (43%, 100%) 75% (52%, 100%) 
East & Southeast Asia 11% (6%, 19%) 58% (29%, 95%) 60% (33%, 95%) 
South Asia 4% (1%, 8%) 13% (4%, 30%) 16% (5%, 29%) 
North America 42% (28%, 53%) 77% (54%, 100%) 87% (64%, 100%) 
Western Europe 17% (10%, 26%) 83% (54%, 95%) 83% (56%, 94%) 
Sub-Saharan Africa 4% (1%, 12%) 13% (3%, 42%) 14% (4%, 44%) 
Latin America 21% (14%, 28%) 75% (48%, 98%) 78% (54%, 99%) 
Middle East & North Africa 2% (1%, 3%) 16% (8%, 26%) 16% (8%, 27%) 
* The extra transmission among PWID was 0. 
 
7.3.4.  Associations of tPAF and country-level variables 
Figure 7.5 shows there is a strong, positive association between the 12-year tPAF for each 
country and the percentage of the country’s prevalent infections that are among PWID. In 
univariable regression analyses (table 7.4), the logit transformed country-level tPAF 
increases linearly with the percentage of a country’s prevalent infections that are among 
PWID [OR 0.09 (95% CrI: 0.02, 0.17), R2 0.31], the country’s GNI coefficient [OR 0.05 (95% 
CrI: 0.00, 0.10), R2 0.05], HCV prevalence among PWID [OR 0.09 (95% CrI: 0.02, 0.17), R2 
0.07], and the population percentage of PWID [OR 2.62 (95% CrI: 0.75, 4.49), R2 0.08]. In the 
multivariable model, only the percentage of a country’s prevalent infections that are among 
PWID was associated with higher 12-year tPAF [aOR 0.26 (95% CrI: 0.13, 0.38), R2 0.36].  
The mixed-effects regression analysis across the 1000 fitted runs for each country found that 
a higher annual general population HCV prevalence growth was associated with a 3.35% 
lower tPAF [-3.35% (95% CI: -3.52%, -3.18%)] per percentage point increase in general 




Figure 7.5: Scatter plot of the association between the PAF of IDU to HCV transmission from 
2018-2030 and the percentage of the country’s prevalent infections that are among PWID in 
2017 for each country*. 
   
* The blue line is a plotted line of best fit* and the grey area is the 95% confidence interval. 
Model equation: tPAF=-0.3149-(0.0372*P_PWID)+(0.4376*P_PWID1/2), where P_PWID is the 






Table 7.4: Univariable and multivariable associations between the PAF of IDU to HCV 
transmission from 2018-2030† and demographic and epidemic-related variables.  
 Dependent variable: tPAF (logit transformed) 
 Coefficient (95% confidence interval) 
Variable* Univariable Multivariable 
GNI per capita (per $1000 US dollars)** 0.05 (0.00, 0.10) [p=0.039] 0.01 (-0.04, 0.07) [p=0.64] 
Population percentage of PWID in adults 2.62 (0.75, 4.49) [p=0.0066] 1.14 (-1.21, 3.50) [p=0.34] 
HCV prevalence among PWID*** 0.09 (0.02, 0.17) [p=0.014] 0.05 (-0.02, 0.12) [p=0.12] 
HCV prevalence among general population*** -0.29 (-1.34, 0.75) [p=0.58] -0.07 (-1.28, 1.13) [p=0.903] 
Injecting duration (years) 0.21 (-0.00, 0.42) [p=0.053] -0.22 (-0.46, 0.02) [p=0.071] 
Percentage of the country’s prevalent infections 
that are among PWID 
0.26 (0.18, 0.34) [p<0.0001] 0.26 (0.13, 0.38) [p<0.0001] 
GNI: Gross National Income 
† Logit transformed 
* All variables are from 2017 except for injecting duration which is taken from surveys 
covering a variety of years for each country. 
** Syria is missing data on GNI per capita. 





7.4.  Discussion 
7.4.1.  Main findings 
Despite PWID comprising less than 0.5% of the global adult population in 2017 and only 
contributing 8% of prevalent infections, removing the transmission risk due to IDU could 
prevent nearly one-half (43%) of all new HCV infections globally from 2018-2030. This 
varied by country and regions. In Sub-Saharan Africa, where the epidemic is thought to be 
driven by medical transmission(185), just over one-tenth of infections are due to the elevated 
risk associated with IDU, whereas in Eastern Europe it is over nine-tenths of infections. In 
HICs, about twice as many infections (79%) would be prevented from removing the 
transmission risk due to IDU than in LMICs (38%). Interestingly, the percentage of a 
country’s prevalent infections that are among PWID is strongly, positively associated with 
the tPAF, as this takes into account the size of the PWID population as well as the 
prevalence of HCV among them. For example, if 5% of the country’s prevalent infections are 
among current injectors then the estimated tPAF is 48%, which increases to 70% if 10% of 
prevalent infections are among PWID.  
 
7.4.2.  Comparison with other literature 
To my knowledge, no paper has estimated the future contribution of IDU-related risk to 
HCV transmission at a global level. Two papers have estimated the current contribution of 
IDU to the global burden of HCV infection or disease(76, 127), but neither accounted for the 
chain of transmission that can occur in the general population due to individuals that were 
infected through IDU. Degenhardt et al. estimated that 39% of disability adjusted life years 
(DALYs) for HCV in 2013 were due to IDU(76), consistent with the magnitude of my 
estimate despite using a very different outcome and methodology. Grebely et al. calculated 
8.5% of all prevalent HCV infections globally were among PWID, comparable to our 
estimate of 8% for prevalent infections in 2017(127). Grebely et al.’s estimate is useful for 
guiding screening and treatment campaigns but does not address the importance of IDU to 
future HCV transmission. A detailed modelling analysis by Heffernan et al. estimated that 
globally 29% (95% CrI: 27%, 32%) of new infections between 2016 and 2030 would be among 
PWID(150). That is a different concept to the tPAF calculated in this chapter as it does not 




found for the tPAF of IDU to HCV (43%), I found the percentage of new infections between 
2018 and 2030 that will be among PWID to be 43% (95% CrI: 24%, 80%). This estimate is 
similar to that of Heffernan et al. when considering the overlapping intervals, with any 
discrepancy likely due to Heffernan et al. extrapolating regional prevalence data to countries 
where it was missing, which tended to be areas with lower percentages of infections among 
PWID, such as Sub-Saharan Africa(150). Otherwise, global modelling by Blach et al. 
simulated the overall HCV epidemics in different countries but did not dynamically model 
HCV transmission or the role of IDU(40). Lastly, my results appear to broadly agree with 
national estimates of the burden of HCV due to injecting risks in the Netherlands and the 
UK(143, 385). These analyses suggest that 28% of current infections in the Netherlands are 
due to IDU(385), within the credibility intervals of my estimate (3-31%), and 34% of the UK’s 
current HCV burden is among PWID(143), very similar to my projections [33% (95% CrI: 
24%-42%)]. 
Lastly, it is important to note that the tPAF used in this chapter differs from the PAF used in 
chapter 3, which is based on the relative risks of being infected. The tPAF (“transmission 
PAF”) used here looks at the effect of reducing the modelled additional transmission rate 
associated with a particular risk factor (IDU) to 0, whereas the PAF calculation used in 
chapter 3 reduces the risk ratio associated with a particular variable in observational data to 
0. The tPAF is likely to produce more accurate quantification of the importance of a risk 
factor as it is in effect looking at a modelled causal relationship, whilst the PAF used in 
chapter 3 only looks at observed associations and cannot capture onward transmission. 
However, the simulation approach tends to lead to larger PAF estimates than the observed 
risk ratio approach due to how both methods account for population mixing(47). Also, my 
measure for the transmission PAF can differ to other estimations as discussed in Brooks-
Pollock and Danon(47). My tPAF more relates to the proportion of transmission that could 
be prevented if a certain risk behaviour was removed or made safe, whereas Brooks-Pollock 
and Danon develop another approach that relates to the proportion of infections that result 
through a specific risk factor, which in some situations may be less than the proportion of 






7.4.3.  Strengths and limitations 
My modelling is comprehensive in coverage as the analysis uses data from HCV epidemics 
in 88 countries, comprising 85% of the world’s population. I account for the role of 
heightened risk among PWID in these HCV epidemics, and incorporate country-level 
demographic information, population growth, and vertical transmission. Importantly, I 
account for all incident infections that result from individuals infected due to IDU, and the 
effect this has on the HCV incidence and prevalence among the general population. This 
enables me to more accurately estimate the role that IDU has on the overall epidemics in 
each country. Despite this, my analysis has limitations. 
The data on the prevalence of IDU, and the prevalence of HCV amongst PWID and the 
general population were variable in quality, possibly impacting on my results. For the 
former two quantities this is partly due to the illicit nature of IDU, which makes PWID a 
difficult population to study and to enumerate accurately. Data for these three quantities 
came from existing systematic reviews, and I modelled all countries that had an estimate for 
each. This meant that for some data estimates it was unclear how they were compiled, some 
were old, and some were uncertain.  
Taking data from disparate sources means some of country-level tPAF estimates may be 
imprecise. However, it is hard to quantify how this affects my results without additional 
data. Data-quality scores are shown in table 6.8, with 46% of countries having a low scored 
general population HCV prevalence estimate, and 20% and 39% of country estimates for 
HCV prevalence among PWID and the proportion of adults that inject drugs, respectively, 
having low scores. Although the majority of these key data points scored highly, only 19 
countries had all three of these key prevalence parameters scored as moderate or better, 
whilst 66 countries have at least two of these parameters scored moderate or better. These 19 
and 66 countries account for 32% and 76% of the global population, respectively. It is 
possible that the PAF projections for the remaining countries may change when better data 
becomes available, with better data being most needed for the HCV prevalence in the 
general population and the size estimates of PWID populations. When only considering the 
66 countries with better data, the global average PAF increases slightly to 49% emphasising 
that not including projections from the countries with worse quality data does not 




better scored estimates mostly being high-income countries where the contribution of IDU to 
HCV transmission is generally greater. 
Additionally, some country’s tPAF estimates were lower than expected, including Spain 
(31%), Greece (23%), and Australia (62%); previous evidence for these countries has 
suggested most transmission was among IDU(16). This discrepancy may be due to data 
issues, or HCV-epidemic factors, such as historically high levels of IDU that have now 
decreased, under-estimates of PWID prevalence, or possibly high numbers of migrants with 
higher HCV risk than the background population. Other modelling from the Netherlands 
has suggested that most HCV infections were among migrants(385). I did not incorporate 
migration in our model due to insufficient data to do this and uncertainty around key 
assumptions, such as their HCV prevalence(378). Although not explicitly included, I would 
consider incoming infections due to migration as something that contributes to the non-IDU 
transmission aspect of the model, just as I would for medical and community transmission. 
Similarly, I was unable to include HCV epidemics among MSM within the model due to a 
scarcity of information around prevalences globally. However, studies indicate that 
although transmission among MSM is much higher than among heterosexual couples, 
incidence and prevalence is still low compared with PWID(414) and likely contributes little 
to the epidemic in comparison(225). Additionally, the model cannot accurately estimate the 
percentage of the population that are ex-injectors or the percentage of infections that are 
among ex-injectors as the model started in 1990 and even modelling further back would not 
necessarily create accurate estimates due to a lack of information about how the prevalence 
of IDU has changed over time. 
I also did not explicitly model what makes up the non-IDU component of HCV 
transmission, which could be due to medical injections, tattooing, body-piercing, barbering, 
etc. Unfortunately, detailed country-level data on these behaviours were unavailable. 
Despite these issues, other country-level estimates seem to agree with my model(143, 385), 
with the low tPAFs of IDU in some HICs implying that our global tPAF estimate for IDU 
may be conservative. Also, general insights about how the tPAF is related to different 
country-level factors should still hold.  
Another limitation of my analysis is that my deterministic models did not capture the 
network effects of how HCV transmits among PWID, which has been shown to be important 




with this question; rather its main aim is to determine how the observed epidemic among 
PWID may contribute to overall levels of transmission in that country. Although I 
acknowledge that network models can better represent transmission dynamics among 
PWID (if sufficient data exists to parameterise them) and the impact of interventions, when 
both types of model are parameterised and calibrated to the same HCV prevalence data 
(with the same population turnover parameters) the resulting incidence projections from a 
mass action model will closely match those of the network model(88, 151, 180, 251). 
For almost all countries included, there is little to no published data to determine the likely 
ongoing evolution of each country’s HCV epidemic. To counter this, I gathered available 
evidence on reductions in HCV transmission risks due to improved blood transfusion 
safety(291) or reductions in unsafe medical injections(283), and so assumed that the 
modelled global epidemic was in decline, consistent with modelling by Blach et al(40). 
However, there is considerable uncertainty in this assumption, so I assumed wide 
uncertainty bounds and undertook sensitivity analyses where I either assumed each 
country’s HCV prevalence trends were stable or varied by region, which both projected 
lower tPAFs (about 30-33%). Importantly, country-level HCV epidemic trajectories are 
highly uncertain with only three countries having two repeated national surveys, 
highlighting the need for further data on this. Additionally, the systematic reviews used for 
this analysis, although from 2017, lacked data from recent years where HCV outbreaks have 
occurred driven by IDU in some countries, notably USA(110) where a higher tPAF is 
estimated when increased numbers of PWID are assumed. The lack of robust data on HCV 
prevalence, especially for the general population, also raises concerns about whether 
countries will be able to reliably ascertain their progress towards WHO’s HCV elimination 
targets or develop plans to reach them. This highlights the crucial role of good data for 
policy making. Importantly, a single inaccurate data point could affect a country’s results, 
implying that careful consideration of the assumptions made are required before using my 
results to inform policy in specific countries.  
Despite the limitations described above, it is also important to note that this paper utilises 
data from 12 reviews, synthesising data from thousands of studies and accounting for the 
uncertainty in these estimates in our projections. This will have minimised the data issues as 




finding that IDU is an important contributor to the global HCV epidemic is robust despite 
data uncertainties.  
 
7.4.4.  Implications  
To my knowledge, this is the first study to fully quantify the future contribution of IDU to 
the global HCV epidemic. The results show that the elevated risks associated with IDU 
account for 43% of global HCV infections over the next 12 years; with this figure being even 
higher in HICs (79%). On average 38% of HCV infections from 2018-2030 are due to IDU in 
LMICs, such as Pakistan (18%) and India (6%), which were discussed in chapters 4 and 5 
and where the contribution is much lower than the global average. This corroborates the 
findings of those chapters that the HCV epidemics in both settings are generalised and 
transmission is due to multiple risk factors. This information is primarily useful for policy-
makers that are uncertain about the importance of combating the HCV epidemic amongst 
PWID, especially for meeting the WHO’s 2030 elimination targets(403). Indeed, globally, my 
results suggest the incidence of HCV in PWID needs to be reduced by at least half to have 
any hope of reducing the overall incidence of HCV by 80%. Such a reduction in incidence 
can be achieved through reducing prevalence or transmission risks, including via micro 
elimination initiatives that either scale-up HCV treatment for PWID (investigated in chapter 
8) or prevention interventions(211), such as needle and syringe provision (NSP) and opiate 
substitution therapy (OST) programs. Newly synthesised data and modelling has shown 
that these interventions can dramatically reduce levels of HCV incidence(110, 287), can be 
cost-effective in various settings(224, 287), and can also prevent other blood-borne viruses 
such as HIV(393). However, the current coverage of NSP and OST is low in most 
countries(209), as is the coverage of direct acting antiviral drug treatment(409), with PWID 
being frequently denied treatment(313). Barriers restricting the coverage of these 
interventions to PWID need to be urgently addressed to achieve the WHO HCV elimination 
targets. In chapter 8 I use the same models covering the 88 countries to look at treatment as 





CHAPTER 8. MODELLING THE POTENTIAL 
PREVENTION BENEFITS OF A TREAT-ALL 
HEPATITIS C VIRUS TREATMENT STRATEGY AT 
GLOBAL-, REGIONAL-, AND COUNTRY-LEVELS: A 
MODELLING STUDY 
The work in this chapter was done in collaboration with Hannah Fraser, Aaron G Lim, 
Josephine G Walker, Amy Peacock, Samantha Colledge, Janni Leung, Jason Grebely, Sarah 
Larney, Natasha K Martin, Louisa Degenhardt, Matthew Hickman, Margaret T May, and 
Peter Vickerman, was commissioned by the World Health Organization and is published in 
the supplement of the 2018 World Health Organization guidelines on HCV(410) and in the 
Journal of Viral Hepatitis(374).  
 
8.1.  Introduction 
Direct-acting antiviral (DAA) treatments have made hepatitis C virus (HCV) an easily 
curable infection(104). Historically the emphasis was on treating people with advanced liver 
disease due to the high prices of treatment(397). However, a wider allocation of treatment is 
required to eliminate HCV. To encourage widespread treatment scale-up, the World Health 
Organization (WHO) developed HCV treatment guidelines in 2018 advising that countries 
should allow access to HCV treatment for all infected individuals: a “treat-all” strategy(408). 
The modelling in this chapter fed into the evidence development for these guidelines. 
In chapter 7, I found that around 43% of all transmission globally would be averted between 
2018 and 2030 if the additional transmission risks associated with injecting drug use (IDU) 
were removed, on average 38% in low- and middle-income countries and 79% in high-
income countries. This indicates that it will be impossible to achieve the WHO targets for 
reducing HCV incidence by 80% without countries achieving a large reduction in HCV 
transmission among PWID, which previous modelling suggests will need a large scale-up in 
treatment(236, 384). Achieving the WHO targets for incidence will require reductions in 




of populations. However, in many countries people who inject drugs (PWID) are denied 
HCV treatment and access is prioritised for those with advanced liver disease(409); a 
situation that would be avoided with a treat-all strategy allowing access to HCV treatment 
for all individuals that seek it. 
A treat-all HCV treatment strategy could also produce clinical benefits, such as reducing the 
risks of severe liver disease(52). Previous analyses have considered who should be treated to 
achieve greatest morbidity and mortality benefits(79, 235, 240), whilst other analyses have 
considered the cost-effectiveness of different treatment strategies(240). However, these 
analyses have generally used static models so have not included prevention benefits of 
treatment unless they focussed on PWID, assuming benefits would be negligible when not 
treating such high-risk groups(34). To help countries and the WHO understand the overall 
benefits of a treat-all policy, the WHO commissioned this analysis to evaluate the prevention 
benefits of HCV treatment and determine how country-level demographic and 
epidemiological differences could affect the prevention benefits achieved. 
 
8.2.  Methods 
The model structure, parameterisation, and calibration used in this chapter are the same as 
that described in Chapter 6. 
 
8.2.1.  Model analyses 
The 1000 full model fits for each country were run over 2018-2038, firstly with that country’s 
baseline level of treatment (counterfactual projections) and then with 50 additional 
individuals being treated in 2018, with the difference in the number of new infections 
between the paired runs being divided by 50 to give the infections averted per additional 
treatment over 20-years. Fifty treatments were chosen to give an estimate of the initial 
prevention benefit of further treatment scale-up while being small enough not to alter the 
course of each country’s ongoing epidemic trajectory. This number gives an estimate of the 
initial prevention benefit of further treatment scale-up. The effect of this treatment 




I considered several scenarios that assumed the treated individuals were either:  
• selected randomly from all infected individuals (treat-all),  
• selected from PWID,  
• selected from people with cirrhosis,  
• selected from people ≥35 years old.  
Infected individuals can overlap between categories, so treatment is randomly allocated 
within the subgroups. For each scenario and country, projections across the 1000 model fits 
were used to produce 95% credibility intervals (95% CrI) for all impact estimates by taking 
the 2.5th and 97.5th percentiles of the 1,000 simulated runs, whilst the main estimate is 
calculated as the median of these runs. For each scenario, regional and global estimates of 
the infections averted per treatment were produced by weighting country-level estimates by 
that country’s relative burden of HCV compared to the modelled regional and global 
burdens. 
 
8.2.2. Associations with infections averted per treatment 
Univariable and multivariable regression models investigated which country-level 
characteristics were associated with the number of infections averted per randomly allocated 
treatment and per treatment among PWID. The country-level characteristics included in 
these analyses were current population growth rate, population-attributable fraction of IDU 
to HCV transmission (the percentage of new HCV infections prevented 2018-2038 if the 
additional transmission risk among PWID was reduced to zero as defined in chapter 7), 
population percentage of PWID among adults, average duration of IDU, HCV prevalence 
among PWID and the general population, and the total number of treatments given in 2017.  
 
8.2.3. Sensitivity analyses 
Sensitivity analyses were run for 100 complete model runs to save computational time, as 
the results for 100 and 1,000 runs were similar. Sensitivity analyses considered the effect of 
specific assumptions in the model: assuming stable HCV epidemics instead of decreasing 




epidemic, assuming longer-term epidemics of IDU in Sub-Saharan Africa and Eastern 
Europe instead of them recently evolving, assuming treatment rates are halved among 
PWID and doubled among people with cirrhosis (but overall allocating the same number of 
treatments), assuming HCV epidemic trajectories vary based on regional data, and treating 
an extra 25 infected individuals instead of 50. I also estimated the prevention impact of on-
going levels of treatment in each country, by comparing the impact achieved over 20 years 
with on-going treatment rates to the impact achieved if the treatments in 2018 had not 
occurred but treatment levels resumed in subsequent years. Lastly, I examined the infections 
averted per treatment when only including the 66 countries with ≥2 of the key prevalence 
parameters scored as moderate or better (table 6.7).  
 
8.3.  Results 
The results of the model fitting are the same as those presented in section 7.3.1. 
 
8.3.1.  Infections averted per treatment 
Globally, the model estimates 0.35 (95% CrI: 0.16, 0.61) infections are averted per treatment 
over the next 20 years from treating people randomly. China, India, Nigeria, Pakistan, and 
Russia, which contain around 52% of infected individuals in the modelled countries, drive 
this global estimate. The estimated infections averted vary substantially across regions and 
countries (figure 8.1; table 8.1). The region with the lowest infections averted per randomly 
allocated treatment is Eastern Europe, 0.06 (95% CrI: -0.03, 0.20), while Sub-Saharan Africa 
has the highest, 0.75 (95% CrI: 0.45, 1.10).  
Table 8.1 and figure 8.1 show the prevention benefit of randomly allocating treatment 
compared to targeting treatment to PWID, patients with cirrhosis, or people aged ≥35. 
Globally, treating PWID achieves the most prevention impact with 1.27 (95% CrI: 0.68, 2.04) 
infections averted per treatment. This ranges from as much as 4.82 (95% CrI: 1.98, 6.86) in 
Madagascar, to negative in Mauritius [–0.52 (95% CrI: –0.60, –0.14)] due to high levels of re-
infection of PWID, although overall numbers of infected individuals still reduce because of 
the additional individuals cured through treatment. Globally, the infections averted per 




≥35 years [0.30 (95% CrI: 0.12, 0.53)] is less but similar to what is achieved from randomly 
allocating treatment. Figure 8.2 shows that for the 88 countries modelled there is a strong 
positive linear trend between the infections averted per randomly allocated treatment and 
the infections averted per treatment targeted to PWID. 
 
Figure 8.1: Chronic HCV infections averted per HCV treatment (2018-2038) globally, by 
country income level and by region; stratified by allocation strategy*.  
 
HICs: High-income countries; LMICs: Low- and middle-income countries 






Table 8.1: The number of chronic HCV infections averted per treatment over 2018-2038 for the different treatment allocation scenarios, for each 
country, region, and globally. 
 
Chronic hepatitis C virus infections averted per treatment for different allocation 
strategies (95% credibility intervals) 
Country 
Random (treat-all) PWID* People with cirrhosis 
People aged ≥35 
years 
Global 0.35 (0.16, 0.61) 1.27 (0.68, 2.04) 0.28 (0.12, 0.49) 0.30 (0.12, 0.53) 
Central Asia 0.32 (0.14, 0.56) 1.66 (1.25, 2.29) 0.24 (0.09, 0.43) 0.26 (0.08, 0.45) 
Kazakhstan 0.26 (0.18, 0.40) 1.42 (1.08, 2.38) 0.14 (0.08, 0.26) 0.16 (0.08, 0.28) 
Kyrgyzstan 0.42 (0.24, 0.62) 2.14 (1.66, 2.78) 0.30 (0.12, 0.48) 0.30 (0.12, 0.48) 
Tajikistan 0.50 (0.24, 0.76) 1.80 (1.36, 2.32) 0.38 (0.14, 0.60) 0.38 (0.14, 0.60) 
Turkmenistan 0.40 (0.20, 0.64) 1.66 (1.10, 2.40) 0.30 (0.12, 0.50) 0.32 (0.14, 0.54) 
Uzbekistan 0.30 (0.10, 0.56) 1.66 (1.26, 2.22) 0.24 (0.08, 0.44) 0.26 (0.06, 0.46) 
Eastern Europe 0.06 (-0.03, 0.20) 0.14 (-0.10, 0.72) 0.05 (-0.02, 0.14) 0.06 (-0.02, 0.16) 
Armenia 0.12 (0.02, 0.26) 0.50 (0.12, 1.02) 0.08 (0.02, 0.20) 0.08 (0.02, 0.22) 
Azerbaijan 0.24 (0.06, 0.46) 0.28 (-0.08, 0.76) 0.20 (0.06, 0.38) 0.22 (0.06, 0.44) 
Belarus 0.00 (-0.10, 0.14) -0.14 (-0.36, 0.34) 0.00 (-0.06, 0.12) 0.00 (-0.06, 0.14) 
Bosnia 0.00 (-0.12, 0.14) 0.02 (-0.18, 0.32) 0.00 (-0.10, 0.08) 0.00 (-0.10, 0.10) 
Bulgaria 0.02 (-0.04, 0.10) -0.02 (-0.20, 0.50) 0.00 (-0.02, 0.10) 0.02 (-0.02, 0.12) 
Czechia 0.80 (0.54, 1.46) 2.48 (1.90, 3.24) 0.50 (0.28, 1.02) 0.60 (0.36, 1.20) 
Estonia 0.40 (0.08, 0.80) 0.68 (0.08, 1.48) 0.28 (0.06, 0.62) 0.32 (0.08, 0.70) 
Georgia 0.40 (0.14, 0.72) 0.74 (0.48, 1.06) 0.32 (0.12, 0.58) 0.34 (0.12, 0.62) 
Hungary 0.20 (0.06, 0.42) 0.94 (0.40, 1.68) 0.16 (0.04, 0.36) 0.18 (0.04, 0.38) 
Latvia 0.06 (-0.06, 0.26) 0.08 (-0.20, 0.70) 0.04 (-0.04, 0.18) 0.06 (-0.04, 0.20) 
Lithuania 0.18 (0.08, 0.36) 0.88 (0.62, 1.30) 0.14 (0.06, 0.30) 0.16 (0.06, 0.32) 
Moldova 0.14 (0.02, 0.30) 0.34 (-0.04, 0.88) 0.10 (0.00, 0.24) 0.12 (0.00, 0.28) 
Poland 0.10 (0.00, 0.26) 0.16 (-0.02, 0.38) 0.08 (0.00, 0.22) 0.10 (0.00, 0.26) 
Romania -0.02 (-0.08, 0.06) -0.26 (-0.38, 0.24) 0.00 (-0.06, 0.06) 0.00 (-0.06, 0.08) 
Russia 0.02 (-0.06, 0.14) 0.02 (-0.22, 0.66) 0.02 (-0.04, 0.08) 0.02 (-0.04, 0.10) 
Slovakia 0.08 (-0.06, 0.28) 0.12 (-0.24, 0.70) 0.04 (-0.04, 0.20) 0.06 (-0.04, 0.24) 





Chronic hepatitis C virus infections averted per treatment for different allocation 
strategies (95% credibility intervals) 
 
Random (treat-all) PWID* People with cirrhosis 
People aged ≥35 
years 
Australasia 0.26 (0.13, 0.49) 0.54 (0.29, 1.00) 0.21 (0.11, 0.41) 0.22 (0.11, 0.43) 
Australia 0.24 (0.14, 0.40) 0.54 (0.34, 0.92) 0.20 (0.12, 0.34) 0.20 (0.12, 0.34) 
New Zealand 0.34 (0.06, 0.90) 0.52 (0.06, 1.34) 0.26 (0.04, 0.72) 0.30 (0.04, 0.80) 
East & Southeast Asia 0.26 (0.09, 0.49) 1.26 (0.70, 2.08) 0.19 (0.04, 0.39) 0.21 (0.04, 0.44) 
China 0.24 (0.10, 0.44) 1.40 (0.82, 2.26) 0.18 (0.04, 0.36) 0.20 (0.04, 0.40) 
Indonesia 0.12 (-0.04, 0.36) -0.10 (-0.26, 0.10) 0.12 (-0.02, 0.30) 0.12 (-0.02, 0.34) 
Japan 0.46 (0.18, 0.88) 1.30 (0.68, 2.18) 0.32 (0.10, 0.66) 0.36 (0.12, 0.72) 
Malaysia 0.32 (0.10, 0.56) 0.58 (0.26, 0.94) 0.26 (0.06, 0.46) 0.28 (0.08, 0.52) 
Myanmar 0.30 (0.18, 0.50) 2.56 (1.96, 3.88) 0.18 (0.06, 0.34) 0.18 (0.06, 0.38) 
Philippines 0.38 (0.16, 0.64) 2.14 (1.14, 3.68) 0.30 (0.12, 0.52) 0.34 (0.14, 0.56) 
Taiwan 0.06 (-0.02, 0.26) -0.08 (-0.24, 0.14) 0.06 (-0.02, 0.22) 0.06 (0.00, 0.26) 
Thailand 0.16 (0.00, 0.38) 0.00 (-0.18, 0.22) 0.14 (0.00, 0.32) 0.16 (0.00, 0.36) 
Viet Nam 0.24 (0.06, 0.44) 0.90 (0.40, 1.58) 0.18 (0.02, 0.34) 0.20 (0.02, 0.38) 
South Asia 0.49 (0.25, 0.76) 1.86 (0.96, 2.75) 0.41 (0.21, 0.63) 0.43 (0.21, 0.67) 
Afghanistan 0.86 (0.34, 1.34) 2.14 (1.16, 3.36) 0.62 (0.16, 1.02) 0.66 (0.18, 1.02) 
Bangladesh 0.40 (0.20, 0.66) 1.90 (1.14, 2.92) 0.32 (0.16, 0.54) 0.34 (0.16, 0.56) 
India 0.44 (0.22, 0.70) 1.74 (1.26, 2.48) 0.38 (0.20, 0.58) 0.40 (0.20, 0.64) 
Iran 0.32 (0.10, 0.64) 0.98 (0.38, 1.86) 0.22 (0.04, 0.46) 0.26 (0.06, 0.52) 
Nepal 0.30 (0.08, 0.56) 1.06 (0.46, 1.94) 0.22 (0.02, 0.42) 0.24 (0.04, 0.46) 
Pakistan 0.58 (0.32, 0.86) 2.08 (0.50, 3.14) 0.48 (0.26, 0.72) 0.50 (0.26, 0.74) 
North America 0.58 (0.22, 1.13) 1.04 (0.44, 2.00) 0.46 (0.18, 0.90) 0.50 (0.20, 0.99) 
Canada 0.30 (-0.06, 0.72) 0.48 (-0.28, 1.28) 0.24 (-0.04, 0.58) 0.26 (-0.04, 0.64) 
USA 0.60 (0.24, 1.16) 1.08 (0.50, 2.06) 0.48 (0.20, 0.92) 0.52 (0.22, 1.02) 
Western Europe 0.32 (0.13, 0.68) 0.91 (0.51, 1.62) 0.24 (0.09, 0.53) 0.27 (0.1, 0.58) 
Albania 0.10 (0.04, 0.24) 0.96 (0.72, 1.36) 0.08 (0.02, 0.18) 0.08 (0.02, 0.20) 
Austria 0.66 (0.38, 1.08) 1.24 (0.72, 1.94) 0.50 (0.26, 0.84) 0.56 (0.28, 0.94) 
Belgium 0.26 (0.06, 0.70) 0.74 (0.20, 1.36) 0.18 (0.02, 0.54) 0.20 (0.04, 0.60) 
Croatia 0.16 (0.06, 0.32) 1.00 (0.70, 1.44) 0.10 (0.04, 0.24) 0.12 (0.04, 0.26) 





Chronic hepatitis C virus infections averted per treatment for different allocation 
strategies (95% credibility intervals) 
 
Random (treat-all) PWID* People with cirrhosis 
People aged ≥35 
years 
Denmark 0.38 (0.28, 0.52) 1.06 (0.80, 1.42) 0.26 (0.16, 0.40) 0.30 (0.20, 0.46) 
Finland 0.06 (-0.02, 0.16) 0.14 (-0.04, 0.68) 0.04 (-0.02, 0.10) 0.04 (0.00, 0.12) 
France 0.28 (0.14, 0.60) 0.76 (0.46, 1.40) 0.22 (0.12, 0.46) 0.24 (0.12, 0.50) 
Germany 0.40 (0.18, 0.80) 0.88 (0.54, 1.38) 0.30 (0.12, 0.62) 0.34 (0.14, 0.70) 
Greece 0.22 (0.04, 0.42) 0.42 (0.20, 0.70) 0.18 (0.04, 0.34) 0.20 (0.04, 0.40) 
Iceland 0.26 (0.18, 0.38) 0.70 (0.44, 1.16) 0.18 (0.14, 0.26) 0.20 (0.14, 0.28) 
Ireland 0.22 (0.06, 0.44) 0.42 (0.14, 0.80) 0.18 (0.04, 0.36) 0.20 (0.04, 0.40) 
Italy 0.24 (0.08, 0.50) 0.86 (0.54, 1.60) 0.16 (0.06, 0.36) 0.18 (0.06, 0.40) 
Luxembourg 0.94 (0.28, 1.60) 1.50 (0.54, 2.52) 0.76 (0.22, 1.30) 0.82 (0.24, 1.38) 
Macedonia 0.08 (0.04, 0.22) 0.32 (0.20, 0.48) 0.04 (0.02, 0.18) 0.06 (0.02, 0.20) 
Malta 0.36 (0.20, 0.64) 1.12 (0.60, 2.18) 0.28 (0.16, 0.48) 0.32 (0.18, 0.54) 
Montenegro 0.12 (0.08, 0.22) 1.00 (0.70, 2.00) 0.06 (0.04, 0.14) 0.06 (0.04, 0.16) 
Netherlands 0.28 (0.12, 0.58) 1.00 (0.38, 1.76) 0.24 (0.10, 0.48) 0.26 (0.10, 0.52) 
Norway 0.64 (0.40, 0.94) 1.32 (0.90, 1.82) 0.50 (0.28, 0.74) 0.56 (0.32, 0.82) 
Portugal 0.24 (0.06, 0.46) 0.44 (-0.14, 0.80) 0.20 (0.06, 0.40) 0.22 (0.06, 0.42) 
Serbia 0.30 (0.22, 0.38) 1.42 (1.12, 2.20) 0.14 (0.10, 0.20) 0.18 (0.12, 0.24) 
Slovenia 0.52 (0.38, 0.74) 1.50 (1.14, 2.18) 0.36 (0.24, 0.54) 0.42 (0.28, 0.62) 
Spain 0.20 (0.08, 0.50) 0.70 (0.38, 1.12) 0.18 (0.06, 0.44) 0.20 (0.06, 0.46) 
Sweden 0.62 (0.10, 1.18) 0.92 (0.00, 1.52) 0.52 (0.08, 1.00) 0.56 (0.10, 1.08) 
Switzerland 0.38 (0.18, 0.64) 0.86 (0.52, 1.32) 0.30 (0.16, 0.52) 0.34 (0.16, 0.56) 
UK 0.50 (0.22, 1.22) 0.96 (0.38, 2.04) 0.36 (0.14, 0.94) 0.40 (0.16, 1.04) 
Sub-Saharan Africa 0.75 (0.45, 1.10) 2.30 (1.38, 3.38) 0.60 (0.33, 0.89) 0.57 (0.33, 0.86) 
Ghana 0.66 (0.40, 0.98) 1.94 (1.40, 2.64) 0.54 (0.32, 0.80) 0.54 (0.34, 0.80) 
Kenya 0.68 (0.38, 1.04) 3.74 (2.22, 5.82) 0.50 (0.26, 0.80) 0.48 (0.26, 0.76) 
Madagascar 0.76 (0.44, 1.16) 4.82 (1.98, 6.86) 0.60 (0.34, 0.94) 0.62 (0.36, 0.94) 
Mauritius -0.10 (-0.26, 0.10) -0.52 (-0.60, -0.14) -0.06 (-0.18, 0.12) -0.04 (-0.18, 0.14) 
Mozambique 0.62 (0.28, 0.96) 0.54 (0.20, 1.00) 0.50 (0.22, 0.80) 0.44 (0.20, 0.72) 
Nigeria 0.76 (0.46, 1.12) 2.02 (1.04, 3.18) 0.62 (0.38, 0.92) 0.60 (0.36, 0.88) 





Chronic hepatitis C virus infections averted per treatment for different allocation 
strategies (95% credibility intervals) 
 
Random (treat-all) PWID* People with cirrhosis 
People aged ≥35 
years 
Tanzania 0.84 (0.54, 1.18) 3.20 (2.34, 4.26) 0.62 (0.30, 0.90) 0.58 (0.30, 0.90) 
Latin America 0.19 (0.03, 0.40) 0.18 (-0.01, 0.40) 0.15 (0.02, 0.32) 0.17 (0.02, 0.37) 
Argentina 0.24 (0.06, 0.46) 0.60 (0.36, 0.90) 0.18 (0.04, 0.36) 0.22 (0.04, 0.42) 
Brazil 0.22 (0.08, 0.40) 0.42 (0.20, 0.68) 0.16 (0.04, 0.32) 0.18 (0.04, 0.36) 
Mexico 0.12 (-0.08, 0.36) -0.50 (-0.60, -0.38) 0.12 (-0.04, 0.32) 0.14 (-0.04, 0.36) 
Uruguay 0.28 (0.12, 0.46) 1.60 (1.16, 2.28) 0.20 (0.06, 0.34) 0.22 (0.08, 0.40) 
Middle East & North Africa 0.20 (0.09, 0.41) 0.84 (0.50, 1.39) 0.18 (0.08, 0.35) 0.19 (0.08, 0.36) 
Egypt 0.18 (0.08, 0.38) 0.78 (0.46, 1.26) 0.18 (0.08, 0.34) 0.18 (0.08, 0.34) 
Israel 0.62 (0.38, 0.88) 1.86 (1.40, 2.42) 0.48 (0.28, 0.70) 0.54 (0.32, 0.78) 
Lebanon 0.92 (0.58, 1.44) 4.22 (3.14, 6.14) 0.66 (0.36, 1.04) 0.74 (0.42, 1.16) 
Libya 0.20 (0.00, 0.42) -0.24 (-0.38, -0.06) 0.18 (0.02, 0.36) 0.20 (0.02, 0.40) 
Morocco 0.34 (0.16, 0.54) 1.16 (0.54, 1.84) 0.28 (0.12, 0.46) 0.30 (0.14, 0.48) 
Saudi Arabia 0.08 (-0.02, 0.40) 0.12 (-0.08, 0.46) 0.08 (-0.02, 0.34) 0.08 (-0.02, 0.38) 
Syria 0.38 (0.18, 0.66) 0.82 (0.20, 1.70) 0.32 (0.14, 0.54) 0.34 (0.16, 0.56) 
Tunisia 0.26 (0.12, 0.50) 1.56 (1.20, 2.08) 0.16 (0.04, 0.34) 0.18 (0.06, 0.40) 




Figure 8.2: Scatter plot of the infections averted per randomly allocated treatment against 
the infections averted per treatment allocated to PWID, both for 2018-2038. 
 
 
8.3.2.  Determinants of impact 
The infections averted per randomly allocated treatment (table 8.2) is positively associated 
with a country’s population growth-rate [multivariable regression coefficient: 0.12 (95% 
Confidence interval [CI]: 0.08, 0.17)], with the univariable association seen in figure 8.3a. The 
infections averted per randomly allocated treatment is also positively associated with the 
percentage of adults that are PWID [coefficient: 0.14 (95% CI: 0.03, 0.24)] (figure 8.3b shows 
the univariable association), whereas it is negatively associated with the HCV prevalence in 
the general population [coefficient: -0.09 (95% CI: -0.15, -0.02)] figure 8.3c, univariable) and 
PWID [coefficient: -0.006 (95% CI: -0.009, -0.003)] (figure 8.3d, univariable). The 
multivariable regression model’s R2-value is 0.58, indicating these variables explain most of 
the variation in estimated infections averted between countries.  
Similarly, the number of infections averted per treatment allocated to PWID was positively 
associated with a country’s population growth-rate (figure 8.4a shows the univariable 
association) [multivariable coefficient: 0.20 (95% CI: 0.07, 0.33)] and the percentage of adults 
that are PWID [coefficient: 0.32 (95% CI: 0.00, 0.64)] (figure 8.4b, univariable). It was 
negatively associated with the prevalence of HCV among the general population 
[coefficient: -0.23 (95% CI: -0.42, -0.03)] (figure 8.4c, univariable) and among PWID 
[coefficient: -0.047 (95% CI: -0.056, -0.039)] (figure 8.4d, univariable). The R2-value for this 






































multivariable model was 0.77. Allocating treatment to PWID resulted in negative infections 
averted in eight (8%) countries that had high (≥61%) chronic HCV prevalence among PWID, 




Table 8.2: Univariable and multivariable regression coefficients, showing associations between demographic and epidemiological variables 
and (a) the number of infections averted per randomly allocated treatment, and (b) the number of infections averted per treatment allocated to 
PWID. 
 
 Infections averted per randomly allocated treatment 
Variable 




coefficient (95% CI) P-value 
Multivariable 
regression coefficient 
(95% CI) P-value 
Population growth rate (% increase in population per 
year)* 
0.6% (-0.8%, 3.8%) 0.13 (0.10, 0.17) <0.001 0.12 (0.08, 0.17) <0.001 
General population chronic HCV prevalence (%)* 1.1% (0.1%, 6.0%) -0.03 (-0.08, 0.03) 0.332 -0.09 (-0.15, -0.02) 0.008 
PWID chronic HCV prevalence (%)* 37.2% (3.9%, 72.7%) -0.009 (-0.012, -0.006) <0.001 -0.006 (-0.009, -0.003) <0.001 
Percentage of adults that are PWID* 0.44% (0.02%, 3.95%) -0.00 (-0.10, 0.10) 0.998 0.14 (0.03, 0.24) 0.010 
Population attributable fraction of HCV due to IDU* 68.9% (1.6%, 100.0%) -0.003 (-0.004, -0.001) 0.001 -0.001 (-0.003, 0.001) 0.378 
Injecting duration (years)** 13.1 (4.4, 24.8) -0.01 (-0.02, 0.00) 0.196 0.01 (-0.00, 0.01) 0.144 
Number of treatments given in 2017 17,274 (0, 600,000) 0.00 (0.00, 0.00) 0.987 0.00 (0.00, 0.00) 0.330 
  Infections averted per PWID allocated treatment 
Population growth rate (% increase in population per 
year)* 
0.6% (-0.8%, 3.8%) 0.46 (0.29, 0.63) <0.001 0.20 (0.07, 0.33) 0.004 
General population chronic HCV prevalence (%)* 1.1% (0.1%, 6.0%) -0.07 (-0.28, 0.14) 0.499 -0.23 (-0.42, -0.03) 0.024 
PWID antibody HCV prevalence (%)* 37.2% (3.9%, 72.7%) -0.058 (-0.067, -0.049)  <0.001 -0.047 (-0.056, -0.039) <0.001 
Percentage of adults that are PWID* 0.44% (0.02%, 3.95%) -0.14 (-0.53, 0.25) 0.471 0.32 (0.00, 0.64) 0.048 
Population attributable fraction of HCV due to IDU* 68.9% (1.6%, 100.0%) -0.014 (-0.020, -0.008) <0.001 -0.005 (-0.011, 0.000) 0.070 
Injecting duration (years)** 13.1 (4.4, 24.8) -0.08 (-0.12, -0.04) <0.001 -0.02 (-0.05, 0.00) 0.077 
Number of treatments given in 2017 17,274 (0, 600,000) 0.00 (0.00, 0.00) 0.991 0.00 (0.00, 0.00) 0.730 




Figure 8.3: Scatter plots of the univariable associations between the number of HCV 
infections averted (2018-2038) per treatment given randomly against country-level variables: 
a) A country’s population growth rate. 
 
b) The percentage of adults that are PWID in 2015. 
 
  

























































































c) The HCV prevalence among the general population in 2015. 
 
d) The HCV prevalence among PWID in 2015. 
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Figure 8.4: Scatter plots of the univariable associations between the number of HCV 
infections averted (2018-2038) per treatment given to PWID, against country-level variables: 
a) A country’s population growth rate. 
 
b) The percentage of adults that are PWID in 2015. 
 
  













































































c) The HCV prevalence among the general population in 2015. 
 
d) The HCV prevalence among PWID in 2015. 
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8.3.3.  Sensitivity analyses 
Sensitivity analyses (figure 8.5 and tables 8.3 and 8.4) show each strategy averts more 
infections if the general population HCV prevalence in each country is stable [0.55 (95% CrI: 
0.36, 0.77) infections averted per treatment with random allocation] instead of decreasing as 
in the baseline projections. The global infections averted per randomly allocated treatment 
increases to 0.65 (95% CrI: 0.30, 1.10) when assuming different regional epidemic trajectories 
(see table 6.6). The regions most affected by this change are Central Asia, Eastern Europe, 
and South Asia, where the infections averted per randomly allocated treatment increase 
from 0.32 (95% CrI: 0.14, 0.56) to 1.40 (95% CrI: -0.33, 2.19), 0.06 (95% CrI: -0.03, 0.20) to 0.60 
(95% CrI: 0.08, 2.21), and 0.49 (95% CrI: 0.25, 0.76) to 0.87 (95% CrI: 0.66, 1.10), respectively. 
In the sensitivity analysis where background treatment rates are halved among PWID and 
doubled for people with cirrhosis this reduces the infections averted per extra randomly 
allocated treatment by around a third to 0.21 (95% CrI: 0.08, 0.40) compared with the 
baseline projections. There are more infections averted per randomly allocated treatment 
when assuming increasing IDU in the USA since 2010(110) [1.02 (95% CrI: 0.30, 2.26) vs 0.60 
(95% CrI: 0.24, 1.16) with a stable proportion of PWID]. Assuming either a decreasing HCV 
epidemic among PWID [0.34 (95% CrI: 0.16, 0.61)] or stable populations of PWID in Eastern 
Europe and Sub-Saharan Africa [0.36 (95% CrI: 0.17, 0.62)] does not much alter the infections 
averted per random treatment, globally, nor does giving an additional 25 treatments rather 
than 50 [0.35 (95% CrI: 0.16, 0.61)] 
Table 8.5 gives the projected number of infections averted from ongoing treatment rates in 
2018 (around 1.5 million globally) compared to if no treatments were given in 2018 but 
resumed in 2019. This suggests 525,764 (95% CrI: 243,948, 980,523) chronic HCV infections 
would be averted over the next 20 years, with similar number of infections averted per 
treatment for each country and globally [0.34 (95% CrI: 0.16, 0.63)] as previously estimated 
for the baseline scenario with 50 additional randomly allocated treatments in 2017. 
When only including the countries with ≥2 key prevalence parameters having a data quality 
score of moderate or better, the infections averted per randomly allocated treatment was 





Figure 8.5: Sensitivity analyses for the number of chronic HCV infections averted per 
treatment over 20 years (2018-2038) for the different treatment allocation scenarios, globally†. 
 
EE: Eastern Europe; SSA: Sub-Saharan Africa 
* Eastern Europe and Sub-Saharan Africa seeded at 101% of the estimate of the proportion of 
adults that are PWID – the same as the other regions. 
** The same number of treatments are given as in the main analyses but the treatment rate 
for PWID is halved, whilst the treatment rate for people with cirrhosis is doubled. The 
treatment rate for those who are neither PWID nor have cirrhosis is also altered and is either 
increased or decreased depending on the epidemic. 
† Sensitivity analyses were run for 100 complete model runs to save computational time, as 





Table 8.3: Sensitivity analyses for the number of chronic hepatitis C virus infections averted per treatment (2018-2038) for the different 
treatment allocation scenarios, for each region and globally*.  
 Hepatitis C virus infections averted per treatment for infected individuals (95% CrI) 
  Random allocation PWID Cirrhotic Age ≥35 years 
Analysis Global       
Main 0.35 (0.16, 0.61) 1.27 (0.68, 2.04) 0.28 (0.12, 0.49) 0.30 (0.12, 0.53) 
Stable gen-pop HCV† 0.55 (0.36, 0.77) 1.50 (0.88, 2.25) 0.44 (0.28, 0.63) 0.47 (0.29, 0.67) 
Decreasing HCV among PWID§ 0.34 (0.16, 0.61) 1.26 (0.70, 2.09) 0.27 (0.12, 0.49) 0.29 (0.13, 0.53) 
No later injecting start year for EE and SSA¶ 0.36 (0.17, 0.62) 1.29 (0.72, 2.09) 0.28 (0.12, 0.49) 0.30 (0.13, 0.54) 
Halved PWID treatment rate, doubled for cirrhosis₡ 0.21 (0.08, 0.40) 0.93 (0.42, 1.69) 0.32 (0.13, 0.61) 0.29 (0.12, 0.54) 
Varied epidemic trajectories by region 0.65 (0.30, 1.10) 1.54 (0.78, 2.48) 0.53 (0.22, 0.90) 0.57 (0.26, 0.98) 
25 additional treatments (rather than 50) 0.35 (0.16, 0.61) 1.26 (0.66, 2.02) 0.27 (0.12, 0.49) 0.30 (0.12, 0.53) 
Analysis Central Asia       
Main 0.32 (0.14, 0.56) 1.66 (1.25, 2.29) 0.24 (0.09, 0.43) 0.26 (0.08, 0.45) 
Stable gen-pop HCV† 0.54 (0.39, 0.69) 1.85 (1.40, 2.36) 0.42 (0.29, 0.57) 0.43 (0.30, 0.59) 
Decreasing HCV among PWID§ 0.33 (0.16, 0.57) 1.73 (1.34, 2.35) 0.25 (0.09, 0.45) 0.26 (0.09, 0.47) 
Halved PWID treatment rate, doubled for cirrhosis₡ 0.18 (0.05, 0.36) 1.42 (1.09, 2.02) 0.28 (0.09, 0.54) 0.25 (0.09, 0.47) 
Varied epidemic trajectories by region 1.40 (-0.33, 2.19) 1.89 (-0.14, 3.18) 1.15 (-0.36, 1.81) 1.25 (-0.29, 1.99) 
25 additional treatments (rather than 50) 0.31 (0.16, 0.53) 1.65 (1.21, 2.28) 0.24 (0.10, 0.43) 0.25 (0.10, 0.47) 
Analysis Eastern Europe       
Main 0.06 (-0.03, 0.20) 0.14 (-0.10, 0.72) 0.05 (-0.02, 0.14) 0.06 (-0.02, 0.16) 
Stable gen-pop HCV† 0.13 (0.01, 0.27) 0.16 (0.16, 0.63) 0.10 (0.10, 0.22) 0.12 (0.12, 0.25) 
Decreasing HCV among PWID§ 0.06 (-0.02, 0.18) 0.14 (-0.09, 0.75) 0.05 (-0.01, 0.15) 0.06 (-0.01, 0.16) 
No later injecting start year for EE and SSA¶ 0.11 (0.03, 0.21) 0.48 (0.12, 0.89) 0.07 (0.01, 0.14) 0.08 (0.03, 0.16) 
Halved PWID treatment rate, doubled for cirrhosis₡ 0.02 (0.00, 0.10) 0.05 (-0.20, 0.68) 0.03 (0.01, 0.18) 0.05 (-0.02, 0.17) 
Varied epidemic trajectories by region 0.60 (0.08, 2.21) 0.58 (0.04, 1.77) 0.50 (0.06, 1.85) 0.58 (0.08, 2.13) 
25 additional treatments (rather than 50) 0.07 (-0.04, 0.21) 0.12 (-0.12, 0.74) 0.04 (-0.02, 0.14) 0.04 (-0.02, 0.17) 
     
     




 Hepatitis C virus infections averted per treatment for infected individuals 
 Random allocation PWID Cirrhotic Age ≥35 years 
Analysis Australasia       
Main 0.26 (0.13, 0.49) 0.54 (0.29, 1.00) 0.21 (0.11, 0.41) 0.22 (0.11, 0.43) 
Stable gen-pop HCV† 0.32 (0.17, 0.52) 0.66 (0.66, 1.06) 0.28 (0.28, 0.46) 0.30 (0.30, 0.49) 
Decreasing HCV among PWID§ 0.24 (0.11, 0.47) 0.54 (0.27, 1.09) 0.20 (0.09, 0.37) 0.20 (0.11, 0.40) 
Halved PWID treatment rate, doubled for cirrhosis₡ 0.12 (0.06, 0.24) 0.34 (0.18, 0.74) 0.21 (0.11, 0.44) 0.26 (0.15, 0.47) 
Varied epidemic trajectories by region 0.43 (0.23, 0.85) 0.82 (0.46, 1.70) 0.37 (0.21, 0.73) 0.39 (0.21, 0.78) 
25 additional treatments (rather than 50) 0.25 (0.15, 0.50) 0.52 (0.31, 1.04) 0.21 (0.11, 0.43) 0.21 (0.11, 0.45) 
Analysis East & Southeast Asia     
Main 0.26 (0.09, 0.49) 1.26 (0.70, 2.08) 0.19 (0.04, 0.39) 0.21 (0.04, 0.44) 
Stable gen-pop HCV† 0.44 (0.25, 0.66) 1.43 (0.93, 2.22) 0.32 (0.16, 0.54) 0.37 (0.18, 0.59) 
Decreasing HCV among PWID§ 0.25 (0.09, 0.51) 1.27 (0.78, 2.19) 0.19 (0.04, 0.40) 0.21 (0.06, 0.44) 
Halved PWID treatment rate, doubled for cirrhosis₡ 0.13 (0.02, 0.30) 0.98 (0.54, 1.88) 0.19 (0.02, 0.47) 0.21 (0.05, 0.44) 
Varied epidemic trajectories by region 0.40 (0.21, 0.62) 1.39 (0.87, 2.36) 0.31 (0.14, 0.48) 0.36 (0.16, 0.54) 
25 additional treatments (rather than 50) 0.26 (0.08, 0.48) 1.23 (0.65, 1.99) 0.18 (0.04, 0.39) 0.22 (0.04, 0.44) 
Analysis South Asia       
Main 0.49 (0.25, 0.76) 1.86 (0.96, 2.75) 0.41 (0.21, 0.63) 0.43 (0.21, 0.67) 
Stable gen-pop HCV† 0.78 (0.57, 0.96) 2.23 (1.23, 3.07) 0.64 (0.47, 0.80) 0.67 (0.49, 0.84) 
Decreasing HCV among PWID§ 0.47 (0.25, 0.75) 1.84 (0.97, 2.81) 0.38 (0.20, 0.62) 0.42 (0.22, 0.66) 
Halved PWID treatment rate, doubled for cirrhosis₡ 0.34 (0.15, 0.55) 1.33 (0.49, 2.17) 0.50 (0.26, 0.82) 0.41 (0.22, 0.66) 
Varied epidemic trajectories by region 0.87 (0.66, 1.10) 2.35 (1.32, 3.35) 0.72 (0.52, 0.91) 0.75 (0.59, 0.95) 
25 additional treatments (rather than 50) 0.48 (0.26, 0.74) 1.87 (0.98, 2.80) 0.40 (0.20, 0.62) 0.43 (0.21, 0.66) 
Analysis North America       
Main 0.58 (0.22, 1.13) 1.04 (0.44, 2.00) 0.46 (0.18, 0.90) 0.50 (0.20, 0.99) 
Stable gen-pop HCV† 0.68 (0.33, 1.19) 1.13 (0.59, 2.14) 0.56 (0.29, 0.96) 0.60 (0.31, 1.05) 
Decreasing HCV among PWID§ 0.43 (0.16, 1.02) 0.81 (0.32, 1.77) 0.37 (0.13, 0.81) 0.39 (0.15, 0.89) 
Halved PWID treatment rate, doubled for cirrhosis₡ 0.23 (0.04, 0.48) 0.58 (0.25, 1.30) 0.42 (0.07, 0.92) 0.55 (0.14, 1.22) 
Varied epidemic trajectories by region 0.60 (0.26, 1.08) 1.00 (0.51, 1.80) 0.50 (0.22, 0.88) 0.54 (0.24, 0.98) 
25 additional treatments (rather than 50) 0.62 (0.18, 1.16) 1.07 (0.42, 1.98) 0.46 (0.15, 0.93) 0.54 (0.15, 1.04) 




 Hepatitis C virus infections averted per treatment for infected individuals 
 Random allocation PWID Cirrhotic Age ≥35 years 
Analysis Western Europe       
Main 0.32 (0.13, 0.68) 0.91 (0.51, 1.62) 0.24 (0.09, 0.53) 0.27 (0.10, 0.58) 
Stable gen-pop HCV† 0.44 (0.21, 0.75) 1.02 (0.58, 1.61) 0.35 (0.15, 0.59) 0.38 (0.16, 0.65) 
Decreasing HCV among PWID§ 0.30 (0.10, 0.68) 0.94 (0.41, 1.55) 0.23 (0.08, 0.52) 0.25 (0.08, 0.58) 
Halved PWID treatment rate, doubled for cirrhosis₡ 0.10 (0.03, 0.24) 0.53 (0.26, 1.04) 0.20 (0.05, 0.43) 0.22 (0.07, 0.49) 
Varied epidemic trajectories by region 0.45 (0.20, 0.88) 1.07 (0.60, 1.81) 0.37 (0.14, 0.70) 0.40 (0.17, 0.77) 
25 additional treatments (rather than 50) 0.33 (0.13, 0.68) 0.94 (0.55, 1.58) 0.27 (0.11, 0.55) 0.28 (0.11, 0.58) 
Analysis Sub-Saharan Africa     
Main 0.75 (0.45, 1.10) 2.30 (1.38, 3.38) 0.60 (0.33, 0.89) 0.57 (0.33, 0.86) 
Stable gen-pop HCV† 1.08 (0.79, 1.34) 2.69 (1.81, 3.83) 0.86 (0.61, 1.09) 0.85 (0.60, 1.06) 
Decreasing HCV among PWID§ 0.77 (0.48, 1.13) 2.24 (1.38, 3.37) 0.62 (0.38, 0.92) 0.58 (0.35, 0.86) 
No later injecting start year for EE and SSA¶ 0.72 (0.42, 1.06) 2.16 (1.41, 3.22) 0.57 (0.31, 0.85) 0.55 (0.33, 0.86) 
Halved PWID treatment rate, doubled for cirrhosis₡ 0.22 (0.02, 0.46) 0.16 (-0.10, 0.44) 0.38 (0.02, 0.74) 0.44 (0.02, 0.72) 
Varied epidemic trajectories by region 0.80 (0.22, 1.20) 1.06 (0.06, 1.54) 0.66 (0.18, 1.00) 0.72 (0.20, 1.10) 
25 additional treatments (rather than 50) 0.72 (0.20, 1.28) 1.04 (0.16, 1.60) 0.60 (0.16, 1.08) 0.64 (0.16, 1.16) 
Analysis Latin America       
Main 0.19 (0.03, 0.40) 0.18 (-0.01, 0.40) 0.15 (0.02, 0.32) 0.17 (0.02, 0.37) 
Stable gen-pop HCV† 0.36 (0.15, 0.53) 0.24 (0.03, 0.46) 0.29 (0.11, 0.44) 0.32 (0.14, 0.49) 
Decreasing HCV among PWID§ 0.19 (0.03, 0.39) 0.24 (0.03, 0.50) 0.14 (0.02, 0.32) 0.16 (0.03, 0.36) 
Halved PWID treatment rate, doubled for cirrhosis₡ 0.08 (0.01, 0.23) -0.08 (-0.23, 0.20) 0.14 (0.01, 0.37) 0.13 (0.01, 0.34) 
Varied epidemic trajectories by region 0.25 (0.08, 0.44) 0.21 (0.01, 0.44) 0.20 (0.05, 0.37) 0.23 (0.07, 0.41) 
25 additional treatments (rather than 50) 0.19 (0.03, 0.40) 0.16 (-0.02, 0.43) 0.15 (0.02, 0.32) 0.15 (0.02, 0.35) 
Analysis Middle East & North Africa     
Main 0.20 (0.09, 0.41) 0.84 (0.50, 1.39) 0.18 (0.08, 0.35) 0.19 (0.08, 0.36) 
Stable gen-pop HCV† 0.33 (0.22, 0.58) 1.03 (0.63, 1.73) 0.30 (0.18, 0.51) 0.30 (0.19, 0.53) 
Decreasing HCV among PWID§ 0.20 (0.09, 0.40) 0.82 (0.52, 1.40) 0.17 (0.08, 0.35) 0.17 (0.08, 0.37) 
Halved PWID treatment rate, doubled for cirrhosis₡ 0.14 (0.06, 0.32) 0.65 (0.43, 1.20) 0.23 (0.11, 0.51) 0.19 (0.08, 0.39) 
Varied epidemic trajectories by region 0.22 (0.13, 0.43) 0.85 (0.57, 1.41) 0.19 (0.12, 0.37) 0.19 (0.12, 0.38) 




EE: Eastern Europe; SSA: Sub-Saharan Africa 
† Seeded at 101% of the general population HCV prevalence estimate 
§ Seeded at the same number as the general population HCV prevalence estimate 
¶ Eastern Europe and Sub-Saharan Africa seeded at 101% of the estimate of the proportion of adults that are PWID – the same as the other 
regions. 
₡ The same number of treatments are given as in the main analyses but the treatment rate for PWID is halved, whilst the treatment rate for 
people with cirrhosis is doubled. The treatment rate for those who are neither PWID nor have cirrhosis is also altered and is either increased or 
decreased depending on the epidemic. 




Table 8.4: Sensitivity analysis where the proportion of adults that are PWID in the USA 
expands from 2010 onwards* - infections averted per treatment 2018-2038. 
Original assumptions for the USA; point estimate (95% Credibility Intervals) 
Random allocation PWID Cirrhotic Age ≥35 years 
0.60 (0.24, 1.16) 1.08 (0.50, 2.06) 0.48 (0.20, 0.92) 0.52 (0.22, 1.02) 
Assuming expanding PWID numbers after 2010 for the USA; point estimate (95% Credibility Intervals) 
Random allocation PWID Cirrhotic Age ≥35 years 
1.02 (0.30, 2.26) 1.92 (0.64, 3.92) 0.78 (0.24, 1.74) 0.84 (0.26, 1.84) 
* From 2010 onwards the rate of initiating injecting is multiplied by 2.9 due to evidence of 
incidence of viral hepatitis C increasing by this amount between 2010 and 2015(57), which is 
thought to be driven by an increase in injecting drug use(330). 
 
Table 8.5: HCV infections averted per treatment given in 2018 using the actual treatment 
numbers for 2017, compared with the estimates from the main model run treating 50 extra 
randomly allocated patients in 2018. 
 
HCV infections averted per treatment using actual 2017 




estimate (95% CrI) Country 
Infections averted 
(95% CrI) Treatments 
Infections averted per 
treatment (95% CrI) 
Kazakhstan 462 (310, 749) 1750 0.26 (0.18, 0.43) 0.26 (0.18, 0.40) 
Kyrgyzstan 42 (25, 68) 100 0.42 (0.25, 0.68) 0.42 (0.24, 0.62) 
Tajikistan NA 0 NA 0.50 (0.24, 0.76) 
Turkmenistan NA 0 NA 0.40 (0.20, 0.64) 
Uzbekistan 490 (205, 880) 1500 0.33 (0.14, 0.59) 0.30 (0.10, 0.56) 
Armenia NA 0 NA 0.12 (0.02, 0.26) 
Azerbaijan 50 (18, 97) 210 0.24 (0.09, 0.46) 0.24 (0.06, 0.46) 
Belarus NA 0 NA 0.00 (-0.10, 0.14) 
Bosnia NA 0 NA 0.00 (-0.12, 0.14) 
Bulgaria 4 (-12, 46) 350 0.01 (-0.03, 0.13) 0.02 (-0.04, 0.10) 
Czechia 697 (456, 1338) 910 0.77 (0.50, 1.47) 0.80 (0.54, 1.46) 
Estonia 286 (40, 634) 908 0.31 (0.04, 0.70) 0.40 (0.08, 0.80) 
Georgia 6432 (2720, 10195) 15400 0.42 (0.18, 0.66) 0.40 (0.14, 0.72) 
Hungary 313 (76, 670) 1477 0.21 (0.05, 0.45) 0.20 (0.06, 0.42) 
Latvia 45 (-75, 246) 1071 0.04 (-0.07, 0.23) 0.06 (-0.06, 0.26) 
Lithuania 278 (109, 547) 1518 0.18 (0.07, 0.36) 0.18 (0.08, 0.36) 
Moldova 38 (3, 96) 300 0.13 (0.01, 0.32) 0.14 (0.02, 0.30) 
Poland 617 (32, 1348) 5800 0.11 (0.01, 0.23) 0.10 (0.00, 0.26) 
Romania -220 (-627, 675) 8131 -0.03 (-0.08, 0.08) -0.02 (-0.08, 0.06) 
Russia 105 (-364, 669) 5500 0.02 (-0.07, 0.12) 0.02 (-0.06, 0.14) 
Slovakia 27 (-10, 100) 316 0.09 (-0.03, 0.32) 0.08 (-0.06, 0.28) 
Ukraine 188 (87, 387) 1750 0.11 (0.05, 0.22) 0.10 (0.06, 0.22) 





HCV infections averted per treatment using actual 2017 




estimate (95% CrI) Country 
Infections averted 
(95% CrI) Treatments 
Infections averted per 
treatment (95% CrI) 
New Zealand 600 (86, 1348) 1882 0.32 (0.05, 0.72) 0.34 (0.06, 0.90) 
China 25550 (12009, 45947) 100000 0.26 (0.12, 0.46) 0.24 (0.10, 0.44) 
Indonesia 59 (-31, 218) 600 0.10 (-0.05, 0.36) 0.12 (-0.04, 0.36) 
Japan 15487 (6298, 36518) 38000 0.41 (0.17, 0.96) 0.46 (0.18, 0.88) 
Malaysia 167 (68, 352) 550 0.30 (0.12, 0.64) 0.32 (0.10, 0.56) 
Myanmar 636 (357, 1078) 2000 0.32 (0.18, 0.54) 0.30 (0.18, 0.50) 
Philippines 216 (86, 382) 550 0.39 (0.16, 0.69) 0.38 (0.16, 0.64) 
Taiwan 293 (-44, 1053) 4000 0.07 (-0.01, 0.26) 0.06 (-0.02, 0.26) 
Thailand 514 (-21, 1000) 3000 0.17 (-0.01, 0.33) 0.16 (0.00, 0.38) 
Viet Nam 1084 (220, 2286) 4500 0.24 (0.05, 0.51) 0.24 (0.06, 0.44) 
Afghanistan 8 (3, 13) 10 0.80 (0.30, 1.30) 0.86 (0.34, 1.34) 
Bangladesh NA 0 NA 0.40 (0.20, 0.66) 
India 50483 (27622, 77496) 115000 0.44 (0.24, 0.67) 0.44 (0.22, 0.70) 
Iran 1876 (724, 3918) 6000 0.31 (0.12, 0.65) 0.32 (0.10, 0.64) 
Nepal NA 0 NA 0.30 (0.08, 0.56) 
Pakistan 86866 (46250, 139750) 161000 0.54 (0.29, 0.87) 0.58 (0.32, 0.86) 
Canada 2778 (-388, 7292) 9500 0.29 (-0.04, 0.77) 0.30 (-0.06, 0.72) 
USA 156699 (66000, 281011) 231000 0.68 (0.29, 1.22) 0.60 (0.24, 1.16) 
Albania 5 (1, 11) 48 0.10 (0.02, 0.23) 0.10 (0.04, 0.24) 
Austria 982 (582, 1748) 1500 0.65 (0.39, 1.17) 0.66 (0.38, 1.08) 
Belgium 295 (68, 684) 1080 0.27 (0.06, 0.63) 0.26 (0.06, 0.70) 
Croatia 24 (10, 46) 150 0.16 (0.07, 0.31) 0.16 (0.06, 0.32) 
Cyprus 13 (4, 25) 46 0.28 (0.09, 0.54) 0.32 (0.10, 0.56) 
Denmark 187 (138, 251) 511 0.37 (0.27, 0.49) 0.38 (0.28, 0.52) 
Finland 17 (-4, 50) 300 0.06 (-0.01, 0.17) 0.06 (-0.02, 0.16) 
France 5460 (3162, 11258) 19300 0.28 (0.16, 0.58) 0.28 (0.14, 0.60) 
Germany 4823 (2042, 10455) 13000 0.37 (0.16, 0.80) 0.40 (0.18, 0.80) 
Greece 239 (74, 440) 1134 0.21 (0.07, 0.39) 0.22 (0.04, 0.42) 
Iceland 59 (40, 77) 200 0.30 (0.20, 0.39) 0.26 (0.18, 0.38) 
Ireland 163 (36, 392) 840 0.19 (0.04, 0.47) 0.22 (0.06, 0.44) 
Italy 9669 (3535, 21828) 43000 0.22 (0.08, 0.51) 0.24 (0.08, 0.50) 
Luxembourg 259 (50, 441) 300 0.86 (0.17, 1.47) 0.94 (0.28, 1.60) 
Macedonia 6 (3, 19) 76 0.08 (0.04, 0.25) 0.08 (0.04, 0.22) 
Malta 25 (15, 43) 70 0.36 (0.21, 0.61) 0.36 (0.20, 0.64) 
Montenegro NA 0 NA 0.12 (0.08, 0.22) 
Netherlands 336 (157, 660) 1200 0.28 (0.13, 0.55) 0.28 (0.12, 0.58) 
Norway 622 (368, 980) 1000 0.62 (0.37, 0.98) 0.64 (0.40, 0.94) 
Portugal 1149 (295, 2136) 4836 0.24 (0.06, 0.44) 0.24 (0.06, 0.46) 
Serbia NA 0 NA 0.30 (0.22, 0.38) 
Slovenia 102 (74, 143) 200 0.51 (0.37, 0.72) 0.52 (0.38, 0.74) 
Spain 6099 (1988, 12549) 29700 0.21 (0.07, 0.42) 0.20 (0.08, 0.50) 





HCV infections averted per treatment using actual 2017 
treatment numbers for 2018 Main model 
random allocation 
estimate (95% CrI) Country 
Infections averted 
(95% CrI) Treatments 
Infections averted per 
treatment (95% CrI) 
Switzerland 1149 (572, 2138) 3200 0.36 (0.18, 0.67) 0.38 (0.18, 0.64) 
UK 7241 (3046, 15826) 14800 0.49 (0.21, 1.07) 0.50 (0.22, 1.22) 
Ghana 13 (8, 19) 20 0.65 (0.40, 0.95) 0.66 (0.40, 0.98) 
Kenya 4 (2, 6) 6 0.67 (0.33, 1.00) 0.68 (0.38, 1.04) 
Madagascar 2 (1, 3) 3 0.67 (0.33, 1.00) 0.76 (0.44, 1.16) 
Mauritius NA 0 NA -0.10 (-0.26, 0.10) 
Mozambique NA 0 NA 0.62 (0.28, 0.96) 
Nigeria 240 (156, 330) 300 0.80 (0.52, 1.10) 0.76 (0.46, 1.12) 
Senegal NA 0 NA 0.76 (0.46, 1.14) 
Tanzania NA 0 NA 0.84 (0.54, 1.18) 
Argentina 275 (77, 514) 1204 0.23 (0.06, 0.43) 0.24 (0.06, 0.46) 
Brazil 8834 (3135, 17196) 45016 0.20 (0.07, 0.38) 0.22 (0.08, 0.40) 
Mexico 58 (-35, 174) 480 0.12 (-0.07, 0.36) 0.12 (-0.08, 0.36) 
Uruguay NA 0 NA 0.28 (0.12, 0.46) 
Egypt 111166 (54718, 238400) 600000 0.19 (0.09, 0.40) 0.18 (0.08, 0.38) 
Israel 913 (572, 1282) 1500 0.61 (0.38, 0.85) 0.62 (0.38, 0.88) 
Lebanon 299 (182, 484) 325 0.92 (0.56, 1.49) 0.92 (0.58, 1.44) 
Libya 64 (0, 133) 288 0.22 (0.00, 0.46) 0.20 (0.00, 0.42) 
Morocco 2479 (1302, 4376) 8000 0.31 (0.16, 0.55) 0.34 (0.16, 0.54) 
Saudi Arabia 329 (-57, 1192) 2800 0.12 (-0.02, 0.43) 0.08 (-0.02, 0.40) 
Syria 4 (2, 7) 10 0.40 (0.20, 0.70) 0.38 (0.18, 0.66) 
Tunisia 279 (108, 570) 1000 0.28 (0.11, 0.57) 0.26 (0.12, 0.50) 
Turkey 40 (23, 74) 194 0.21 (0.12, 0.38) 0.22 (0.12, 0.42) 
Total 
525764 (243948, 





8.4.  Discussion 
8.4.1.  Main findings 
My modelling suggests that one infection will be prevented over the next 20 years for every 
three randomly allocated HCV treatments undertaken globally. The number of HCV 
infections that are averted will vary by region and country, with twenty randomly allocated 
treatments being needed to prevent one infection in Eastern Europe, but less than two in 
Sub-Saharan Africa. Targeting treatment to people aged ≥35 or with cirrhosis is likely to 
produce similar prevention benefits. However, targeting PWID could achieve greater 
impact, with over one infection being prevented for every PWID treated globally but with 
impact varying considerably by country and region. Results suggest the prevention impact 
of randomly allocating treatment or treating PWID will be greater in countries with high 
population growth and higher percentage of adults that are PWID but will be reduced in 
countries with high HCV prevalence among PWID and the general population, due to 
greater re-infection following treatment. The number of treatments given in 2017 was not 
associated with the number of infections averted per treatment. In sensitivity analyses, 
assuming a stable general population HCV prevalence, rather than decreasing, or varying 
HCV epidemic trajectories by region resulted in more infections averted per treatment. 
Whereas, assuming that treatment rates among PWID are halved and doubled for those with 
cirrhosis resulted in fewer infections averted per treatment, as targeting PWID will result in 
higher potential prevention benefits.  
 
8.4.2. Strengths and limitations  
Section 7.4.3 discusses the strengths and limitations of the model used and the data that 
parameterise it. The analysis in this chapter, commissioned by the WHO to focus on the 
prevention benefits of a treat-all policy, does not consider morbidity or mortality benefits. 
These outcomes have been considered in previous economic models, which emphasise the 
importance of treating individuals with cirrhosis for reducing the burden of liver-related 
deaths(79, 240). This model does not consider the impact of scaling up prevention 
interventions (eg. opiate substitution treatment [OST] and needle and syringe programs 
[NSP]) as the WHO’s focus was the prevention benefits of treatment. Countries are at 




impact differently across settings. To investigate this, I included the number of treatments in 
2017 in the regression analyses, which found no effect of baseline treatment numbers. I also 
examined this issue in a sensitivity analysis which considered the impact of additional 
treatment rates, suggesting similar infections averted per treatment. 
 
8.4.3.  Comparison to other studies 
Other modelling analyses have considered the prevention benefits of HCV treatment among 
PWID, MSM, and the general population(28, 34, 70, 86, 144, 218, 234, 235, 239, 240), with 
Martin et al. finding higher infections averted per treatment when treating PWID than 
ex/non-PWID with lower infection rates(240). Similarly to this chapter, some analyses of 
PWID HCV epidemics have also suggested that less prevention benefit will be achieved in 
settings with higher or increasing HCV prevalence among PWID(73, 110, 235, 240). The 
global HCV modelling analysis by Heffernan et al. that also identified negative infections 
averted when the pool of susceptible individuals is increased in certain settings where HCV 
prevalence among PWID was very high, although they did not estimate infections averted 
per treatment(150). Ayoub et al.’s modelling study in Egypt found between 0.08 and 0.11 
infections averted per treatment over 15 years, similar to the 0.18 (95% CrI: 0.08, 0.38) that I 
found for the treat-all strategy(28). Meanwhile, a modelling paper by Lim et al. in Pakistan 
found 0.56 infections averted in Pakistan over 15 years, whilst in Pakistan I found 0.58 (95% 
CrI: 0.32, 0.86) infections averted over 20 years(218). 
 
8.4.4.  Implications 
These analyses show that globally, a moderate prevention impact (one infection prevented 
per three treatments undertaken) can be achieved with a treat-all strategy, with greatest 
benefit achieved in countries with high population growth, including many LMICs and 
countries such as Pakistan and India that were investigated in chapters 4 and 5. These 
findings are useful for policy-makers as they provide an understanding of the prevention 
benefits of widespread treatment scale-up when planning for the WHO 2030 HCV 
elimination targets(402). The analyses suggest that countries in some regions, such as Sub-




treatment than other regions, such as Eastern Europe and Latin America, due to having 
growing populations and generalised epidemics. However, many countries lack the 
resources to treat HCV(125), or screening may present a barrier to treatment scale-up due to 
their HCV epidemics being generalised(76). This issue will be particularly pertinent for 
countries with high burdens of other infectious diseases, where policy makers may focus 
their resources on more acute diseases rather than HCV. Only with substantial donor 
support, or considerable improvements in access to HCV DAA therapies and diagnostic 
tests, will such countries be able to substantially scale-up treatment for HCV.  
Importantly, my analyses also re-emphasized the prevention benefits of targeting PWID, as 
PWID were the subgroup for whom treatment produced the most infections averted 
globally and for most countries. This is due to the higher likelihood of PWID transmitting 
HCV relative to other subgroups(169). In chapter 7, I found that HCV transmission risks 
associated with IDU will account for 43% of all transmission globally from 2018 to 2030, so it 
is key that PWID are allowed access to treatment. However, PWID comprise only a fraction 
of the overall HCV burden globally(127), and so any elimination strategy must also target 
other groups, especially in settings with high rates of infection due to nosocomial factors, 
such as Pakistan (chapter 4)(218, 371). In the DAA era of treatment as prevention, reinfection 
rates are now being estimated and have been high in some settings, for example 21.5 re-
infections per 100 person‐years in Dundee(322), and low in others, such as 3.1 per 100 
person-years in British Columbia, although this rate was 10.2 per 100 person-years among 
younger PWID(315). In scenarios where infection rates are high, treatment rates among 
PWID need to be increased to high levels and HCV prevention interventions (OST and NSP) 
need to be scaled up to reduce these high re-infection risks(150, 287). Either way, these 
insights emphasise the need to allocate resources to treating PWID, either due to the greater 
prevention benefits achieved and/or to gain control of the epidemic among PWID; crucial 
for achieving elimination. 
 
8.4.5.  Conclusions 
In this chapter, I used dynamic HCV transmission modelling to determine the HCV 
infections averted per DAA treatment at a global, regional, and country-level for a random 




and people aged over 35), and evaluating how the impact achieved depends on different 
country-specific factors. This chapter’s findings highlight that, globally, treating PWID 
averts the most infections per treatment. A treat-all strategy, treating those aged ≥35 years, 
or those with cirrhosis all avert roughly the same amount of infections. However, impact 
will vary by region and country, with negative infections being averted for PWID in some 
countries with very high HCV prevalence rates among PWID and some countries getting 
more impact from treating randomly rather than targeting PWID. The WHO’s 2030 HCV 
elimination targets(403) include aims for reducing both HCV-related mortality and HCV 
incidence. Other analyses have shown that treating those with advanced liver disease is the 
best strategy for reducing HCV-related mortality(79, 240). The results in the chapter 7 
indicated that reducing HCV incidence in PWID will be necessary for reaching the global 
HCV incidence target. The results of previous analyses have shown that targeting treatment 
at PWID is one method that can help achieve such as reduction, via treatment as 
prevention(70, 109), with this chapter suggesting that that many HCV infections would be 
averted through this strategy. The work in this chapter was commissioned as part of the 
WHO’s new guidelines for a treat-all strategy(408). Such a strategy would reduce practical 
obstacles to treatment, such as screening to prioritise individuals with advanced disease, 
and could be considered more equitable by allowing all those who seek treatment to access 
it, including often stigmatised groups such as PWID(77). There are other issues to consider, 
mainly surrounding resourcing for the costs of testing and treatment and ensuring that 
those with severe liver disease are treated. However, on a global scale, a treat-all strategy as 
outlined by the WHO is advisable as it allows flexibility regarding the epidemiology of HCV 





CHAPTER 9. DISCUSSION 
In this thesis, I investigated the epidemiology of HCV in different settings around the world. 
Firstly, I used data from two household serosurveys to look at the associations between 
various risk factors and HCV prevalence in two generalised epidemics settings: Pakistan 
and Punjab, India. Secondly, I developed a global model of country-level HCV epidemics to 
estimate the contribution of injecting drug use (IDU) to global HCV transmission and to 
quantify the prevention benefits of HCV treatment when targeted to different subgroups of 
infected individuals. This second analysis focussed on the benefits of a treat-all strategy, as 
outlined in the WHO’s 2018 HCV guidelines, and compared that to what is achieved 
through targeting other subgroups. In this discussion chapter, I will recap the main findings 
and their implications, discuss the limitations of each chapter, and consider how this work 
could be developed further. 
In chapter 4, I focused on Pakistan using a national serosurvey with an estimated anti-HCV 
prevalence of around 4.8%(371). I found that healthcare-related exposures, including 
childbirth and the number of medical injections received in the last year, were associated 
with prevalent HCV infection(371). I also found that low socio-economic status, marriage, 
and some common community risk exposures, such as going to a barber, were associated 
with an increased risk of HCV infection. These findings add weight to the evidence that 
unsafe healthcare interventions are important contributors to Pakistan’s HCV epidemic(10), 
but also suggest that a range of other exposures could be contributing to the epidemic. 
Several of these associations are likely markers for other risk factors. For example, low socio-
economic status could result in poor access to quality healthcare(177), whilst marriage may 
be acting as a marker of either intrafamilial transmission or shared risk factors outside of the 
household, which requires further investigation(280). A limitation of the serosurvey in 
Pakistan is that it did not ask about transmission routes such as male circumcision(281), 
female genital mutilation(187), or childbirth, which had to be estimated indirectly. The 
findings of this serosurvey may not be generalisable to other settings, even those with high 
HCV prevalences. For instance, some risk factors identified may be particularly prevalent in 
Pakistan, whilst some medical exposures may not carry the same risk in other locations.  
In chapter 5, I found an anti-HCV prevalence of 3.6% in a serosurvey of Punjab state, 
India(346). Living in rural areas, being aged 40-59, and being male were all positively 




blood transfusion, or had low levels of education, and not receiving their last medical 
injection from a medical doctor(346). These associations suggest that several health-related 
exposures are important in Punjab, India, whilst the associations with low education and 
rural areas likely indicate that other HCV transmitting behaviours or practices are common 
among these subgroups. Similarly to the serosurvey in Pakistan, the findings from Punjab 
are not necessarily generalisable to other HCV epidemic settings. Likewise, this serosurvey 
did not include questions about all possible risk factors, such as male circumcision(16). Only 
five respondents, 0.1% of those sampled, reported that they had ever injected drugs. This 
could be an accurate estimate, with small numbers being reported due to the relatively 
modest overall sample size (n=5,543) or could be under-reported due to issues of social-
desirability bias, a problem common to all household serosurveys and one that may also 
affect other variables, as is the case with recall bias. Additionally, it could be that many 
people who inject drugs (PWID) are homeless or incarcerated and so would not be picked 
up by a household survey resulting in an under-estimate. The sampling frame used in the 
Punjab serosurvey excluded newly built peri-urbans slums, which could also lead to an 
under ascertainment of IDU due to poverty being common among PWID(368).  
A universal weakness of this type of cross-sectional serosurvey, including the Pakistan and 
Punjab serosurveys, is that it is impossible to ascertain when the infections occurred. This 
means that whilst many of the questions are asking about behaviours in the last year or six 
months, the individuals may have been infected many years ago, before the scope of the 
question, which may mean that the importance of some risk factors is underestimated. An 
example of this, for both Pakistan and Punjab, is the relatively weak association between 
medical injections and HCV, which is known to be a key risk factor for HCV in both 
settings(10, 80). Unfortunately, the current contribution of unsafe medical injections is 
unclear as a huge reduction in the number of new HCV infections due to unsafe medical 
injections has been estimated between 2000 and 2010(283). This limitation of timeliness does 
not mean the results are without implications. Determining associations with prevalent 
infections is still of use for understanding a setting’s HCV epidemiology and for designing 
screening programmes where knowing who is likely to be infected allows for targeting of 
testing to subgroups with specific risk behaviours that are likely to have a higher yield of 
infected individuals. Other analyses have highlighted the advantages of designing screening 
algorithms that account for the results of serosurveys, with a study of 87,000 people 




tested, which had a 38% anti-HCV prevalence(191). This understanding of a setting’s 
epidemiology becomes particularly important later in the course of testing and treatment 
programmes when the number of infected individuals is lower and risk-based screening 
strategies become more useful. 
Whilst chapters 4 and 5 looked at risk factors for HCV infection in two generalised 
epidemics, chapter 7 used modelling to look at the concentration of epidemics by attempting 
to quantify the contribution of IDU to global HCV epidemics. I estimated that globally, 
around 43% of all HCV transmission between 2018 and 2030 will be due to IDU, varying 
from 14% in Sub-Saharan Africa to 96% in Eastern Europe(373). This quantification of the 
importance of IDU to future HCV transmission is important for country-level policy makers, 
allowing them to better understand the degree to which they should allocate resources to 
PWID. Whilst in some countries the contribution of IDU is low, for example 6% in India and 
18% in Pakistan, these findings show that globally it will not be possible to hit the WHO’s 
2030 targets for an 80% reduction in incidence without hugely reducing transmission among 
PWID(403). This is particularly important in high-income countries where the contribution 
of IDU is 79%. This reduction in transmission among PWID could be brought about through 
various evidence-based methods such as needle and syringe provision (NSP), opiate 
substitution therapy (OST)(288), or through using HCV treatment as a prevention 
strategy(109), which I went on to investigate in chapter 8. 
Whereas in chapters 4, 5, and 7 I investigated risk factors for prevalent and incident 
infections, chapter 8 looked at averting infections through treatment as prevention for 
different infected subgroups. I found that globally, on average, treating PWID resulted in 
more infections averted per treatment, 1.27 over twenty years, than other infected subgroups 
due to high transmission rates. I also found that a treat-all strategy, as outlined in the 
WHO’s 2018 HCV guidelines(408), for which these analyses were commissioned(410), 
would on average avert 0.35 infections per treatment over twenty years. Treating infected 
individuals aged over 30 years or those with cirrhosis would avert a similar, but slightly 
lower amount of infections to a treat-all strategy.  
The number of infections averted with a treat-all strategy varied by region, from 0.06 per 
treatment over twenty years in Eastern Europe to 0.75 in Sub-Saharan Africa. When treating 
infected PWID the regional number of infections averted varied from 0.14 per treatment 




4.82 infections were averted per treatment in Madagascar and -0.52 in Mauritius (with 
negative infections averted indicating reinfection of those treated). The number of infections 
averted with a treat-all strategy was positively associated with higher population growth 
and the percentage of adults that are PWID, and negatively associated with the HCV 
prevalence among PWID and the general population, whilst the number averted by treating 
PWID was associated with the same factors. This study quantifies treatment as prevention 
on a global scale and highlights how the epidemiology in a setting affects how many 
infections are averted. These findings support, and are quoted as such, for the WHO’s 
recommendations for a treat-all strategy, irrespective of disease stage(408, 410).  
The findings of chapter 8 can help those designing treatment programmes in settings such as 
Pakistan(255) and Punjab, India(80), to understand how treating specific subgroups will 
affect the number of treatments that will be required to meet the WHO’s elimination 
targets(403). However, the model only produced results at country-level, so would have to 
be adapted for a particular sub-national setting such as Punjab, which does not have the 
same epidemic characteristics as India overall(121), with Punjab having a much higher HCV 
prevalence than India(121). 
Additionally, a limitation of the modelling in chapter 8 is that it does not examine the effect 
that varying stages of treatment scale-up would have on the number of infections averted 
for each country. Modelling work by Metzig et al. focused on PWID, found that the 
increased pool of susceptibles becoming reinfected at very low levels of treatment coverage 
reduces the effect of treatment as prevention(251). However, as coverage subsequently 
increases to a level that is sufficiently large then treatment as prevention becomes more 
effective(251). Using 50 treatments for HCV to investigate the number of infections averted 
across different countries can be difficult to interpret as whilst 50 is a very small number of 
additional treatments for a setting such as Pakistan, it is a large amount for a country such as 
Iceland. The role of scale-up on treatment as prevention across these diverse settings 
included in this chapter of my thesis could be investigated in detail in future modelling. 
Suitable data to allow me to build the models used in chapters 7 and 8 were only available 
for 88 countries, which, although constituting 85% of the world’s population, is less than 
half of all the countries in the world. This highlights the paucity of epidemiological data 
regarding the number of PWID in many countries, as well as a lack of data on HCV 




available for a country, one or more of these important parameters for building the model 
were often graded as low-quality by the literature review it was taken from. Of the 88 
countries included, only 19 had all three key parameters rated as moderate or better. This 
lack of good quality data highlights there is a large gap in the evidence. Future modelling 
exercises such as those presented here would benefit from better quality data from more 
countries, particularly in Sub-Saharan Africa.  
Other data that could improve the models were also lacking. Data on migration were not 
available for all countries included in the models, particularly in low- and middle-income 
countries. There was also a lack of information on the prevalence of HCV among migrants, 
which is likely to be lower than the prevalence of HCV of their source country because of a 
healthy migrant effect where only those in good health or those that are wealthier are able to 
migrate(120). Whilst one review has looked at this for migration from endemic regions to 
high-income countries(128), and studies have investigated the contribution of migration to 
HCV in the EU(99, 302), data is not available for many of the countries that we modelled. 
The models could be further improved if there were country-level, longitudinal data 
available that quantified the risks due to particular risk factors such as unsafe medical 
injections. Data detailing the availability of OST and NSP over time, including when they 
were first implemented in each country, were not available at the time of writing. Such data 
would allow an in-depth look at how such interventions affect the ongoing HCV epidemics 
in each country. Although other modelling analyses have managed to use current estimates 
of intervention coverage(209), indicating that the current data can be used if certain 
assumptions are made, these model projections had to make a number of simplifying 
assumptions. 
My findings in chapter 4, on the contributions of various risks in the Pakistan 
serosurvey(371), have fed into a detailed mathematical modelling analysis of Pakistan’s 
HCV epidemic(218). Further modelling using the results of my analyses on the serosurvey in 
Pakistan is underway, incorporating testing into the model. My results in chapter 5 from the 
serosurvey in Punjab, India(346), could be used to develop a detailed mathematical model of 
the HCV epidemic in that setting. This model could use the results of the serosurvey to 
model different screening strategies to estimate the number of individuals that require 




could also ascertain whether Punjab’s treatment programme is currently on track to meet 
these targets and, if not, what is needed to meet them(80). 
My results in chapter 7 showed that IDU is a key contributor for HCV transmission in most 
settings around the world, so future modelling exercises should endeavour to take the role 
of IDU into account(373). As further data becomes available, the model used in chapters 7 
and 8 could be applied to other countries, allowing for the estimation of the contribution of 
HCV due to IDU in that setting and quantifying the effect of treatment as prevention. The 
models could also be adapted to settings where more detailed information is available, 
which is the case for Indonesia where a project is underway looking at what is required for 
elimination and estimating the associated costs. Additionally, the models could be extended 
in a similar way globally, as in a recently published study detailing how elimination can be 
reached on a worldwide scale(150). Such an analysis could be improved upon by 
incorporating key data when it becomes available, such as on HCV among migrants and 
longitudinal trends in NSP and OST coverage. With better data on HCV and its risk factors, 
models can more fully describe an HCV epidemic in a particular setting and the likely effect 
of interventions.  
To conclude, I hope that the findings of this thesis will be further used by policy makers 
designing HCV testing and treatment programmes in the hope of meeting the WHO’s 2030 
elimination targets(403). The work in this thesis is particularly relevant for those designing 
testing programmes in Pakistan(255) and Punjab, India(80), which contain a large segment 
(around 14%) of the global burden of HCV(40). However, the work is also relevant for those 
looking to understand how to best allocate resources to reduce the transmission of HCV in 
dozens of countries globally. For meeting the WHO’s targets, my work highlights the 
importance of reducing transmission among PWID and that allowing access to DAA 
treatment for PWID could result in many infections averted globally(403). Overall, my work 
in this thesis adds to the body of evidence for understanding the epidemiology of HCV in 
various settings around the world, which will be vital if the WHO’s 2030 HCV elimination 
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APPENDIX TO CHAPTER 7 
Appendix table 7.1: HCV transmission parameters* among the general population and 
people who inject drugs (PWID). 
 Transmission parameters (95% credibility intervals) 
Country General population (β) PWID (θ) 
Kazakhstan 0.0012 (0.0000, 0.0270) 0.5549 (0.4409, 0.9079) 
Kyrgyzstan 0.0365 (0.0041, 0.0607) 0.4676 (0.3592, 0.8775) 
Tajikistan 0.0515 (0.0173, 0.0786) 0.5958 (0.4466, 1.0845) 
Turkmenistan 0.0443 (0.0179, 0.0692) 0.5559 (0.4063, 1.0192) 
Uzbekistan 0.0381 (0.0089, 0.0656) 0.4587 (0.3312, 0.8418) 
Armenia 0.0085 (0.0000, 0.0224) 0.3014 (0.2379, 0.4369) 
Azerbaijan 0.0235 (0.0070, 0.0411) 0.4361 (0.3471, 0.6763) 
Belarus 0.0019 (0.0000, 0.0182) 0.4146 (0.3436, 0.5666) 
Bosnia 0.0000 (0.0000, 0.0031) 0.3202 (0.2831, 0.3932) 
Bulgaria 0.0000 (0.0000, 0.0142) 0.4215 (0.3515, 0.6085) 
Czech Republic 0.0116 (0.0000, 0.0275) 0.2702 (0.2264, 0.3999) 
Estonia 0.0000 (0.0000, 0.0072) 0.4185 (0.3583, 0.5157) 
Georgia 0.0000 (0.0000, 0.0160) 0.3034 (0.2468, 0.4038) 
Hungary 0.0173 (0.0028, 0.0327) 0.3356 (0.2639, 0.5363) 
Latvia 0.0000 (0.0000, 0.0103) 0.4341 (0.3488, 0.5445) 
Lithuania 0.0067 (0.0000, 0.0217) 0.3155 (0.2648, 0.4786) 
Moldova 0.0133 (0.0000, 0.0283) 0.3258 (0.2595, 0.4624) 
Poland 0.0083 (0.0000, 0.0245) 0.3526 (0.3083, 0.4869) 
Romania 0.0000 (0.0000, 0.0144) 0.5035 (0.3877, 0.6627) 
Russia 0.0000 (0.0000, 0.0141) 0.4163 (0.3474, 0.5627) 
Slovakia 0.0062 (0.0000, 0.0229) 0.3482 (0.2794, 0.4923) 
Ukraine 0.0000 (0.0000, 0.0140) 0.2344 (0.1806, 0.3665) 
Australia 0.0215 (0.0035, 0.0359) 0.2375 (0.1882, 0.3864) 
New Zealand 0.0135 (0.0000, 0.0288) 0.3142 (0.2412, 0.4764) 
China 0.0166 (0.0000, 0.0344) 0.3604 (0.2618, 0.6583) 
Indonesia 0.0164 (0.0000, 0.0365) 0.6285 (0.4898, 1.1142) 
Japan 0.0000 (0.0000, 0.0151) 0.3690 (0.2867, 0.5806) 
Malaysia 0.0264 (0.0000, 0.0475) 0.3393 (0.2756, 0.5183) 
Myanmar 0.0127 (0.0000, 0.0328) 0.5381 (0.4001, 1.0930) 
Philippines 0.0346 (0.0140, 0.0522) 0.3880 (0.2869, 0.7131) 
Taiwan 0.0091 (0.0000, 0.0284) 0.3605 (0.2742, 0.6109) 
Thailand 0.0182 (0.0000, 0.0375) 0.5718 (0.4270, 1.0401) 
Viet Nam 0.0189 (0.0000, 0.0365) 0.4905 (0.3518, 0.9202) 
Afghanistan 0.0422 (0.0018, 0.0647) 0.3912 (0.2958, 0.6647) 
Bangladesh 0.0293 (0.0149, 0.0449) 0.3526 (0.2582, 0.6167) 
India 0.0329 (0.0187, 0.0471) 0.3300 (0.2521, 0.5846) 
Iran 0.0107 (0.0000, 0.0281) 0.3437 (0.2578, 0.5785) 
Nepal 0.0190 (0.0000, 0.0351) 0.4520 (0.3206, 0.8031) 
Pakistan 0.0395 (0.0224, 0.0552) 0.3894 (0.1510, 0.8511) 
Canada 0.0130 (0.0000, 0.0283) 0.3449 (0.2390, 0.5760) 
USA 0.0173 (0.0000, 0.0342) 0.2002 (0.1526, 0.3445) 
Albania 0.0066 (0.0000, 0.0195) 0.2095 (0.1585, 0.3493) 
Austria 0.0000 (0.0000, 0.0155) 0.2679 (0.2157, 0.4166) 
Belgium 0.0000 (0.0000, 0.0211) 0.2595 (0.1836, 0.4671) 
Croatia 0.0076 (0.0000, 0.0215) 0.2179 (0.1690, 0.3515) 
Cyprus 0.0233 (0.0043, 0.0404) 0.3175 (0.2354, 0.5717) 
Denmark 0.0039 (0.0000, 0.0200) 0.1792 (0.1419, 0.2760) 
FYROM 0.0009 (0.0000, 0.0168) 0.3069 (0.2446, 0.4949) 
Finland 0.0000 (0.0000, 0.0078) 0.2910 (0.2415, 0.4114) 




 Transmission parameters (95% credibility intervals) 
Country General population (β) PWID (θ) 
Germany 0.0068 (0.0000, 0.0251) 0.2758 (0.2134, 0.4547) 
Greece 0.0197 (0.0036, 0.0348) 0.3000 (0.2315, 0.5252) 
Iceland 0.0000 (0.0000, 0.0173) 0.4142 (0.3355, 0.6434) 
Ireland 0.0128 (0.0000, 0.0297) 0.3445 (0.2739, 0.5643) 
Italy 0.0000 (0.0000, 0.0161) 0.2615 (0.1652, 0.4608) 
Luxembourg 0.0078 (0.0000, 0.0288) 0.3922 (0.3053, 0.5833) 
Malta 0.0093 (0.0000, 0.0262) 0.2012 (0.1517, 0.3426) 
Montenegro 0.0000 (0.0000, 0.0119) 0.3467 (0.2663, 0.6136) 
Netherlands 0.0196 (0.0032, 0.0356) 0.2675 (0.2062, 0.4653) 
Norway 0.0121 (0.0000, 0.0279) 0.2895 (0.2267, 0.4639) 
Portugal 0.0000 (0.0000, 0.0171) 0.4132 (0.2976, 0.7454) 
Serbia 0.0000 (0.0000, 0.0053) 0.2280 (0.1865, 0.3367) 
Slovenia 0.0028 (0.0000, 0.0206) 0.2069 (0.1611, 0.3256) 
Spain 0.0250 (0.0081, 0.0401) 0.3389 (0.2622, 0.5964) 
Sweden 0.0151 (0.0000, 0.0371) 0.3409 (0.2737, 0.5077) 
Switzerland 0.0080 (0.0000, 0.0260) 0.3226 (0.2439, 0.5766) 
UK 0.0027 (0.0000, 0.0221) 0.4220 (0.3515, 0.5903) 
Ghana 0.0507 (0.0344, 0.0678) 0.3440 (0.2786, 0.5063) 
Kenya 0.0424 (0.0232, 0.0612) 0.4664 (0.3733, 0.7531) 
Madagascar 0.0525 (0.0330, 0.0709) 0.2679 (0.1444, 0.4235) 
Mauritius 0.0063 (0.0000, 0.0255) 0.5430 (0.4808, 0.7071) 
Mozambique 0.0457 (0.0233, 0.0658) 0.5539 (0.4480, 0.8560) 
Nigeria 0.0554 (0.0374, 0.0737) 0.1533 (0.0672, 0.2790) 
Senegal 0.0569 (0.0376, 0.0757) 0.4350 (0.3485, 0.6628) 
Tanzania 0.0476 (0.0112, 0.0682) 0.4446 (0.2958, 0.8229) 
Argentina 0.0178 (0.0003, 0.0332) 0.2851 (0.2310, 0.4611) 
Brazil 0.0114 (0.0000, 0.0275) 0.3256 (0.2664, 0.4884) 
Mexico 0.0196 (0.0018, 0.0359) 0.5666 (0.4646, 0.8733) 
Uruguay 0.0144 (0.0000, 0.0294) 0.1693 (0.1351, 0.2912) 
Egypt 0.0412 (0.0214, 0.0593) 0.3221 (0.2065, 0.6465) 
Israel 0.0366 (0.0179, 0.0528) 0.2428 (0.1961, 0.4018) 
Lebanon 0.0414 (0.0108, 0.0602) 0.4069 (0.3018, 0.7549) 
Libya 0.0219 (0.0031, 0.0381) 0.9148 (0.6745, 1.6960) 
Morocco 0.0247 (0.0064, 0.0407) 0.3450 (0.2528, 0.5824) 
Saudi Arabia 0.0092 (0.0000, 0.0345) 0.6855 (0.5189, 1.1848) 
Syria 0.0359 (0.0179, 0.0539) 0.5669 (0.3980, 1.0766) 
Tunisia 0.0076 (0.0000, 0.0273) 0.4432 (0.3156, 0.8650) 
Turkey 0.0055 (0.0000, 0.0273) 0.5272 (0.3984, 0.9477) 
*The transmission parameters for the general population (β) and PWID (θ) are used to 
calculate the transmission rates through multiplication with the HCV prevalences in the 






Appendix table 7.2: Percentage differences between target prevalences and fitted values. 
 Median (95% credibility intervals), to 4 decimal places 
Country Adult % PWID PWID % chronic HCV Gen-pop % chronic HCV 
Overall 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 23.1888) 0.0000 (0.0000, 19.5878) 
Kazakhstan 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 30.3155) 0.0000 (0.0000, 4.3707) 
Kyrgyzstan 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Tajikistan 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Turkmenistan 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Uzbekistan 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Armenia 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 24.2182) 0.0000 (0.0000, 2.4835) 
Azerbaijan 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Belarus 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 26.3122) 0.0000 (0.0000, 9.7487) 
Bosnia 0.0000 (0.0000, 0.0000) 0.5768 (0.0000, 1.9393) 12.4833 (0.0000, 31.1541) 
Bulgaria 0.0000 (0.0000, 0.0000) 1.3755 (0.0000, 25.4172) 0.9233 (0.0000, 16.8026) 
Czech Republic 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 13.5840) 0.0000 (0.0000, 5.1109) 
Estonia 0.0000 (0.0000, 0.0000) 15.957 (0.0000, 32.1406) 3.5712 (0.0000, 6.8400) 
Georgia 0.0000 (0.0000, 0.0000) 5.2998 (0.0000, 30.2172) 0.0744 (0.0000, 0.4336) 
Hungary 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0001) 0.0000 (0.0000, 0.0001) 
Latvia 0.0000 (0.0000, 0.0000) 8.0438 (0.0000, 31.3363) 1.7592 (0.0000, 6.5260) 
Lithuania 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 17.7356) 0.0000 (0.0000, 10.1816) 
Moldova 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 7.8567) 0.0000 (0.0000, 2.1969) 
Poland 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 6.1191) 0.0000 (0.0000, 10.6574) 
Romania 0.0000 (0.0000, 0.0000) 1.6976 (0.0000, 30.0756) 0.3841 (0.0000, 7.9480) 
Russia 0.0000 (0.0000, 0.0000) 11.4323 (0.0000, 32.0523) 0.7320 (0.0000, 3.7018) 
Slovakia 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 17.6179) 0.0000 (0.0000, 8.0233) 
Ukraine 0.0000 (0.0000, 0.0000) 0.0677 (0.0000, 31.3127) 0.0082 (0.0000, 5.7633) 
Australia 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0003) 0.0000 (0.0000, 0.0004) 
New Zealand 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 14.3745) 0.0000 (0.0000, 6.2953) 
China 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 5.2793) 0.0000 (0.0000, 2.7310) 
Indonesia 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 2.0484) 0.0000 (0.0000, 12.7867) 
Japan 0.0000 (0.0000, 0.0000) 6.2041 (0.0000, 30.4503) 3.8911 (0.0000, 22.0100) 
Malaysia 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 23.9627) 0.0000 (0.0000, 9.4064) 
Myanmar 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 26.3299) 0.0000 (0.0000, 2.8791) 
Philippines 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Taiwan 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 10.9844) 0.0000 (0.0000, 6.7234) 
Thailand 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 2.3005) 0.0000 (0.0000, 3.8096) 
Viet Nam 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 3.1905) 0.0000 (0.0000, 1.4454) 
Afghanistan 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.9701) 0.0000 (0.0000, 0.4177) 
Bangladesh 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
India 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Iran 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 8.6769) 0.0000 (0.0000, 18.0241) 
Nepal 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 2.5258) 0.0000 (0.0000, 3.4996) 
Pakistan 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Canada 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 9.3889) 0.0000 (0.0000, 11.0014) 
USA 0.0000 (0.0000, 0.0000) 5.0788 (0.3235, 11.5012) 19.7636 (0.9881, 32.3413) 
Albania 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 25.6438) 0.0000 (0.0000, 5.9925) 
Austria 0.0000 (0.0000, 0.0000) 1.1589 (0.0000, 12.6917) 4.3463 (0.0000, 29.3384) 
Belgium 0.0000 (0.0000, 0.0000) 0.0027 (0.0000, 3.7323) 0.0060 (0.0000, 10.1140) 
Croatia 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 8.5050) 0.0000 (0.0000, 8.2879) 
Cyprus 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Denmark 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 13.5931) 0.0000 (0.0000, 15.3433) 
FYROM 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 5.3951) 0.0000 (0.0000, 22.0363) 




Country Adult % PWID PWID % chronic HCV Gen-pop % chronic HCV 
France 0.0000 (0.0000, 0.0000) 2.4406 (0.0898, 11.7872) 12.1664 (0.6639, 31.1497) 
Germany 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 10.9042) 0.0001 (0.0000, 24.2749) 
Greece 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0002) 0.0000 (0.0000, 0.0002) 
Iceland 0.0000 (0.0000, 0.0000) 1.3938 (0.0000, 13.3933) 5.2428 (0.0000, 31.048) 
Ireland 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 4.9363) 0.0000 (0.0000, 9.1627) 
Italy 0.0000 (0.0000, 0.0000) 3.1544 (0.0000, 31.5321) 0.4526 (0.0000, 6.4067) 
Luxembourg 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 18.3903) 0.0000 (0.0000, 16.6488) 
Malta 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 6.8324) 0.0000 (0.0000, 11.0054) 
Montenegro 0.0000 (0.0000, 0.0000) 6.4577 (0.0000, 30.9746) 3.1795 (0.0000, 14.3764) 
Netherlands 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Norway 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 5.4320) 0.0000 (0.0000, 12.1772) 
Portugal 0.0000 (0.0000, 0.0000) 0.2116 (0.0000, 3.5705) 0.5945 (0.0000, 8.8305) 
Serbia 0.0000 (0.0000, 0.0000) 11.5035 (0.0000, 31.1178) 8.4594 (0.0000, 20.0265) 
Slovenia 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 23.4785) 0.0000 (0.0000, 19.5172) 
Spain 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0002) 0.0000 (0.0000, 0.0002) 
Sweden 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 24.6035) 0.0000 (0.0000, 17.9099) 
Switzerland 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 3.3232) 0.0000 (0.0000, 6.5402) 
UK 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 11.5702) 0.0000 (0.0000, 16.8252) 
Ghana 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Kenya 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Madagascar 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Mauritius 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 26.2514) 0.0000 (0.0000, 7.1136) 
Mozambique 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Nigeria 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Senegal 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Tanzania 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Argentina 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.3733) 0.0000 (0.0000, 0.4496) 
Brazil 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 12.8522) 0.0000 (0.0000, 6.1677) 
Mexico 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Uruguay 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 2.8755) 0.0000 (0.0000, 0.8262) 
Egypt 0.0000 (0.0000, 0.0000) 9.6947 (4.5902, 16.2080) 12.1368 (0.7298, 29.0261) 
Israel 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Lebanon 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Libya 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Morocco 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Saudi Arabia 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 12.3862) 0.0000 (0.0000, 27.4478) 
Syria 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 0.0000) 
Tunisia 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 5.2494) 0.0000 (0.0000, 7.0606) 
Turkey 0.0000 (0.0000, 0.0000) 0.0000 (0.0000, 28.0645) 0.0000 (0.0000, 10.8709) 





Appendix table 7.3: Prior and posterior distributions of the general population HCV prevalence, PWID HCV prevalence, and the percentage of 
adults that are PWID. 
 General population HCV prevalence PWID HCV prevalence Adult % PWID 
 Median (minimum, maximum) Median (minimum, maximum) Median (minimum, maximum) 
Country Prior Posterior Prior Posterior Prior Posterior 
Afghanistan 0.89% (0.33%, 1.54%) 0.90% (0.35%, 1.54%) 29.7% (21.3%, 38.4%) 29.7% (21.3%, 38.4%) 0.80% (0.52%, 1.08%) 0.80% (0.52%, 1.08%) 
Albania 2.13% (1.39%, 2.91%) 2.14% (1.43%, 2.91%) 24.3% (19.1%, 30.2%) 23.8% (13.6%, 29.0%) 0.42% (0.29%, 0.55%) 0.42% (0.29%, 0.55%) 
Argentina 0.98% (0.25%, 1.53%) 0.99% (0.28%, 1.53%) 40.4% (36.5%, 44.3%) 40.3% (36.5%, 44.2%) 0.29% (0.29%, 0.30%) 0.29% (0.29%, 0.30%) 
Armenia 2.77% (1.85%, 3.78%) 2.77% (1.95%, 3.78%) 29.7% (20.6%, 40.0%) 29.3% (16.7%, 39.0%) 0.77% (0.41%, 1.34%) 0.76% (0.42%, 1.33%) 
Australia 1.07% (0.87%, 1.41%) 1.07% (0.90%, 1.41%) 40.1% (36.5%, 43.7%) 40.1% (35.6%, 43.5%) 0.60% (0.44%, 0.75%) 0.60% (0.44%, 0.75%) 
Austria 0.32% (0.08%, 0.50%) 0.35% (0.13%, 0.55%) 43.2% (38.2%, 49.0%) 42.2% (33.5%, 48.6%) 0.32% (0.22%, 0.42%) 0.31% (0.22%, 0.41%) 
Azerbaijan 2.58% (1.70%, 3.52%) 2.58% (1.70%, 3.45%) 43.2% (32.7%, 54.1%) 43.3% (32.9%, 53.9%) 0.61% (0.49%, 0.74%) 0.62% (0.50%, 0.74%) 
Bangladesh 0.98% (0.17%, 1.76%) 1.01% (0.17%, 1.73%) 26.7% (17.5%, 36.2%) 26.6% (17.6%, 35.5%) 0.07% (0.06%, 0.07%) 0.07% (0.06%, 0.07%) 
Belarus 1.11% (0.59%, 2.02%) 1.13% (0.62%, 1.97%) 40.5% (29.7%, 51.8%) 38.7% (23.5%, 51.2%) 0.59% (0.23%, 0.95%) 0.59% (0.23%, 0.95%) 
Belgium 0.51% (0.10%, 0.79%) 0.52% (0.14%, 0.79%) 41.4% (32.8%, 50.3%) 41.2% (32.4%, 49.7%) 0.36% (0.24%, 0.49%) 0.36% (0.24%, 0.49%) 
Bosnia 0.07% (0.05%, 0.09%) 0.08% (0.05%, 0.11%) 27.8% (19.0%, 37.2%) 27.4% (18.9%, 36.5%) 0.17% (0.11%, 0.22%) 0.17% (0.11%, 0.22%) 
Brazil 1.02% (0.81%, 1.23%) 1.02% (0.81%, 1.23%) 47.3% (43.3%, 51.3%) 47.0% (34.5%, 51.1%) 0.68% (0.51%, 0.87%) 0.68% (0.52%, 0.86%) 
Bulgaria 1.06% (0.50%, 1.72%) 1.08% (0.53%, 1.77%) 47.7% (43.1%, 52.5%) 46.2% (31.6%, 52.0%) 0.38% (0.30%, 0.45%) 0.38% (0.30%, 0.45%) 
Canada 0.73% (0.47%, 1.02%) 0.74% (0.48%, 1.02%) 56.1% (44.2%, 72.4%) 55.7% (42.0%, 71.1%) 0.39% (0.31%, 0.47%) 0.39% (0.31%, 0.47%) 
China 0.77% (0.58%, 0.98%) 0.77% (0.59%, 0.98%) 27.3% (17.1%, 38.0%) 27.2% (17.1%, 37.4%) 0.25% (0.19%, 0.31%) 0.25% (0.19%, 0.31%) 
Croatia 0.66% (0.36%, 1.01%) 0.66% (0.39%, 1.03%) 26.1% (19.7%, 33.1%) 25.9% (18.7%, 32.7%) 0.23% (0.18%, 0.29%) 0.23% (0.18%, 0.29%) 
Cyprus 0.64% (0.32%, 1.33%) 0.64% (0.32%, 1.31%) 35.2% (30.6%, 40.1%) 35.3% (31.2%, 39.7%) 0.08% (0.04%, 0.12%) 0.08% (0.04%, 0.12%) 
Czech Republic 0.35% (0.14%, 0.49%) 0.35% (0.15%, 0.50%) 12.8% (9.9%, 16.0%) 12.6% (8.6%, 15.5%) 0.64% (0.61%, 0.67%) 0.64% (0.61%, 0.67%) 
Denmark 0.43% (0.33%, 0.52%) 0.44% (0.33%, 0.58%) 30.2% (25.2%, 35.7%) 29.7% (21.2%, 35.5%) 0.44% (0.35%, 0.52%) 0.44% (0.35%, 0.52%) 
Egypt 6.88% (6.33%, 7.49%) 7.73% (6.57%, 9.79%) 34.0% (24.2%, 44.4%) 30.7% (20.5%, 41.0%) 0.21% (0.13%, 0.28%) 0.21% (0.14%, 0.28%) 
Estonia 1.28% (1.03%, 1.46%) 1.32% (1.04%, 1.49%) 55.0% (45.3%, 64.6%) 46.1% (32.3%, 62.4%) 1.09% (0.71%, 1.72%) 1.08% (0.71%, 1.71%) 
FYROM 0.36% (0.24%, 0.48%) 0.37% (0.24%, 0.54%) 44.1% (40.9%, 47.7%) 43.8% (38.9%, 47.4%) 0.16% (0.11%, 0.21%) 0.16% (0.11%, 0.21%) 




 General population HCV prevalence PWID HCV prevalence Adult % PWID 
 Median (minimum, maximum) Median (minimum, maximum) Median (minimum, maximum) 
Country Prior Posterior Prior Posterior Prior Posterior 
France 0.57% (0.32%, 0.80%) 0.63% (0.42%, 0.87%) 45.4% (41.5%, 49.1%) 46.2% (40.1%, 53.6%) 0.20% (0.16%, 0.23%) 0.20% (0.16%, 0.23%) 
Georgia 5.40% (4.56%, 6.35%) 5.41% (4.58%, 6.29%) 48.0% (39.0%, 57.2%) 44.3% (29.0%, 57.0%) 4.26% (0.61%, 7.81%) 4.23% (0.70%, 7.81%) 
Germany 0.42% (0.21%, 0.65%) 0.43% (0.22%, 0.65%) 46.1% (41.2%, 51.2%) 45.7% (36.9%, 50.5%) 0.24% (0.03%, 0.45%) 0.23% (0.04%, 0.44%) 
Ghana 1.96% (0.85%, 3.86%) 1.91% (0.88%, 3.79%) 28.2% (23.8%, 32.9%) 28.2% (24.0%, 32.9%) 0.05% (0.03%, 0.07%) 0.05% (0.03%, 0.07%) 
Greece 1.17% (0.35%, 1.85%) 1.17% (0.39%, 1.83%) 46.7% (42.3%, 51.2%) 46.6% (42.3%, 51.2%) 0.07% (0.06%, 0.09%) 0.07% (0.06%, 0.09%) 
Hungary 0.82% (0.28%, 1.89%) 0.84% (0.28%, 1.89%) 32.4% (21.1%, 45.3%) 32.6% (21.4%, 44.3%) 0.06% (0.03%, 0.08%) 0.06% (0.03%, 0.08%) 
Iceland 0.29% (0.23%, 0.35%) 0.31% (0.24%, 0.44%) 44.7% (40.8%, 48.4%) 43.6% (35.5%, 48.4%) 0.24% (0.16%, 0.32%) 0.24% (0.16%, 0.32%) 
India 0.72% (0.40%, 1.18%) 0.73% (0.40%, 1.18%) 31.3% (26.0%, 36.7%) 31.4% (26.0%, 36.5%) 0.02% (0.01%, 0.03%) 0.02% (0.01%, 0.03%) 
Indonesia 0.55% (0.08%, 1.08%) 0.55% (0.11%, 1.07%) 56.5% (52.2%, 61.3%) 56.4% (52.3%, 60.9%) 0.11% (0.09%, 0.13%) 0.11% (0.09%, 0.13%) 
Iran 0.44% (0.15%, 0.79%) 0.44% (0.17%, 0.79%) 34.7% (21.8%, 47.8%) 34.3% (21.8%, 46.4%) 0.28% (0.19%, 0.37%) 0.28% (0.19%, 0.37%) 
Ireland 0.68% (0.47%, 1.14%) 0.68% (0.47%, 1.13%) 52.9% (49.0%, 56.8%) 52.8% (46.6%, 56.8%) 0.27% (0.20%, 0.33%) 0.27% (0.20%, 0.33%) 
Israel 1.16% (0.61%, 1.50%) 1.15% (0.65%, 1.47%) 31.2% (25.6%, 37.0%) 31.2% (25.6%, 37.0%) 0.41% (0.28%, 0.54%) 0.41% (0.28%, 0.54%) 
Italy 2.54% (1.17%, 5.29%) 2.58% (1.26%, 5.15%) 41.1% (36.0%, 46.5%) 38.9% (25.7%, 46.0%) 0.85% (0.57%, 1.13%) 0.85% (0.57%, 1.12%) 
Japan 0.75% (0.31%, 1.39%) 0.79% (0.38%, 1.46%) 41.1% (34.3%, 48.6%) 38.1% (24.4%, 46.9%) 0.47% (0.36%, 0.58%) 0.47% (0.36%, 0.58%) 
Kazakhstan 1.43% (0.63%, 2.16%) 1.48% (0.71%, 2.16%) 28.6% (25.0%, 32.8%) 27.3% (17.3%, 31.9%) 1.00% (0.65%, 1.42%) 0.99% (0.65%, 1.38%) 
Kenya 0.47% (0.15%, 0.72%) 0.48% (0.16%, 0.72%) 11.8% (7.6%, 16.7%) 11.8% (7.7%, 16.5%) 0.12% (0.03%, 0.20%) 0.12% (0.04%, 0.20%) 
Kyrgyzstan 1.66% (0.77%, 3.29%) 1.69% (0.82%, 3.19%) 21.4% (18.7%, 24.1%) 21.4% (15.1%, 24.0%) 0.77% (0.51%, 1.10%) 0.77% (0.51%, 1.10%) 
Latvia 1.70% (1.18%, 2.30%) 1.75% (1.26%, 2.33%) 51.7% (45.1%, 58.1%) 47.3% (31.7%, 57.4%) 0.93% (0.73%, 1.17%) 0.93% (0.74%, 1.15%) 
Lebanon 0.22% (0.08%, 0.49%) 0.22% (0.08%, 0.47%) 16.3% (10.5%, 23.3%) 16.4% (10.7%, 22.9%) 0.14% (0.09%, 0.19%) 0.14% (0.09%, 0.19%) 
Libya 0.83% (0.74%, 0.92%) 0.83% (0.74%, 0.92%) 64.8% (60.3%, 69.1%) 64.9% (60.3%, 69.0%) 0.05% (0.01%, 0.10%) 0.05% (0.01%, 0.10%) 
Lithuania 1.35% (0.83%, 1.93%) 1.36% (0.87%, 2.02%) 28.6% (25.6%, 31.5%) 28.3% (19.8%, 31.2%) 0.23% (0.12%, 0.34%) 0.22% (0.12%, 0.33%) 
Luxembourg 0.85% (0.40%, 1.17%) 0.85% (0.43%, 1.20%) 57.6% (52.5%, 62.8%) 56.9% (41.6%, 62.1%) 0.57% (0.45%, 0.69%) 0.57% (0.45%, 0.68%) 
Madagascar 0.86% (0.53%, 1.24%) 0.85% (0.53%, 1.22%) 3.9% (1.6%, 6.4%) 3.9% (1.6%, 6.3%) 0.22% (0.02%, 0.58%) 0.22% (0.03%, 0.58%) 
Malaysia 1.91% (0.20%, 4.82%) 1.87% (0.45%, 4.78%) 42.6% (38.3%, 46.9%) 42.4% (28.9%, 46.9%) 1.33% (1.12%, 1.55%) 1.33% (1.13%, 1.55%) 
Malta 0.28% (0.19%, 0.43%) 0.29% (0.19%, 0.43%) 17.9% (9.3%, 26.9%) 20.0% (13.7%, 26.9%) 0.26% (0.18%, 0.35%) 0.27% (0.18%, 0.35%) 




 General population HCV prevalence PWID HCV prevalence Adult % PWID 
 Median (minimum, maximum) Median (minimum, maximum) Median (minimum, maximum) 
Country Prior Posterior Prior Posterior Prior Posterior 
Mexico 1.02% (0.81%, 1.21%) 1.02% (0.81%, 1.25%) 70.6% (66.4%, 74.9%) 70.6% (66.7%, 74.9%) 0.18% (0.12%, 0.25%) 0.18% (0.12%, 0.25%) 
Moldova 2.66% (1.58%, 3.25%) 2.67% (1.65%, 3.31%) 34.8% (23.2%, 47.0%) 34.7% (23.2%, 46.5%) 0.40% (0.25%, 0.54%) 0.39% (0.26%, 0.54%) 
Montenegro 0.85% (0.57%, 1.15%) 0.88% (0.58%, 1.21%) 30.8% (27.3%, 34.5%) 28.6% (19.5%, 34.5%) 0.40% (0.27%, 0.53%) 0.39% (0.27%, 0.52%) 
Morocco 0.95% (0.74%, 1.34%) 0.96% (0.75%, 1.33%) 37.2% (22.9%, 51.5%) 37.5% (24.0%, 50.9%) 0.13% (0.07%, 0.20%) 0.13% (0.07%, 0.20%) 
Mozambique 1.79% (0.11%, 4.95%) 1.78% (0.14%, 4.95%) 47.3% (42.5%, 51.7%) 47.2% (42.5%, 51.6%) 0.20% (0.00%, 0.41%) 0.20% (0.00%, 0.41%) 
Myanmar 1.11% (0.60%, 1.75%) 1.10% (0.60%, 1.67%) 18.8% (16.6%, 21.4%) 18.6% (11.9%, 21.3%) 0.48% (0.33%, 0.64%) 0.48% (0.33%, 0.64%) 
Nepal 0.50% (0.33%, 0.68%) 0.50% (0.34%, 0.68%) 35.0% (23.5%, 46.1%) 34.7% (24.3%, 46.0%) 0.20% (0.19%, 0.21%) 0.20% (0.19%, 0.21%) 
Netherlands 0.16% (0.05%, 0.27%) 0.16% (0.06%, 0.27%) 39.2% (34.4%, 44.8%) 39.2% (34.5%, 44.8%) 0.03% (0.02%, 0.04%) 0.03% (0.02%, 0.04%) 
New Zealand 1.09% (0.61%, 1.62%) 1.10% (0.61%, 1.61%) 53.8% (46.6%, 61.8%) 53.3% (38.4%, 61.0%) 0.73% (0.50%, 0.96%) 0.73% (0.51%, 0.96%) 
Nigeria 1.59% (1.43%, 1.83%) 1.59% (1.44%, 1.81%) 4.2% (2.5%, 6.3%) 4.2% (2.5%, 6.3%) 0.35% (0.24%, 0.46%) 0.35% (0.24%, 0.46%) 
Norway 0.40% (0.31%, 0.51%) 0.40% (0.32%, 0.56%) 45.9% (41.1%, 50.9%) 45.7% (38.7%, 50.9%) 0.25% (0.21%, 0.29%) 0.25% (0.21%, 0.29%) 
Pakistan 3.82% (3.55%, 4.14%) 3.82% (3.56%, 4.11%) 30.6% (4.7%, 62.0%) 30.1% (5.2%, 62.0%) 0.37% (0.32%, 0.42%) 0.37% (0.32%, 0.42%) 
Philippines 0.68% (0.22%, 1.28%) 0.68% (0.22%, 1.28%) 22.1% (10.5%, 35.6%) 22.1% (10.5%, 35.6%) 0.04% (0.03%, 0.05%) 0.04% (0.03%, 0.05%) 
Poland 0.60% (0.40%, 0.81%) 0.60% (0.40%, 0.81%) 41.6% (36.9%, 47.6%) 41.5% (36.4%, 47.6%) 0.27% (0.18%, 0.36%) 0.27% (0.18%, 0.36%) 
Portugal 1.13% (0.35%, 2.05%) 1.16% (0.39%, 2.08%) 62.3% (55.1%, 69.3%) 61.7% (54.6%, 69.2%) 0.22% (0.19%, 0.25%) 0.22% (0.19%, 0.25%) 
Romania 2.25% (1.99%, 2.55%) 2.29% (2.02%, 2.74%) 58.4% (54.0%, 63.3%) 56.2% (39.0%, 62.3%) 0.64% (0.47%, 0.83%) 0.64% (0.47%, 0.83%) 
Russia 2.59% (0.83%, 3.93%) 2.70% (0.90%, 3.91%) 47.8% (40.2%, 55.5%) 42.1% (28.5%, 54.5%) 1.79% (0.95%, 2.67%) 1.76% (0.97%, 2.66%) 
Saudi Arabia 0.35% (0.27%, 0.43%) 0.36% (0.28%, 0.52%) 53.4% (48.5%, 58.3%) 52.9% (41.8%, 57.6%) 0.20% (0.13%, 0.27%) 0.20% (0.13%, 0.27%) 
Senegal 1.20% (0.02%, 3.27%) 1.23% (0.02%, 3.20%) 27.6% (21.6%, 34.4%) 27.6% (21.6%, 34.4%) 0.08% (0.05%, 0.11%) 0.08% (0.05%, 0.11%) 
Serbia 0.36% (0.23%, 0.48%) 0.38% (0.26%, 0.55%) 18.4% (15.2%, 21.8%) 16.2% (11.4%, 20.8%) 0.49% (0.41%, 0.58%) 0.49% (0.41%, 0.58%) 
Slovakia 0.99% (0.60%, 1.40%) 1.00% (0.62%, 1.43%) 38.9% (24.8%, 53.8%) 37.8% (22.0%, 53.2%) 0.56% (0.35%, 0.88%) 0.56% (0.35%, 0.88%) 
Slovenia 0.28% (0.21%, 0.36%) 0.29% (0.21%, 0.39%) 21.6% (18.2%, 25.3%) 20.9% (14.2%, 24.8%) 0.42% (0.30%, 0.55%) 0.42% (0.30%, 0.55%) 
Spain 1.06% (0.30%, 1.87%) 1.08% (0.29%, 1.83%) 50.4% (47.2%, 53.7%) 50.4% (47.2%, 57.4%) 0.07% (0.05%, 0.10%) 0.08% (0.05%, 0.10%) 
Sweden 0.41% (0.33%, 0.50%) 0.41% (0.32%, 0.58%) 57.9% (54.1%, 61.6%) 57.9% (49.1%, 75.4%) 0.24% (0.04%, 0.61%) 0.23% (0.04%, 0.61%) 
Switzerland 0.99% (0.57%, 1.27%) 1.01% (0.57%, 1.27%) 52.9% (47.6%, 58.5%) 52.7% (47.0%, 57.9%) 0.24% (0.19%, 0.29%) 0.24% (0.19%, 0.29%) 




 General population HCV prevalence PWID HCV prevalence Adult % PWID 
 Median (minimum, maximum) Median (minimum, maximum) Median (minimum, maximum) 
Country Prior Posterior Prior Posterior Prior Posterior 
Taiwan 2.91% (1.56%, 5.53%) 2.96% (1.56%, 5.44%) 57.9% (54.4%, 61.5%) 57.6% (45.5%, 61.5%) 0.30% (0.20%, 0.40%) 0.30% (0.20%, 0.39%) 
Tajikistan 1.71% (0.54%, 3.29%) 1.72% (0.55%, 3.28%) 29.9% (25.9%, 33.6%) 29.9% (26.2%, 33.6%) 0.47% (0.31%, 0.65%) 0.47% (0.31%, 0.65%) 
Tanzania 2.43% (0.16%, 5.59%) 2.50% (0.20%, 5.45%) 19.6% (15.1%, 24.1%) 19.5% (12.4%, 23.7%) 1.24% (0.72%, 1.74%) 1.24% (0.72%, 1.74%) 
Thailand 1.04% (0.48%, 2.36%) 1.03% (0.49%, 2.28%) 56.0% (50.7%, 61.9%) 55.8% (48.0%, 61.3%) 0.11% (0.03%, 0.18%) 0.11% (0.03%, 0.18%) 
Tunisia 0.76% (0.16%, 1.21%) 0.75% (0.17%, 1.20%) 20.0% (17.1%, 23.2%) 19.9% (16.9%, 23.2%) 0.21% (0.14%, 0.29%) 0.21% (0.14%, 0.28%) 
Turkey 0.80% (0.42%, 1.47%) 0.83% (0.44%, 1.42%) 30.9% (27.8%, 34.0%) 30.3% (19.9%, 33.9%) 0.42% (0.28%, 0.55%) 0.42% (0.29%, 0.55%) 
Turkmenistan 2.28% (0.60%, 3.34%) 2.30% (0.65%, 3.34%) 29.5% (21.6%, 38.4%) 29.4% (22.9%, 37.5%) 0.40% (0.27%, 0.53%) 0.40% (0.28%, 0.53%) 
UK 0.38% (0.27%, 0.53%) 0.39% (0.27%, 0.57%) 32.1% (21.5%, 43.3%) 31.5% (20.7%, 43.3%) 0.40% (0.38%, 0.42%) 0.40% (0.38%, 0.42%) 
USA 1.01% (0.88%, 1.17%) 1.21% (0.84%, 1.52%) 40.2% (28.5%, 52.6%) 37.6% (25.4%, 52.6%) 1.31% (0.59%, 1.86%) 1.22% (0.62%, 1.84%) 
Ukraine 2.19% (0.64%, 3.25%) 2.25% (0.70%, 3.21%) 38.3% (33.9%, 42.8%) 36.6% (23.6%, 42.6%) 1.07% (0.54%, 1.79%) 1.06% (0.55%, 1.73%) 
Uruguay 0.74% (0.50%, 0.99%) 0.74% (0.51%, 0.99%) 16.2% (13.7%, 18.7%) 16.1% (10.7%, 18.7%) 0.40% (0.10%, 0.86%) 0.40% (0.10%, 0.85%) 
Uzbekistan 5.45% (3.08%, 6.83%) 5.45% (3.22%, 6.69%) 25.2% (21.9%, 29.1%) 25.2% (19.0%, 29.1%) 0.49% (0.32%, 0.69%) 0.49% (0.32%, 0.69%) 
Viet Nam 0.99% (0.75%, 1.31%) 0.99% (0.75%, 1.31%) 37.2% (26.6%, 48.2%) 37.1% (27.0%, 48.0%) 0.25% (0.19%, 0.31%) 0.25% (0.19%, 0.31%) 





Appendix figure 7.1: Model runs showing time trends in the total population (top left), the percentage of the adult population that are people 
who inject drugs (top right), the prevalence of hepatitis C virus amongst the general population (bottom left), and the prevalence of hepatitis C 
virus amongst people who inject drugs (bottom right) for each country modelled. The black, vertical lines show the range of values that could 
be sampled.  
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The HCV prevalence for many runs appears to curve upwards for runs that previously had decreasing prevalence as the transmission rates 
were fit for the population change for 1990 and 2015. The same transmission rates are then used from 2015 onwards, however, the UN 
projected population estimates often increase at a slower rate after 2015, meaning the same transmission rate causes an increase in prevalence. 
This also applies to other countries. 
The HCV prevalence among the general population and PWID reaches 0% for some runs in countries where treatment numbers are already 
high, such as Egypt, France, and the USA. This is because the model assumes these annual treatment numbers continue for future years. The 
model does not include diagnosis as a barrier to starting treatment as screening patterns are difficult to predict and are likely to evolve to 
maintain treatment rates. For example, Egypt screened 30 million people (roughly a quarter of their population) in a period of around four 






Appendix table 7.4: Sensitivity analyses for the population attributable fraction (tPAF) of injecting drug use (IDU) to hepatitis C virus (HCV) 
transmission from 2018 to 2030, with 95% credibility intervals.  
 Population Attributable Fraction of injecting drug use to hepatitis C virus transmission 2018-2030 
 






Stable proportion of 
adults that are 
PWID in 1990 in EE 
and SSA** 
Altered treatment 
rates for PWID 






Global 43% (24%, 66%) 33% (20%, 54%) 43% (23%, 66%) 43% (25%, 66%) 43% (23%, 66%) 30% (15%, 51%) 
Central Asia 36% (18%, 76%) 23% (13%, 44%) 36% (19%, 77%) 36% (18%, 76%) 36% (18%, 76%) 4% (1%, 15%) 
Kazakhstan 99% (71%, 100%) 79% (57%, 100%) 99% (70%, 100%) 99% (71%, 100%) 99% (71%, 100%) 45% (9%, 100%) 
Kyrgyzstan 52% (22%, 95%) 36% (17%, 85%) 51% (22%, 97%) 52% (22%, 95%) 52% (22%, 95%) 8% (1%, 47%) 
Tajikistan 41% (17%, 84%) 28% (14%, 55%) 40% (17%, 86%) 41% (17%, 84%) 41% (17%, 84%) 6% (1%, 36%) 
Turkmenistan 33% (16%, 77%) 21% (12%, 59%) 33% (16%, 80%) 33% (16%, 77%) 33% (16%, 77%) 4% (0%, 30%) 
Uzbekistan 21% (9%, 68%) 13% (6%, 25%) 20% (9%, 68%) 21% (9%, 68%) 21% (9%, 68%) 1% (0%, 7%) 
Eastern Europe 96% (65%, 99%) 81% (54%, 96%) 96% (66%, 99%) 96% (70%, 99%) 96% (65%, 99%) 45% (10%, 86%) 
Armenia 79% (41%, 100%) 45% (27%, 68%) 79% (41%, 100%) 74% (31%, 100%) 79% (41%, 100%) 4% (0%, 28%) 
Azerbaijan 52% (31%, 76%) 36% (25%, 56%) 52% (31%, 77%) 51% (27%, 92%) 52% (31%, 76%) 5% (0%, 21%) 
Belarus 100% (67%, 100%) 72% (40%, 100%) 100% (67%, 100%) 100% (63%, 100%) 100% (67%, 100%) 32% (6%, 90%) 
Bosnia 100% (97%, 100%) 100% (89%, 100%) 100% (97%, 100%) 100% (100%, 100%) 100% (97%, 100%) 96% (59%, 100%) 
Bulgaria 100% (63%, 100%) 72% (52%, 100%) 100% (63%, 100%) 100% (65%, 100%) 100% (63%, 100%) 36% (8%, 84%) 
Czech Republic 89% (69%, 100%) 76% (57%, 96%) 89% (68%, 100%) 94% (56%, 100%) 88% (69%, 100%) 50% (17%, 90%) 
Estonia 100% (96%, 100%) 100% (89%, 100%) 100% (95%, 100%) 100% (96%, 100%) 100% (93%, 100%) 93% (54%, 100%) 
Georgia 100% (68%, 100%) 91% (60%, 100%) 100% (68%, 100%) 100% (57%, 100%) 100% (73%, 100%) 61% (11%, 100%) 
Hungary 30% (13%, 74%) 16% (6%, 37%) 29% (12%, 73%) 20% (6%, 71%) 30% (13%, 74%) 5% (1%, 23%) 
Latvia 100% (85%, 100%) 92% (73%, 100%) 100% (85%, 100%) 100% (91%, 100%) 100% (83%, 100%) 51% (15%, 100%) 
Lithuania 76% (37%, 100%) 42% (27%, 65%) 76% (37%, 100%) 72% (32%, 100%) 78% (38%, 100%) 9% (0%, 32%) 
Moldova 56% (27%, 100%) 30% (20%, 48%) 56% (27%, 100%) 48% (19%, 100%) 56% (27%, 100%) 6% (0%, 25%) 
Poland 87% (62%, 100%) 65% (53%, 89%) 87% (62%, 100%) 96% (56%, 100%) 86% (62%, 100%) 28% (12%, 64%) 
Romania 100% (64%, 100%) 70% (57%, 100%) 100% (64%, 100%) 100% (78%, 100%) 100% (62%, 100%) 33% (12%, 76%) 
Russia 100% (73%, 100%) 90% (61%, 100%) 100% (74%, 100%) 100% (80%, 100%) 100% (73%, 100%) 60% (13%, 100%) 
Slovakia 86% (61%, 100%) 70% (50%, 100%) 87% (61%, 100%) 96% (50%, 100%) 86% (60%, 100%) 38% (8%, 76%) 
Ukraine 100% (53%, 100%) 76% (42%, 100%) 100% (51%, 100%) 100% (53%, 100%) 100% (53%, 100%) 30% (6%, 99%) 
Australasia 69% (43%, 100%) 52% (34%, 85%) 69% (43%, 100%) 69% (43%, 100%) 74% (49%, 100%) 48% (29%, 80%) 
Australia 66% (41%, 100%) 48% (32%, 81%) 65% (40%, 100%) 66% (41%, 100%) 72% (48%, 100%) 44% (27%, 75%) 




 Population Attributable Fraction of injecting drug use to Hepatitis C virus transmission 2018-2030 






Stable proportion of 
adults that are 
PWID in 1990 in EE 
and SSA** 
Altered treatment 
rates for PWID 






East & Southeast Asia 58% (29%, 95%) 42% (25%, 73%) 59% (29%, 97%) 58% (29%, 95%) 59% (29%, 95%) 44% (24%, 75%) 
China 56% (28%, 95%) 39% (24%, 68%) 57% (27%, 99%) 56% (28%, 95%) 56% (28%, 95%) 45% (24%, 72%) 
Indonesia 73% (35%, 100%) 48% (23%, 100%) 74% (35%, 100%) 73% (35%, 100%) 73% (35%, 100%) 39% (19%, 95%) 
Japan 100% (71%, 100%) 96% (59%, 100%) 100% (72%, 100%) 100% (71%, 100%) 100% (70%, 100%) 100% (78%, 100%) 
Malaysia 67% (26%, 100%) 52% (24%, 100%) 68% (26%, 100%) 67% (26%, 100%) 67% (26%, 100%) 52% (23%, 100%) 
Myanmar 72% (34%, 100%) 59% (33%, 98%) 74% (33%, 100%) 72% (34%, 100%) 72% (34%, 100%) 51% (27%, 88%) 
Philippines 14% (4%, 40%) 8% (3%, 19%) 12% (4%, 38%) 14% (4%, 40%) 14% (4%, 40%) 7% (3%, 21%) 
Taiwan 62% (19%, 100%) 27% (12%, 56%) 62% (19%, 100%) 62% (19%, 100%) 61% (19%, 100%) 36% (15%, 68%) 
Thailand 41% (15%, 100%) 24% (10%, 64%) 41% (15%, 100%) 41% (15%, 100%) 41% (15%, 100%) 24% (9%, 65%) 
Viet Nam 56% (30%, 98%) 41% (25%, 69%) 57% (30%, 100%) 56% (30%, 98%) 57% (30%, 98%) 36% (23%, 69%) 
South Asia 13% (4%, 30%) 9% (4%, 22%) 13% (3%, 30%) 13% (4%, 30%) 13% (4%, 30%) 10% (3%, 20%) 
Afghanistan 61% (35%, 99%) 51% (29%, 98%) 62% (34%, 100%) 61% (35%, 99%) 61% (35%, 99%) 52% (25%, 97%) 
Bangladesh 15% (5%, 46%) 9% (4%, 31%) 14% (5%, 45%) 15% (5%, 46%) 15% (5%, 46%) 7% (4%, 28%) 
India 5% (3%, 13%) 3% (2%, 9%) 5% (2%, 13%) 5% (3%, 13%) 5% (3%, 13%) 4% (2%, 8%) 
Iran 84% (55%, 100%) 67% (42%, 100%) 86% (55%, 100%) 84% (55%, 100%) 84% (54%, 100%) 82% (52%, 100%) 
Nepal 70% (47%, 100%) 51% (32%, 97%) 72% (47%, 100%) 70% (47%, 100%) 70% (47%, 100%) 48% (31%, 83%) 
Pakistan 19% (1%, 48%) 13% (3%, 33%) 18% (1%, 49%) 19% (1%, 48%) 19% (1%, 48%) 12% (1%, 26%) 
North America 77% (54%, 100%) 67% (46%, 93%) 74% (50%, 100%) 80% (56%, 100%) 70% (33%, 100%) 74% (55%, 100%) 
Canada 82% (55%, 100%) 72% (46%, 100%) 83% (56%, 100%) 82% (55%, 100%) 81% (53%, 100%) 80% (54%, 100%) 
USA 77% (54%, 100%) 67% (46%, 93%) 73% (49%, 100%) 80% (56%, 100%) 69% (31%, 100%) 74% (55%, 100%) 
Western Europe 83% (54%, 95%) 65% (41%, 89%) 83% (54%, 95%) 83% (52%, 95%) 84% (54%, 95%) 62% (39%, 86%) 
Albania 65% (25%, 100%) 28% (17%, 48%) 63% (24%, 100%) 64% (26%, 100%) 65% (25%, 100%) 6% (2%, 21%) 
Austria 100% (82%, 100%) 94% (68%, 100%) 100% (82%, 100%) 100% (82%, 100%) 100% (81%, 100%) 100% (73%, 100%) 
Belgium 96% (56%, 100%) 82% (48%, 100%) 97% (55%, 100%) 96% (56%, 100%) 96% (57%, 100%) 74% (46%, 100%) 
Croatia 72% (37%, 100%) 42% (26%, 71%) 72% (35%, 100%) 72% (37%, 100%) 71% (37%, 100%) 14% (4%, 44%) 
Cyprus 37% (13%, 78%) 18% (8%, 53%) 35% (12%, 79%) 37% (13%, 78%) 37% (13%, 78%) 19% (8%, 45%) 
Denmark 92% (59%, 100%) 70% (48%, 100%) 95% (58%, 100%) 92% (59%, 100%) 92% (60%, 100%) 71% (47%, 100%) 
FYROM 91% (56%, 100%) 72% (46%, 100%) 93% (56%, 100%) 91% (56%, 100%) 91% (56%, 100%) 32% (9%, 80%) 
Finland 100% (88%, 100%) 100% (76%, 100%) 100% (88%, 100%) 100% (88%, 100%) 100% (87%, 100%) 100% (79%, 100%) 
France 93% (59%, 100%) 69% (53%, 98%) 92% (56%, 100%) 96% (61%, 100%) 95% (65%, 100%) 67% (45%, 91%) 




 Population Attributable Fraction of injecting drug use to Hepatitis C virus transmission 2018-2030 






Stable proportion of 
adults that are 
PWID in 1990 in EE 
and SSA** 
Altered treatment 
rates for PWID 






Greece 23% (10%, 65%) 12% (7%, 25%) 23% (10%, 67%) 23% (10%, 65%) 22% (10%, 63%) 13% (7%, 31%) 
Iceland 100% (96%, 100%) 100% (88%, 100%) 100% (98%, 100%) 100% (96%, 100%) 100% (84%, 100%) 100% (89%, 100%) 
Ireland 82% (50%, 100%) 56% (35%, 97%) 83% (50%, 100%) 82% (50%, 100%) 81% (49%, 100%) 62% (42%, 100%) 
Italy 100% (55%, 100%) 77% (38%, 100%) 100% (54%, 100%) 100% (55%, 100%) 100% (56%, 100%) 76% (39%, 100%) 
Luxembourg 96% (76%, 100%) 92% (67%, 100%) 97% (76%, 100%) 96% (76%, 100%) 95% (75%, 100%) 87% (63%, 100%) 
Malta 83% (43%, 100%) 61% (36%, 96%) 84% (43%, 100%) 83% (43%, 100%) 84% (46%, 100%) 61% (34%, 100%) 
Montenegro 100% (68%, 100%) 81% (51%, 100%) 100% (68%, 100%) 100% (68%, 100%) 100% (68%, 100%) 39% (13%, 100%) 
Netherlands 57% (20%, 88%) 33% (18%, 70%) 56% (19%, 90%) 57% (20%, 88%) 61% (20%, 90%) 35% (20%, 69%) 
Norway 85% (61%, 100%) 69% (53%, 100%) 86% (61%, 100%) 85% (61%, 100%) 84% (60%, 100%) 73% (54%, 100%) 
Portugal 100% (72%, 100%) 76% (43%, 100%) 100% (71%, 100%) 100% (72%, 100%) 100% (71%, 100%) 71% (40%, 100%) 
Serbia 100% (88%, 100%) 98% (73%, 100%) 100% (89%, 100%) 100% (88%, 100%) 100% (88%, 100%) 64% (27%, 100%) 
Slovenia 97% (68%, 100%) 84% (54%, 100%) 100% (68%, 100%) 97% (68%, 100%) 95% (67%, 100%) 84% (56%, 100%) 
Spain 31% (15%, 70%) 19% (8%, 53%) 31% (14%, 71%) 31% (15%, 70%) 34% (15%, 74%) 19% (9%, 42%) 
Sweden 90% (41%, 100%) 75% (32%, 100%) 92% (40%, 100%) 90% (41%, 100%) 88% (40%, 100%) 78% (30%, 100%) 
Switzerland 92% (52%, 100%) 57% (35%, 91%) 92% (49%, 100%) 92% (52%, 100%) 92% (54%, 100%) 59% (34%, 92%) 
UK 97% (86%, 100%) 89% (76%, 100%) 98% (86%, 100%) 100% (80%, 100%) 97% (86%, 100%) 87% (75%, 100%) 
Sub-Saharan Africa 13% (3%, 42%) 11% (2%, 36%) 13% (2%, 42%) 12% (2%, 43%) 13% (3%, 42%) 12% (2%, 41%) 
Ghana 3% (1%, 7%) 2% (1%, 5%) 3% (1%, 7%) 2% (1%, 7%) 3% (1%, 7%) 2% (1%, 6%) 
Kenya 29% (15%, 56%) 23% (11%, 47%) 28% (14%, 54%) 22% (8%, 52%) 29% (15%, 56%) 26% (11%, 51%) 
Madagascar 6% (1%, 29%) 5% (0%, 15%) 6% (0%, 26%) 3% (0%, 11%) 6% (1%, 29%) 5% (1%, 22%) 
Mauritius 88% (55%, 100%) 73% (48%, 100%) 89% (55%, 100%) 100% (63%, 100%) 88% (55%, 100%) 82% (51%, 100%) 
Mozambique 20% (5%, 64%) 14% (3%, 54%) 20% (5%, 64%) 19% (4%, 56%) 20% (5%, 64%) 22% (3%, 69%) 
Nigeria 1% (0%, 3%) 1% (0%, 3%) 1% (0%, 3%) 1% (0%, 4%) 1% (0%, 3%) 1% (0%, 4%) 
Senegal 11% (3%, 40%) 6% (3%, 17%) 11% (3%, 39%) 8% (2%, 43%) 11% (3%, 40%) 9% (3%, 27%) 
Tanzania 34% (13%, 95%) 33% (10%, 86%) 34% (13%, 96%) 38% (12%, 100%) 34% (13%, 95%) 32% (11%, 83%) 
Latin America 75% (48%, 98%) 54% (39%, 80%) 76% (48%, 99%) 75% (48%, 99%) 75% (48%, 98%) 64% (45%, 88%) 
Argentina 60% (32%, 98%) 37% (23%, 64%) 60% (32%, 100%) 61% (31%, 100%) 60% (32%, 98%) 50% (29%, 90%) 
Brazil 87% (59%, 100%) 70% (51%, 100%) 89% (59%, 100%) 87% (59%, 100%) 87% (59%, 100%) 78% (56%, 100%) 
Mexico 55% (30%, 95%) 32% (24%, 52%) 56% (30%, 96%) 55% (30%, 95%) 55% (30%, 95%) 43% (29%, 63%) 
Uruguay 48% (22%, 99%) 29% (11%, 68%) 46% (20%, 100%) 48% (22%, 99%) 48% (22%, 99%) 41% (19%, 75%) 




 Population Attributable Fraction of injecting drug use to Hepatitis C virus transmission 2018-2030 






Stable proportion of 
adults that are 
PWID in 1990 in EE 
and SSA** 
Altered treatment 
rates for PWID 






Middle East & North Africa 16% (8%, 26%) 11% (5%, 22%) 15% (8%, 26%) 16% (8%, 28%) 17% (8%, 29%) 14% (7%, 24%) 
Egypt 5% (2%, 10%) 3% (1%, 8%) 4% (2%, 10%) 5% (2%, 12%) 6% (2%, 13%) 4% (2%, 9%) 
Israel 38% (19%, 67%) 25% (16%, 52%) 34% (18%, 65%) 38% (19%, 67%) 38% (19%, 67%) 28% (16%, 51%) 
Lebanon 49% (18%, 89%) 33% (14%, 82%) 48% (17%, 91%) 49% (18%, 89%) 50% (19%, 89%) 45% (18%, 99%) 
Libya 38% (12%, 92%) 22% (9%, 51%) 39% (12%, 93%) 38% (12%, 92%) 38% (12%, 92%) 36% (15%, 68%) 
Morocco 41% (17%, 75%) 21% (13%, 40%) 41% (16%, 76%) 41% (17%, 75%) 41% (17%, 75%) 35% (17%, 62%) 
Saudi Arabia 87% (64%, 100%) 84% (58%, 100%) 88% (65%, 100%) 87% (64%, 100%) 85% (62%, 100%) 96% (65%, 100%) 
Syria 17% (6%, 47%) 8% (4%, 27%) 17% (6%, 47%) 17% (6%, 47%) 17% (6%, 47%) 14% (6%, 35%) 
Tunisia 78% (42%, 100%) 55% (28%, 86%) 77% (41%, 100%) 78% (42%, 100%) 78% (43%, 100%) 80% (43%, 100%) 
Turkey 92% (58%, 100%) 74% (39%, 100%) 95% (59%, 100%) 92% (58%, 100%) 92% (59%, 100%) 90% (49%, 100%) 
* Decreasing at the same rate as the HCV prevalence among the general population 
** EE: Eastern Europe; SSA: Sub-Saharan Africa 
*** Treatment numbers remain the same as in the main analysis but treatment rates among PWID are halved and among people with cirrhosis 
are doubled. This can also mean an alteration in the treatment rates (either an increase or a decrease depending on the country) for people that 
do not inject drugs and do not have cirrhosis. 
 
 
 
